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1 Introduction 
1.1 The concept of epigenetics 
The one thing all known organisms share is the matter of genetic information. However, pure 
genetic material is not enough to bring an organism to life. The genetic code needs to be 
interpreted and that, in case of multicellular organisms, in various ways. The initial step of 
interpretation is transcription of distinct parts of the present genetic makeup, which is thought to 
be initiated and controlled by three mechanisms. Firstly, intrinsic promoters and the transcription 
machinery itself seem to partly control the process. Secondly, specific transcription factors 
influence and target the transcription machinery
1,2
. Finally, the genetic material, deoxyribonucleic 
acid (DNA), is not found naked in the nucleus, but associated with proteins in a structure called 
chromatin. Post-replicational modifications of the DNA as well as of other chromatin components, 
especially histones, affect the accessibility of genetic material. 
The later is nowadays addressed by the term “epigenetics”, which was coined initially by Conrad 
Waddington to describe the “causal interactions between genes and their products, which bring 
the phenotype into being”
3
. The human organism, for example, is composed of over 400 different, 
more or less stable cell types, which descended from one single cell, the zygote. Despite sharing 
an identical genotype (with a few exceptions), each emerging cell type is characterized by a 
specific gene expression profile and function. The different interpretations of the same genetic 
information are facilitated by the epigenome, which allows for stable and, ideally, inheritable 
changes of gene expression without altering the actual DNA sequence. Along with non-coding 
RNAs
4
, DNA methylation and histone modifications encompass the major epigenetic 
mechanisms
5-7
 and will be addressed in this work. 
The functionality of epigenetic mechanisms as well as their own regulation is of high interest. 
Many common diseases such as cancer and degenerative diseases exhibit an altered 
epigenome
8,9
. Still, even in the healthy organism the basic mechanisms regulating epigenetic 
modifications are not fully understood and key regulators are rarely known. Against this 
background, the present work particularly focuses on identification of genetic factors, which cause 
variations in the epigenome among individuals, especially at the level of DNA methylation. 
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1.1.1 DNA methylation 
The genetic code is written by the four bases adenine, guanine, thymine, and cytosine, but 
modified versions of the latter also contribute to the informational content. One of them is 5’-
methylcytosine (5mC), which results from covalent modification of the carbon 5 position of 
cytosines mainly in the context of cytosine followed by guanine (CpG dinucleotides, CpGs), a 
reaction catalyzed by DNA methyltransferases (DNMTs)
10,11
. DNA methylation is in general 
associated with gene silencing
12-14
 and is implicated in a multitude of biological processes such as 
mammalian X-inactivation
15-17
, genomic imprinting
18-20
, genomic stability
21,22
, silencing of harmful 
DNA sequences
23-25
, and embryonic development
26,27
. Findings linking aberrant DNA methylation 
patterns to abnormal developmental processes and diseases underpin its importance
28,29
. For 
example, acute myeloid leukemia shows well-documented evidence of abnormal global DNA 
methylation phenotypes
30,31
. In normal cells, CpG dinucleotides are generally methylated on a 
global scale. They exhibit an unequal distribution throughout the mammalian genome, but appear 
less frequently than statistically expected. The phenomenon could be explained by evolutionary 
depletion of CpGs due to spontaneous deamination of 5mC. The resulting product thymine, which 
is a naturally occurring genomic base, is not detected as misplaced leading to an accumulation of 
Cytosine to Thymine conversions over time
32
. Exceptions of the rule constitute CpG islands 
(CGIs), where CpG dinucleotides cluster with very high density. CGIs were initially defined as 
sequence stretches of at least 200 bp with a GC content above 50% and a ratio of observed 
versus expected CpG frequency of 0.6
33
. CpGs of CGIs are, in contrast to those in CpG-poor 
regions, usually unmethylated
34
. CGIs are frequently associated with promoters of ubiquitously 
expressed genes (housekeeping genes) and genes that are important for embryonic 
development. Promoters of highly tissue-specific genes exhibit lower CpG frequencies
35,36
. 
 
1.1.1.1 Setting and erasing methylation at CpG dinucleotides 
So far, three families of DNA methyltransferases (DNMTs) have been identified in eukaryotes, 
namely DNMT1, DNMT2, and DNMT3
37-41
. They share ten characteristic sequence motifs, most of 
them being highly conserved (Figure 1-1). Among the conserved motifs is the catalytically active 
prolylcysteinyl dipeptide, which is required for methylation
42,43
. DNMT1, DNMT3A, and DNMT3B 
are capable of methylating cytosines at the carbon 5 position in the presence of the methyl group 
donor S-adenosyl methionine (SAM). The proposed mechanism
44
 is depicted in Figure 1-2A. 
DNMT3a and DNMT3b are abundantly expressed during germ cell development and early 
embryogenesis but can hardly be detected in somatic cells, with the exception of adult stem 
cells
45
. Both enzymes function as de novo methyltransferases and are essential for correct 
embryonic development
26,28,46
. DNMT1, also referred to as maintenance methyltransferase, is 
ubiquitously expressed and has a 5-10 fold higher preference for hemi-methylated DNA
10,47
. It is 
recruited inter alia via nuclear protein 95 (NP95 or Uhrf1) to replication foci
48
 and copies DNA 
methylation marks from the parental strand onto the newly synthesized daughter strand. The 
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clonal propagation of DNA methylation patterns facilitates inheritance during cell replication and 
thus maintenance of lineage commitment
49
. 
The remaining, structurally related members of the DNMT families do not methylate DNA. DNMT2 
seems to be capable of methylating RNA molecules
50
, whereas DNMT3L lacks the required amino 
acids for transmethylation completely and plays a role in stimulating de novo methylation, inter 
alia at imprinted loci
51-54
. 
 
 
 
 
Figure 1-1 The DNA methyltransferase protein family 
With the exception of DNMT3L, all known DNA methyltransferases (Dnmts) share the catalytic 
methyltransferase (MTase) domain, but only DNMT1 and DNMT3A/B accept DNA as substrate for 
methylation. The regulatory domains (cysteine-rich zinc finger (CXXC) domain, tandem bromo-adjacent 
homology (BAH) domains, replication foci targeting sequence) of DNMT1 seem to be involved in targeting 
the enzyme, but this function is still discussed controversially for CXXC and BAH. DNMT3 isoforms all 
contain a conserved proline-tryptophan-tryptophan-proline (PWWP) motif and/or a pleckstrin-homology 
domain (PHD) that are involved in chromatin targeting. Nuclear localization signal (NLS). (Adopted from 
‘Atlas of Genetics and Cytogenetics in Oncology and Haematology’
55
) 
 
 
Although DNA methylation is comparatively stable and maintained during cell proliferation, 
especially local tissue-specific methylation patterns are subject to dynamic changes
56-59
. Due to 
lacking evidence for a direct demethylation activity, passive loss of DNA methylation during 
replication (in the absence of maintenance activity) was initially assumed as the general 
mechanism for DNA demethylation
60,61
. However, cellular events like the genome-wide erasure of 
paternal methylation patterns during early embryogenesis could only be explained by active 
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removal of the methyl group
62,63
. In the past, evidence for a major active DNA demethylation 
process accumulated
27,64,65
. In 2009, Tahiliani et al. finally identified TET1, a member of the ten-
eleven translocation (TET) family, to oxidize 5mC to 5’-hydroxymethyl cytosine (5hmC), which 
seems to be in most cases the initiation step in active DNA demethylation
66
. Since then, several 
mechanisms were proposed for the complete removal of the initial methyl mark including the base 
excision repair pathway
67,68
 (Figure 1-2B). The Tet family comprises three members, Tet1, Tet2, 
and Tet3, which all share the catalytic domain required for oxidation of 5mC. Tet1 and Tet3 also 
share a CXXC domain, which function is largely unknown. The CXXC domain of Tet2 is encoded 
in a separate gene (Cxxc4)
69
. Although it was suggested that the CXXC domain might guide 
binding towards CpG-rich transcription start sites
70-75
, the mechanisms targeting Tet enzymes are 
still under discussion
76
. All three members seem to be involved in the reprogramming events 
during early embryonic development. Tet1 and Tet2 were found highly expressed in primordial 
germ cells
77,78
, whereas Tet3 is mainly expressed in the oocyte
79
. High levels of Tet1 and Tet2 
were also detected in ES cells, the inner cell mass of blastocysts as well as the early mouse 
epiblast, but depletion of either Tet1 or Tet2, respectively, did not affect normal development
80-82
. 
Thus, Tet1 and Tet2 are assumed to have a compensatory role. In contrast, homozygous Tet3 
mutations led to neonatal lethality and support its importance for normal development
79
. Tet 
proteins also seem to play a role in somatic tissues; Tet2, for example, is essential for the 
development of the hematopoietic lineage
83,84
. 
Finally, 5hmC does not only seem to be an intermediate of the active DNA demethylation process, 
but is assumed to also have a regulatory function by recruiting its own set of readers
85
. The 
consequences of the regulatory function are largely unknown as yet. 
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Figure 1-2 Cycle of DNA methylation and demethylation 
(A) Proposed mechanism for CpG methylation: the target cytosine is everted from the DNA helix and 
inserted into the active site of the enzyme. Subsequently, a cysteine thiolate (prolylcysteinyl active site 
dipeptide) adds covalently to the 6th position and results in a reactive 4,5-enamine that attacks the methyl-
group of SAM (S-adenosyl methionine, methyl-donor). Finally, β-elimination releases the enzyme.
44
            
(B) Proposed pathways of active demethylation: the methyl group at cytosines (5mC) can be removed by 
repeated oxidation through TET oxygenase and include the intermediates 5-hydroxymethylcytosine (5hmC), 
5-formylcytosine (5fC), and 5-carboxycytosine (5caC). Involvement of TDG, a member of the base excision 
repair pathway, and yet unknown decarboxylase were also proposed to return from oxidized intermediates to 
unmethylated cytosine (C). (Adopted from Huang et al.
86
) 
 
 
Although the factors directly involved in setting, maintaining, and erasing DNA methylation, 
namely the DNMTs and TET proteins, are identified and characterized to a certain extent, very 
little is known about how de novo methylation is targeted to specific sites in the genome. Three 
possible mechanisms were proposed. Firstly, target loci might be recognized by DNMT3 enzymes 
themselves by specific DNA or chromatin binding domains. The PWWP domain of DNMT3b, for 
example, shares structural similarities with the tudor domain of p53-binding protein 1 (53BP1). 
53BP1 that is implicated in DNA repair is directed by its tudor domain to methylated H3K79 
residues
87,88
. However, the PWWP domain does not show any sequence preference
89
 and thus 
requires additional factors to direct sequence-specific binding. Secondly, the RNA-mediated 
interference (RNAi) system might facilitate de novo methylation of specific DNA sequences. In 
plants, RNAi-mediated transcription silencing often results in de novo methylation of the silenced 
gene
90
. Similar mechanisms were reported for mammalian cell-culture systems
91,92
. Thirdly, 
DNMT3a and DNMT3b might be recruited through protein-protein interactions. Interaction of 
DNMTs with known transcription factors could be demonstrated
93-95
. Lately, evidences for novel 
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epigenetic modifiers that target DNA methylation have accumulated. Ratnam et al. characterized 
a novel epigenetic modifier, which recognizes its target sequence, a transgene promoter, by a 
zinc finger motif and recruits chromatin modifier to promote silencing
96
. Another group applied a 
mutagenesis screening to identify trans-acting epigenetic modifiers that affect methylation of a 
GFP transgene as well as the agouti viable yellow (A
vy
) allele
97,98
. Transgenes integrate in the 
genome generally in a multi-copy array. Methylation of the A
vy
 allele depends on silencing of an 
integrated retrotransposons. Based on these findings, it was assumed that the epigenetic 
modifiers influence silencing of repetitive sequences. Furthermore, an emerging role of long non-
coding RNAs in guiding the silencing machinery to distal genomic regions was described
99,100
. 
Identifying additional trans-acting epigenetic modifier will help to increase the understanding of 
their regulatory mechanisms and thus the regulatory network that forms the basis of epigenetics. 
1.1.1.2 Methyl-CpG binding proteins, the readers of DNA methylation 
Silencing through DNA methylation is assumed to be mediated mainly by two major mechanisms. 
Firstly, the methyl group can mask the genome by simply preventing binding of transcription 
factors (TFs) required for expression
101-103
. The second mechanism requires "readers" of the 
methyl mark to transmit the epigenetic information to downstream regulatory proteins and 
integrate DNA methylation in the epigenetic network
104,105
. 
One group of proteins that bind to methylated CpGs (methyl-CpG binding proteins, MBPs) 
constitutes the methyl-binding domain (MBD) protein family
41
 (Figure 1-3). The shared MBD 
domain was initially characterized in the chromosomal Methyl-CpG binding protein 2 (MeCP2). 
Via its MBD domain, MeCP2 binds to DNA strands with one or more methylated CpGs by 
recognizing their hydration shell
106,107
. The conserved sequence of the MBD domain was used to 
identify the other four members of the MBD family. MeCP1, which was actually the 1
st
 identified 
methyl-CpG binding activity, is a complex containing MBD2
108,109
. MBD2 promotes binding to 
unrelated DNA sequences with methylated CpGs (mCpGs) in a salt concentration-dependent 
manner
110,111
. Together with MBD1, which in contrast seems to exhibit sequence preferences
112
, 
these three members of the MBD family have a long-accepted implication in methylation-
dependent repression of transcription
113
. 
The other two members of the MBD family were just recently associated with mCpG-mediated 
repression. MBD3, although bearing a MBD domain, shows no mCpG binding activity, but binds to 
unmethylated CpGs instead
114
. Nevertheless, MBD3 is associated with the Nucleosome 
Remodeling Deacetylase (NuRD) co-repressor complex, which seems to be targeted inter alia by 
biochemical interaction of MBD3 with MBD2. The importance of MBD3 is supported by the 
lethality of post-implantational embryos in Mbd3
-/-
 mice
115
. The 5
th
 member of the MBD family, 
MBD4, was initially thought to be involved DNA mismatch repair due to its carboxy-terminal DNA 
glycosylase domain and interaction with mutL homolog 1 (MHL1)
116
. However, the binding of 
MBD4 to a limited number of oncogene promoters suggests a combinatory mechanism of the 
MBD and the mismatch repair domains. The hypermethylated and thus repressed state of these 
cancer-promoting genes seems to be maintained by reversing 5mC to T conversions
117
. All 
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members of the MBD family, except for MBD3, seem to bind mCpGs depending on the 
methylation density. This is in line with their redundant function
114,118
. However, the methylation-
independent binding patterns are specific and differ between the different MBD proteins
114
. 
Kaiso and the SET-Ring finger associated (SRA) domain-containing family comprise an exception 
among MBPs since they completely lack the MBD domain. On the one hand, Kaiso achieves 
recognition of methylated DNA by a carboxy-terminal Cys2His2 zinc finger domain
119
. In addition, it 
also recognizes a non-methylated consensus sequence making it a bifunctional chromosomal 
protein
120
. On the other hand, the SRA domain recognizes hemi-methylated DNA
121
. A prominent 
member of the SRA domain-containing protein family is NP95/Uhrf1 that plays an important role of 
maintaining methylation patterns by recruiting Dnmt1 to replication foci
48,122
 (Figure 1-3). 
The binding sites of each of the MBPs seem to be specific and mutually exclusive, but the 
targeting mechanisms are not completely understood as yet
123-125
. 
 
 
 
 
Figure 1-3 Methyl-CpG binding proteins 
The family of MBPs comprises all members of the methyl-binding domain (MBD) protein family and Kaiso. 
MeCP2 is the founding member of the MBD family and harbors a conserved MBD domain to bind methylated 
DNA sequences as well as a transcriptional repressor domain (TRD). In addition to these domains, MBD1 
also contains 3 cysteine rich zinc fingers (CXXC), which seems to provide an interaction platform with other 
proteins
126
. In MBD2, the MBD domain overlaps with the TRD domain and the protein also harbors a glycine-
argenine (GR) repeat. The MBD domain of MBD3 is mutated and not able to bind to methylated DNA. MBD4 
contains a MBD domain to bind to methylated DNA, but lacks a TRD domain; instead it contains a 
glycosylase activity which is important for its function in DNA repair. Kaiso depends on zinc finger (ZF) 
domains to recognize methylated DNA and promotes transcriptional repression by its Broad-Complex, 
Tramtrack and Bric a brac (POZ/BTB) domain. Uhrf1 is a member of the SET-Ring finger associated (SRA) 
domain family and binds to hemi-methylated DNA. It also contains a ubiquitin-like (UBQ) domain, a plant 
homeodomain (PlHD) as well as a Ring finger (RING) domain. (Adapted from Klose et al.
127
). 
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Except for MBD4, all MBD family members interact with or are part of complexes containing 
histone deacetylases
108,115,124,128-131
. Histone deacetylases belong to histone-modifying activities 
that promote gene silencing by higher compaction of the chromatin and will be discussed together 
with other modifying enzymes in the following chapter. 
 
There are additional ways how DNA methylation could mediate its repressiveness. It was shown 
that transcription factors are not always repelled by the methyl mark, but can also recognize and 
specifically bind to methylated CpGs
85,132
. DNA methylation was also found to influence histone 1 
(H1) binding, which lashes the wrapping of DNA in nucleosomes
133
 and seems to diminish 
elongation capacity of the RNA Polymerase II transcription machinery within the gene body
134
. 
Still, the underlying mechanisms are poorly understood and under discussion. 
1.1.2 The histone code 
In vivo, the DNA molecule is not found naked in the nucleus, but associated with proteins, a 
structure known as chromatin. Although the methyl group itself can directly prevent binding of 
transcription factors by masking their binding site
101
, transcriptional silencing by DNA methylation 
seems to be more efficient in a chromatin context
135,136
. In line with these findings, DNMTs 
associate with chromatin co-repressor complexes containing histone methyltransferases and 
deacetylases
137-139
, thereby contributing directly to transcriptional repression. The indirect 
silencing effect of DNMTs via CpG methylation is mediated by MBPs, which are also associated 
with histone-modifying complexes
108,115,124,128,130
. 
The most basic feature of DNA packaging is the nucleosome. Nucleosomes are composed of 146 
Watson-Crick base pairs of DNA wrapped around a cylindrical histone complex. They form a 
structure similar to beads on a string separated by DNA stretches termed linker DNA. Histones 
constitute the core component of the nucleosome by forming an octamer composed of two 
molecules of each of the histones H2a, H2b, H3, and H4. A 5
th
 member of the histone family, 
linker histone H1, completes and tightens the nucleosome assembly by localizing to the site of the 
core particle where DNA enters and exits
140-143
. Long non-structured amino(NH2)-terminal tails 
protrude from the main globular domains, which reside within the nucleosome. Post-transcriptional 
modification of histones appears mainly at the NH2-terminal tails with a variety of different 
chemical groups. The modifications regulate the transcriptional state of the associated DNA 
sequence
144,145
; a mechanism referred to as the "histone code" 
146
. The accessibility and flexibility 
of the tails allow for interaction with other nucleosomes and the connecting linker DNA as well as 
regulatory factors
147,148
. In this context it was found that the regulatory outcome of individual 
modifications depends on adjacent modifications and that some of them are interdependent. 
Thus, a specific histone mark can have either repressive or activating consequences, depending 
on the modification environment it is found in. 
"Writers" of the histone code add and remove at least eight distinct chemical residues including 
methyl and acetyl groups on over 60 distinct histone positions
149
 (Figure 1-4). Site-specific 
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targeting of histone-modifying enzymes is achieved in several ways. The transcription as well as 
the replication machinery seems to recruit histone modifiers
150-152
. Furthermore, methylated DNA 
attracts histone-modifying enzymes via MBPs
108,115,124,128,130
. Recently, is was also proposed that 
non-coding RNAs direct histone-modifying activities
100,150,153
. This was shown for the Xist RNA in 
X chromosome inactivation
154
. 
 
 
 
 
Figure 1-4 Post-translational modifications of histone tails 
The NH2-terminals of the four core histones (H2A/B, H3, and H4), which are part of the nucleosome, as well 
as of the linker histone H1 are subject to numerous post-translational modifications. In addition to acetylation 
and methylation of the indicated residues, many other amino acids are subject to post-translational 
modifications, which include phosphorylation, sumoylation, and ubiquitinylation. The well-studied residues 
(lysine 4 and 27 of histone H3) are highlighted by bold letters. (Adopted from “Pluripotent stem cells”
155
) 
 
 
Two well-studied histone modifications are lysine acetylation and methylation. Depending on the 
modified residue, these modifications represent key switches of repression as well as 
transcription. Due to their essential regulatory function, the following sections will focus on these 
two modifications. 
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1.1.2.1 Histone acetylation 
The four core histones can be acetylated by histone acetyltransferases (HATs) at specific 
lysines
156-158
. This results in neutralizing their positive charge. A more open chromatin structure is 
the consequence of the altered electrostatic histone-DNA interaction by hyperacetylation
159,160
. 
Furthermore, acetylated residues can provide binding sites for bromodomain-containing factors 
involved in gene activation
158,161
 and prime repressed genes for subsequent activation
162
. In this 
context, H3K27ac is of much interest since it marks active enhancers but also promoters and 
gene bodies
163,164
. 
Histone deacetylases (HDACs) can reverse active chromatin structure by removing the acetyl 
mark from lysine residues. In addition to inducing a closed chromatin structure, HDACs interact 
with other repressor proteins. They are recruited to sites of methylated CpGs by MBPs as well as 
sites marked by repressive histone marks and associate with transcriptional repressor complexes. 
1.1.2.2 Histone methylation 
Another well-studied histone modification is methylation, which can occur at specific lysines and 
argenines of histone H3 and H4 in the mono-, di-, or in case of lysines, trimethylated form
149
. 
Histone methyltransferases (HMTs) are generally more specific about their target residue than 
HATs and almost all HMTs contain a SET domain. Histone methylation can either be active or 
repressive, depending on the modified residue and neighboring modifications. H3K4 methylation, 
which is the prime example for actively marked regions and is associated with the presence of 
RNA Polymerase III, is catalyzed inter alia by trithorax-group (TrxG) proteins and their mammalian 
homologues
165
. H3K27 is methylated by polycomb-group (PcG) proteins and associated with 
repression
166,167
. Both protein families were initially identified as key regulators of developmental 
processes in Drosophila
168
. 
Promoters of actively transcribed genes generally show high levels of H3K4 trimethylation 
(H3K4me3)
167,169
. However, genes with bivalently marked promoters (H3K4me3/H3K27me3) 
appear inactive and could be poised for lineage-specific activation or repression
170,171
. H3K4me1 
is also associated with activation but mainly found in intragenic regions of actively transcribed 
genes and at enhancers
172,173
. In combination with H3K27ac or H3K9ac, H3K4me1 marks active 
enhancers, whereas inactive and poised enhancers are marked by H3K4me1 and 
H3K27me3
163,164
. These findings suggest that PcG activity generally dominates over TrxG activity. 
Furthermore, there seem to be two distinct modes of regulation of promoter activity depending on 
the CpG content. In ES cells, CpG-rich promoters are targeted by mammalian homologues of 
TrxG proteins (mixed-lineage Leukemia, MLL) and drive transcription unless actively repressed by 
PcG activity
174
. Another factor that is involved in shaping the unique CpG islands chromatin 
architecture in mammals is the CXXC zinc finger protein 1 (CFP1). It recognizes non-methylated 
CpG-rich regions by its CXXC zinc finger domain and recruits the Set1 complex. The Set1 
complex contains a histone methyltransferase resulting in increased methylation of H3K4 at CpG 
islands
175-177
. A subset of CpG-rich promoters seems to lose the recruiting capacity for TrxG 
proteins upon lineage commitment. Other epigenetic modifications such as DNA methylation 
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might account for this phenomenon. CpG-poor promoters behave in the exact opposite way. They 
seem to be inactive by default and do not need further repression by PcG proteins. Selective 
activation of the promoters could be propagated by cell type- or tissue-specific factors
167,178
. 
Other methylated histone residues such as H3K9me3 are associated to silencing of centromeres, 
transposons and tandem repeats
167,179
. 
In addition to the direct effect on chromatin structure (histone-histone and histone-DNA 
interaction, respectively), effector proteins “read” histone modifications and mediate their 
regulatory information
180
. 
1.1.2.3 Translation of the histone code 
“Readers” of the histone code bind to specific modifications on distinct histone residues by 
chromatin-binding domains and transmit the detected epigenetic information. The readers often 
provide the effector function themselves and induce further modifications, ATP-dependent 
remodeling of the chromatin fiber, transcriptional elongation, and DNA repair 
mechanisms
149,181,182
. Two well-characterized binding domains are the bromodomain and the 
chromodomain, which bind to acetylated and methylated histone residues, respectively
149
. 
A well-studied example for gene silencing is the hierarchical recruitment of PcG activity. Polycomb 
repressor complex 2 (PRC2) binds to and promotes H3K27me3 by its enhancer of zeste homolog 
2 (Ezh2) subunit (SET domain-containing methyltransferase), a histone mark associated with 
transcriptional repression. H3K27me3 is recognized by the chromodomain of Polycomb (Pc), a 
subunit of PRC1, resulting in a resistance to remodeling complexes and thus stabilization of the 
repressive chromatin structure
183,184
. A recently published work by Cao et al. also demonstrated 
that interaction of PRC2 and PRC1 is not only achieved by trimethylation of H3K27, but also by 
protein-protein interaction promoted by enhancer of embryonic development (Eed)
185
. 
Furthermore, Ezh2 was shown to interact with DNMTs, allowing for de novo methylation to finally 
lock the gene in a repressed state
186
 (Figure 1-5A). 
The TrxG activity is an example for gene activation. TrxG protein complexes and their mammalian 
homologues can recognize and promote H3K4 methylation residues by their SET domain. 
Furthermore, the associated complexes also contain HATs and remodeling factors, enzymatic 
activities that lead to a more accessible chromatin structure and thus facilitate transcription
187-189
 
(Figure 1-5B). 
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Figure 1-5 Repressive and active chromatin structures exemplified by (A) Polycomb- and (B) 
Trithorax-mediated regulation 
(A) Enhancer of zeste 2 (Ezh2) is a histone methyltransferase (HMT) part of the Polycomb repressive 
complex 2 (PRC2) and promotes H3K27 trimethylation (me3). H3K27me3 recruits PRC1 by Polycomb (Pc) 
and ubiquitinylates (ub) H2AK119. These histone modifications lead to increased compaction of the 
chromatin and can also attract Dnmts to lock the repressive state by methylated CpGs. (B) The Trithorax 
group (TrxG) complex recognizes H3K4 dimethylation (me2) by the Set domain of WD repeat domain 5 
(WDR5) and promotes further methylation of H3K4 by HMTs that are part of the complex. The TrxG complex 
also interacts with histone acetylases (HATs) and chromatin remodelers to facilitate a more accessible 
chromatin structure. (Adopted from Veazey et al.
190
) 
1.1.3 Non-coding RNAs 
In addition to DNA methylation and post-translational modification of histones, a third mechanism 
associated with epigenetic regulation of the genetic make-up is provided by non-coding RNAs 
(ncRNAs)
4
. In contrast to protein-coding RNAs, this class of transcripts is not translated into 
proteins and can be retained in the nucleus. They can interact with other RNAs, but also with 
transcription factors, chromosomal proteins and the DNA itself. In addition to transfer RNAs 
(tRNAs) and ribosomal RNAs (rRNAs), which are involved in the translational process required for 
protein synthesis
191
, many other functionally important classes of ncRNAs have been identified. 
The regulatory potential of RNA molecules was first observed in plants
192-194
 and later described 
as RNA interference (RNAi) in C. elegans
195
. The silencing effect of the involved small RNA 
molecules (micro RNAs (miRNAs) and small interfering RNAs (siRNAs)) is controlled by the RNA-
induced silencing complex (RISC) and complementary interaction with mRNA
196,197
. In addition, 
small RNAs were also found to have an implication in gene activation when they are 
complementary to the promoter of target gene, but the mechanism is understood less well
198,199
. 
Furthermore, the class of small ncRNAs comprise other RNA molecules such as small nucleolar 
RNAs (snoRNAs), small nuclear RNAs (snRNAs), exosomal RNAs (exRNAs), and Piwi-interacting 
RNAs (piRNAs). 
In addition to the armada of small ncRNAs, long non-coding RNAs (lncRNAs) are larger than 
200 nt
200
 and seem to affect gene expression at the pre-transcriptional level
201
. The best-studied 
lncRNA is involved in mammalian X chromosome inactivation and encoded by the Xist gene
202,203
. 
In females, the XIST RNA is transcribed from the future inactivated X chromosome and acts in cis 
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on the chromosome of origin. XIST-dependent recruitment of PRC2 and PRC1 leads to the 
chromosome-wide accumulation of repressive histone modifications such as H3K27me3 and 
fortified also by DNA methylation. Another example for a long non-coding, but trans-acting RNA is 
HOTAIR, which is required for silencing of the HOXD locus
204
. HOTAIR also seems to involve the 
recruitment of the Polycomb silencing machinery. Further examples for regulatory lncRNA, which 
seemed to mainly act in cis or at least in the context of the chromosome of origin, exist and also 
include RNAs that promote gene activation
99,201,205-207
. Since most of the eukaryotic genome is 
transcribed, the regulatory mechanisms involving ncRNAs receive increasing attention. 
 
The discussed epigenetic mechanisms are made responsible for one-way commitment during 
development. But in addition to the developmental program, environmental impacts manifest also 
in the epigenome. To restart the circle of life, all acquired memory from tissue-specificity as well 
as from external influences need to be reversed. This reprogramming takes places during early 
embryonic development and is the subject of the following chapter. 
1.2 Epigenetic reprogramming during embryogenesis 
Somatic methylation patterns are comparatively stable and facilitate lineage restriction during 
development. In contrast, germ cells and preimplantated embryos show genome-wide epigenetic 
reprogramming as depicted in Figure 1-6. The reprogramming events are essential to reset 
imprinting patterns and restore totipotency. They are also assumed to prevent transgenerational 
inheritance of epimutations
208
. 
For premordial germ cells (PGCs), the direct progenitors of sperm and oocytes, demethylation 
seems to restore their developmental potential
209,210
. PGCs arise around embryonic development 
day 7.5 (E7.5) from the epiblast
211,212
. Despite still harbouring a high level of pluripotency, the 
epiblast is already committed to somatic lineages and globally methylated
213
. Global DNA 
demethylation in PGCs appears to be active and involves oxidation as well as deamination of 
mCpGs and subsequent removal by base excision repair (BER)
212,214-216
. Since the actual window 
of DNA demethylation in PGCs is not fully determined as yet, a combination of active conversion 
of mCpG and passive loss of the intermediates by cell division is possible. Intracisternal A-particle 
(IAP) retrotransposons constitute an exception to the global wave of DNA demethylation and have 
the potential to facilitate transgenerational epigenetic inheritance
217,218
. PGC reprogramming goes 
beyond DNA demethylation and affects the general chromatin structure by exchange of histone 
variants and increasing levels of H3K27me3
213,219
. Regarding imprinted regions, the parental DNA 
methylation pattern is removed and re-established depending on the sex of the organism
19
. 
Mature gametes once again exhibit higher levels of DNA methylation achieved by de novo DNA 
methyltransferases DNMT3A and DNMT3B. Each of the enzymes is recruited by their non-
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catalytic ortholog DNMT3L to distinct loci marked by histones lacking H3K4 methylation
220-222
. 
However, the underlying mechanisms are still poorly understood. 
A second phase of global reprogramming is found in the zygote immediately after fertilization and 
is thought to erase epigenetic signatures in gametes (except at imprinted loci) as well as to regain 
nuclear totipotency essential for normal development
208
. Epigenetic reprogramming of the parental 
genomes takes place while both genomes are still separated in the two pronuclei. It is 
characterized by asymmetric, independent DNA demethylation of the two parental haploid 
genomes. In sperm, the paternal genome, tightly packed in protamines (instead of histones) and 
with a DNA methylation landscape similar to somatic cells
223,224
, is maximally condensed and 
inactive to the greatest possible extend. Demethylation occurs rapidly and actively on a global 
scale shortly after fertilization
62,63
 and includes pluripotency genes such as Oct4 and Nanog
225
. 
Several mechanisms seem to contribute to the active removal of mCpGs at specific loci and form 
a complex demethylation network. 5mC can be erased by iterative TET3-catalysed oxidation via 
5hmC
79,226
. In addition, the elongator complex was shown to be required for complete paternal 
demethylation
227
. Finally, components of the BER seem to specifically localize to the paternal 
nucleus and are necessary to reach low DNA methylation levels
77
. Paternal demethylation is 
completed passively by replication-dependent depletion with the lowest levels of DNA methylation 
measured in blastocysts
228,229
. Again, IAP sequences escape demethylation, as well as paternally 
imprinted loci and centromeric regions marked by heterochromatin
217,230
. The maternal genome 
exhibits generally lower levels of DNA methylation
223,224
 and is protected from active 
demethylation by PcG protein PCG7. PCG7 further protects paternally imprinted loci
231,232
. 
Furthermore, the oocyte-derived maintenance activity (DNMT1o) is excluded from the nuclei 
during early cell divisions
233
. Loss of methylation in the maternal genome completely depends on 
passive, replication-dependent depletion of mCpGs
226
. Similar to the paternal genome, lowest 
levels of DNA methylation are measured in the blastocyst stage
208
. 
After specification of the inner cell mass (ICM) and implantation of the embryo, the process of 
gastrulation starts. It is accompanied by global remethylation of the genome, which contributes to 
lineage restriction and loss of pluripotency
213,234-236
. Loss of Tet1 expression during implantation, 
which replaces Tet3 activity in later stages of preimplantated embryos
237
, seems to be essential 
for re-methylation in the epiblast and subsequent stable silencing of genes in somatic tissues
238
. 
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Figure 1-6 Reprogramming events during early embryonic development 
In the first reprogramming event following fertilization, DNA methylation marks of the two parental gametes 
are erased in two independent processes. Firstly, the paternal pronucleus (in blue) undergoes rapid 
demethylation, potentially in a combination of active and passive mechanisms. Subsequently, the maternal 
pronucleus (in red) gradually loses DNA methylation in a passive process involving several cell divisions. Re-
establishment of DNA methylation starts in the inner cell mass (ICM) of the embryonic blastocyst in the 
course of advancing differentiation and constitutes an epigenetic barrier (dashed line) in the developmentally 
more restricted epiblast. The epigenetic signature is inherited to the primordial germ cells (PGCs), but erased 
again on a global scale in a second reprogramming event to restore full developmental pluripotency. 
Differential DNA methylation patterns at imprinted regions, which are protected from first reprogramming 
event in the fertilized zygote, are also reset in PGCs. With progressing development into fully specialized 
gametes, DNA methylation is re-established leading to a restricted developmental potency. This epigenetic 
barrier (dashed line) will be removed once more in the zygote of the next generation. (Adopted from 
Seisenberg et al.
208
)  
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1.3 Regulators of inter-individual epiphenotypes 
Nowadays the term „epigenetics“ is used for a plethora of regulatory mechanisms that alter gene 
activity and expression without a change in the actual genomic sequence. The importance of this 
layer of regulation is accepted widely. In particular, the number of diseases associated with 
epigenetic aberrations is increasing rapidly and comprises, among many others, 
cardiovascular
239,240
, pulmonary
241
, psychiatric
242
, and dementia disorders
243,244
 as well as 
cancer
245-247
. In this context, it is still not fully understood if aberrant epigenetic patterns are the 
cause or consequence of these illnesses
9,248
. For some illnesses, distinct epigenetic patterns were 
linked to disease susceptibility
249
. In addition to the implicated effects on medical conditions, 
epigenetic variations affect the healthy organism by shaping behavioral, biochemical, and 
physiological phenotypes. Deeper understanding of factors that regulate the epigenome will be 
crucial to further unwind the complex network that determines cell identity and thus the 
fundaments of health and disease. 
The individual convertibility of the epigenome can be addressed, for example, in studies with 
monozygotic twins. Despite sharing the identical genetic blueprint, epigenetic variations were 
described for monozygotic twins
250-253
. Although environmental effects such as nutrition are known 
to affect the epigenome
254-256
, their influence does not seem to be sufficient to explain the entire 
spectrum of observed variations. Furthermore, the majority of studies addressed environmental 
effects in utero and should thus not affect twins. The idea of spontaneous epimutations and the 
formation of epialleles arose
257
. However, the changes might also be caused by spontaneous 
genetic aberrations introduced, for example, by transposable elements or point mutations
258
. 
One of the most-intensively studied epigenetic modifications is DNA methylation, which is involved 
in gene silencing
12,14,136
. Still, very little is known about how de novo methylation is targeted to 
specific sites in the genome. In case of the maintenance DNA methyltransferase Dnmt1, the local 
pattern of hemi-methylated CpG dinucleotides could be sufficient to target the enzymatic 
activity
10,47
. However, de novo DNA methyltransferases, which exhibit no sequence 
specificity
24,38,259
, require other factors involved in a targeting mechanism. Several studies could 
demonstrate that the local genomic sequence affects site-specific epiphenotypes
260-262
. A possible 
explanation might be that each allele permits the binding of distinct regulators that recruit different 
sets of epigenetic modifiers. However, cis-acting genetic determinants of epigenetic variations 
reveal little about factors that direct site-specific epigenetic regulation. These factors, however, 
are important, as they provide fundamental insight into epigenetic regulation. Despite the 
increasing number of studies characterizing factors of the epigenetic targeting machinery
96,98,99
, 
the catalog of described targeting factors is rather insufficient. Hence, further investigation on the 
influence of genetic determinants on the epigenetic variation is required. 
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2 Research Objectives 
Epigenetic alterations contribute to phenotypic variations and are assumed to affect disease 
susceptibility. The effects of epigenetic mechanisms were extensively studied in the past decade. 
However, very little is still known about the key players directing epigenetic modifications to their 
target site. Recent studies revealed that although epigenetic mechanisms do not alter the 
genomic sequence of their target, their recruitment depends on genetic determinants that can 
either act in cis
260-262
 or in trans
98,99,263
. Trans-acting epigenetic modifiers are of particular interest, 
since the knowledge of their function will improve the basic understanding of epigenetic regulation 
and malfunction. 
The main focus of the present thesis was the identification of the epigenetic modifier responsible 
for strain-specific DNA methylation at the Isoc2b promoter region. Linkage analysis in hybrids of 
the differentially methylated mouse strains should determine the genomic localization of the 
responsible genetic trait. Since the differentially methylated region (DMR) seemed to be 
established during early embryogenesis, an in vitro embryonic stem cell (ESC) differentiation 
model should recapitulate the epiphenotypes observed in vivo. ESCs would represent a 
convenient model for further characterization of the trans-acting epigenetic modifier. Moreover, 
global profiling of active histone marks should help to identify novel DMRs and thus further 
potential targets of the epigenetic modifier. Additional target sites would facilitate the 
understanding of the involved regulatory network. 
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3 Materials & Equipment 
3.1 Equipment 
8-Channel PipettorImpact2 Equalizer 384 Thermo Fisher Scientific, Hudson, NH, USA 
Autoclave  Technomara, Fernwald, Germany 
Bioanalyzer 2100 Agilent Technologies, Böblingen, Germany 
Biofuge fresco Heraeus, Osterode, Germany 
BioPhotometer  Eppendorf, Hamburg, Germany 
Caliper LabChip Perkin Elmer, Waltham, MA, USA 
Casy Cell Counter Innovatis/Roche, Basel, Schweiz 
Covaris S2 Covaris, Woburn, USA 
Cryo 1 °C Freezing Container Thermo Fisher Scientific, Hudson, NH, USA 
Electrophoresis equipment  Biometra, Göttingen, Germany 
Electrophoresis equipment (PFGE) Biostep, Jahnsdorf, Germany 
Gel Doc XR+ System Bio-Rad Laboratories, Munich, Germany 
GenePulser II Bio-Rad, Munich, Germany 
Heat sealer Eppendorf, Hamburg, Germany 
Hemocytometer Marienfeld, Lauda-Königshofen, Germany 
Illumina Genome Analyzer Illumina, San Diego, CA, USA 
Illumina HiSeq1000 Illumina, San Diego, CA, USA 
Incubators  Heraeus, Hanau, Germany 
Intelli-Mixer RM-2L Elmi-Tech, Riga, Latvia 
LC480 Lightcycler Roche, Basel, Switzerland 
Magnetic Partical Concentrator  Life Technologies, Carlsbad, CA, USA 
MassARRAY Compact System Sequenom, San Diego, CA, USA 
MassARRAY MATRIX Liquid Handler Sequenom, San Diego, CA, USA 
MassARRAY Phusio chip module Sequenom, San Diego, CA, USA 
Megafuge 3,0 R Heraeus, Osterode, Germany 
Microscopes Zeiss, Jena, Germany 
Multifuge 3S-R Heraeus, Osterode, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop 1000 PeqLab, Erlangen, Germany 
PCR Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
pH-Meter  Knick, Berlin, Germany 
Picofuge Heraeus, Osterode, Germany 
Pipetboy Integra Biosciences, Fernwald, Germany 
Pipettes Gilson, Milddleton, WI, USA 
Pipettes Eppendorf, Hamburg, Germany 
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Power supplies  Biometra, Göttingen, Germany 
Pulsed Field Electrophoresis equipment GE Healthcare, Chalfont St Giles, UK 
Pulsed field gel electrophoresis equipment Biostep, Jahnsdorf, Germany 
QIAvac 96 Qiagen, Venlo, The Netherlands 
Qubit Life Technologies, Carlsbad, CA, USA 
Realplex Mastercycler epGradient S Eppendorf, Hamburg, Germany 
Rocking plattform HS250 IKA Labortechnik, Staufen, Germany 
Sonifier 250  Branson, Danbury, USA 
Sonifier 250  Branson, Danbury, CT, USA 
Sonorex Ultrasonic Bath Bandelin, Berlin, Germany 
Sorvall RC 6 plus Thermo Fisher Scientific, Hudson, NH, USA 
Speed Vac Christ, Osterode, Germany 
Thermomixer  Eppendorf, Hamburg, Germany 
TissueLyser Qiagen, Venlo, The Netherlands 
Typhoon 9200 Molecular Dynamics, Krefeld, Germany 
UV Stratalinker 4800 Stratagene, La Jolla, CA, USA 
Veriti 384 well Thermal Cycler Life Technologies, Carlsbad, CA, USA 
Vortexer Scientific Industries Ink., Bohemia, NY, USA 
Water purification system  Millipore, Eschborn, Germany 
Waterbath Julabo, Seelstadt, Germany 
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3.2 Consumables 
8-channel pipettor tips Impact 384 Thermo Fisher Scientific, Hudson, NH, USA 
Adhesive PCR sealing film Thermo Fisher Scientific, Hudson, NH, USA 
Ampure XP Magnetic Beads Beckman Coulter Genomics, Krefeld, Germany 
Cell culture dishes Nunc/Thermo Fisher Scientific, Hudson, NH, USA 
Cell culture dishes Greiner Bio-one, Frickenhausen, Germany 
CLEAN resin Sequenom, San Diego, CA, USA 
Cryo tubes  Corning, Corning, NY, USA 
Disposable scalpel (No. 11) Feather, Osaka, Japan 
Dynabeads Magnetic Beads Life Technologies, Carlsbad, CA, USA 
GenePulser Electroporation Cuvette (1mm) Bio-Rad, Munich, Germany 
Heat sealing film  Eppendorf, Hamburg, Germany 
Hybridisation Mesh Labnet, Woodbridge, NJ, USA 
MATRIX Liquid Handler D.A.R.Ts tips Thermo Fisher Scientific, Hudson, NH, USA 
Micro test tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Micro test tubes DNA LoBind (0.5, 1.5, 2 ml) Eppendorf, Hamburg, Germany 
Non-Adhesive sealing film (LightCycler) Roche, Basel, Switzerland 
nProteinA Sepharose 4 FastFlow GE Healthcare, Munich, Germany 
Nylon membrane Roche, Basel, Switzerland 
PCR plate 384 well (LightCycler) Roche, Basel, Switzerland 
PCR plate 384 well (MassARRAY) Thermo Fisher Scientific, Hudson, NH, USA 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Pipettes  Costar, Cambridge, USA 
Plug molds Bio-Rad, Munich, Germany 
Sepharose CL-4 Beads Sigma-Aldrich, Munich, Germany 
SpectroCHIP bead array Sequenom, San Diego, CA, USA 
Sterile combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Sterile micropore filters  Millipore, Eschborn, Germany 
Sterile plastic pipettes Costar, Cambridge, USA 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
Tubes (5ml, 15 ml, 50 ml, 220 ml)  Falcon, Heidelberg, Germany 
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3.3 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Deisendorf, Germany) or Merk Millipore 
(Darmstadt, Germany) unless otherwise mentioned. 
3.4 Enzymes, Kits, and products for molecular biology 
Agarase NEB, Frankfurt, Germany 
Baysilone (Silicone for PFGE) Bayer, Leverkusen, Germany 
Bioanalyzer DNA HS Kit Agilent Technologies, Santa Clara, CA, USA 
Bioanalyzer mRNA Nano Kit 
Bioanalyzer mRNA Pico Kit 
Bioanalyzer RNA 6000 Kit 
Bovine Serum Albumin Sigma-Aldrich, Munich, Germany 
CasyTON Roche, Basel, Switzerland 
Cell Culture Medium Supplement Life Technologies, Carlsbad, CA 
DIG PCR labeling Kit Roche, Basel, Switzerland 
DNA Ladder 1 kb plus 
Invitrogen/Life Technologies, Carlsbad, CA, 
USA 
DNA ladder 50 bp NEB, Frankfurt, Germany 
DNA ladder Generuler 50 bp Thermo Fisher Scientific, Waltham, MA, USA 
DNA ladder  HindIII Fragments 
Invitrogen/Life Technologies, Carlsbad, CA, 
USA 
DNA light loading dye (6x)  NEB, Frankfurt, Germany 
DNeasy Blood & Tissue Kit Qiagen, Venlo, The Netherlands 
dNTPs GE Healthcare, Buckinghamshire, UK 
dUTP GE Healthcare, Buckinghamshire, UK 
Enzymatics enzymes for NGS library Prep NEB, Frankfurt, Germany 
Ethidium bromide Sigma-Aldrich, Munich, Germany 
Expand High Fidelity PCR System Roche, Basel, Switzerland 
EZ DNA methylation kit Zymo Research, Orange, USA 
Fermentas DNA loading dye (6x) Thermo Fisher Scientific, Waltham, MA, USA 
Fetal Bovine Serum Gibco/Life Technologies, Carlsbad, CA, USA 
Glycogen Ambion/Life Technologies, Carlsbad, CA, USA 
L(+)-Arabinose  Sigma-Aldrich, Munich, Germany 
LabChip XT DNA Chips Perkin Elmer, Waltham, MA, USA 
Lipofectamin 2000 
Invitrogen/Life Technologies, Carlsbad, CA, 
USA 
Lysozyme Sigma-Aldrich, Munich, Germany 
MinElute PCR Purification Kit Qiagen, Venlo, The Netherlands 
NEBNext DNA Library Prep Reagent Set NEB, Frankfurt, Germany 
NEXTflex indexed adapters Bioo Scientific, Austin, TX, USA 
Nuclease-free water Gibco/Life Technologies, Carlsbad, CA, USA 
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NucleoBond BAC 100 Kit Macherey-Nagel, Düren, Germany 
NucleoSpin Plasmid Quick Pure  Kit Macherey-Nagel, Düren, Germany 
Oligo Only Kit Illumina, San Diego, CA, USA 
Phusion Hot Start High-Fidelity DNA Polymerase  Thermo Fisher Scientific, Waltham, MA, USA 
Phusion Taq Polymerase Thermo Fisher Scientific, Waltham, MA, USA 
PI-SceI  NEB, Frankfurt, Germany 
Proteinase K  Roche, Basel, Switzerland 
QIAquick Gel Extraction Kit Qiagen, Venlo, The Netherlands 
QIAquick PCR Purification Kit Qiagen, Venlo, The Netherlands 
QuantiFast SYBR green  Qiagen, Venlo, The Netherlands 
Qubit DNA HS Kit Life Technologies, Carlsbad, CA 
Random Decamers Ambion/Life Technologies, Carlsbad, CA, USA 
Restriction endonucleases 
NEB, Frankfurt, Germany 
Roche, Basel, Switzerland 
Reverse Transkriptase SuperSkript II Kit Promega, Madison, WI, USA 
RiboZero Kit (mouse) Epicentre, Madison, Wi, USA 
RNase  Roche, Basel, Switzerland 
RNase A Sequenom, San Diego, CA, USA 
Rnase T1 (cloned) Life Technologies, Carlsbad, CA 
Rneasy Micro & Mini Kit Qiagen, Venlo, The Netherlands 
rRNA Removal Magnetic Kit (mouse) Epicentre, Madison, Wi, USA 
SAM (S-adenosyl-methionine) NEB, Frankfurt, Germany 
ScriptSeq Kits Epicentre, Madison, WI, USA 
Shrimp Alkaline Phosphatase (SAP) Sequenom, San Diego, CA, USA 
Spectinomycin Sigma-Aldrich, Munich, Germany 
SssI CpG methylase NEB, Frankfurt, Germany 
StrataClone
TM PCR Cloning Kit Agilent Technologies, Santa Clara, CA, USA 
Taq DNA Polymerase Roche, Basel, Switzerland 
T-Cleavage MassCleave Reagent kit Sequenom, San Diego, CA, USA 
 
3.5 Antibiotics 
Ampicillin Ratiopharm, Ulm, Germany 
Chloramphenicol Sigma-Aldrich, Munich, Germany 
Kanamycin Roth, Karlsruhe, Germany 
Spectinomycin Sigma-Aldrich, Munich, Germany 
Geneticin Gibco/Life Technologies, Carlsbad, CA, USA 
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3.6 Molecular weight standards 
Generuler 50 bp, 50bp, 1 kb Plus, and Lambda DNA-HindIII Fragments DNA Ladders were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA), Invitrogen/Life Technologies 
(Darmstadt, Germany), and NEB (Frankfurt am Main, Germany), respectively. 
3.7 Cell lines 
JM8 murine embryonic stem cells (C57BL/6N background), 
provided by AG Gessner 
(University Hospital Regensburg, Regensburg, 
Germany) 
BALB/c murine embryonic stem cells (BALB/cJ background), 
provided by AG Gessner 
(University Hospital Regensburg, Regensburg, 
Germany) 
MEF Mouse embryonic fibroblast 
generated from mouse embryos E14.5 (129/SvJ x 
C57BL/6 background) in our laboratory 
 
3.8 E. coli strains 
StrataClone SoloPack competent cells express Agilent, La Jolla, CA, USA 
SW106 provided by Don Court Lab 
(GRCBL, Frederick National Laboratory for 
Cancer Research, Frederick, MD, USA) 
DH10B Invitrogen/Life Tech., Darmstadt, Germany 
3.9 Deoxyribonucleic acids 
3.9.1 Murine genomic DNA 
Murine genomic deoxyribonucleic acid (DNA) was in general prepared according to section 
4.3.1.2 from mice that were bred either at Jackson Laboratories or Charles River Laboratories or, 
as stated for some hybrids, in our own stable. The only exception is genomic DNA from BALB/cJ 
and BALB/cByJ spleen that was prepared and distributed by Jackson Laboratories. 
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3.9.2 Circular DNA 
3.9.2.1 Plasmids 
pSC-A-amp/kan Agilent, La Jolla, CA, USA 
pNel provided by George Kotzamanis 
(Dept. Histology and Embryology 
Medical School, University of Athens, 
Greece) 
pJM2545 provided by the Larin Monaco Group 
(Wellcome Trust Centre for Human 
Genetics, Oxford, UK) 
3.9.2.2 Bacterial Artificial Chromosomes 
Using DIG-labeled probes to screen for BACs representing parts of the 9 Mb candidate region on 
chromosome 12 (mm9_chr12:16902483-26024113), the BACs listed in the following table were 
selected from the CHORI-28 BAC library (BALB/cByJ background). The anchor BAC was selected 
from the RPCI-94 BAC library (C. briggsea background). 
 
Table 3-1 List of Bacterial Artificial Chromosomes 
 
RP94-1A1 Anchor BAC CH28-313E22 CH28-334B18 CH28-360N6
CH28-277O6 CH28-314I19 CH28-335P5 CH28-363H2
CH28-290B2 CH28-315E5 CH28-335M3 CH28-363M8
CH28-292M2 CH28-315O11 CH28-335E2 CH28-363M15
CH28-292G19 CH28-316I23 CH28-339I15 CH28-363K13
CH28-295K18 CH28-316E21 CH28-339K16 CH28-364E16
CH28-295F17 CH28-317N16 CH28-339P13 CH28-365B22
CH28-295G20 CH28-317O18 CH28-340B11 CH28-365M12
CH28-296C19 CH28-317D4 CH28-343C13 CH28-365O7
CH28-297K5 CH28-318E2 CH28-343N22 CH28-365O12
CH28-300I24 CH28-320F16 CH28-343O11 CH28-367A20
CH28-301D22 CH28-320E21 CH28-344E3 CH28-367A18
CH28-301N22 CH28-320I8 CH28-345K5 CH28-368L22
CH28-302A6 CH28-322L14 CH28-345O3 CH28-369P21
CH28-301J16 CH28-322M24 CH28-347B19 CH28-369L12
CH28-302G5 CH28-324E19 CH28-348E10 CH28-371D6
CH28-302K17 CH28-325D12 CH28-352J5 CH28-372J22
CH28-303D21 CH28-325I8 CH28-354K16 CH28-372P3
CH28-304M14 CH28-327A7 CH28-355C15 CH28-373C16
CH28-306H10 CH28-327L17 CH28-355I8 CH28-375E19
CH28-307N18 CH28-328L21 CH28-356C17 CH28-375N9
CH28-310I2 CH28-330D9 CH28-357O17 CH28-375K3
CH28-311A16 CH28-331F12 CH28-358G15
CH28-311E14 CH28-332I14 CH28-358K12
CH28-311M1 CH28-332M24 CH28-359M10
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3.10 Oligonucleotides 
The following oligonucleotide sequences are complementary to the indicated reference genome, 
exceptions are marked. The primers were purchased from Metabion or Sigma-Aldrich, 
respectively. 
3.10.1 PCR primers 
Table 3-2 PCR primer sequences 
 
3.10.2 RT-qPCR primers 
Table 3-3 RT-qPCR primer sequences 
 
 
Gene symbol Genome Primer sequence (sense & antisense)
Nol10 mm9 5'-TGTCATGTAATCTGATGGGCT-3'
5'-CTTCATTAGTCTCTGCTTGGT-3' (antisense specific for C57BL/6 strains)
5'-CTTCACTAGTCTCTGCTTGGT-3' (antisense specific for BALB/c strains)
Gene symbol Genome Primer sequence (sense & antisense)
Isoc2a mm9 5'-GATGCCTGTTCTTCTCGAAGCC-3'
5'-GGAAAGCTCCACTCTGTCTCATCC-3'
Isoc2b mm9 5'-TGGCGTCTTTCTGTCCACGAG-3'
5'-TTGCCTTGGAAGAAGCCTAACAG-3'
Nol10_exon 12-14 mm9 5'-TTAATGATGTTTGCCTCTATCCCAGCTC-3'
5'-CAAGTTGTCCAGGAAGGAACACCA-3'
Nol10_exon19-20 mm9 5'-AGGAGCAACTGAAGGAGGACCA-3'
5'-GCTTCAAGTTTCAAACGATCTTCCAGAG-3'
Oct4 mm9 5'-GAAAGCGAACTAGCATTGAGAACCGT-3'
5'-TTACAGAACCATACTCGAACCACATCC-3'
Rn18s (18S) hg18 5'-ACCGATTGGATGGTTTAGTGAG-3'
5'-CCTACGGAAACCTTGTTACGAC-3'
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3.10.3 qPCR primers 
Table 3-4 qPCR primer sequences 
 
  
Gene symbol Genome # Primer sequence (sense & antisense)
Gapdh mm9 5'-CCCATCACGTCCTCCATCATCC-3'
5'-ACGGGTCTAGGGATGCTGGT-3'
"empty" mm5 5'-GAAACCCTCACCCAGGAGATACAC-3'
5'-TGCAGTGGGACTTTATTCCATAGAAGAG-3'
"intergenic" mm9 5'-GGGAGCGAAGGATACAGGGA -3'
5'-CTACAGAGGACAGCAGAGAAGCA-3'
Isoc2b mm9 1 5'-GCAAGGGAGGTCTCCAACAC-3'
5'-CATTCAGGGAGCACAGATGGGA-3'
2 5'-TTGTGAGCCATTCTGGAAGAGGAG-3'
5'-GGCTATGCAGTCTCAGGTCAAACAC-3'
3 5'-CTCAGTTCGCCAGATTTGATCGAG-3'
5'-CAATTACGTGCTCCTCTGTATCGCT-3'
4 5'-TCTGAATGACGGGATGGTGGG-3'
5'-CGAACTCGAACCTGGGACCT-3'
5 5'-CGTTCGCCTCACTCTGTTCTACTC-3'
5'-TTTCATTGGTCCTACCCTCTGTCTC-3'
6 5'-AATCTTGGCTAGTGTAGGGTTCATGG-3'
5'-ACTCGTGCTTCAGCCTTCCT-3'
7 5'-ATGGTGGCGCAAATGTTTAGTTCC-3'
5'-TTTCGAGACAGGACTTACTTCCGT-3'
8 5'-GTACTCAGAAGTGGAGACAGGAGG-3'
5'-GGGTTTACAGTCCTCGTTAGCCA-3'
9 5'-ATGGGATGGGACTGGGAAGG-3'
5'-GCACTTGAGTTCACTGTTCTGGG-3'
Myod1 mm9 5'-GCATTCCAACCCACAGAACCT-3'
5'-GAGTCGTCTTAACTTTCTGCCACTC-3'
Snrpn mm8 5'-ACATTCCGGTCAGAGGGACAGAG-3'
5'-CCGCAATGGCTCAGGTTTGTC-3'
"TARBAC2.1" - 5'-CAATGCCTGCCGTATATCCTTACTG-3'
5'-CGTATGCTGTATCTGTTCGTTGACC-3'
TRPE E. coli 5'-TGGTTTCCGTGCCGCATAT-3'
5'-AATTTCTCCAGCGCGAATCG-3'
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3.10.4 Primers for the MassARRAY system (Sequenom) 
The primers were purchased from Sigma-Aldrich. 
3.10.4.1 EpiTYPER primers 
Table 3-5 EpiTYPER primer sequences 
 
 
 
Table 3-6 EpiTYPER primer sequences for novel candidate DMRs 
 
Gene symbol Genome Primer sequence
Isoc2b mm8 Epi19 10F 5'-aggaagagagGGGGATATAGATGGGAGAGGATTTA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACTATTTACAAACCCACCATCCC-3'
Epi21 10F 5'-aggaagagagGGTGGGTTTGTAAATAGTTAGTAAGTAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACTCTCAACCAAAACCCTCCCT-3'
Epi22 10F 5'-aggaagagagTTGGTAAGTAGTGGGGGAAAATGTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATTCATAACACCATCCACTCCATC-3'
Nanog mm9 JW4 10F 5'-aggaagagagTGGTAGAATTAAGAGGTTGTTAGGTTGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTAAACCCATAAATCAAAAAAATCAAAATA-3'
Pdgfrb mm8 Epi26 10F 5'-aggaagagagGGTGATTGAAGGTTTTAGGTTGTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTCCAAAAACCCTCCACTAAAAATAAAC-3'
ID
Gene symbol Genome Primer sequence
1700012B07Rik mm9 SQ62_C57BL/6 10F 5'-aggaagagagGGGAAATTTTTGGGTTAGTAGGAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACACAAACAAATCCTATCCCC-3'
SQ62_BALB/c 10F 5'-aggaagagagGGGAAATTTTTGGTTTAGTAGGAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACCACAAACAAATCCTATCCCC-3'
SQ63_C57BL/6 10F 5'-aggaagagagGTTGGTTTAGGGGTTTTTTATTTTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCAACCCATCCCACTAATTTCATA-3'
SQ63_BALB/c 10F 5'-aggaagagagGTTGGATTAGGGGTTTTTTATTTTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCATCCCATCCCACTAATTTCATA-3'
1700030K09Rik mm9 LaMa06 10F 5'-aggaagagagGATTTGAGTTGTTTATTGGTGGGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCCTAAAAAATCATACCCCATC-3'
LaMa07 10F 5'-aggaagagagTGTTTAAATTGGGAGTTATTGGTGGAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAATAAACAACTCAAATCACAATCCC-3'
2410066E13Rik mm9 LaMa42 10F 5'-aggaagagagTTTAGGTGGGGGAGGTGAGTTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTACCAAAACATCTCCATAAAAACCC-3'
2610035D17Rik mm9 SQ77_C57BL/6 10F 5'-aggaagagagTGGGTTAAAGGAAAGGTATTGGTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAATAACACCCATATATCCCTATTC-3'
SQ77_BALB/c 10F 5'-aggaagagagTGGGTTAAAGGAAAGGTATTGGTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAATAACACTCATATATCCCTAATC-3'
4931429I11Rik mm9 SQ29 10F 5'-aggaagagagGTATAGTTTGTGGTTTGGGAGGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATCCAAAATTACCCTTTTTAAAACAAATAA-3'
SQ30 10F 5'-aggaagagagGTATAGTTTGTGGTTTGGGAGGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACAATAAATCCAAAATTACCCTTTTTAAA-3'
6330545A04Rik mm9 SQ75 10F 5'-aggaagagagTTGTGATTGTGGAGAAGTTGGTTAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCAAACTCAAAATACAACCAATTCAATC-3'
SQ76 10F 5'-aggaagagagTTGGTTTTGTTTGTTTTGTTTGTAATTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTCAAAAATAACACTTAATCTCCCCC-3'
a mm9 LaMa11 10F 5'-aggaagagagAGGGTAGAATAGGTTTTGAGAGTGATAATG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTTCAAAAATCCAACCAACAAATAAC-3'
LaMa12 10F 5'-aggaagagagTAATTTTTTAAGAGTTGTAGAAGGGTTTAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACTAATAAAACCTAAAACCAAAAC-3'
LaMa13 10F 5'-aggaagagagGTTTTTTGGGAGGGTTTTTAGGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACTATTCTTACCCCTCCCTTAACC-3'
ID
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Gene symbol Genome Primer sequence
Acacb mm9 SQ37 10F 5'-aggaagagagAGTAGGATGGAAGGTTTGGTTTATGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAAACACAACAAAATCACCAACTC-3'
SQ38_C57BL/6 10F 5'-aggaagagagAGGTGTTAAGGGGTAGATAGTTGATTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAATTTAAATTTCCCAAAATCTAAAACAAT-3'
SQ38_BALB/c 10F 5'-aggaagagagAGGTGTTAAGGGGTAGATAGTTGATTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAATTTAAATTTCCCAAAATCTAAAACAAT-3'
AI480653 mm9 LaMa52 10F 5'-aggaagagagGGATTGGTTATATGTGTTAGTTTTTTGAAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAATCTCCCCAACTCTCTCCTAC-3'
LaMa53_C57BL/6 10F 5'-aggaagagagTAGAGGGTTGGGTAGATTTAGGAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCAAAACACTTACACAAAAATCAAC-3'
LaMa53_BALB/c 10F 5'-aggaagagagTAGAGGGTTGGGTAGATTTAGAGAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCAAAACACTTACACAAAAATCAAC-3'
Aim1l mm9 SQ61_C57BL/6 10F 5'-aggaagagagTTTGAGGTTGTTGGAGTTATTGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCAACCCCCAAAAAATACTAACT-3'
SQ61_BALB/c 10F 5'-aggaagagagTTTGAGGTTGTTGGAGTTATTGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCAATCCCCAAAAAATACTAACT-3'
Ang mm9 LaMa54 10F 5'-aggaagagagTTTAGGGGTTTATGTAGATTGAGTGAAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACCAAAAAACTTCCTTTCCTAC-3'
LaMa55_C57BL/6 10F 5'-aggaagagagTTTGAAATTTAGATTTAAAGGATATTTTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAATCCTAAATACCTCCAACAAC-3'
LaMa55_BALB/c 10F 5'-aggaagagagTTTGAAATTTAGATTTAAAGGATATTTTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAATCCTAAATACCTCCAAAAAC-3'
Apobec2 mm9 LaMa28 10F 5'-aggaagagagTTTTTAGGGGAGGAAAGGAAGTAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACAAAAACTAAAACCACACCCC-3'
LaMa29 10F 5'-aggaagagagTGTTTATTTTGTGGGTTTGGGATTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTTCTTCCTCTCCCATAAATTTAAAATTTC-3'
Apobec3 mm9 SQ35_C57BL/6 10F 5'-aggaagagagGTGGGTAGTTTAGTTGTAAGTGGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACCTTAATCAAAAAAATAAAATC-3'
SQ35_BALB/c 10F 5'-aggaagagagGTGGGTAGTTTAGTTGTAAGTGTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACCTTAATCAAAAAAATAAAATC-3'
SQ36_C57BL/6 10F 5'-aggaagagagTTTGGTTTAATTGGTAGTTTTGGTTGTAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTACAAACCCCACCTTCTTCCTACAT-3'
SQ36_BALB/c 10F 5'-aggaagagagTTTGGTTTAATTGGTAGTTTTGTTTGTAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTACAAACCCCACCTTCTTCCTACTT-3'
Atp9a mm9 SQ17 10F 5'-aggaagagagGGTATAAAGAGTTTATAAGATGGTAGTTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAAAAAATACAAAATCCCAAACC-3'
SQ18 10F 5'-aggaagagagGGGTAGGGAGGAGGGGATATTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCAAACACAAAAAACCCACAA-3'
B3galtl mm9 SQ64 10F 5'-aggaagagagTGGGGTGGGTTTATTTGGTAGATAGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCAAAACTTCTATTCCCTCAACCA-3'
C530028O21Rik mm9 SQ15 10F 5'-aggaagagagTTGGGTGTTTTTTTTAAATTTTTTGGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTCCAAAACATACCTACCCCTTC-3'
SQ16 10F 5'-aggaagagagAGGGATTTGGAGGGAGTATTTAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAACCCAAAACCCCTACCC-3'
Ccnjl mm9 LaMa04 10F 5'-aggaagagagGAGTTAGTGATTTAGTTAGTTTTGGGAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCTACCCTCAATAACCCTAATCCTC-3'
Col6a4 mm9 SQ65_C57BL/6 10F 5'-aggaagagagTATTTTTAGAGGTAGGTTGGGTGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAAATTTTCCTTCCAAAAAAAA-3'
SQ65_BALB/c 10F 5'-aggaagagagTATTTTTAGAGGTAGGTTGGATGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAAATTTTCCTTCCAAAAAAAA-3'
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Dcaf7 mm9 LaMa37 10F 5'-aggaagagagGGGGTGGGATTTTATATATAATATATTTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTCCTTATAAATCCAAAATCTAAACC-3'
LaMa38 10F 5'-aggaagagagGGTTGTGGAGTTTTTGTTTTTAGTTGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCAACCTCCCTAAAAATCCCTATA-3'
Dnahc2 mm9 SQ31 10F 5'-aggaagagagTATTTGAGATTATAGTTGAGGGGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATATTCAAAATCTTCAAAACCTCTC-3'
Dnajc4 mm9 SQ40 10F 5'-aggaagagagGTAGGGGTAGTTGGAGTAATAGGGA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTACCCCCAATAAAAAATCAAAAAC-3'
SQ41 10F 5'-aggaagagagATTGAGATTTAATGGATTTTTGGGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACAAACCAAAACTCAAATTCCC-3'
SQ42 10F 5'-aggaagagagTTAAGGAGTTTGTGAGTGGGGTAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCCCCAAAAATCCATTAAATCTC-3'
Dst mm9 SQ03 10F 5'-aggaagagagTTTAGGGTTTTTTAAAGTTATTTATTTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTACTTTCCCCAACCCATCTTAAAAC-3'
SQ04 10F 5'-aggaagagagTAGTAATTTGGGTTATGGTGAGTGGA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTCTATTTAAAACCCACAACAAATACC-3'
SQ05 10F 5'-aggaagagagTATTTTTATAGGTTTGGAGGTATTTTTGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACTTCCAACCTCCTCAATAAACAC-3'
Fabp6 mm9 LaMa31 10F 5'-aggaagagagTGAGGAGGGTTTATAGAGAGAGAAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAAAACTCAAACTTTCCCAAAC-3'
LaMa32 10F 5'-aggaagagagTTTTTGTTTGTAATTGTGTAGGTTAAAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACAACTCATCCCCTCAAAATTCTATC-3'
Foxn3 mm9 SQ72 10F 5'-aggaagagagGGAAGGTGGTTTTTATTTGGTAAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTTAATCTTACTCCTTTCTCCCCTATTTC-3'
SQ73 10F 5'-aggaagagagTGTAAATTTTTTGAGAAAAATTATAGAGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATAATAACTTACCAAAAATAACATTCTCTC-3'
Fut10 mm9 SQ32 10F 5'-aggaagagagAAGTATTGATATGATGTTTTGAAATAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATAATATAATCTCTTCAACAAACCC-3'
SQ33 10F 5'-aggaagagagGGAATAAGGTTAGTTGATGTTTAGGAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACCAAATCAAACCCTACCTA-3'
Galnt10 mm9 LaMa47 10F 5'-aggaagagagAGGGAAATTTGAAGGTTGTTAAAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATATCACCCAACAAAAAAACAATTC-3'
LaMa48_C57BL/6 10F 5'-aggaagagagGGAAGTTTTTGTGGTTTTTGTTTAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACAACCCAACCCTCTATAACC-3'
LaMa48_BALB/c 10F 5'-aggaagagagGGAAGTTTTTGTGGTTTTTGTTTAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAACAACCCAACCCTCTATAATC-3'
Gm8884 mm9 LaMa25 10F 5'-aggaagagagATGGGAGATGGTTAAGTTTTAGGGTAAAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAATACCCTACCCCCACCAAAAAT-3'
H2-Ke6 mm9 LaMa17 10F 5'-aggaagagagGAGGGAGGGGGAGGTTAATATTAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTCACAAATTCAAAAATTCCCTCTCAA-3'
LaMa18 10F 5'-aggaagagagTTAGTTTAGAGGGAGATGGGTTTTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTATCCTTCCCCTAACTCCTAATAAAAACAA-3'
H2-T10 mm9 LaMa05 10F 5'-aggaagagagGTTTGGGGAGAGGAGGGTTATAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAAAATCCCTCCCAAACAATAACTC-3'
Hdhd3 mm9 SQ19 10F 5'-aggaagagagAGGTAGGTTGAGGTTTAGTTAGGAATTAGA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACAAAAAACCCAAAACTCAAC-3'
SQ20 10F 5'-aggaagagagGGGGTTAAGTTTATTGTTGGTTGGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATCCCCTAAATATCTCCATCCCAC-3'
Hes1 mm9 LaMa16 10F 5'-aggaagagagAAGGGGAATTAAGGGGAATTATATTTGTTA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAACCCCTACCTCCAACCAAC-3'
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Hist2h2bb mm9 LaMa14 10F 5'-aggaagagagTTTTTGTTGAGTGAAGATTGTTTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCAACCTAAAAAAAATTCCACTATTTTC-3'
LaMa15 10F 5'-aggaagagagGTAGTTATTAGTGTAATTTGTGGTAGGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCACCATCATTTAATTATAAACTATAACC-3'
Hist4h4 mm9 LaMa01 10F 5'-aggaagagagTTGTTTGGGTGTATTTTTTTATTGGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAATTCCAAACCTCCACACCTAC-3'
Hopx mm9 SQ06_C57BL/6 10F 5'-aggaagagagTTTAAAAAGAGGATGGTGTTGAGATAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTCCTCCTCTCCATCCTTAATCAAATTA-3'
SQ06_BALB/c 10F 5'-aggaagagagTTTAGAAAGAGGATGGTGTTGAGATAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTCCTCCTCTCCATCCTTAATCAAATTA-3'
SQ07 10F 5'-aggaagagagAGTTGTTTTAGGGATTGAGGATATT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATACTCATAACTCAACCTTCTCCAC-3'
Hoxa1 mm9 SQ12 10F 5'-aggaagagagTTAAGGATGGGGTATTTTAGAAAGGAGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCTTTAATCCCAATACTCCAAATC-3'
SQ13 10F 5'-aggaagagagTTTGTTATTGAGTGATTGGATTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAAAAAACCAAAAAACCTCATCC-3'
SQ14 10F 5'-aggaagagagTTAGTTTAGTTTTTTGGGTTGGGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAATTCATTCTTACATTATCCATCTATCA-3'
Krt10 mm9 SQ50 10F 5'-aggaagagagTTTTGTTATGTGTAGTGTTGAAGGAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACAACTCTCCCAAATTCAAAACCAA-3'
SQ51 10F 5'-aggaagagagTTTGGGTTTGGGTAAGTTTTGTTATGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATCTTCCTAAATCCCATATTTCACCTTAA-3'
Krt222 mm9 LaMa26 10F 5'-aggaagagagATTTTGGATTTGATTTTTTTGATGGTATTA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAAACCTTAAAAACTCCCTACAAACC-3'
LaMa27 10F 5'-aggaagagagTTGATAATGTTGTTTATTGGTTTGTAGGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCAACATAACTTACCACAAAACCC-3'
Lnx2 mm9 LaMa49 10F 5'-aggaagagagTTTGTTTTTTTTGATGATAAGGATTTAGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAACCTCACATTCACTAACAAAATTACTT-3'
LaMa50_C57BL/6 10F 5'-aggaagagagTTTGTGTGGGAATATTTTTAGGATAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTCAACCAACTATTTCTAATAACCAAAATC-3'
LaMa50_BALB/c 10F 5'-aggaagagagTTTGTGTGGGAATATTTTTAGGATAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTCCACCATCTATTTCTAATAACCAAAATC-3'
LOC100233207 mm9 LaMa51_C57BL/6 10F 5'-aggaagagagGGAGGTTTTAATTAGGGGAAGTGTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACAAAAAAACTAAAACACAAAACCAACC-3'
LaMa51_BALB/c 10F 5'-aggaagagagGGAGGTTTTAATTAGGGGAAATGTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACAAAAAAACTATAACACAAAACCAACC-3'
Lpar2 mm9 LaMa36 10F 5'-aggaagagagTAATTTTGGGTTAGGAGAAGGATTGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCCCAAAAACCAAAAACTAAAAC-3'
Ly6d mm9 SQ57 10F 5'-aggaagagagGGGATTTGGGTTGTTATTTATTTGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCTCATCCTTCAACCTAAACACTT-3'
Lynx1 mm9 SQ34 10F 5'-aggaagagagGTTTTGTTTTAGGTTTGGTTTGAGGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATCCATTACCAAAAAAAATTTATCCC-3'
Mllt4 mm9 SQ68 10F 5'-aggaagagagGTTTTAGGAAAAAGGAAGTTTAGGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAACCCACCCCAAAATAAAACTAC-3'
SQ69 10F 5'-aggaagagagATTGGGGTAGTTTGGGGAAGAATAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTCCCAACTAAAAAAACAAAAACTCTAAC-3'
Morn3 mm9 LaMa34 10F 5'-aggaagagagGGTTAATAAGATTGGTGTTTATGGGATAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAATAATAAAACACCTTCCTACTTTCAAA-3'
LaMa35 10F 5'-aggaagagagTGAAAGTAGGAAGGTGTTTTATTATTTGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATAATCTTTAAATCCCCACTATTAATCTCC-3'
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Naip1 mm9 LaMa21 10F 5'-aggaagagagAAATTTTGAATATATTTTTGGGTGATAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCTAACTCCATTTCCTTCAAAACC-3'
LaMa22 10F 5'-aggaagagagTTTTTTATTTTAGGATAATAGGAGAGAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCAATAAAAATTTCCAAAAACTC-3'
LaMa23 10F 5'-aggaagagagGTGTGAAGTTTGTGGTAAGATATGATGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTCCCTCCAAAAAATTACCATTACTAAC-3'
LaMa24 10F 5'-aggaagagagGAAGAGAATAAATAAGGGTTAGGATTGTAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCACTCTTATACAAAAAAACTTCACAC-3'
Obfc1 mm9 SQ22 10F 5'-aggaagagagAGGGGATTATTATTAGTTGTGAAGAAATAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACAAAAACAACCAACCAAAATTACC-3'
SQ23 10F 5'-aggaagagagTGTTAGGGGATTATTATTAGTTGTGAAGAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACAAAAACAACCAACCAAAATTACC-3'
Parp2 mm9 SQ58 10F 5'-aggaagagagTATAGTAGTGTAAAAAGGTGAGTTTGGAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCACACCAAAAAAAACTAAAAAAAACA-3'
Pbx4 mm9 LaMa02 10F 5'-aggaagagagGTTTTGGGAATAGGAGATATTGGAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATACCCTCTATATCCACCCAACTCC-3'
LaMa03 10F 5'-aggaagagagGAGGATTAGAAGAGAATTTTTGTTTTTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATCCATCACTCCAAACTCAACTACAC-3'
Phf20 mm9 LaMa30 10F 5'-aggaagagagTGTGTTTATGAAGTGGTTTGGGTAGAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCACAAACACAAAACTAAACCTCC-3'
Pisd-ps2 mm9 SQ08_C57BL/6 10F 5'-aggaagagagGATGTTGTTAGTTTTAGGTTTTTGTTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCATAATAAAATCTCACCTAAATAAAC-3'
SQ08_BALB/c 10F 5'-aggaagagagGATGTTGTTAGTTTTATGTTTTTGTTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACCATAATAAAATCTCACCTAAATAAAC-3'
SQ09_C57BL/6 10F 5'-aggaagagagGGGGTTTTATTTGAGTGAGTATGAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCCAAATTCCTATCTCTACTTTTCC-3'
SQ09_BALB/c 10F 5'-aggaagagagGGGGTTTTATTTGAGTGAGTATGAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCCCATATTCCTATCTCTACTTTTCC-3'
Prelid2 mm9 SQ21 10F 5'-aggaagagagGGGGATGTGGGTGTGATTTATAGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCACACCCTCTACCAAAAAAAC-3'
Ptpn14 mm9 SQ01 10F 5'-aggaagagagTTGGAAGTTAGTGGTGGGGATTTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACACAAAACAAACTTTAAACTCTAC-3'
SQ02_C57BL/6 10F 5'-aggaagagagAGGTATAGGATAAGTTTTGGGTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAATTCTTAACCCTTTCTCCTCCCC-3'
SQ02_BALB/c 10F 5'-aggaagagagAGGTATAGAATAAGTTTTGGGTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAATTCTTAACCCTTTCTCCTCCCC-3'
Pxmp4 mm9 SQ46 10F 5'-aggaagagagGGAGAGTTGTGTAGTTAGAGTTTAGGGTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAAACAAAACAAAAAAAACCCCAATT-3'
SQ47 10F 5'-aggaagagagTGTTAGTTTTTGGTTAGTTAGGATTTTTGA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAAACAAAAAAAACCCCAATTTAAAAC-3'
Rpn1 mm9 SQ48_C57BL/6 10F 5'-aggaagagagAAAAATTTGGTATTGTAATTAAAAGATTAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAACAAAAATACCTATCCACACAC-3'
SQ48_BALB/c 10F 5'-aggaagagagAAAAATTTGGTATTGTAATTAAAAGATTAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAACAAAAATACCTATCCACACAC-3'
SQ49 10F 5'-aggaagagagTTTTGTTTGTTGATGTTAATGGTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTAAAAAACCAAACTTCATTCCTTTAACC-3'
Scml4 mm9 SQ70 10F 5'-aggaagagagTAAATTGTGTTTTTATTTTAAATTTTTTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCTCAACAAACAACACCCTAATCAA-3'
SQ71 10F 5'-aggaagagagATGGAAATTTATTGTTGTAGTTATGGTAAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAAACAAACATACAAACCCTCCC-3'
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Sertad2 mm9 SQ66 10F 5'-aggaagagagTTTTTGGGTAGTGTATGGAGTTGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCACTTTATTCCATTTTACTATCTTCCT-3'
SQ67 10F 5'-aggaagagagTTTTTGGGGGAGGTTTTATTTGTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAACACCTAAACTAATTTATTTCCTTCAT-3'
Sfpq mm9 LaMa39 10F 5'-aggaagagagTTTTAATGATAATGGAGTAATGGAGTGTGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAAATCTCTCAACCTTCCTCAAACC-3'
Sh3pxd2a mm9 SQ59 10F 5'-aggaagagagGGTTAATAGTTTATTTGATTTTTTTTGTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTAAAATACTCTCTCTCCTATCTCCCC-3'
SQ60 10F 5'-aggaagagagATTTTTTTTAAGTTAGTTTTGAAAGTTAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAACACCTACTATATACCAAACACC-3'
Ska1 mm9 SQ39 10F 5'-aggaagagagGGTTGGTTGTGGTTATAGAGGATAATTAAT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACTTCCAAAACCCAAATTCAAACAA-3'
Slc25a28 mm9 SQ74 10F 5'-aggaagagagAAAGGTTTATGATTATTGGAAAATAAGAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACATTTCACCAAATAACATTTCACTTAAA-3'
Slc38a1 mm9 SQ45 10F 5'-aggaagagagGTTAAGTTTGGTTTGGGAGTTGGAGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATCCCCTAACAACTAACCCCCTACA-3'
Spaca4 mm9 LaMa33 10F 5'-aggaagagagTGGTATTTAGTGTTGTGAAGGTTTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCTTCCCCTCTTTCAACTAAAATT-3'
St6galnac5 mm9 LaMa19 10F 5'-aggaagagagGATTTTGTTTTAAGGTTTTAATTGGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATTTAACTAAATCCACAAATCTTTTT-3'
LaMa20 10F 5'-aggaagagagAATTTTGTATAAGGGGTGGTATTAAAAGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAAAATTACTTCTACACTCCAAACCAAC-3'
Stt3b mm9 LaMa45 10F 5'-aggaagagagTGGGGTTATGAGTTTAGAGTTTTTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctATCCACATCCTATCCCCTAATCAAAC-3'
LaMa46_C57BL/6 10F 5'-aggaagagagTTGTAGTTATATTGGGAAGATGGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTAAACCTATATCCAAACTCATCCTTATAC-3'
LaMa46_BALB/c 10F 5'-aggaagagagTTGTAGTTATATTGGGAAGATGGAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTAAACCTATATCCAAACTCATTCTTATAC-3'
Sv2c mm9 SQ26 10F 5'-aggaagagagTAGTGGAAGTTAGTAGGATGGGGATG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTCCAACACATTAAACCAAAAAAAA-3'
SQ27 10F 5'-aggaagagagTTGTGTTTTTGTTTTTTGTAGAGTAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATTTATATTCTAATACTTAACCACCTTTC-3'
Tns3 mm9 SQ54 10F 5'-aggaagagagGAAGTGAGTAAATAGGTTAAGTTTTAAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAATAAACAACCACAAAAAAATCTA-3'
SQ55 10F 5'-aggaagagagGAGGTTGAAGGAGGGAATTAAAATTATGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCAAATCCAATACAAACCAAACCTT-3'
SQ56 10F 5'-aggaagagagTTTTGGAAAAGGGGATTTTGAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCCATCCCAATATACACTCCATA-3'
Tspan32 mm9 LaMa08 10F 5'-aggaagagagAGAGATATGTGTTTTTTGGGATTTTTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAATCTTATTCCTCTCCAACTCTTATCCC-3'
Tusc1 mm9 SQ10 10F 5'-aggaagagagGGTTGGAGTTTAGGAGTTTAGGATTTTAAA-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTACAACTACACCTAAAACAACAAAAC-3'
SQ11_C57BL/6 10F 5'-aggaagagagGTTTTTGTAGTTGTATTTAGAGTAGTAGGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTCAAAAACTCAAAACTTCAAACTTCC-3'
SQ11_BALB/c 10F 5'-aggaagagagGTTGTTGTAGTTGTATTTAGAGTAGTAGGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTCAAAAACTCAAAACTTCAAACTTCC-3'
Usp51 mm9 SQ28 10F 5'-aggaagagagAGTTGGAGTTGGTGTGATAAGTAGT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTTCTTCCCAAACTTAAAAATAAACC-3'
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3.10.4.2 iPLEX primers 
The primer sequences for the genome-wide linkage analysis as well as for the fine-mapping 
approach will be available upon publication. 
  
Gene symbol Genome Primer sequence
Utp23 mm9 SQ24 10F 5'-aggaagagagGGTGGTTTAAATAGGTATGAAGATTATTAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCACAACTAAATCTCTCCCATAAAATAAC-3'
SQ25 10F 5'-aggaagagagTTATTTAGAAGGATTTGGTAGGGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAAACTCCTCTACACAAAAAACTCC-3'
Wasf2 mm9 LaMa40 10F 5'-aggaagagagGAGGTTTAAATTGGGATGAATGGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAAAACTCTAAACCCCCTCCCAATC-3'
LaMa41 10F 5'-aggaagagagTGGGTTTGAATGTTTTTTGTTTGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctAACCAACCAATCCTTCTTCCTATACC-3'
Ykt6 mm9 SQ52 10F 5'-aggaagagagTTTTATTGAGGGTTTGGGGTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCTCACCAACCACCCCTACAAACTA-3'
SQ53 10F 5'-aggaagagagGAGAGAGGGAAATTGTTTGAGTTTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCCAAAATATTCCCTACTACCCAC-3'
Ypel3 mm9 LaMa43 10F 5'-aggaagagagTTATTAAATATGGGGAAAGAAAGAAGTTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCCACTACCCTCAACCTAAAAAATCC-3'
LaMa44 10F 5'-aggaagagagATTGGGTTTTTTGTGGTAGATTTTTAAAAG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAACCAAAAACAAAAACCAAAATTATCA-3'
Zfp459 mm9 LaMa09 10F 5'-aggaagagagGTTTTTTATTTTGTTTTGTAATTTTATTTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACCTAAACTCCAAAAAATTCTTCTC-3'
LaMa10 10F 5'-aggaagagagTTTTTTTGGAAATTTGTAGTAGAGTGTGG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctACACATAACCTCAAAAAACATTCTTCC-3'
Zfp760 mm9 SQ43 10F 5'-aggaagagagAGGATGGTAGTGTTTATGGTGAGGTT-3'
T7R 5'-cagtaatacgactcactatagggagaaggctCAACCCACTAATTCAAATCCCTTATC-3'
SQ44 10F 5'-aggaagagagTGGTTAAGGATGGTAGTGTTTATGGTG-3'
T7R 5'-cagtaatacgactcactatagggagaaggctTAACCCAACCCACTAATTCAAATCC-3'
ID
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3.10.5 Primers for hybridization probes 
The primers were purchased from Sigma-Aldrich. 
Table 3-7 Primers for hybridization probes (BAC library screening) 
 
 
ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin1 chr12:16981570-17031570 5'-TACACTGCCTTCCACATCACAC-3'
5'-ACATTCTGACTCCTCCCTCCCT-3'
bin2 chr12:17031571-17081571 5'-GGACTCTGTGTATCTCTTCTGGG-3'
5'-AGTTGAAGTCTCAGGGTACTCCA-3'
bin3 chr12:17081572-17131572 5'-ACAACTCAAGATTCCAAGCCAG-3'
5'-CCCTACCCACATATCCCTCAG-3'
bin4 chr12:17131573-17181573 5'-GTCTGTTCCATAGCCACTCCTG-3'
5'-GGCAATAAACCCAACAAACTTCC-3'
bin5 chr12:17181574-17231574 5'-GAGGAAGGTGAGAAAGACAAGAAGG-3'
5'-GCTGATTGAGACTGATTGAGTGAC-3'
bin6 chr12:17231575-17281575 5'-CCCATTGAACTAAACACAGCTCAG-3'
5'-ATTTCCAGGTAGTCGGTAGCAG-3'
bin7 chr12:17281576-17331576 5'-AGTAAACTATCTGCCCTTCTCCTG-3'
5'-GAACCTCTTCACTCGGACACTG-3'
bin8 chr12:17331577-17381577 5'-TCAATGTATTAGCCAGAGTCACC-3'
5'-CAGCATGGGTAAGTAGTTTATCTTGTC-3'
bin9 chr12:17381578-17431578 5'-TGAGGCAACACCAACAAACTG-3'
5'-AAACAAGAAATCTGAAGACCACTCC-3'
bin10 chr12:17431579-17481579 5'-GAAACAGCCAGACCTAACCAC-3'
5'-AATGATCCTTTGACACGTAGCCA-3'
bin11 chr12:17481580-17531580 5'-CCCAGTTACATAACCAAGACAGCA-3'
5'-CACAAGGACCCATCAGGAAGAG-3'
bin12 chr12:17531581-17581581 5'-CCTCCTTCCCTACCTTCTGTC-3'
5'-GGCATTTCACTCTTCTCTTGGG-3'
bin13 chr12:17581582-17631582 5'-GTGGATGATCAAGGCTCAATGGG-3'
5'-CTAGCAAAGCGACCAGAAACAG-3'
bin14 chr12:17631583-17681583 5'-ATAGCCGTGTGATAAGCCTCC-3'
5'-TGTAATCTGTAACTAACCTCTGCCC-3'
bin15 chr12:17681584-17731584 5'-GATGACGCTCTCATTTCCTCCT-3'
5'-AGGGTGTCTAACAGGATTTGGA-3'
bin15 chr12:17681584-17731584 5'-CCTACAACCCAGCGATAATCCC-3'
5'-CCTCAGCCCATCCCAATATCTC-3'
bin16 chr12:17731585-17781585 5'-CAGCCCTAGACTCTCATAGTTCC-3'
5'-TCCCTTAGCACCACCAAACATCC-3'
bin17 chr12:17781586-17831586 5'-CTGACCCACCCTGTAATGATCC-3'
5'-GTTCTCCAGCTAGCCAAGATCC-3'
bin18 chr12:17831587-17881587 5'-AGCTTCATCTCAGGGTCTCCT-3'
5'-ATAGCTCCGTGCACAAGTGACC-3'
bin19 chr12:17881588-17931588 5'-CTTCCGACAGCACATCAATCAG-3'
5'-TTCCACCATTAACCTCAGAAGCC-3'
bin20 chr12:17931589-17981589 5'-AAGTCCTGAGTGTCCTGTCCT-3'
5'-CCACGACTGAGCTGTATCTGAG-3'
bin21 chr12:17981590-18031590 5'-GCTTATAACGTCCTTCACATTCCC-3'
5'-AGCCGAATGGAAATTCAAACCC-3'
bin22 chr12:18031591-18081591 5'-CTACCCTGCTCTATCCTAGTCCTG-3'
5'-GATGCCCTCTACAATTCATTCCC-3'
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ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin23/20/44 chr12:18081592-18131592 5'-TGTGTTCTTATGTTGTGTCCCTG-3'
chr12:17931589-17981589 5'-GCCCATTATCCTCAGTGTTTGTC-3'
chr12:19131613-19181613
bin24 chr12:18131593-18181593 5'-CAGCCTGTACCATAACACAATACC-3'
5'-CTGCCAACAATACAGCCTAGAG-3'
bin28 chr12:18331597-18381597 5'-GTAGCCCGATAAGACTCCCAC-3'
5'-TGAACAGAAGCCCACAATACCA-3'
bin29 chr12:18381598-18431598 5'-CCAAACCCTTCCCTACTTCTGTC-3'
5'-TGTTCTGCCTCTAGTTATTCCCA-3'
bin30 chr12:18431599-18481599 5'-ACAGCAGCAAGAATATCCTAAACC-3'
5'-ATTGTGCGAATATGACAGTCCCA-3'
bin31 chr12:18481600-18531600 5'-CTGACTGACCATCCAACTTCCA-3'
5'-TCCTTCTGTGAGTGTTCTATATTAGCC-3'
bin32 chr12:18531601-18581601 5'-CATGTTGGGAAGAGACAGGGA-3'
5'-CATTGCTCTATGGATTTAGGTGACTG-3'
bin33 chr12:18581602-18631602 5'-CTTTAGTAATCCCTAAGCCGCAC-3'
5'-ACCTCTGTCTTCAGCCTTACC-3'
bin34 chr12:18631603-18681603 5'-GTTGGTCATCTTGGTTGTGCTC-3'
5'-GGAATGTGAGGAATGTGGGTG-3'
bin35 chr12:18681604-18731604 5'-TCCATGCCCTAGCTGTATCCT-3'
5'-TCTCTGCCATCAACAGTTTCAC-3'
bin36 chr12:18731605-18781605 5'-GTCCCTAACCCTCACAATCGT-3'
5'-GCTCCATCTGAGTACAGCACC-3'
bin39 chr12:18881608-18931608 5'-CCCTAGAGACTTAGACCAGCAG-3'
5'-CTTCCAGACATCCGTTTCCAG-3'
bin40 chr12:18931609-18981609 5'-AAGTCCTATAGAATGTCCTTAACACCC-3'
5'-TTTAGGCTCCAACAACTCCCAG-3'
bin42 chr12:19031611-19081611 5'-ACACATTATGTCTGTCTTTCTTCCCTG-3'
5'-CAGGTCCAGGCTCTTTAACCC-3'
bin43 chr12:19081612-19131612 5'-TCCTGTTCTCTGGTATCACCC-3'
5'-CCCAGAACACTCTAGGAAAGACAG-3'
bin45/37 chr12:19181614-19231614 5'-AACCCTGAGCTACCTTCTCCA-3'
chr12:18781606-18831606 5'-GTCCATCTTGCTTCCAAACTTCC-3'
bin46/59/100 chr12:19231615-19281615 5'-CCATGTAGTGACCTTCTTTGCC-3'
chr12:19881628-19931628 5'-ATTCATAGTGTCTGATGCCCTGTG-3'
chr12:21931669-21981669
bin47 chr12:19281616-19331616 5'-GCATCACCACCATTGTTCAGAG-3'
5'-GGACCCATAGACCCTCTTTCTG-3'
bin48 chr12:19331617-19381617 5'-GGATGGAAGAATCAATATGCTAGTGAG-3'
5'-TAACCAGCTTAGAAATCACAACGG-3'
bin49 chr12:19381618-19431618 5'-CCAGGACTTCATAGCGATTTGG-3'
5'-AGACAACAGCCTTGGAGATCAG-3'
bin50 chr12:19431619-19481619 5'-CCCAAAGTCCAGATCTATCATCCTG-3'
5'-AAATGTCCTTAAACTCCAAACTCCC-3'
bin51 chr12:19481620-19531620 5'-GCTACATCCTTCCTTCCATCCC-3'
5'-TACAGCCTTCCCTTCTACCCA-3'
bin53 chr12:19581622-19631622 5'-AAGTCCCAGTGACATATCCCTG-3'
5'-GTCTTGCCTCACCTAAAGTCCC-3'
bin54 chr12:19631623-19681623 5'-CCAAGATAGCAACATGTCCTTATTTCC-3'
5'-CTTTCCTGAATATTGTAACCGGCT-3'
bin55/44 chr12:19681624-19731624 5'-AAAGATTGAGTGGTCTACTGTCCT-3'
chr12:19131613-19181613 5'-CTTATGTGCTGTGAGAAGTGGG-3'
bin56 chr12:19731625-19781625 5'-TCCTCACACTCCTATTAACAAGCAG-3'
5'-GAGACAGAGAAACTGAACCACCA-3'
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ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin57 chr12:19781626-19831626 5'-TTTCTGAGAGTCACCTACAGCC-3'
5'-TCACAGATACAGCTCAGTCATGG-3'
bin58 chr12:19831627-19881627 5'-GACAATCATTGCCCTCACTCAG-3'
5'-AACAAGGGTAAACGCATAAAGCAG-3'
bin59 chr12:19881628-19931628 5'-CCTGCTACAGAAAGTGATTCACCT-3'
5'-GATGTCACCTGTGTAATGCTCTG-3'
bin60 chr12:19931629-19981629 5'-CCACTATTTGCCACAGACAGAG-3'
5'-CATCGGTTCACTACTGCTACAC-3'
bin61 chr12:19981630-20031630 5'-CAAATCTGCTTGTCCCATTACATTCTG-3'
5'-CTCAGGTTGGCATATTGTCCC-3'
bin62 chr12:20031631-20081631 5'-TTCACAGTAGTAAGCAGCATCTTCC-3'
5'-GTTTGTTCCAGTACTCCTCTCCTC-3'
bin63 chr12:20081632-20131632 5'-GGCTCCCGTGGAACTATAGAC-3'
5'-TCTTGTCCTATTCTGTATCAGTGTCTC-3'
bin64 chr12:20131633-20181633 5'-AAATTCCCAGCTCCCACTATCC-3'
5'-TCTTTGTTATCTTCTATGTCCCTCTCC-3'
bin65 chr12:20181634-20231634 5'-CTGCTTCTGCGTTTACTTCTTGG-3'
5'-GCTTGGATCACTCCTTTGTTCTC-3'
bin66 chr12:20231635-20281635 5'-CTTCTTGGGTTGGTCATCTTCGT-3'
5'-AGAAATGTGAGGGATGTGGGTG-3'
bin67 chr12:20281636-20331636 5'-TGGGATCATTAGAGGAAGCACAG-3'
5'-TGTCTGGGATGGAGTAGAAGTG-3'
bin69 chr12:20381638-20431638 5'-GCTGCTTCTTCATTCACTTCTTGG-3'
5'-GGATCACTCCTTTGCTCTCCTG-3'
bin70 chr12:20431639-20481639 5'-AGAACTGATAAATCTGCCTTGCTC-3'
5'-CCTCTTATCTGATGCCTAATGCCTG-3'
bin72 chr12:20531641-20581641 5'-CTCAGCCCACAGGAAGAAGAC-3'
5'-CATCAAAGATACTCATCACCAGACC-3'
bin73/80 chr12:20581642-20631642 5'-TCTCCTCGCTGTCAAAGAATGTG-3'
chr12:20931649-20981649 5'-CATTGATTTATCTCCCTGGCTCC-3'
bin74 chr12:20631643-20681643 5'-GAGGAGGTGATGTGGTGAGAG-3'
5'-GTGGACAAGCCTCAGTATGGT-3'
bin75 chr12:20681644-20731644 5'-CTCAGAAAGACACAGATGCTATTAGG-3'
5'-TACTTCTTATACACCCTTGCCCAG-3'
bin76 chr12:20731645-20781645 5'-GTACCTGGTTCTGCTCTCCTG-3'
5'-CACAGCCAACCTGCAAATTCTC-3'
bin78 chr12:20831647-20881647 5'-GCTCTTTCACTCTACCCTTTGAC-3'
5'-TACTCCATCCCAGACACCCTC-3'
bin79 chr12:20881648-20931648 5'-GGCTCACACTTCATACCATACAC-3'
5'-ATAATTTCCTCTTCCCTCCCTC-3'
bin80/125 chr12:20931649-20981649 5'-CCCTTGGCTCTTGTTACTCTCC-3'
chr12:23181694-23231694 5'-GCTCTTGGAAATAGCCCTTCAG-3'
bin81 chr12:20981650-21031650 5'-TCTTCATAGCTTCATTCATTCCTACCC-3'
5'-GAAACCAATCCCACCCTAACTG-3'
bin82 chr12:21031651-21081651 5'-GCCGAAGTAAAGAAATGACCCAC-3'
5'-GGTTAGACTCTCCTAGATTCCAAACTG-3'
bin83 chr12:21081652-21131652 5'-AAAGCTGTCACTCAGAAAGCCT-3'
5'-TGATCCCAAATAGGTCTCAGCA-3'
bin84 chr12:21131653-21181653 5'-CTCAGCCCATCTTTGTTCCTC-3'
5'-GCCCAAACCACTTTCATTTCAC-3'
bin85 chr12:21181654-21231654 5'-GTGTTCTGCTAATAAATCCTCGTTCAG-3'
5'-CAAATGCCACCAAGAAGCCTC-3'
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ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin86 chr12:21231655-21281655 5'-TTATCTCCCGCTCCCAAACAG-3'
5'-GACTAATTCTGCCAGTAATCCCAC-3'
bin87 chr12:21281656-21331656 5'-TTTCCCTCCCACAGAACTCTC-3'
5'-ATCTCTGGCTTGGTTGACTCAC-3'
bin88 chr12:21331657-21381657 5'-CAAATGAAACTACATCAGTCGCCAC-3'
5'-GGGAGCAAACTGACTTATCTGAC-3'
bin89 chr12:21381658-21431658 5'-TCTGCTCAATAAACACCCTTCTG-3'
5'-AGAGTAGAGTCACTTTCCAACCA-3'
bin90 chr12:21431659-21481659 5'-ACTCCTTCCACACCTAAATGCC-3'
5'-GCTCTAATCCCACTTCCTGCTC-3'
bin91 chr12:21481660-21531660 5'-AGTAAGTCTCCCACCTTCCAG-3'
5'-GTTCTGCCTTTGAGCATTTCCA-3'
bin92/165 chr12:21531661-21581661 5'-CTTTGATGTTTCTTGGTTTGGTCTG-3'
chr12:25181734-25231734 5'-ACTCACTGGTCATTCTTCACCC-3'
bin93/25 chr12:21581662-21631662 5'-GCCTTCCAATCTGATGACTTCTG-3'
chr12:18181594-18231594 5'-GCTACATCTCCCACCTCATCC-3'
bin94/77 chr12:21631663-21681663 5'-GTGTTAACTCTTGTCAGCTTCGG-3'
chr12:20781646-20831646 5'-GAGGCTTGTGTTCCAACAGAC-3'
bin95/71/100 chr12:21681664-21731664 5'-GCAACGAATCCATGTGTCACTG-3'
chr12:20481640-20531640 5'-AGAACTGAGTGAGGAAATACCTGAG-3'
chr12:21931669-21981669
bin97 chr12:21781666-21831666 5'-ACACATACATCCATCCTCTTATTCCC-3'
5'-TGGACATCTGCCCTACATCCT-3'
bin98/69 chr12:21831667-21881667 5'-TATTCACAGTTGCCTGCCTGAG-3'
chr12:20381638-20431638 5'-TCTTCCCAGACATTGCCTTCC-3'
bin99/68 chr12:21881668-21931668 5'-CACCAGAGAAGCCCATACTTGAG-3'
chr12:20331637-20381637 5'-TAAGCCACTTTATTTGCCAGGAG-3'
bin101 chr12:21981670-22031670 5'-ATGGTCGGTGAAATCCTTGTG-3'
5'-TTCCTGTTCTCTGGTATCATCCC-3'
bin102/124/159 chr12:22031671-22081671 5'-ATGACACATGCACAATCTCTGG-3'
chr12:23131693-23181693 5'-TCAGATTTGTTTGGGTACTTGGG-3'
chr12:24881728-24931728
bin103/117 chr12:22081672-22131672 5'-CATCTGCCAGTATTACTGACACCT-3'
chr12:22781686-22831686 5'-GTATCCGTTCTCCTTCACCCT-3'
bin104/116 chr12:22131673-22181673 5'-TATCTTCTCTATCCCTCTCCTACTCC-3'
chr12:22731685-22781685 5'-ATTCCCAACTCCTGCTTTCCC-3'
bin105/115 chr12:22181674-22231674 5'-CAATGCCACCATTAGCCTCAG-3'
chr12:22681684-22731684 5'-CCTCTGGTTCTCTTGGGTGTC-3'
bin106/111/114 chr12:22231675-22281675 5'-CTGCCCATTATCCTTAGTGTTTGTC-3'
chr12:22481680-22531680 5'-TGTGTTCTTATGTTGTGTCCCTG-3'
chr12:22631683-22681683
bin107/143/136 chr12:22281676-22331676 5'-AAGGTAGGGACACAGATTTGGA-3'
chr12:24081712-24131712 5'-TCTGGAACGTCTTGAATCACTTAGG-3'
chr12:23731705-23781705
bin108/137/143 chr12:22331677-22381677 5'-ACAGTAACTTTCCAGCCTCCTC-3'
chr12:23781706-23831706 5'-TCTTTCCCTTCCTCTCATCCC-3'
chr12:24081712-24131712
bin110/104/115 chr12:22431679-22481679 5'-CTCTCACTTCAGATTCTAGCAGGG-3'
chr12:22131673-22181673 5'-CCAGGACTTCATAGGGATTTGGT-3'
chr12:22681684-22731684
bin113/107/136/142 chr12:22581682-22631682 5'-AAGGCAGACATCAAGGTAGGG-3'
chr12:22281676-22331676 5'-AGCAAAGCACTCGTATTCCTG-3'
chr12:23731705-23781705
chr12:24031711-24081711
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ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin118/101/149 chr12:22831687-22881687 5'-GACTCAAGCATCTATACTTCAAGAACC-3'
chr12:21981670-22031670 5'-GACATTCCACTACACCCAGACAG-3'
chr12:24381718-24431718
bin119/67/70 chr12:22881688-22931688 5'-CCCATCTCACTGCTTCCTCTG-3'
chr12:20281636-20331636 5'-CTTCTAAGTCCCTCCCTTGGT-3'
chr12:20431639-20481639
bin120/148 chr12:22931689-22981689 5'-TCCTTGCTGCCAAACAATGTG-3'
chr12:24331717-24381717 5'-TTGATTCATCTCCCTGGCTCC-3'
bin121/44/123 chr12:22981690-23031690 5'-AAATCCTTCCCTGCCTCTGTC-3'
chr12:19131613-19181613 5'-TGTTCTGCCTCTAGTTATTCCCA-3'
chr12:23081692-23131692
bin123/160 chr12:23081692-23131692 5'-AAGTCCCAGTGACATTTCCCTG-3'
chr12:24931729-24981729 5'-GTCTTGCTTCACCTAAAGTCCC-3'
bin126 chr12:23231695-23281695 5'-CTGTAGAGGGATGTGGAGAATGG-3'
5'-GAGCAAAGGAAATGTAATCATCGGT-3'
bin128/52/155 chr12:23331697-23381697 5'-AATTCCCAGCTCCCACTTTCC-3'
chr12:19531621-19581621 5'-TCTTCTCTGTCCCTCTCCTACTC-3'
chr12:24681724-24731724
bin129/153 chr12:23381698-23431698 5'-GTGCTCTGCTCTGTTTCTTTCTG-3'
chr12:24581722-24631722 5'-GACCACAGCATTCATTCACCT-3'
bin138/134/145 chr12:23831707-23881707 5'-GAAGCTGTTTCCCTTTCCTACC-3'
chr12:23631703-23681703 5'-CATTGTGTCTGTCTTTCTTCCCTG-3'
chr12:24181714-24231714
bin139/133/146 chr12:23881708-23931708 5'-TCTTGTTCTTTGCCCTCACCTC-3'
chr12:23581702-23631702 5'-GGCTGTTTGTTGAATTTGCTCC-3'
chr12:24231715-24281715
bin142/106/112 chr12:24031711-24081711 5'-GGAAGGAAGGACACTCAGGAC-3'
chr12:22231675-22281675 5'-CATCTCTATGCCTCCTACTCGCC-3'
chr12:22531681-22581681
bin144/41/108/137 chr12:24131713-24181713 5'-AAAGGAAGGAGGAAAGGTTTGGG-3'
chr12:18981610-19031610 5'-GGATACAGGGTTTGTCTTCGTAGG-3'
chr12:22331677-22381677
chr12:23781706-23831706
bin145 chr12:24181714-24231714 5'-CTGCTTCCTGGTCTTTCACTG-3'
5'-GTGGTATGTTCTAAACATCTGCCTC-3'
bin146 chr12:24231715-24281715 5'-CTCTCCCTATGCTCTTTCCCA-3'
5'-ATACCCAAGGATTGACCCTCTC-3'
bin147/38/132/140 chr12:24281716-24331716 5'-TCCTTCTCACTGTCCCTCTCC-3'
chr12:18831607-18881607 5'-CCTGTCTGTTCCCATTTCCCTC-3'
chr12:23531701-23581701
chr12:23931709-23981709
bin148/131/151 chr12:24331717-24381717 5'-GTAAGAAATGCCTCCATACCTGATCTC-3'
chr12:23481700-23531700 5'-TGTGTCCCTGTTCCAAGTGTG-3'
chr12:24481720-24531720
bin149/130/152 chr12:24381718-24431718 5'-AGGTAATAAGACTAAGCAGGAGAGG-3'
chr12:23431699-23481699 5'-CAACACATCCCTAAGATTACAATCCC-3'
chr12:24531722-24581722
bin150 chr12:24431719-24481719 5'-GTAGATGCCCTCTAAATTCATTCCC-3'
5'-AGATATTCTACCCTGCTCTATCCTAGTC-3'
bin151/131/148 chr12:24481720-24531720 5'-CACGCTAATAACTCCCACCTATCAC-3'
chr12:23481700-23531700 5'-GCCACTTTGCCTTTCTGAACTG-3'
chr12:24331717-24381717
bin152 chr12:24531722-24581722 5'-TGTCTGTCAAATCTAATCCCTGCT-3'
5'-ATCCACTCACCTCACTGAACAC-3'
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ID
50 kb bin
(mm9) Primer sequence (sense & antisense)
bin153 chr12:24581722-24631722 5'-ACAAACTCTGAAACAATGGTGGTG-3'
5'-ACACAAATGCACAAATGGTACACAG-3'
bin154 chr12:24631723-24681723 5'-CTGATCTCACTGGCTGTCTCTG-3'
5'-CCTGGAACATGAACGATGGAG-3'
bin155 chr12:24681724-24731724 5'-CATCTTCATCACAGAGGACACCA-3'
5'-CCTTTAGTTTGTTGAATCTGCCGA-3'
bin156/127 chr12:24731725-24781725 5'-AATCATTGTCCTCATTCGGTCTACAG-3'
5'-AAGAGTGACAAGGCATGTCCC-3'
bin157 chr12:24781726-24831726 5'-AGACTATTCACAGATGCCTGCC-3'
5'-TCTTCCCAGACATTGCCTTCC-3'
bin158/124 chr12:24831727-24881727 5'-CAAGAGTTACGGAACCAGAGGAG-3'
5'-CCAAGAGAAAGCACATACACCC-3'
bin159 chr12:24881728-24931728 5'-CTTGGATCATGCCTTTGCTCTC-3'
5'-GCTTCTGCGTTCACTTCTTGG-3'
bin160/122 chr12:24931729-24981729 5'-CCACACCTTGAACATGAACACTG-3'
5'-ACTCCATCCATACTAGGCCCA-3'
bin161/122 chr12:24981730-25031730 5'-CACAAAGCATCCACTCACCTC-3'
5'-CTATGTCAACGTTCTTCCTGCC-3'
bin162 chr12:25031731-25081731 5'-GGACTTCACCTTAGCATTTCTCCC-3'
5'-CACAAGCTCTATTGCCCTCAG-3'
bin164 chr12:25131733-25181733 5'-GGCAGGTTCACAAGGTTACAG-3'
5'-ACATCTACATTTCTCACATCCACGA-3'
bin165 chr12:25181734-25231734 5'-GAGTCCATGAGTATCGGTGAGAG-3'
5'-TGTTTCCTTGCTGGTATCATCCC-3'
bin166 chr12:25231735-25281735 5'-GCCATCTACATCTTTAAACCCAGAG-3'
5'-TCTAAGACACCTTCCCAAGCC-3'
bin167 chr12:25281736-25331736 5'-GCTCCTCACTCTGACCTATGTC-3'
5'-AGAAATGAAGAACACCGTATACCCT-3'
bin168 chr12:25331737-25381737 5'-AGAACCTCCTCTCCACCTCTG-3'
5'-TCAGCCTACAGTTATGTAACACCA-3'
bin169 chr12:25381738-25431738 5'-CCTGCCACCATCACATTTCAC-3'
5'-CCATAAAGCTCATTTGTCCGCC-3'
bin170 chr12:25431739-25481739 5'-AGAATCACGCTGGTATGAGATGAC-3'
5'-CATTATAAGTCCGTATGTTCTCCTCTCC-3'
bin171 chr12:25481740-25531740 5'-TAAGTGCATACAACCCTAGCCT-3'
5'-ACCACATCTTTCTAAGCGCCT-3'
bin172 chr12:25531741-25581741 5'-CGAGCAGGTAAGAGTGATAGGT-3'
5'-ATGGGTTCTGAAGATGTGAGGG-3'
bin173 chr12:25581742-25631742 5'-CCGTCTCCGTTCCAGATACTC-3'
5'-TCGTTCTCTGCTCATCCACAG-3'
bin174 chr12:25631743-25681743 5'-CCCTTCAAAGATCCTTGTACAACCA-3'
5'-CCCTGTCATTCCTACTGCCTC-3'
bin175 chr12:25681744-25731744 5'-ACACCACTAATAAAGGCCACCA-3'
5'-CTGTCTTCGTCACTACCACCC-3'
bin176 chr12:25731745-25781745 5'-GATTTCAGACAACCCAGGACAG-3'
5'-GTTCACCACAGCTAAGTCACAC-3'
bin177 chr12:25781746-25831746 5'-CCCTGCTATGTGTTCCTTCCTC-3'
5'-CCTACCCTCCCTCTTATCTCCTC-3'
bin178 chr12:25831747-25881747 5'-TCTTTGACCAGATCTACTTTCTCACC-3'
5'-TTGACCTGTGGCTGATAAGAACC-3'
bin179 chr12:25881748-25931748 5'-GCCCATAAAGCTTACTGTTCCC-3'
5'-ATTCCTGATGCCTCTAACTCCA-3'
bin180 chr12:25931749-25981749 5'-TAGAGGTAATCAGGTAGAGGGAGG-3'
5'-CAAGGTAGCAAGGGATAGAGATGTG-3'
bin181 chr12:25981750-26031750 5'-CAGTACCGAGACAATCTTAGAACCC-3'
5'-GATACTCAACTCCTCCATCAGCC-3'
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Table 3-8 Primers for anchor hybridization probe (BAC library screening) 
 
3.11 Antibodies for immunoprecipitation experiments 
Table 3-9 Antibodies for immunoprecipitation experiments 
 
3.12 Databases and software 
The following databases and software tools were used to design experiments and process data, 
respectively. If no version is stated, the detailed information can be found in the corresponding 
methods sections. 
 
AxioVision Rel. 4.8 Zeiss, Oberkochen, Germany 
BioEdit version 7.0.9.0 http://www.mbio.ncsu.edu/BioEdit/bioedit.html 
Bowtie http://bowtie-bio.sourceforge.net/index.shtml 
Bowtie2 http://bowtie-bio.sourceforge.net/bowtie2/index.shtml 
CorelDraw X4 Corel, Ottawa, Ontario, Canada 
EpiTYPER 1.2 Sequenom, San Diego, CA, USA 
Fastqc http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ 
GeneRunner version 3.05 http://www.generunner.com 
GEO Database http://www.ncbi.nlm.nih.gov/geo/ 
Homer http://homer.salk.edu/homer/ 
ImageLab v4.0 Bio-Rad, Munich, Germany 
MethPrimer http://www.urogene.org/methprimer 
Microsoft Excel 2003/2007 Microsoft Deutschland GmbH 
Mouse Genome Informatics (MGI) http://www.informatics.jax.org/ 
Mouse Genomes Project http://www.sanger.ac.uk/resources/mouse/genomes/ 
ORF Finder http://www.ncbi.nlm.nih.gov/gorf/gorf.html 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net/ 
PubMed  http://www.ncbi.nlm.nih.gov/entrez 
R http://www.r-project.org/ 
ID
Genomic region
(C. briggsea ) Primer sequence (sense & antisense)
anchor chrIII:13541331-13541734 5'-CAGATAGAAGTAGATGAACACCGCC-3'
5'-GTCATTCATCATGTGGCTTCGTC-3'
Antigene Assay Origin Company Order#/Lot#
5hmC hmeDIP rabbit Active Motif ab39791/15413007
H3K4me1 ChIP rabbit Abcam  ab8895/937164 & 962543
H3K4me3 ChIP rabbit Millipore 04-745/DAM1494280
H3K27ac ChIP rabbit Abcam ab4729/961080 & GR45851-1
IgG ChIP rabbit Millipore 12-370/DAM1713234 & NG1893918
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R Studio v0.97.551 http://www.rstudio.com/ 
RSEM http://deweylab.biostat.wisc.edu/rsem/ 
Trinity http://trinityrnaseq.sourceforge.net/ 
Typer 4.0 Sequenom, San Diego, CA, USA 
USCS Genome Browser http://www.genome.ucsc.edu 
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4 Methods 
Unless otherwise mentioned, all methods were based on protocols described in “Current protocols 
of Molecular Biology”
264
, and in the “Molecular Cloning: A Laboratory Manual”
265
. 
4.1 General cell and bacteria culture methods 
4.1.1 Cell line cultures 
4.1.1.1 Murine embryonic stem cells 
Culture conditions and passaging 
The murine embryonic stem (ES) cell line JM8 was cultured in ES cell (ESC) medium at 37°C with 
FCS (fetal calf serum, 10%), CO2 (7%) and high humidity (95%) in general without mouse 
embryonic fibroblasts (MEFs). Instead, new ESC culture dishes are coated with 0.1% gelatine 
solution prior to use (min. 5 min at room temperature (RT)
266
. 
The cells were seeded with ~4x10
4
 cells / cm
2
 at a concentration of ~3x10
5
 cells / ml, supplied 
with fresh media every day and passaged every second day (in a 1:3-1:4 ratio). 
For passaging, the adherent cells were first washed twice with PBS (volume similar to that of the 
culture medium) and then trypsinized for 7 min at 37 °C, 7% CO2. Trypsinization was stopped by 
adding 4 Vol of ESC medium. The cell suspension was either splitted on 3-4 dishes of the same 
size or transferred completely to a dish with the next bigger diameter (12-well < 6-well < 6 cm < 10 
cm). The suspension volume was adjusted with fresh ESC medium. Approximate cell numbers for 
each size of culture dish as well as volumes of medium and trypsin are listed in Table 4-1. 
 
Table 4-1 ESC culture: Volumes and cell numbers for various culture dishes 
 
ESC medium (10% FBS) Trypsin (1x)
12-well 3.5 cm
2
~0.45 Mio 600 µl 80 µl
6-well 9.6 cm
2
~1.2 Mio. 1.3 ml 150 µl
6 cm 28.3 cm
2
~3.5 Mio. 3.7 ml 400 µl
10 cm 78.5 cm
2
~10 Mio. 10 ml 1 ml
Volume
Cell numberAreaCulture dish
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Undifferentiated murine ES cells form compact colonies with a refractive, defined edge and have a 
high nucleus/cytoplasm ratio. The colonies are bigger in size when cultured without MEFs and 
less convex. 
Culture on MEFs and MEF removal 
In case of BALB/c ESCs, cells start to differentiate when cultured without MEFs longer than 3 
passages. Cytostatic MEFs were plated (~10
5
 cells/cm
2
) on the designated dish shortly before a 
frozen ESC aliquot is thawed or before ESCs are trypsinized for passaging. MEFs sediment faster 
than ESCs and will form a single-cell layer on, which the ESCs will form their colonies. 
In order to differentiate the ESCs, the MEFs have to be removed from the culture. Due to their 
mitotic inactivation, MEFs are subsequently diluted in the co-culture. To accelerate the removal, 
the co-culture suspension was transferred to an uncoated dish of the same size after washing and 
trypsinizing. After the plate was incubated at normal culture conditions for up to two hours the 
cells still in suspension or loosely attached to the dish surface (mainly ESCs), respectively, were 
transferred to a gelatin-coated dish of the same side leaving the already adherent MEFs behind. 
Unspecific differentiation of ESCs into embryoid bodies 
Adherent, MEF-free cells were washed and trypsinized as for passaging. Undissociated cell 
aggregates were removed by sedimentation by gravity for 10-15 min at 4°C to obtain a single cell 
suspension. The supernatant was transferred to a new vial and cells were counted with CASY 
and/or Neubauer hemocytometer (see section 4.1.1.2). Cells were seeded for embryoid body (EB) 
formation at a concentration of ~2.5x10
5
 cells / ml in EB medium according to the following table. 
Transfection with Lipofectamine® 2000 
One day prior transfection, adherent MEF-free ESCs are washed and trypsinized and seeded into 
gelatin-coated 12-well dishes (1x10
5
 cells / well in 600 µl ESC medium). After o/n culture at 
normal conditions the medium is changed (710 µl) 1 h before transfection. In the meantime, 3.8 µl 
of Lipofectamine
®
 2000 are mixed with 95 µl transfection medium by pipetting and incubated for at 
least 5 min at RT. 500 ng of BAC DNA is also mixed in separate 95 µl transfection medium by 
pipetting. Both solutions are mixed by pipetting and incubated at RT for 20 min. The mix is added 
to the cells dropwise while the plate is shaked. The cells are incubated under normal culture 
conditions and supplemented with fresh ESC medium the next day (600 µl). Selection with 
Geneticin (G418, 1:250 diluted in ESC medium) was started at day 2 after transfection to select 
for transfected ESC clones. As negative control, one well was transfected with 1xTE without any 
BAC DNA. ESC medium containing G418 (1:250) was changed every 2
nd
 to 3
rd
 day. After 10 days 
of G418 selection (all cells in negative control were dead by then) the cells were washed and 
trypsinized (incubation at 37 °C for 9 min to achieve better dissociation of colonies) and plated into 
new, gelatin-coated 12-well dishes with ESC medium without G418. The transfected ESC clones 
are passaged three more times without G418 selection prior to EB formation (see above). 
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Freezing and thawing ESCs 
In general, when cells were about to be splitted (1:3 to 1:4) the supernatant was removed and the 
adherent cells were washed twice with PBS (volume similar to that of the culture medium). Cells 
were trypsinized (Table 4-1) for 7 min at 37 °C, 7% CO2. Trypsinization was stopped by adding 
4 Vol of ESC medium. For each plate, the cells were split in two aliquots and centrifuged for 
5 min, 200xg, RT. The supernatant was removed and the cells were resuspended in 200-1000 µl 
ice-cold ES Freeze medium (ESC medium containing 10% DMSO) depending on plate size. The 
cell suspension was transferred to a 2 ml cryo vial (Corning) and after o/n freezing in a Cryo 1 °C 
Freezing Container (Nalgene) at -80 °C stored at -196 °C. 
For thawing, the cryo vials are removed from -196 °C and placed in an incubator at 37 °C. 
Immediately after complete thawing, ESC medium (10x the Volume of the freezing medium) is 
added to the cell suspension to dilute DMSO. If the Volume exceeds the required culture Volume, 
the cells are harvested by centrifugation (5 min, 200xg, RT) and resuspended in the 
appropriate Volume of ESC medium. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
ESC medium   per 500 ml  DMEM Knock-Out 
(Gibco/Life Tech. #10829-018) 
0.1 mM  1 ml β-Mercaptoethanol 
(Gibco/Life Tech. # 31350-010, 50 mM) 
2 mM  5 ml L-Glutamine 
(Biochrom KG, #K0302, 200 mM) 
50 U/ml  2.5 ml Penicillin-Streptomycin 
(Gibco/Life Tech. #15140-122, 10000 U/ml) 
1800 U/ml 90 µl LIF (ESGRO) 
(Chemicon/Millipore #ESG1107, 10
7
 U/ml) 
10% 55 ml ESC culture-suitable fetal bovine 
serum (FBS) 
(Gibco/Life Tech., Batch 41F5283K) 
       Store at 4 °C 
 
EB medium   similar to ESC medium, but without LIF supplementation 
 
Gelatin Solution   0.1%  1 g Gelatin 
(Sigma-Aldrich, #G1890) 
        Add 1 l ddH2O, autoclaved 
 
Trypsin Solution   1x  4 ml Trypsin/EDTA/NaOH 
       (PAN, #P10-024100, 10x) 
       Ad 40 ml PBS (1x), store at 4 °C 
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PBS    1x   Phosphate-buffered saline 
       (Sigma-Aldrich, #D8537) 
 
Transfection reagent      Lipofectamine
®
 2000 
(Invitrogen/Life Tech., #11668-019) 
       Store at 4 °C 
 
Transfection medium  1x   OPTI-MEM I 
(Gibco/Life Tech., # 31985-062) 
       Store at 4 °C 
 
Selective Antibiotic (G418) 50 mg/ml  Geneticin
®
 (G418 Sulfate) 
(Gibco/Life Tech., # 10131-019) 
       Store at 4 °C 
 
Culture Dishes 
 ESC culture  12-well   Nunc, #150628 
    6-well   Nunc, #140675 
    6 cm   Nunc, #150288 
    10 cm   Nunc, #172958 
 EB Formation  6-well   Greiner Bio-one, #657970 
    6 cm   Greiner Bio-one, #628102 
    9.4 cm   Greiner Bio-one, #633102 
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4.1.1.2 Assessing cell number and vitality 
Neubauer Hemocytometer 
The total number of cells and their vitality can be determined microscopically using Trypan blue 
exclusion. The cell suspension was suitably diluted with Trypan blue solution and counted in a 
Neubauer hemocytometer. Dead cells appear dark blue and are clearly distinguishable from living 
cells in the microscope. The concentration of viable cells was then calculated using the following 
equation: 
 
Number of viable cells/ml = N×D×10
4
 
 N: average of unstained cells per corner square (1 mM containing 16 sub-squares) 
 D: dilution factor 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Trypan blue solution  0.2%  200 mg Trypan blue 
       (Sigma-Aldrich, #T6146) 
 Ad 100 ml 0.9% NaCl solution 
       Store at 4 °C 
 
NaCl solution   0.9%  900 mg Sodium chloride 
       (AppliChem, #A3597) 
       Ad 100 ml ddH2O, autoclave 
CASY Cell Counter (Innovatis) 
Cell suspension was diluted 1:200 in CasyTON solution. Cells are soaked through a glass 
capillary three times and counted and sized. According to the size distribution settings listed 
below, cells per ml (total, viable) and their average cell diameter are determined: 
 
 Murine ESC: CL 7.65 µm NL 6.3 µm CR 20 µm NR 20 µm 
   (Dilution: 2x10
-2
; 50 µl cell suspension in 10 ml CasyTON) 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
CasyTON      CasyTON 
       (Roche, #05651808001) 
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4.1.2 Bacterial culture 
4.1.2.1 Bacterial growth medium 
E .coli strains were streaked out on solid LBAmp agar and grown for 12-36 h. DH10B, DH5α, PIR1, 
and TOP10 strains were grown at 37 °C, SW106 strains at 30 °C. Single colonies were picked 
and inoculated in LB medium containing the appropriate selection antibiotics and grown overnight 
at 37 °C or 30 °C, respectively, on a shaker at 200 rpm. 
 
Table 4-2 Antibiotics for selective bacterial culture 
Antibiotic Solvent 
Stock 
concentration 
Dilution in 
media 
Final 
concentration 
Ampicillin (Amp) ddH2O 100 mg/ml 1:1000 100 µg/ml 
Chloramphenicol (CM) Ethanol (100%) 20 mg/ml 1:2000 12.5 µg/ml 
Kanamycin (Kan) ddH2O 50 mg/ml 1:1000 50 µg/ml 
Spectinomycin (Sp) ddH2O 50 mg/ml 1:1000 50 µg/ml 
 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Lysogeny broth (LB) medium 170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave 
 
LB agar plates   1.5%  15 g Bacto
TM
 Agar 
       (BD, #214010) 
    170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with 1 M NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave, and cool to 50 °C 
 Add required antibiotics (see Table 4-2) 
 Pour into 10 cm Petri dishes, store inverted at 4 °C 
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NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
Petri dishes   9.4 cm   Greiner Bio-one, #633102 
4.1.2.2 Transformation of E. coli 
Heat shock transformation 
Subcloning of PCR products was performed by transformation of chemically competent E. coli 
cells part of either the StrataClone
TM
 PCR Cloning Kit (Agilent Technologies) or the TOPO
®
 TA 
Cloning
®
 Kit (Life Technologies), respectively, according to the manufacturer’s instructions (see 
section 4.3.3.1).  
Electroporation 
Transformation of larger DNA constructs and subsequent transformation was done by 
electroporation rather than heat shock. 
To obtain electrocompetent cells, the E. coli strain of interest was inoculated from glycerol stock 
overnight on a shaker at 30°C/37°C (as required, see section 4.1.2.1) in 10 ml LB medium and, 
where necessary, with the appropriate antibiotics. The next day, the preculture was inoculated in 
fresh medium with a 1:100 dilution and incubated on a shaker (vigorously) at 30 °C/37 °C until 
OD600 reaches 0.6-0.9. Bacteria suspension was cooled on ice for 15 min while shaking and then 
harvested (30 min, 2900xg, 4 °C). The pellet was washed twice with 200 ml and 100 ml ice-cold 
sterile ddH2O per 250 ml suspension. Each pellet from 250ml suspension was washed with 20 ml 
ice-cold sterile glycerol/ddH2O (10%). Each pellet was finally resuspended in 500 µl ice-cold 
sterile glycerol/ddH2O (10%), which rendered ~ 1 ml of electrocompetent bacteria. The bacteria 
were used directly for electroporation (40 µl per reaction) or stored at -80 °C in aliquots. 
 
500 ng plasmid or 2 µl of BAC mini prep (see section 4.3.1.1) were placed on the wall in the gap 
of a 1 mM electroporation cuvette (Bio-Rad). 40 µl of electrocompetent E. coli were pipetted over 
the DNA into the gap. Electroporation was performed with the GenePulser II (Bio-Rad) at 200, 
1.8 kV, 25 µF. The time constant for successful electroporation lies within 4.5-5.5 msec. After 1 h 
recovery at 30/37 °C on a shaker (250 rpm) the cells are plated onto LB agar plates with suitable 
selective antibiotics. 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
LB (Lysogeny broth) medium 170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave 
 
LB plates   1.5%  15 g Bacto
TM
 Agar 
       (BD, #214010) 
    170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave, and cool to 50 °C 
 Add required antibiotics (see Table 4-2) 
 Pour into 10 cm Petri dishes, store inverted at 4 °C 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
Glycerol/ddH2O   10%  10 ml Glycerol 
       (Sigma-Aldrich, #G5516) 
       Ad 100 ml nuclease-free ddH2O, autoclave 
 
Petri dishes   9.4 cm   Greiner Bio-one, #633102 
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4.1.2.3 Glycerol stock 
For long-term storage, bacteria were stored in autoclaved LB-Glycerol medium (60%). 250 µl of 
bacterial suspension was added to 750 µl of LB-Glycerol media, mixed, and stored at -80 °C. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
LB (Lysogeny broth) medium 170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave 
 
LB-Glycerol medium  60%  60 ml Glycerol 
       (Sigma-Aldrich, #G5516) 
40 ml LB (Lysogeny broth) medium 
 Autoclave 
 
4.2 Laboratory animals 
All laboratory animals were purchased from Charles River Laboratories (Sulzfeld, Germany) as 
direct or indirect distributor if not stated otherwise. 
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4.3 General molecular biological methods 
4.3.1 Preparation and analysis of DNA 
4.3.1.1 Isolation of circular DNA from E. Coli 
Plasmid isolation 
Mini preparation 
Plasmid preparation for up to 15 µg from single E. coli colonies was done with the NucleoSpin
®
 
Plasmid Quick Pure Kit (Macherey-Nagel) following the manufacturer’s instructions. Insert-
containing plasmid preparations were identified by restricted digest with EcoRI (recognition sites 
adjacent to cloning site, 2 h at 37 °C) (see Table 4-3). 
Cell pellets can be stored at -20 °C until preparation. Plasmid preparations were stored at -20 °C. 
 
Midi preparation 
Plasmid preparation for up to 100 µg from single E. coli colonies was done with the Plasmid Midi 
Kit (Qiagen) following the manufacturer’s instructions. Insert-containing plasmid preparations were 
identified by restricted digest with EcoRI (recognition sites adjacent to cloning site) (see 
Table 4-3). Cell pellets can be stored at -20 °C until preparation. Plasmid preparations were 
stored at -20 °C. 
 
Control digest and Gel Electrophoresis 
The obtained plasmid preparation was digested with EcoRI (NEB) for 2h at 37°C. 
 
Table 4-3 Reaction composition for plasmid control digest 
Component Volume Final concentration 
Plasmid prep 3 µl n.a. 
Nuclease-free ddH2O 5.5 µl n.a. 
EcoRI Buffer (10×) 1 µl 1× 
EcoRI (20 U/µl) 0.5 µl 10 U/reaction 
Final Volume 10 µl  
 
The resulting fragments (empty plasmid and the inserted amplicon) were separated by gel 
electrophoresis (1% agarose gel, 100 V, 40min) together with a suitable DNA ladder to test for 
insert presence and size. 
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BAC isolation 
Mini preparation 
The protocol was adopted from “BAC transgenesis protocol v2.9”
267
. 
Cells from 1.5ml of an overnight culture were harvested by centrifugation (> 8000xg, 20 sec, 4 °C) 
in a 2ml tube and resuspended in 250 µl Solution 1. Cells were lysed by addition of 250 µl 
Solution 2. Tubes were inverted two times to mix resuspended cells with Solution 2. The 
suspension was neutralized by addition of 350 µl ice-cold Solution 3. Tubes were inverted two 
times to mix lysed cells with Solution 3. The suspension was incubated on ice for 5 min prior to 
centrifugation (> 8000xg, 4 min, 4 °C). The BAC-containing supernatant was transferred to new 
1.5 ml tube containing 750 ml Isopropanol (100%). The BAC DNA was precipitated (> 13000xg, 
10 min, 4 °C), washed with 500 µl Ethanol (70%) (> 13000xg, 3 min, 4°C), and resuspended in 
10 µl nuclease-free water (O/N, 37 °C). 
If the BAC DNA was subject to restricted digest, 25 U of RNase T1 (cloned) were added to the 
pellet. Cell pellets can be stored at -20 °C until BAC preparation. BAC preparations were stored at 
4 °C after resuspension. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)  0.5 M  186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
SDS    10%  100 g Sodium dodecyl sulfate 
       (Sigma-Aldrich, #L4390) 
       Ad 1 l nuclease-free ddH2O 
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Solution 1   50 mM  1.08 g D-(+)-Glucose (Sigma-Aldrich, #G8270) 
    25 mM  5 ml Tris/HCl (1 M, pH 8.0) 
    10 mM  4 ml EDTA/NaOH (0.5 M, pH°8.0) 
       Ad 200 ml nuclease-free ddH2O, filtrate to sterilize 
 
Solution 2   1%  20 ml SDS (10%) 
    0.2 M  40 ml NaOH (1 M) 
       Ad 200 ml nuclease-free ddH2O, filtrate to sterilize 
 
Solution 3   3 M  58.8 g Potassium acetate 
(Merck/Millipore, #104820) 
      Dissolve in 100-160 ml nuclease-free ddH2O 
    11.5%  23 ml Acetic acid (glacial) 
       (Merck/Millipore, #100063, 100%) 
       Ad 200 ml nuclease-free ddH2O, autoclave 
 
 
Maxi preparation 
Plasmid preparation for up to 150 µg from single E. coli colonies was done with the NucleoBond® 
Xtra BAC Kit (Macherey-Nagel) following the manufacturer’s instructions. 
250 – 400 ml of LBAntibiotics were inoculated from a pre-culture (250 rpm, 8 h, 30 °C; 1:500 dilution) 
and grown overnight (200 rpm, max. 16 h, 30 °C). Cells were harvested by centrifugation (2900xg, 
20 min, 4 °C). 
Purified BAC DNA was eluted from the column with 6.5 ml ELU-BAC buffer and resuspended in 
25-200 µl Tris/HCl (10 mM, pH 8.0) (o/n, RT) after isopropanol precipitation. 
Cell pellets can be stored at -20 °C until preparation. BAC preparations were stored at 4 °C after 
resuspension. 
 
Control digest and gel electrophoresis 
The obtained BAC preparation was digested with HindIII restriction enzyme (NEB) and the 
fragment pattern assessed by gel electrophoresis (1%, 35-75 V, 5.5-15 h). 
 
Table 4-4 Reaction composition for BAC control digest with HindIII 
Component BAC mini Prep BAC Maxi Prep Final concentration 
BAC Preparation 10 µl 2 µl n.a. 
Nuclease-free ddH2O 2 µl 10 µl n.a. 
NEB Buffer 2 (10x) 1.5 µl 1.5 µl 1x 
HindIII (20 U/µl) 1.5 µl 1.5 µl 30 U/rxn 
Final Volume 15 µl 15 µl  
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4.3.1.2 Isolation of genomic DNA from mammalian cells 
Genomic DNA was isolated using the Blood & Cell Culture DNA Midi Kit (Qiagen) or, for smaller 
cell numbers, the DNeasy Blood & Tissue Culture Kit (Qiagen) according to the manufacturer’s 
instructions. DNA concentration was determined with the NanoDrop spectrophotometer and 
quality was assessed by agarose gel electrophoresis (see section 4.3.1.4). 
Genomic DNA preparation from single cell suspensions 
Genomic DNA from single cells suspensions were prepared according to the Animal Blood Spin-
Column Protocol (DNeasy Blood & Tissue Kit) for up to 5x10
6
 cells or the 100/G Cell Culture 
Protocol (Blood & Cell Culture DNA Kit), respectively, for larger cell numbers. 
Genomic DNA preparation from tissues and embryoid bodies 
Genomic DNA from tissues and embryoid bodies were prepared according to the Animal Tissue 
Spin-Column Protocol (DNeasy Blood & Tissue Kit) for up to 25 mg. Embryoid bodies were lysed 
in proteinase K-containing ATL buffer for at least 30 min at 56 °C on a shaker (1100 rpm). Tissues 
were disrupted with the TissueLyser (Qiagen) (see Table 4-5) and lysed in proteinase K-
containing ATL buffer over night at 56 °C on a shaker (1100 rpm). In case of spleen tissue, 
another 10 µl proteinase K were added the next day and incubation at 56 °C was continued for 
two hours. 
 
Table 4-5 TissueLyser settings 
Tissue TissueLyser Settings 
Testis 1x 20 sec, 15 Hz 
Cerebellum 1x 20 sec, 15 Hz 
Brain 1x 20 sec, 15 Hz 
Spleen 2x 20 sec, 15 Hz 
Liver 3x 20 sec, 15 Hz 
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4.3.1.3 Fragmentation of genomic DNA and chromatin 
Sonication of genomic DNA 
Genomic DNA can also be fragmented by sonication. The advantage compared to enzymatic 
digestion is a homogeneous fragmentation. Before sonication, gDNA was initially sheared using a 
20 gauge needle (BD) attached to a 2 ml syringe (BD) to reduce viscosity before quantification 
with the NanoDrop ND 1000 spectrophotometer (Peqlab). Sonication to a mean fragment size of 
300–400 bp was carried out with the Branson Sonifier 250 (Danbury) using the following settings 
for 5 µg gDNA in 500 µl TE (1x, pH 8) buffer: 
duty cycle  80% 
output   0.5 
sonication time 2 x 30sec 
Fragment range was controlled by agarose gel electrophoresis (1%, 110 V, 30 min; see section 
4.3.1.4). 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)  0.5 M  186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
20 gauge needle      20 G Microlance 3 
       (BD, #301300) 
 
2 ml syringe      BD Discardit® II 
       (BD, #300928) 
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Sonication of chromatin 
Crosslinked chromatin, e.g. for ChIP assays, can be fragmented by sonication. After crosslinking 
with formaldehyde and lysing the fixed cells according to section 4.3.1.17, sonication of chromatin 
was performed with the following setting: 
output   3 
sonication time 5 x 10sec 
(after each sonication step, place sample on ice to cool again) 
 
The fragmented lysate was centrifuged at 4 °C for 5 min at 13000g to pellet remaining cell debris. 
The supernatant was transferred to new 1.5 ml tube. To control and assess fragmentation range 
by agarose gel electrophoresis (see section 4.3.1.4), 30 µl of the sonicated and cleared lysate 
were prepared according to section 4.3.1.17. 
Focused Ultrasonication of genomic DNA (Covaris) 
In terms of reproducibility, fragmentation by focused ultrasonication with the Covaris S2 system 
(Covaris) is favored in general. 
Ultrasonication was done in microTUBEs (Covaris). The best fragmentation result is obtained 
when diluting the DNA sample to a concentration of 25 ng/µl, but up to 5 µg (in 130 µl) can be 
processed per reaction. 
 
Table 4-6 Parameters for Focused Ultrasonication with Covaris 
Target base pair 
(Peak) 
200 bp 300 bp 400 bp 650 bp 
Intensity 5 4 4 3 
Duty Cycle 10% 10% 10% 5% 
Cycles per Burst 200 200 200 200 
Treatment Time 180 sec 80 sec 55 sec 65 sec 
     
Temperature 7 °C 7 °C 7 °C 7 °C 
Water Level S2 12 12 12 12 
 
Fragment range was controlled by agarose gel electrophoresis (1%, 110 V, 30 min; see section 
4.3.1.4) 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)  0.5 M  186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
20 gauge needle      20 G Microlance 3 
       (BD, #301300) 
 
2 ml syringe      BD Discardit® II 
       (BD, #300928) 
 
microTUBE      microTUBE 
       (Covaris, #520045) 
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4.3.1.4 Agarose gel electrophoresis 
The required amount of agarose (according to Table 4-7) was added to the corresponding amount 
of TAE (1x). The slurry was heated in a microwave oven until the agarose was completely 
dissolved. Ethidium bromide was added after cooling the solution to 50 °C. The gel was cast, 
mounted in the electrophoresis tank and covered with TAE (1x). DNA-containing samples were 
diluted 4:1 with DNA loading dye (5x), mixed, and loaded into the slots of the submerged gel. 
Depending on the size and the desired resolution, gels were run at 35-100 V for 30 min to 16 h. 
 
Table 4-7 Agarose concentrations for different separation ranges 
Agarose concentration in gel in% Efficient range of separation in kb 
0.5 genomic DNA 
1.0 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
 
DNA fragments of specific sizes can be extracted after separation (see section 4.3.1.6). 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
SDS    10%  100 g Sodium dodecyl sulfate 
       (Sigma-Aldrich, #L4390) 
       Ad 1 l nuclease-free ddH2O 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
Glacial AcOH      Acetic acid (>99.7%) 
       (Sigma-Aldrich, #320099) 
 
NaOAc/AcOH (pH 7.8)  1 M  82 g Sodium acetate anhydrous 
       (Sigma-Aldrich, #2889) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with glacial AcOH to pH 7.8 
 Ad 1 l nuclease-free ddH2O, autoclave 
 
TAE (50x)   2 M  252.3 g Tris ultrapure 
       (AppliChem, #A1086) 
    250 mM  250 ml NaOAc/HOAc, pH 7.8 
    50 mM  18.5 g Ethylenediaminotetraacetic acid disodium salt 
       dehydrate (AppliChem, #A2937) 
       Ad 1 l nuclease-free ddH2O, autoclave 
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TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)   0.5 M  186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
DNA loading dye (5x)  50 mM  500 µl Tris/HCl, pH 8.0 
    1%  500 µl SDS (20%) 
    50 mM  1 M EDTA/NaOH (0.5 M, pH 8.0) 
    40%  4 ml Glycerol (anhydrous) 
       (AppliChem, #A1123) 
    1%  10 mg Bromphenol blue 
       (Sigma-Aldrich, #B0126) 
       Ad 10 ml nuclease-free ddH2O, store at 4°C 
 
X% Agarose X%  X g Biozym LE Agarose 
    (Biozym, # 840004) 
 Add 100 ml TAE (1x) per 1 g agarose and heat in a 
microwave until agarose is completely dissolved 
       Cool to 50 °C and add 5 µl Ethidium bromide 
(10 mg/ml) (Sigma) 
 
DNA ladder     50 bp 50 bp DNA ladder 
(NEB, #N3236) 
      100 bp 1 kb Plus DNA ladder 
       (Invitrogen/Life Tech., #10787018) 
      >100 bp  DNA/Hind III Fragments 
       (Invitrogen/Life Tech., 5612013) 
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4.3.1.5 Pulsed-field gel electrophoresis (PFGE) 
BAC preparation with low contamination of genomic DNA from the host strain (E. coli) is needed 
for sequence analysis. PFGE enables separation of larger fragments with different sizes. 
600 µl LBCM are inoculated from a glycerol stock and incubated at 30°C on a shaker (150 rpm) for 
6 h. 15 ml LBCM are inoculated with 500 µl preculture in a 50 ml conical tube (Falcon) and 
incubated o/n at 30°C on a shaker (150 rpm) for max. 16 h. The cells are harvested by 
centrifugation (30 min, 1000xg, 4°C) and washed once with ice-cold 10 ml PET-IV. Cell pellets are 
carefully resuspended by vortexing (volume depends on bacterial growth and is roughly 140 µl). 
The resuspended pellets are subsequently warmed to 42 °C and mixed with the same Volume of 
prewarmed LowMelt agarose (2%, 42°C) by pipetting. The agarose-cell mix was immediately 
transferred to a disposable plug molder (Bio-Rad) and cooled for at least 15 min at 4 °C for 
hardening. The solid cell-containing agarose beads are transferred to a 96-deep well plate and 
incubated o/n at 37 °C with 250 µl lysozyme mix to lyse immobilized cells and to degrade RNAs. 
The beads were washed twice with TE (1x, pH 8) before addition of 250 µl PK mix and o/n 
incubation at 47 °C. Beads should appear pallid and clear and kept at 4 °C. The beads were 
washed twice with 250 µl TE (1x, pH 8) and store in fresh 250 µl TE (1x, pH 8) on at 4 °C. 
Remaining protein and cell debris were removed by gel electrophoresis in a 1% agarose gel 
(0.5x TAE, 90 min, 160 V, 4 °C). The immobilized BAC DNA was linearized with PI-SceI after o/n 
incubation at 4 °C with 250 µl PI-SceI digest mix for 3-3.5 h at 37 °C. The beads were washed 
twice with 250 µl TE (1x, pH 8) and store again in fresh 250 µl TE (1x, pH 8) on at 4 °C. The 
linearized BAC DNA was then separated by Pulsed Field Gel Electrophoresis in 1% LowMelt 
agarose (0.5x TAE, 20 h, 400 mA, 100 W) according to the following settings: 
   8 h: 3 sec10 sec (in total 4430 pulses) 
   12 h: 10 sec80 sec (in total 958 pulses) 
The gel was stained for 60 min in 300 ml EtBr-containing TAE (0.5x) (20 µl aqueous EtBr solution 
(1%) per 300 ml 0.5x TAE). BAC-containing bands were cut out with disposable plastic cuvettes 
and transferred to 2 ml DNA loBind reaction tubes (Eppendorf). Agarose was melted at 72 °C in a 
water bath (15-30 min) and then cooled to 42 °C in a heating block. Melted agarose was digested 
by adding 5 U Agarase (NEB) and 25 µl TAE (12.5x) per tube and incubating o/n at 42 °C on a 
shaking (350 rpm) heating block. 
BAC DNA was recovered from the remaining solution by Isopropanol precipitation. The solution 
was mixed with 70 µl NaOAc (3 M, pH 5.2) and incubated on ice for 30 min. Undigested remaining 
agarose was removed by centrifugation (15 min, >13000xg, 4 °C) and the supernatant was 
transferred to a new 2 ml tube containing 6 µl NaOAc (3 M, pH 5.2) and 2 µl Linear acrylamide 
(5 mg/ml) (Invitrogen/Life Tech.). After o/n incubation at -20 °C the precipitated DNA was pelleted 
by centrifugation (min. 45 min, >13000xg, 4 °C) and washed once with 70% EtOH (-20 °C). The 
DNA pellet was dried at 37 °C and resolved in 20 µl TE (1x, pH 8) o/n at 4 °C. 
BAC-E. coli DNA ratio was determined by qPCR (see section 4.3.1.10) with BAC- and E. coli-
specific primers (see Table 3-4). 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
LB0 medium and antibiotics    see section 4.1.2.1 
 
PET-IV buffer   10 mM  1,21 g Tris ultrapure 
       (AppliChem, #A1086) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with HCl to pH 7.6 
    1 M  58.44g Sodium chloride 
       (AppliChem, #A3597) 
       Ad 1 l nuclease-free ddH2O, autoclave 
 
Glacial AcOH      Acetic acid (>99.7%) 
       (Sigma-Aldrich, #320099) 
 
NaOAc/AcOH (pH 5.2)  3 M  24.6 g Sodium acetate anhydrous 
       (Sigma-Aldrich, #2889) 
       Dissolve in 50 ml nuclease-free ddH2O 
       Adjust with glacial AcOH to pH 5.2 
 Ad 100 ml nuclease-free ddH2O, autoclave 
 
NaOAc/AcOH (pH 7.8)  1 M  82 g Sodium acetate anhydrous 
       (Sigma-Aldrich, #2889) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with glacial AcOH to pH 7.8 
 Ad 1 l nuclease-free ddH2O, autoclave 
 
TAE (50x)   2 M  252.3 g Tris ultrapure 
       (AppliChem, #A1086) 
    250 mM  250 ml NaOAc/AcOH, pH 7.8 
    50 mM  18.5 g Ethylenediaminotetraacetic acid disodium salt 
       dehydrate (AppliChem, #A2937) 
       Ad 1 l nuclease-free ddH2O, autoclave 
 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
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EDTA/NaOH (pH 8)   0.5 M  186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
LowMelt Agarose   2%   2g Biozym Plaque Agarose 
       (Biozym, #840100) 
       Ad 10 ml TAE (1x), heat in microwave to dissolve 
 
Agarose    Biozym LE Agarose 
    (Biozym, # 840004) 
 
Lysozyme mix     22.5 ml EC-Lyse solution 
      2.5 ml Lysozyme solution (10x) 
    0.5 µg/ml 1.25 µl RNase (10 mg/ml, Sequenom) 
       Prepare freshly 
 
EC-Lyse buffer   6 mM  0,72 g Tris ultrapure 
       (AppliChem, #A1086) 
    1 M  58.44 g Sodium chloride 
       (AppliChem, #A3597) 
    100 mM  37.22 g Ethylenediaminotetraacetic acid disodium salt 
       dehydrate (AppliChem, #A2937) 
    0.5%  0.5 g Brij-58 
(Sigma-Aldrich, # P5884) 
    0.2%  0.2 g Deoxycholate (Sigma-Aldrich, #D6850) 
    0.5%  25 ml Laurosyl-sarcosine sodium salt solution 
       (20%) (Fluka, #61747) 
       Dissolve in 500 ml nuclease-free ddH2O 
 Adjust with NaOH to pH 9.0 to enable EDTA/NaOH 
solving 
       Adjust with HCl to pH 7.5 
       Ad 1 l nuclease-free ddH2O, store at 4 °C 
 
Lysozyme solution  10x  7.2 mg Lysozyme from chicken egg white 
(Sigma-Aldrich, #L6878) 
       Dissolve in 1 ml Tris/HCl (10 mM, pH 8) 
 Sterile-filtrated, stable at 4 °C for up to 1 month 
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NDS buffer   0.5 M  186.1 g Ethylenediaminotetraacetic acid disodium salt 
       dehydrate (AppliChem, #A2937) 
       Ad 950 ml nuclease-free ddH2O, autoclave 
    1%  50 ml Laurosyl-sarcosine sodium salt solution 
       (20%) (Fluka, #61747) 
       Store at room temperature 
 
PK mix    50 µg/ml 25 µl Proteinase K (20 mg/ml) 
       (Ambion/Life Tech., # AM2548) 
       Ad 10 ml NDS buffer 
 
PI-SceI digest mix  20 U/µl  100 µl PI-SceI 
(NEB, #R0696L; 5 U/µl) 
1x  2.5 ml PI-SceI buffer (10x) (NEB) 
    1x  250 µl BSA (100x) (NEB) 
       Ad 25 ml nuclease-free ddH2O 
 
Plastic cuvettes      PLASTIBRAND™ standard disposable 
Cuvettes (Sigma-Aldrich, #Z330396) 
 
Plug molds      50-well disposable plug molds 
       (Bio-Rad, #1703713) 
 
4.3.1.6 Purification of DNA fragments by gel extraction 
DNA fragments were size-separated by agarose gel electrophoresis (with DNA-intercalating dye, 
e.g. Ethidium bromide) (see section 4.3.1.4). The fragment of interest was excised under UV 
illumination. Fragments were purified by gel extraction using QIAquick Gel Extraction Kit (Qiagen) 
following the supplier’s instructions. 
4.3.1.7 Purification of DNA by phenol/chloroform extraction 
Before starting, two MaXtract High Density tubes (Qiagen) per sample were centrifuged (13000xg 
for 5 min) to pellet the containing gel. 1 Vol Phenol:Chloroform:Isoamylalcohol (25:24:1; pH 8) 
was mixed with the DNA-containing solution directly in a prepared MaXtract tube. The tube was 
centrifuged at 13000xg for 5 min to separate the aqueous and the organic phase. The upper DNA-
containing, aqueous phase was transferred to new MaXtract tubes and mixed with 1 Vol 
Chloroform:Isoamylalcohol (24:1). Both phases were separated again by centrifugation. The 
aqueous phase was then transferred to a new 1.5 ml tube and DNA was recovered by ethanol 
precipitation (see section 4.3.1.9). 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Phenol:Chloroform:Isoamylalcohol  25:24:1   Phenol-chloroform-isoamyl alcohol mixture 
       (Sigma-Aldrich, #77617) 
       Store at 4 °C 
 
Chloroform:Isoamylalcohol 24:1   Chloroform:Isoamyl alcohol 
       (Sigma-Aldrich, #C0549) 
       Store at 4 °C 
4.3.1.8 Polyethylene glycol 8000 (PEG8000) precipitation of DNA 
For precipitation of DNA from small Volumes, e.g. PCR reactions or endonuclease digestions, 
one Volume of PEG8000 Mix was added to the DNA-containing solution, vortexed and incubated 
for 10 min at RT. After centrifugation (10 min, > 13000xg, RT), the supernatant was discarded and 
the precipitated DNA was washed by carefully adding 200 µl EtOH (100%) to the (often invisible) 
pellet. Following centrifugation (10 min, > 13000xg, RT), the supernatant was carefully removed. 
The pellet was dried and resuspended in H2O in 50-75% of the initial Volume. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
PEG8000 Mix   26.2%  26.2 g PEG 8000 
    0.67 M  22 ml NaOAc/AcOH (3 M, pH 5.2) 
    0.67 M  660 µl MgCl2 (1 M) 
       Ad 100 ml nuclease-free ddH2O 
 
Glacial AcOH      Acetic acid (>99.7%) 
       (Sigma-Aldrich, #320099) 
 
NaOAc/AcOH (pH 5.2)   3 M  24.6 g Sodium acetate 
       Dissolve in 50 ml nuclease-free ddH2O 
       Adjust with AcOH to pH 5.2 
       Ad 100 ml nuclease-free ddH2O 
 
MgCl2    1 M  9.5 g Magnesium chloride 
       (Sigma-Aldrich, #M8266) 
       Ad 100 ml nuclease-free ddH2O 
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4.3.1.9 Alcohol precipitation of DNA 
Ethanol precipitation 
To precipitate DNA from a solution, 0.1 Vol NaOAc/AcOH (3 M, pH 5.2) and 2.5 Vol EtOH (100%) 
were added and the mixture was incubated for min. 1 hour at -20 °C. The precipitated DNA was 
pelleted by centrifugation (45 min, >13000xg, 4 °C). Precipitated DNA was washed once with 1 ml 
EtOH (80%) and dissolved in TE (1x, pH 8.0), Tris/HCl (10 mM, pH 8.0) or nuclease-free ddH2O 
(pH 8.0), respectively. In case of low initial DNA concentration, carriers such as glycogen or linear 
acrylamide (1-3 µg/precipitation) can be added to the solution prior to precipitation. 
Isopropanol precipitation 
To precipitate DNA from a large Volume, precipitation of DNA with isopropanol is preferred. 
0.1 Vol NaOAc (3 M, pH 5.2) and 0.4 Vol isopropanol (100%) were added to the solution, mixed, 
and immediately centrifuged (45 min, >13000xg, 4 °C) to avoid co-precipitation of salt. 
Precipitated DNA was washed once with 1 ml EtOH (70%) and dissolved in TE (1x, pH 8.0), 
Tris/HCl (10 mM, pH 8.0) or nuclease-free ddH2O (pH 8.0), respectively. In case of very low initial 
DNA concentration, carriers such as Glycogen or Linear acrylamide (1-3 µg/precipitation) can be 
added to the solution prior to precipitation. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
EtOH    70%  70 ml Ethanol p.a. 
       (Roth, #9065.3, ≥99.8%) 
       Ad 100 ml nuclease-free ddH2O 
 
    80%  80 ml Ethanol p.a. 
       (Roth, #9065.3, ≥99.8%) 
       Ad 100 ml nuclease-free ddH2O 
 
Isopropanol      2-Propanol p.a. 
       (Merck/Millipore, #1096342511) 
 
Glacial AcOH      Acetic acid (>99.7%) 
       (Sigma-Aldrich, #320099) 
 
NaOAc/AcOH (pH 5.2)   3 M  24.6 g Sodium acetate 
       Dissolve in 50 ml nuclease-free ddH2O 
       Adjust with AcOH to pH 5.2 
       Ad 100 ml nuclease-free ddH2O 
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NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)   0.5 M 186.1 g Ethylenediaminotetraacetic acid 
disodium salt dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
Glycogen   5 mg/ml   Glycogen 
(Ambion/Life Tech. #AM9510) 
 
Linear acrylamide  5 mg/ml   Linear acrylamide  
(Ambion/Life Tech. #AM9520) 
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4.3.1.10 Polymerase chain reaction 
Polymerase chain reaction (PCR) allows the amplification of specific DNA segments. A thermo 
stable DNA polymerase synthesizes the sister strand of a heat-denatured single-stranded DNA 
when deoxynucleotide triphosphates are added under appropriate conditions
268
. The 
polymerization reaction is “primed” with small oligonucleotides that anneal to the template DNA 
strand through base pairing giving the reaction its specificity by defining the borders of the 
amplified segment. 
 
Standard PCR to amplify specific target regions was performed with the Expand High Fidelity 
PCR System (Roche) according to the following protocol. 
 
Table 4-8 Reaction composition for standard PCR 
Component  Volume  Final concentration  
Mix 1 
genomic DNA template x μl 10-250 ng 
nuclease-free ddH2O 21.6 – x µl n.a. 
dNTPs (25 mM each) 0.4 µl 0.2 mM each 
Primer_forward (10 µM)  1.5 μl 0.3 μM 
Primer_reverse (10 µM) 1.5 μl 0.3 μM 
Final Volume 25 µl  
Mix 2 
nuclease-free ddH2O 19.25 µl n.a. 
10x Buffer 5 µl 1x 
Taq Polymerase (3.6 U/µl) 0.75 µl 2.6 U 
Final Volume 25 µl  
 
Mix 1 and 2 were mixed on ice immediately before starting the cycling protocol. 
 
Table 4-9 Cycling protocol for standard PCR 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  94 °C 2 min 1× 
Denaturation 94 °C 15 sec 
32× Annealing 45-65 °C 30 sec 
Extension 72 °C 45 sec – 2 min 
Final extension 72 °C 7 min 1x 
Cooling 4 °C hold 
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Quantitative real-time PCR (qPCR) 
QPCR was used to test for specific DNA enrichment by Methyl-CpG immunoprecipitation (MCIp, 
see section 4.3.1.15), Chromatin immunoprecipitation (ChIP, see section 4.3.1.17), Pulsed-Field 
Gel Electrophoresis (PFGE, see section 4.3.1.5), as well as for local expression analysis after 
reverse transcription PCR (see section 4.3.2.2). QPCR was performed with the QuantiFast SYBR 
Green Kit (Qiagen) in 96-well format adapted to the Eppendorf Realplex Mastercycler EpGradient 
S system (Eppendorf) and 384-well format adapted to the LightCycler480 system (Roche) (Table 
4-10 & Table 4-11). The relative amount of amplified DNA was measured through the emission of 
light by the SYBR green dye after each extension step. Specificity of the amplification product was 
determined by a melting curve. 
 
Table 4-10 Reaction composition for quantitative PCR 
Component  Volume  Final concentration  
SYBR Green mix (2×) 5 μl 1× 
Nuclease-free ddH2O 2 μl n.a. 
Primer_forward (10 µM)  0.5 μl 0.5 μM 
Primer_reverse (10 µM) 0.5 μl 0.5 μM 
Template DNA 2 µl n. a. 
Final Volume 10 µl  
 
Table 4-11 Cycling protocol for quantitative PCR 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  95 °C 5 min 1× 
Denaturation 95 °C 8 sec 
45× 
Annealing & Extension 60 °C 20 sec 
Final denaturation 95 °C 15 sec 
1× 
Final extension 60 °C 15 sec 
Melting Curve 60  95 °C 10 min 1× 
Cooling 4 °C hold 
 
To calculate amplification efficiency, a dilution series (e.g. 1:10; 1:50; 1:100, 1:1000) of a suitable 
DNA sample was additionally measured for each amplicon. The software automatically calculated 
relative DNA amounts based on the generated slope and intercept. Specific amplification was 
determined by melting curve analysis. Data were imported and processed in Microsoft Excel 
2010. All samples were generally measured in duplicates. 
 
Unless otherwise mentioned genomic sequences for primer design were extracted from the mm9 
reference sequence using the UCSC Genome Browser. In general, primers were designed with 
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PerlPrimer software and evaluated using in silico PCR and BLAT functions of the UCSC Genome 
Browser and GeneRunner software. The following settings were used to design specific primers: 
 
   Primer Tm:  65-68 °C (max 2 °C difference) 
Primer length:  18-28 bp 
Amplicon size:  70-150 bp 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
QuantiFast SYBR Green PCR Kit    Qiagen (#204056) 
4.3.1.11 In vitro methylation and demethylation of genomic DNA 
In vitro methylation 
In order to generate fully methylated DNA as a control for methylation analysis, gDNA was 
methylated using SssI methyltransferase (New England Biolabs). S-adenosyl methionine (SAM) 
was used as a methyl donor. In general the following reaction conditions were used: 
 
Table 4-12 Reaction composition for in vitro methylation 
Component  Volume  Final concentration  
Nuclease-free ddH2O 84.5 – x µl n. a. 
genomic DNA x μl 20 µg 
Buffer NEB2 (10×) 10 μl 1× 
S-adenosyl methionine (32 mM) 0.5 µl 160 µM 
SssI (4 U/µl)  5 µl 20 U 
Final Volume 100 µl  
 
After 2 hours incubation at 37°C the reaction was supplied with additional 0.75 µl SAM and 1 µl 
SssI followed by incubation of another hour. 
To inactivate the SssI methyltransferase the sample was incubated at 65°C for 20min. 
If necessary, in vitro methylated genomic DNA was cleaned up with the QIAquick PCR Purification 
according to the manufacturer’s instructions. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
CpG methyltransferase (SssI)    M. SssI 
NEB (#M0226S) 
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In vitro demethylation 
Unmodified cytosines as well as modified (e.g. methylated cytosine) pair with guanine during 
replication of DNA. Thus, genomic DNA was in vitro demethylated by whole genome amplification 
with either the REPLI-g Mini or Midi Kit (Qiagen) according to the manufacturer’s instruction. If 
necessary, in vitro demethylated genomic DNA was cleaned up with the QIAquick PCR 
Purification according to the manufacturer’s instructions. 
 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
REPLI-g Kit      Qiagen (#150023, 150043) 
4.3.1.12 Bisulfite treatment of genomic DNA 
Cytosine derivates undergo reversible reactions with sodium bisulfite, yielding a 5,6-Dihydro-6-
sulfonate, which deaminates under alkaline conditions leaving uracil whereas 5-methylcytosine is 
not affected by this reaction
269
. After PCR amplification, unmethylated cytosine appears as 
thymine in contrast to 5-methylcytosine, which remains as cytosine. 
Bisulfite conversion was performed with the EZ DNA Methylation Kit (Zymo Research) according 
to the manufacturer’s instructions. Bisulfite conversion was optimised with the following incubation 
protocol: 
 
Table 4-13 Cycling protocol for bisulfite treatment 
Cycle step  Temperature  Time  Number of cycles  
Denaturation 95 °C 30 sec 
20× 
Sulfonation 50 °C 15 min 
Cooling 4 °C hold 
 
The bisulfite-treated DNA was recovered by adding nuclease-free water (10 µl/10 ng input DNA) 
directly to the column centre and centrifugation for 30 seconds at 9500xg. The procedure yields 
bisulfite-converted DNA with a concentration of 7-8 ng/µl. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
EZ DNA Methylation Kit (single columns)    Zymo Research (#D5002) 
EZ-96 DNA Methylation Kit (96-well format)    Zymo Research (#D5004) 
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4.3.1.13 Sanger sequencing of DNA and sequence analysis 
To amplify specific genomic regions, primers were designed and evaluated as described in 
section 4.3.1.10. Thermocycling parameters are also enlisted in section 4.3.1.10. Positive and 
specific amplification was evaluated by agarose gel electrophoresis (see section 4.3.1.4). PCR 
reactions were either gel-purified using agarose gel electrophoresis followed by purification with 
QIAquick Gel Extraction Kit (Qiagen) (see section 4.3.1.4 & 4.3.1.6) or directly used for PEG8000 
precipitation (see section 4.3.1.8). Sanger sequencing was done by Geneart/Life Technologies 
(Regensburg, Germany). Purified PCR products can directly be sequenced using one of the PCR 
primers. To obtain sequence information of single DNA strands, the PCR product was subcloned 
with the StrataClone PCR Cloning Kit (Agilent Technologies) or the TOPO TA Cloning Kit 
(Invitrogen/Life Technologies), respectively (see section 4.3.3.1). Plasmids from individual clone 
were isolated with NucleoSpin
®
 Plasmid Quick Pure Kit (Macherey-Nagel) and sequenced with 
one of the backbone primers. The obtained sequence was analyzed with the UCSC Browser and 
GeneRunner as well as the BioEdit Software.  
 
Bisulfite sequencing 
A common method for analyzing cytosine methylation is bisulfite sequencing
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. Bisulfite treatment 
of DNA generates methylation-dependent sequence variations: Cytosine (C) is deaminated to 
uracil, which generates thymine (T) after PCR amplification whereas 5-methylcytosine (5mC) 
remains unaffected (see section 4.3.1.12). This methylation-dependent difference can be detected 
by sequencing. All reagents were purchased from Sequenom unless otherwise mentioned. 
 
Table 4-14 Reaction composition for PCR amplification prior to bisulfite sequencing 
Component  Volume  Final concentration  
Nuclease-free ddH2O 6.44 μl  n. a.  
PCR buffer (10×) 1 μl  1×  
dNTPs (25 mM) 0.08 μl  200 μM each  
Primer_10F (10 µM) 0.2 μl  0.2 μM  
Primer_T7R (10 µM) 0.2 μl  0.2 μM  
Bisulfite-converted DNA 2 µl ~ 20 ng 
DNA Polymerase 
(5 U/µl)  
0.08 µl 0.4 U/reaction 
Final Volume 10 µl  
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Table 4-15 Cycling protocol for PCR amplification prior to bisulfite sequencing 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  95 °C  1 min  1×  
Denaturation 95 °C 15 sec 
40× Annealing 56-62 °C 15 sec 
Extension  72 °C 30 sec 
Final extension  72 °C 7 min 1×  
Cooling 4 °C hold 
 
To determine the methylation status of each CpG dinucleotide in dependence of the genetic 
context, the PCR product was in general subcloned prior to sequencing (see section 4.3.3.1). 
PCR primers were especially designed to amplify bisulfite-treated DNA (MethPrimer, 
www.urogene.org/methprimer/). This software excludes regions with CpG dinucleotides as 
potential primer binding sites in order to obtain methylation status-independent primers. 
The following settings were used for the MethPrimer software: 
 
    Min.  Opt.  Max. 
Product size (bp) 250  350  450 
Primer Tm (°C)  55  59  65 
Primer size (bp) 20  25  30 
 
Product CpGs: 4  Primer non-CpG ‘C’s: 4 
Primer Poly X: 5  Primer Poly T: 5 
 
Specific 5’ tags were added to the primer sequences to allow for mass spectrometric analyses of 
bisulfite-treated DNA with the MassARRAY compact system (see section 4.3.1.14). 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Complete PCR Reagent Set     Sequenom 
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4.3.1.14 MassARRAY® system (Sequenom) 
The MassARRAY system is a matrix-assisted laser desorption/ionization time of flight mass 
spectrometer (MALDI-TOF MS) to quantitatively and qualitatively analyze nucleic acids. In our 
laboratory, we use this system for quantitative assessment of DNA methylation (EpiTYPER) and 
genotyping (iPLEX). All reagents were purchased from Sequenom unless otherwise mentioned. 
All centrifugation steps were carried out at 3000rpm unless otherwise mentioned. 
EpiTYPER: Quantitative DNA methylation analysis 
DNA samples for quantitative methylation analysis are initially bisulfite-treated, resulting in the 
conversion of unmethylated cytosines to uracil, whereas methylated cytosines remain unchanged. 
This conversion reaction allows for accurate discrimination between methylated and unmethylated 
cytosines at CpG dinucleotides. Following bisulfite treatment, genomic DNA consists of two non-
complementary single-stranded DNA populations. Subsequently, PCR primer pairs for a region of 
interest are designed to amplify either the forward and reverse strand of bisulfite-treated genomic 
DNA. A T7 polymerase promoter tag is added to the 5’ end of the reverse primer to facilitate 
in vitro transcription. A 10-mer tag is added to the 5’ end of the forward PCR primer to minimize 
melting temperature differences between both primers during PCR cycling. 
Following PCR, unincorporated dNTPs are dephosphorylated by treatment with Shrimp alkaline 
phosphatase (SAP). Reverse transcription is performed using a chemically modified T7 RNA 
polymerase, which utilizes a mixture of ribonucleotides and deoxyribonucleotides when 
synthesizing the RNA strand. In parallel with the reverse transcription the cleave reaction is 
achieved using the pyrimidine-specific Ribonuclease A (RNase A) enzyme, which cleaves at 
pyrimidines (C and T) only on the newly synthesized transcript. By incorporating a non-cleavable 
dCTP (deoxyribonucleotide) into the transcript, RNase A is unable to cleave at C and can only 
cleave at T (T-specific cleavage) yielding a population of single-stranded cleavage fragments 
(Figure 4-1). A methylated cytosine is represented by a G nucleotide in the cleavage fragment, 
whereas an unmethylated cytosine is represented by an A nucleotide. The mass difference of 16 
Dalton between G (329 Da) and A (313 Da) is easily detected by MALDI-TOF MS. Depending on 
the number of methylated CpG sites within a cleavage fragment, the difference in mass will 
increase in 16 Da units. As already mentioned, in the following procedure this methylation-specific 
difference is not addressed by sequencing but for generating methylation-depending mass 
differences to be analyzed by mass spectrometry. A detailed description of the method is given by 
Ehrich et al.
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 and in the EpiTYPER User Guide (www.sequenom.com). 
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Figure 4-1 Schematic outline of the EpiTYPER technology 
Genomic DNA is isolated and bisulphite treated to generate methylation specific mass differences. Regions 
of interest are amplified by PCR following in vitro transcription and base specific cleavage (in the figure U-
specific, in the assay used for this work T-specific). Mass differences are then analyzed with MALDI-TOF MS 
(Figure taken from www.sequenom.com). 
 
Primer design 
Genomic DNA sequences were downloaded from the University of California, Santa Cruz genome 
browser (http://www.genome.ucsc.edu). In order to maximize coverage, both the forward and 
reverse strand of a target region were included for amplicon design. The selected genomic 
sequence was subsequently exported to the primer design software MethPrimer 
(http://www.urogene.org/methprimer). Once genomic DNA is uploaded into this application, an in 
silico bisulfite conversion is performed to facilitate the primer design. PCR primer design criteria 
consist of the following: An optimal primer melting temperature of 62 °C (range: Tm=56-64 °C); 
Primer length ranges from 20-30 nucleotides, excluding tag addition. Amplicons vary from 100-
500 bp in length, with a desired length of 400 bp. All primers designed for methylation analysis 
using the MassCLEAVE assay are listed in section 3.10.4.1. Primers were ordered in 96-well 
format at 100 µM concentration (Sigma-Aldrich). Prior to PCR set up, a 96-well primer mix plate 
(Sarstedt V-bottom, Newton, USA) was assembled, with each well containing 1 µl of both the 
forward and reverse primers of a primer pair and 198 µl ddH2O to give a final concentration of 
0.5 µM each. 
 
To facilitate reverse transcription of the amplified target region by T7 RNA Polymerase (see 
“Reverse transcription and RNA base-specific cleavage”), all reverse primers were tagged at the 
5’ end with the T7 promoter sequence; to balance for the elongated length of the reverse primer, 
all forward primer carry a 10mer tag at the 5’ end: 
Forward tag  (10F)  5’-AGGAAGAGAG 
 Reverse tag (T7R)  5’-CAGTAATACGACTCACTATAGGGAGAAGGCT 
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Bisulfite treatment 
Bisulfite conversion of genomic DNA was performed with the EZ DNA Methylation Kit
TM
 (Zymo 
Research) according to section 4.3.1.12. 
 
PCR amplification 
PCR master mixes were prepared in 384-well plates (Thermo Scientific) and made as follows per 
reaction according to the manufacturer’s instructions: 
 
Table 4-16 Reaction composition for EpiTYPER PCR 
Component Volume per single reaction Final concentration 
Nuclease-free ddH2O 1.42 µl n. a. 
PCR Buffer (10×) 0.5 µl 1× 
dNTPs (25 mM each) 0.04 µl 200 µM 
Taq Polymerase (5 U/µl) 0.04 0.2 U 
DNA template 1 µl 5 – 10 ng 
Final Volume 3 µl  
 
To each reaction 2 µl primer mix was added giving a final reaction Volume of 5 µl, with the final 
concentration of 500 pM of the forward and reverse primer. The plate was sealed with adhesive 
PCR sealing foil (Thermo Scientific), centrifuged, and incubated in a Veriti 384-well thermal cycler 
(Applied Biosystems) with the following program: 
 
Table 4-17 Cycling protocol for EpiTYPER PCR 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  94 °C  4 min  1×  
Denaturation 94 °C 20 sec 
45× Annealing 59 °C 30 sec 
Extension  72 °C 1 min 
Final extension  72 °C 3 min 1×  
Cooling 4 °C hold 
 
Shrimp alkaline phosphatase (SAP) treatment 
Unincorporated nucleotides would disturb downstream applications and are enzymatically 
inactivated. Under alkaline conditions SAP removes phosphate groups from several substrates 
including deoxynucleotide triphosphates, rendering it unavailable for further polymerase-catalyzed 
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reactions. The SAP solution was prepared according to the manufacturer’s instructions (Table 
4-18). 
 
Table 4-18 Reaction composition for EpiTYPER SAP treatment 
Component Volume per single reaction 
Nuclease-free ddH2O 1.7 µl 
SAP mix 0.3 µl 
Final Volume 2 µl 
 
2 µl of the SAP mixture was added to each PCR reaction with the 96-channel pipetting robot 
MassARRAY Liquid Handler. The plate was sealed with adhesive PCR sealing foil (Thermo 
Scientific), centrifuged, and incubated as follows on a Veriti 384-well thermal cycler (Applied 
Biosystems): 
 
Table 4-19 Cycling protocol for EpiTYPER SAP treatment 
Cycle step  Temperature  Time  
Dephosphorylation 37 °C  20 min  
SAP heat inactivation 85 °C 5 min 
Cooling  4 °C hold 
 
Reverse transcription and RNA base-specific cleavage 
The PCR reaction was in vitro transcribed into RNA with the T7 RNA polymerase, which was 
guided to the amplified PCR-products by the introduced T7 promoter tag in the reverse primer. 
Transcription/Cleavage reaction was performed using a single mix containing according to the 
manufacturer’s instructions. 
 
Table 4-20 Reaction composition for EpiTYPER Transcription/Cleavage reaction 
Component Volume per single reaction 
Nuclease-free ddH2O 3.21 µl 
T7 polymerase buffer (5×) 0.89 µl 
Cleavage mix (T mix) 0.22 µl 
DTT (100 mM) 0.22 µl 
T7 R&DNA Polymerase (50 U/µl) 0.4 µl 
RNaseA 0.06 µl 
Final Volume 5 µl 
 
5 µl of the transcription/cleavage mix and 2 µl of the SAP-treated PCR reaction were transferred 
into a new 386-well plate with the 96-channel pipetting robot MassARRAY Liquid Handler, sealed 
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with adhesive PCR sealing foil (Thermo Scientific),centrifuged, and incubated on a Veriti 384-well 
thermocycler C (Applied Biosystems) for three hours at 37°C. 
Desalting the cleavage reaction 
Because salt ions are co-vaporized when acquired during MALDI-TOF analysis they would be 
visible in the mass spectra. Since this would irritate the analysis of the mass spectra the reactions 
need to be desalted. For desalting of the transcription/cleavage mix 15 μl water was added to 
each reaction with the MassARRAY Liquid Handler (Matrix) followed by the addition of 6 mg 
CLEAN resin per reaction. This mix was rotated for slowly for 30 minutes and centrifuged for 
10 min at 3000 rpm to collect the resin at the bottom of the wells. 
 
Transfer on SpectroCHIP and acquisition 
The SpectroCHIP holds the matrix-consisting of a crystallized acidic compound on, which the 
sample probes are spotted on. The analyte’s solvent dissolves the matrix, which recrystallizes 
when the solvent evaporates. By that the analyte molecules are enclosed in the crystals. 
The DNA samples are transferred on a SpectroCHIP with the Fusio
TM
 Chip Module and analyzed 
with the MassARRAY Compact System MALDI-TOF MS (all Sequenom). The co-crystallized 
analyte is acquired with a laser while the matrix is predominantly ionized, protecting the DNA from 
the disruptive laser beam. Eventually the charge is transferred to the sample and charged ions are 
created, which are accelerated in a vacuum towards a detector that measures the particles’ time 
of flight. 
 
Data processing 
Acquired data were processed with the EpiTYPER Analyzer software (v1.2, Sequenom). The MS 
is calibrated with a four point calibrant (Sequenom) containing 1479, 3004, 5044.4, and 8486.6 Da 
particles. Relative to this calibration, the accelerated analytes generate signal intensity (y-axis) 
versus mass (kDa, x-axis) plots. With the sequence of every amplicon known, the software can 
virtually process the sequence and predict the fragments from the in vitro transcription/RNase 
digestion and relocate CpG units. Each CpG-containing fragment is called a CpG unit, which can 
contain more than one CpG site. If more than one CpG sites are contained within one fragment, 
they get a sum methylation value since the software averages the methylation of the individual 
CpG sites. If expected and incoming information match, the signal intensities of the methylated 
and unmethylated DNA templates are compared and quantified. A normal calibrated system is 
able to measure fragments between a range of 1500 and 7000 Da. Fragments outside of this 
range and fragments whose mass peaks are overlapping with multiple other fragments cannot be 
analyzed. 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
EZ DNA Methylation Kit (single columns)    Zymo Research (#D5002) 
EZ-96 DNA Methylation Kit (96-well format)    Zymo Research (#D5004) 
 
Complete PCR Reagent Set     Sequenom 
MassCLEAVE T7 Kit       
SpectroCHIP
®
 Arrays (incl. Resin)       
 
384-well plate       Thermo Scientific (#TF0384) 
 
Adhesive PCR Foil Seal      Thermo Scientific (#AB0558) 
 
iPLEX: Genotyping polymorphisms 
Similar to the mass difference between (hydroxy)methylated and unmethylated cytosines after 
bisulfite conversion, the iPLEX assay uses mass differences to distinguish alleles at single 
nucleotide polymorphisms (SNP) and short Insertions/Deletion. It uses single base extension 
(SBE) to incorporate mass-modified di-dNTP terminators, thereby creating allele-specific products 
with significant masses differences detectable by MALDI-TOF MS
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. 
Starting with genomic DNA, the region of interest is amplified by PCR and subsequent SAP 
treatment neutralizes unincorporated dNTPs. Post-PCR SBE with mass-modified di-dNTP 
terminators is performed with a single primer binding in direct proximity to the allelic base. 
Depending on the zygosity of the analyzed region, either a unique SBE product (homozygous) or 
two distinct SBE products (heterozygous) are detected. In case of two SBE products, the mass 
difference is unique depending on the incorporated nucleosides and makes them distinguishable 
in MALDI-TOF MS spectra. Using the Assay Designer Software (Sequenom), multiplex reactions 
combining up to 36 individual SBE reactions can be designed. 
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Figure 4-2 Schematic outline of the iPLEX technology 
The region containing the SNP of interest is amplified by PCR rendering a fragment of ~100bp in size. 
Excess dNTPs are inactivated by shrimp Alkaline Phosphatase (SAP) treatment. The iPLEX Gold reaction 
elongates an oligonucleotide that binds with its 3’ end to the SNP position by a single base into the SNP site. 
After a clean-up step the sample is spotted onto a 384 MassARRAY chip and subject to MALDI-TOF MS 
analysis. Up to 36 individual SNP positions can be assessed in one reaction by designing compatible capture 
and extension primer with the Sequenom Assay Design software. (Adopted from iPLEX Gold Application 
Guide) 
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PCR amplification 
PCR Mastermixes were prepared according to the manufacturer’s instructions and dispensed in 
384-well plates (Thermo Scientific). The Mastermix (Table 4-21) contains multiplexed Capture 
Primer mixes according to assay design. 
 
Table 4-21 Reaction composition for iPLEX PCR 
Component Volume per single reaction Final concentration 
Nuclease-free ddH2O 1.850 µl n. a. 
PCR Buffer (10×) 0.625 µl 1.25x 
MgCl2 (25 mM) 0.325 µl 1.625 mM 
dNTPs (25 mM each) 0.100 µl 500 µM 
Primer mix (500 nM each) 1.000 µl 100 nM 
Taq Polymerase (5 U/µl) 0.100 µl 0.5 U 
Final Volume 5 µl  
 
10ng of the corresponding genomic DNA was added to each well. 
The plate was sealed with adhesive PCR sealing foil (Thermo Scientific), centrifuged, and 
incubated in a Veriti 384-well thermal cycler (Applied Biosystems) (see Table 4-22). 
 
Table 4-22 Cycling protocol for iPLEX PCR 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  94 °C  15 min  1×  
Denaturation 94 °C 20 sec 
45× Annealing 56 °C 30 sec 
Extension  72 °C 1 min 
Final extension  72 °C 3 min 1×  
Cooling 4 °C hold 
 
 
Shrimp alkaline phosphatase (SAP) treatment 
Unincorporated nucleotides would disturb downstream applications and are enzymatically 
inactivated. Under alkaline conditions SAP removes phosphate groups from several substrates 
including deoxynucleotide triphosphates, rendering it unavailable for further polymerase catalyzed 
reactions. The SAP solution was prepared according to the manufacturer’s instructions (see Table 
4-23). 
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Table 4-23 Reaction composition for iPLEX SAP treatment 
Component Volume per single reaction 
Nuclease-free ddH2O 1.530 µl 
SAP buffer (10x) 0.170 µl 
SAP enzyme (1 U/µl) 0.300 µl 
Final Volume 2 µl 
 
2 µl of the SAP mixture was added to each PCR reaction with the 96-channel pipetting robot 
MassARRAY Liquid Handler. The plate was sealed with adhesive PCR sealing foil (Thermo 
Scientific), centrifuged, and incubated on a Veriti 384-well thermal cycler (Applied Biosystems) 
(see Table 4-24). 
 
Table 4-24 Cycling protocol for iPLEX SAP treatment 
Cycle step  Temperature  Time  
Dephosphorylation 37 °C  40 min  
SAP heat inactivation 85 °C 5 min 
Cooling  4 °C hold 
 
 
iPLEX SBE reaction 
For each assay, a specific extension primer binds next to the SNP site with its 3’ end in direct 
proximity to the SNP position. The iPLEX Gold reaction cocktail contains modified nucleotides that 
prevented extension by more than one base. Depending on the plex level, the cocktail 
composition varies 
 
 
Table 4-25 Reaction composition for iPLEX assay (2-18 plex) 
Component Volume per single reaction 
Final concentration 
(in 9 µl) 
Nuclease-free ddH2O 0.7395 µl n. a. 
iPLEX Buffer Plus (10×) 0.2 µl 0.222x 
iPLEX Termination Mix 0.1 µl 0.5 x 
Primer mix (7 µM : 14 µM) 0.94 µl 0.73 µM : 1.46 µM 
iPLEX enzyme 0.0205 µl 0.5 x 
Final Volume 2 µl  
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Table 4-26 Reaction composition for iPLEX assay (19-36 plex) 
Component Volume per single reaction 
Final concentration 
(in 9 µl) 
Nuclease-free ddH2O 0.619 µl n. a. 
iPLEX Buffer Plus (10×) 0.2 µl 0.222x 
iPLEX Termination Mix 0.2 µl 1 x 
Primer mix 
(8 µM : 10 µM : 15 µM) 
0.94 µl 
0.52 µM : 1.04 µM : 
1.57 µM 
iPLEX enzyme 0.041 µl 1 x 
Final Volume 2 µl  
 
Table 4-27 Cycling protocol for iPLEX SBE reaction 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  94 °C  30 sec  1×  
Denaturation 94 °C 5 sec  
 
 
5×             40× 
Annealing 52 °C 5 sec 
Extension  80 °C 5 sec 
Final extension  72 °C 3 min 1×  
Cooling 4 °C hold 
 
Desalting the cleavage reaction 
Because salt ions are co-vaporized when acquired during MALDI-TOF analysis they would be 
visible in the mass spectra. Since this would irritate the analysis of the mass spectra the reactions 
need to be desalted. For desalting of the transcription/cleavage mix 16 μl water was added to 
each reaction with the MassARRAY Liquid Handler (Matrix) followed by the addition of 6 mg 
CLEAN resin per reaction. This mix was rotated for slowly for 30 minutes and centrifuged for 
10 min at 3000 rpm to collect the resin at the bottom of the wells. 
 
Transfer on SpectroCHIP and acquisition 
The SpectroCHIP holds the matrix-consisting of a crystallized acidic compound on, which the 
sample probes are spotted on. The analyte solvent dissolves the matrix, which recrystallizes when 
the solvent evaporates and encloses the analyte molecules. 
The DNA samples are transferred on a SpectroCHIP with the Fusio
TM
 Chip Module and analyzed 
with the MassARRAY Compact System MALDI-TOF MS (all Sequenom). The co-crystallized 
analyte is acquired with a laser while the matrix is predominantly ionized, protecting the DNA from 
the disruptive laser beam. Eventually the charge is transferred to the sample and charged ions are 
created, which are accelerated in a vacuum towards a detector that measures the particles’ time 
of flight. 
Methods 
  83 
Data processing 
Acquired data were processed with the TYPER software (v4.0, Sequenom). The MS is calibrated 
with a three point calibrant (Sequenom) containing 5044.4, 8486.6, and 9977.6 Da particles. 
Relative to this calibration the accelerated analytes generate signal intensity (y-axis) versus mass 
(kDa, x-axis) plots. With the sequence of every potential SBE product known, the software can 
virtually predict the fragments mass. The extension primers are designed to fall within a range of 
4500 and 8500 Da after SBE. Due to the mass modification of the incorporated nucleotides during 
SBE, differentially extended extension primers theoretically separate well in the mass spectra 
allowing for SNP genotyping.  
Selection criteria for SNPs used in linkage analysis 
(i) SNPs needed to differ between C57BL/6 and BALB/c and be detected as homozygous in 
both strains (to reduce the probability of being false-positive) 
(ii) SNPs enlisted in the dbSNP database and already evaluated for genotyping microarrays 
were preferable (to reduce the probability of being false-positive) 
(iii) Only for genome-wide SNP panel: C57BL/6 SNP variants needed to be identical in less 
than six of the other 14 inbred strains (to select for C57BL/6-specific SNPs) 
(iv) A minimum distance to adjacent SNPs or neighboring repeats exceeding 80 bp was 
preferable (to provide for an unique sequence context) 
(v) On average, one informative SNP per 10 Mb (genome-wide analysis) or 0.5 Mb (fine 
mapping analysis), respectively, was selected (to achieve an even coverage of the whole 
mouse genome). 
Default amplicon design settings (100 bp on average) for SNP capture PCR and the “high 
multiplex (36)” design option to facilitate maximum multiplex level. Assay design was generally 
performed with “constrict” settings to exclude repetitive sequences (mm9 annotation available at 
www.repeatmasker.org) from assay design. Furthermore, in the case of closely located SNPs, the 
binding sites for the corresponding primers were confirmed to not intersect with SNPs annotated 
by the Mouse Genomes Project (release REL-1005) to ensure unbiased binding of both capture 
and SBE oligos. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Complete PCR Reagent Set     Sequenom 
iPLEX Kit        
SpectroCHIP
®
 Arrays (incl. Resin)      
 
384-well plate       Thermo Scientific (#TF0384) 
 
Adhesive PCR Foil Seal      Thermo Scientific (#AB0558) 
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4.3.1.15 Methyl-CpG immunoprecipitation (MCIp) 
MCIp is based on an immobilizable MBD2-Fc fusion protein and enables rapid enrichment of 
CpG-methylated (mCpG) DNA as well as fractionation of DNA fragments according to their 
methylation level. DNA affinity of the antibody-like protein is dependent on the density of 
methylated CpGs and salt concentrations in the buffer. MCIp was performed with the EpiMark® 
Methylated DNA Enrichment Kit (NEB), which is based on a method established in our laboratory. 
The method allows for the fractionation of DNA fragments according to their mCpG level as well 
as the enrichment of methylated DNA fragments. Fractionation is achieved by washing the 
immobilized MBD2-Fc-bound DNA fragments with increasing NaCl concentration in the wash 
buffer. Murine genomic DNA fragments that exhibit low to intermediate methylation levels reside in 
fractions obtained from washing with buffer of 150-500 mM NaCl concentration. Remaining bound 
DNA fragments, which exhibit high methylation levels, can be totally recovered by washing with 
buffer of ≥ 1000 mM NaCl concentration. To enrich in general for methylated DNA fragments, all 
remaining bound DNA fragments after washing with buffer of 150 mM NaCl concentration can be 
recovered by incubating the immobilized DNA in nuclease-free ddH2O at 65 °C for 15 min. Both 
protocols can be combined. 
MCIp was performed according to the manufacturer’s instructions. Fragments with low to 
intermediate methylation level were eluted by washing with 150 mM and 500 mM NaCl wash 
buffer. Highly methylated fragments were recovered by incubation with 52 µl nuclease-free ddH2O 
at 65 °C for 15 min. Fractions obtained by increasing NaCl concentration in the wash buffer where 
desalted using the PCR Purification Kit (Qiagen) prior to subsequent assays. 
Successful fractionation was confirmed by quantitative PCR (qPCR, at the imprinted Snrpn locus 
and other loci with known methylation levels. In somatic cells, imprinted regions exhibit allele-
specific DNA methylation depending on the parental origin. For Snrpn, the paternal allele is, in 
contrast to the completely methylated maternal allele, free of DNA methylation. The paternal allele 
resides in the lower salt fractions (50% recovery) whereas the maternal allele was enriched in the 
fraction with the highest salt concentration (1000 mM) (50% recovery). In contrast, wash fractions 
with intermediate salt concentration are depleted of fragments from the Snrpn locus. Additional 
loci with known methylation pattern can be tested to validate successful enrichment of highly 
methylated DNA fragments (see Table 4-28). 
 
Table 4-28 Control loci for MCIp enrichment by qPCR 
Gene symbol Expected outcome in H2O fraction (spleen, cerebellum) 
Gapdh (promoter) Ubiquitously expressed  depletion of mCpGs 
Myod1 (promoter) Muscle-specifically expressed  enrichment of mCpGs 
Snrpn (promoter) Imprinted region  50% enrichment of mCpGs 
‘empty’ CpG-free region  depletion of mCpGs 
Isoc2b (promoter) 
Only expressed in C57BL/6  depletion of mCpGs in C57BL/6, 
enrichment in BALB/c 
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4.3.1.16 Hydroxymethylcytosine methylated DNA immunoprecipitation 
(hMeDIP) 
Hydroxymethylation of CpGs (5hmC) occurs during the process of active DNA demethylation
66
. 
DNA fragments carrying this modification can be enriched using a specific antibody against 5hmC. 
The Covaris Ultra-Sonifier was used to guarantee reproducible statistically fragmentation results. 
3.25 µg genomic DNA were diluted with TE (1x, pH 8.0) to a final concentration of 25 ng/µl and 
sonified according to the “200 bp” setting in Table 4-6. Successful sonication was assessed by gel 
electrophoresis (2% agarose, see section 4.3.1.4). Per immunoprecipitation, 1 µg of fragmented 
DNA was adjusted to 270 µl with TE (1x, pH 8.0). Diluted DNA was denatured at 95 °C for 10 min 
immediately followed by cooling on ice for 10 min to obtain single-stranded DNA fragments. After 
addition of 30 µl IP buffer (10x) and 1 µg of the 5hmC-specifc antibody the DNA antibody mix is 
incubated at 4 °C for 2-3 h on a rotator (~4-6 rpm). Per precipitation 30 µl of Dynabeads are 
batch-washed twice for 5 min at RT in BSA/PBS solution overhead on a shaker and recovered 
using a magnetic rack. The washed beads were resuspended in 30 µl IP buffer (1x) per 30 µl 
Dynabeads and added to the samples (30 µl each). After incubation at 4 °C for maximal 2 h on a 
rotator (~4-6 rpm) the beads are recovered using a magnetic rack and washed three times with 
700 µl IP buffer (1x). Elution of the trapped DNA fragments was achieved by resuspension and 
incubation for 3 h at 50 °C in 250 µl Proteinase K digestion buffer and 3.5 µl Proteinase K. 
Trapping the beads on a magnetic rack allows the recovery of the DNA fragment-containing 
supernatant, which is then purified as well as 10% of the initial input DNA using QIAquick PCR 
Purification Kit (Qiagen) with 30 µl prewarmed EB buffer (55 °C, applied twice) for 
elution.Successful enrichment was confirmed by qPCR at other loci with known methylation 
levels. The choice depended on the cell type source of the processed genomic and is stated in 
detail in the results’ sections. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Sodium phosphate (monobasic) 2 M  276 g Anhydrous Sodium phosphate monobasic 
       (Sigma-Aldrich, #S8282) 
       Ad 1 l nuclease-free ddH2O 
 
Sodium phosphate (dibasic) 2 M  284 g Anhydrous di-Sodium hydrogen phosphate 
       (Merck Millipore, #1065590500) 
       Ad 1 l nuclease-free ddH2O 
 
Sodium phosphate buffer (pH 7.0) 1 M  39 ml Sodium phosphate (monobasic) 
      61 ml Sodium phosphate (dibasic) 
      100 ml nuclease-free ddH2O 
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IP buffer (10x)   100 mM  100 ml Sodium phosphate buffer (1 M, pH7.0) 
    1.4 M  81.8 g Sodium chloride 
       (AppliChem, #A3597) 
    0.5%  5 ml Triton
TM
 X-100 
       (Sigma-Aldrich, #T8787) 
       Ad 1 l nuclease-free ddH2O 
 
IP buffer (1x)   1x  1 ml IP buffer (10x) 
      9 ml TE (1x, pH 8.0) 
 
 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
 
Tris/HCl (pH 8)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 8 
       Ad 1 l nuclease-free ddH2O 
 
HCl    37%   Hydrochloric acid (fuming) 
       (Merck/Millipore, #100317) 
 
EDTA/NaOH (pH 8)  0.5 M  186.1 g Ethylenediaminotetraacetic acid disodium salt 
dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
BSA    1%  100 mg Bovine serum albumin 
       (Sigma-Aldrich, #A4503) 
       Ad 10 ml nuclease-free ddH2O 
 
BSA/PBS solution  0.1%  1 ml BSA (10 mg/ml) 
      9 ml Phosphate-buffered saline 
       (Sigma-Aldrich, #P4417) 
 
Proteinase K digestion buffer 50 mM  2 ml Tris/HCl (1 M, pH 8.0) 
    10 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
    0.5%  5 ml SDS (10%) 
       Ad 100 ml nuclease-free ddH2O 
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SDS    10%  100 g Sodium dodecyl sulfate 
       (Sigma-Aldrich, #L4390) 
       Ad 1 l nuclease-free ddH2O 
 
Proteinase K (-20°C)   20 mg/ml 25 mg Proteinase K 
       (Roche, #03115836001) 
      1.25 ml nuclease-free ddH2O 
 
Dynabeads (4 °C)      Dynabeads® Protein A 
       (Life Tech., #10008D) 
4.3.1.17 Chromatin immunoprecipitation (ChIP) 
Tissue preparation and mincing 
ChIP samples were prepared from fresh tissue. DNA and its associated proteins (chromatin) are 
crosslinked by formaldehyde fixation. To obtain homogenous fixation results, tissue samples need 
to be dissociated to obtain single cell suspensions or suspensions close to single cells, 
respectively. Tissue samples were cut into small pieces in sterile culture dishes filled with cold 
PBS/PMSF on ice. For spleen, samples were minced by pressing the tissue through cell strainer 
in presence of cold PBS/PMSF. For cerebellum, the pieces were transferred together with 200 µl 
PBS/PMSF into a fresh 1.5 ml tube and homogenized with a mini pestle (pointed shape fits into 
bottom of 1.5 ml tube). The cell suspensions was centrifuged at 4 °C for 10 min at 365 xg and the 
pellet resuspended in 25 ml cold PBS/PMSF. Cells were washed twice with 15 ml PBS/PMSF and 
collected each time by centrifugation at 4 °C for 8 min AT 365xg. Afterwards, the cells were 
aliquoted. For spleen, cells were counted in a hemocytometer and the concentration was adjusted 
to 10 Mio cells per 10 ml PBS/PMSF. For cerebellum, one half of a cerebellum roughly comprises 
10 Mio cells (according to tissue weight); two minced quarter portions of a cerebellum were 
combined and resuspended in 10 ml cold PBS/PMSF. 
Crosslinking with formaldehyde 
Formaldehyde causes crosslinking of molecules within the range of 2 Angstrom. Batch 
crosslinking of multiples of 10 Mio cells required adjustment of final PBS/PMSF volume. Per 10 ml 
cell suspension (10 Mio cells), 270 µl formaldehyde (37%) was added, mixed by inversion, and 
incubated at RT for 10 min. During the incubation time, the tube was inverted several times to 
prevent settling of cells. Crosslink reaction was stopped by addition of 1/20 Vol Glycine (2.625 M) 
and 5 min incubation at RT. Again, the tubes were inverted several times during incubation. The 
fixed cells were harvested by centrifugation at 4 °C for 10 min at 365 xg and the supernatant 
discarded. The pellet was washed twice with cold PBS/PMSF as before. Pellets can be stored at -
80 °C up to months after snap freezing in N2 (l). 
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Cell and nuclei lysis 
Crosslinked chromatin was isolated from fixed cells after lysis. Per 10 Mio cells, the pellet was 
resuspended in 250 µl of Suspension Buffer and lysed on ice for 10 min by addition of 250 µl of 
Cell Lysis Buffer and mixing. The lysate was transferred to a new 1.5 ml tube and centrifuged at 
4 °C for 5 min at 700 xg to pellet the nuclei. The nuclei were then lysed by resuspension in 450 µl 
Nuclear Lysis Buffer. The lysed nuclei can be stored in Nuclear Lysis Buffer at -80 °C up to 
months after snap freezing in N2 (l). 
Fragmentation of chromatin 
The chromatin was sonicated with a Branson Sonifier 250 according to section 4.3.1.3. After 
sonication, the lysate was cleared from remaining cell debris by centrifugation at 4 °C for 5 min at 
13000g. To evaluate the fragmentation size, 30 µl of the sonicated and cleared lysate was mixed 
with 14 µl NaCl (5 M) and 26 µl L2 (without PMSF and inhibitors) and incubated o/n at 65 °C to 
reverse the crosslinking. After digestion of RNAs with 2.3 µl RNase A for 1 h at 37 °C, the sample 
was purified with the QIAquick PCR Purification Kit according the manufactor’s instructions. The 
sample was eluted in 30 µl EB buffer and size-separated by agarose gel electrophoresis (2% 
agarose gel, 50 bp ladder) according to section 4.3.1.4. The remaining lysate can be stored at -
80 °C up to months. 
Immunoprecipitation 
For each immunoprecipitation (IP), 80 µl of cleared lysate (chromatin of ~2 Mio cells) were used. 
For normalization purposes, per sample 4 µl of lysate (5% of IP) were retained as input. Before 
the actual IP, all IP aliquots from one chromatin batch were subject to pre-clearing. Per IP, 50 µl 
pre-clearing beads were washed twice by repeated centrifugation at RT for 1 min at 600 xg and 
resuspension in TE (1x) buffer. The washed beads were diluted to the initial volume with Dilution 
buffer (DB, w/o inhibitors). After addition of 25 µl BSA (20%) and 4 µl Glycogen per ml pre-
clearing beads, the beads were incubated on a rotor for at least 2 h at RT. For pre-clearing, the 
chromatin batch was diluted with 1.5 Volume DB (with inhibitors, results in 200 µl diluted lysate 
per IP) and incubated with 50 µl pre-clearing beads per IP on a rotor at 4 °C for 2 h. To recover 
the pre-cleared lysate, the mix was centrifuged at 4 °C for 5 min at 13000 xg and the supernatant 
transferred to a new 1.5 ml tube. 
Per IP, 200 µl of pre-cleared lysate were transferred to 0.5 ml tubes and after addition of 2.4 µg of 
the desired antibody the mix was incubated o/n on a rotor at 4 °C. In parallel to the o/n incubation 
of the chromatin antibody mixture, 40 µl Protein A-coated beads per individual IP for the 
subsequent pull down of the antibody-bound chromatin fragments were prepared. The beads 
were washed twice by repeated centrifugation at RT for 1 min at 600 xg and resuspension in TE 
(1x) buffer. The washed beads were diluted to the initial volume with Dilution buffer (DB, w/o 
inhibitors). After addition of 25 µl BSA (20%) and 4 µl Glycogen per ml Protein A-coated beads, 
the beads were incubated o/n on a rotor at 4 °C. To pull down the chromatin-antibody complexes, 
40 µl of blocked beads were added to each IP sample and incubated on a rotor for 4 h at 4 °C. 
The beads with the bound chromatin-antibody complex were centrifuged at 4 °C for 5 min at 
1100xg. Unspecifically bound chromatin was washed away by repeated washing steps with 
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increasing stringency. The beads were resuspended twice in 400 µl of each of the three washing 
buffers (WBI-III) and incubated on a rotor for 5 min at RT after each resuspension. Final washing 
step was performed by three times resuspension in 400 µl TE (1x) buffer. To elute the bound 
chromatin-antibody complexes, the beads were incubated with 110 µl Elution Buffer (EB) for 
20 min at RT (shaking every 5 min). After centrifugation at 4 °C for 1 min at 600xg, 100 µl 
supernatant were transferred to a new 1.5 ml tube. Elution was repeated with additional 110 µl 
Elution Buffer and incubation for 10 min and after centrifugation, another 100 µl supernatant was 
combined with the first 100 µl eluate. Crosslinking of the eluted chromatin fragments was reversed 
by incubation with 5 µl Proteinase K (20 µg/µl) o/n at 65 °C. In parallel, 4 µl input were diluted to 
200 µl with Elution Buffer and also subject to Proteinase K treatment. 
Clean up 
The DNA fragments released from the recovered chromatin as well as from the input sample by 
Proteinase K treatment were purified by RNase A digestion (0.33 µg/µl, 2 h at 37 °C) and 
subsequent clean up with the QIAquick PCR purification kit according to the manufacturer’s 
instructions. DNA is loaded onto the column by centrifugation at 6700xg and eluted after 2 min 
incubation at RT with 52.5 µl prewarmed Elution Buffer (55 °C, part of the kit). 
Validation by qPCR 
To validate specific enrichment by immunoprecipitation, 10 µl of the eluate were diluted with 
Elution Buffer for subsequent qPCR according to section 4.3.1.10. The following loci were tested 
for specific enrichment. 
 
Table 4-29 Control loci for ChIP validation by qPCR 
Gene symbol Expected outcome (spleen, cerebellum) 
Gapdh (promoter) Ubiquitously expressed  enrichment of active histone marks 
Myod1 (promoter) Muscle-specifically expressed  depletion of active histone marks 
‘Intergenic’ Depletion of active histone marks 
Isoc2b (promoter) 
Only expressed in C57BL/6  enrichment of active histone marks 
in C57BL/6, depletion in BALB/c 
 
40 µl were processed for Next Generation Sequencing-compatible library preparation (see section 
4.3.1.18). 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
Formaldehyde   37%   Formaldehyde 
       (Merck Millipore, #8187081000) 
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Glycine    2.625 M  9.85 g Glycine 
       (Roth, #3908.1) 
       Ad 50 ml nuclease-free ddH2O 
 
BSA    20%  2 g Bovine serum albumin 
       (Sigma-Aldrich, #A4503) 
       Ad 10 ml nuclease-free ddH2O 
 
Glycogen   5 mg/ml   Glycogen 
       (Life Techn., #AM9510) 
 
HEPES/KOH (pH 7.9)  1 M  238.3 g 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid 
       (Sigma-Aldrich, #H3357) 
       Adjust with KOH to pH 7.9 
       Ad 1 l nuclease-free ddH2O 
 
KCl    2 M  149.1 g Potassium chloride 
       (Merck Millipore, #1049360250) 
       Ad 1 l nuclease-free ddH2O 
 
EDTA/NaOH (pH 8)  0.5 M  186.1 g Ethylenediaminotetraacetic acid disodium salt 
dehydrate (AppliChem, #A2937) 
       Dissolve in 500 ml nuclease-free ddH2O 
       Adjust with NaOH to pH 8.0 
 Ad 1 l nuclease-free ddH2O 
 
PMSF    100 mM  1.74 g Phenylmethanesulfonyl fluoride 
       (Sigma-Aldrich, #P7626) 
       Ad 100 ml Isopropanol (p.a.) 
       (Merck Millipore, #1096342511) 
 
NaCl    5 M  29.2 g Sodium chloride 
       (AppliChem, #A3597) 
       Ad 100 ml nuclease-free ddH2O 
 
Tris/HCl (pH 7.4)   1 M  121.1 g Tris ultrapure 
       (AppliChem, #A1086) 
       Adjust with HCl to pH 7.4 
       Ad 1 l nuclease-free ddH2O 
 
TE (1x, pH 8.0)   10 mM  10 ml Tris/HCl (1 M, pH 8.0) 
    1 mM  2 ml EDTA/NaOH (0.5 M, pH 8.0) 
       Ad 1 l nuclease-free ddH2O 
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SDS    20%  20 g Sodium dodecyl sulfate 
       (Sigma-Aldrich, #L4390) 
       Ad 100 ml nuclease-free ddH2O 
 
Empigen BB   30%  3 ml Empigen BB detergent (100%) 
       (Sigma-Aldrich, #45165) 
      7 ml nuclease-free ddH2O 
 
Triton X-100   10%  1 ml Triton X-100 (100%) 
       (Sigma-Aldrich, #T8787) 
      9 ml nuclease-free ddH2O 
 
LiCl    2.5 M  10.6 g Lithium chloride 
       (Merck Millipore, # 438002) 
       Ad 100 ml nuclease-free ddH2O 
 
Deoxycholate   10%  1g Sodium deoxycholate 
       (Sigma-Aldrich, #D6750) 
       Ad 10 ml nuclease-free ddH2O 
 
NaHCO3   1 M  84 g Sodium hydrogen carbonate 
       (Merck Millipore, #1063290500) 
       Ad 1 l nuclease-free ddH2O 
 
Cell Buffer Mix (CBM)  10 mM  1 ml HEPES/KOH (1 M, pH 7.9) 
    85 mM  4.25 ml KCl (2 M) 
    1 mM  200 µl EDTA/NaOH (500 mM, pH 8.0) 
      91.55 ml nuclease-free ddH2O 
 
 immediately before use, add the following inhibitors per ml CBM: 
    1 mM  10 µl PMSF (100 mM) 
      20 µl Inhibitor Mix (50x) 
       (Roche, #04693132001) 
 
Suspension Buffer    900 µl CBM 
      100 µl nuclease-free ddH2O 
 
Cell Lysis Buffer     900 µl CBM 
    1%  100 µl NP-40 (10%) 
       (Roche, #11332473001) 
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Nuclear Lysis Buffer  50 mM  5 ml Tris/HCl (1 M, pH 7.4) 
    1%  5 ml SDS (20%) 
    0.5%  1.667 ml Empigen BB (30%) 
    10 mM  2 ml EDTA/NaOH (500 mM, pH 8.0) 
      83.33 ml nuclease-free ddH2O 
 
 immediately before use, add the following inhibitors per ml Nuclear Lysis Buffer: 
    1 mM  10 µl PMSF (100 mM) 
      20 µl Inhibitor Mix (50x) 
       (Roche, #04693132001) 
 
Dilution Buffer (DB)  20 mM  2 ml Tris/HCl (1 M, pH 7.4) 
    100 mM  2 ml NaCl (5 M) 
    2 mM  400 µl EDTA/NaOH (500 mM, pH 8.0) 
    0.5%  5 ml Triton X-100 (10%) 
      87.6 ml nuclease-free ddH2O 
 
immediately before use, add the following inhibitors per ml Dilution Buffer: 
    1 mM  10 µl PMSF (100 mM) 
      20 µl Inhibitor Mix (50x) 
       (Roche, #04693132001) 
 
Wash Buffer 
 WBI   20 mM  2 ml Tris/HCl (1 M, pH 7.4) 
    150 mM  3 ml NaCl (5 M) 
    0.1%  500 µl SDS (20%) 
    1%  10 ml Triton X-100 (10%) 
    2 mM  400 µl EDTA/NaOH (500 mM, pH 8.0) 
      84.1 ml nuclease-free ddH2O 
 WBII   20 mM  2 ml Tris/HCl (1 M, pH 7.4) 
    500 mM  10 ml NaCl (5 M) 
    1%  10 ml Triton X-100 (10%) 
    2 mM  400 µl EDTA/NaOH (500 mM, pH 8.0) 
      84.1 ml nuclease-free ddH2O 
 WBIII   10 mM  1 ml Tris/HCl (1 M, pH 7.4) 
 (protect from light!) 250 mM  10 ml LiCl (2.5 M) 
    1%  10 ml NP-40 (10%) 
    1%  10 ml Deoxycholat (10%) 
    1 mM  200 µl EDTA/NaOH (500 mM, pH 8.0) 
      68.8 ml nuclease-free ddH2O 
 
Elution Buffer   0.1 M  500 µl NaHCO3 (1 M) 
    1%  250 µl SDS (20%) 
      4.25 ml nuclease-free ddH2O 
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4.3.1.18 Library preparation for next generation sequencing 
Next generation sequencing (NGS) libraries were prepared to be sequenced on Illumina platforms 
(GenomeAnalyzer, HiSeq1000). In general, DNA loBind tubes (Eppendorf) were used. Library 
preparation was subsequently enhanced during the time of this thesis, resulting in three different 
preparation protocols (NGS library protocol I, II & III). The protocol used for the individual library 
preparations will be indicated in the results’ section. Library preparation of RNA samples for NGS 
is described separately in section 4.3.2.3. 
NGS library protocol I 
Using the NEBNext DNA Library Prep Reagent Set for Illumina (NEB) and the Oligo Only Kit 
(Illumina) immunoprecipitation (IP) samples were first subject to end repair to convert overhangs 
of double stranded DNA fragments into phosphorylated blunt ends (see Table 4-30). 
 
Table 4-30 Reaction composition for end repair (NGS library protocol I) 
Component  Volume  Final concentration  
Nuclease-free ddH2O 0.8 μl n.a. 
T4 DNA Ligase buffer with 10 mM ATP (10x) 5 μl 1x (1 mM ATP) 
dNTP mix (10 mM each) 2 μl 0.4 mM each 
T4 DNA polymerase 1 μl n.a. 
Klenow DNA Polymerase 0.2 μl n.a. 
T4 Polynucleotide Kinase 1 µl n.a. 
IP DNA sample* 40 μl n.a. 
Final Volume 50 µl 
* For input: 10 ng, add 40 µl nuclease-free ddH2O 
 
The reaction mix was incubated at 20 °C for 30 min in a thermal cycler and subsequently purified 
using the QIAquick PCR Purification Kit (Qiagen) with an advanced protocol: After binding the 
sample to the column, the flow-through was transferred back onto the column and centrifuged 
again. After washing with 750 µl PE buffer, the column was transferred to a new collection tube 
and the empty column centrifuged at RT for 2 min at 13000xg. The column was transferred to a 
new 1.5 ml tube and the residual PE buffer was aspirated from the purple ring inside the column. 
After air-drying the column for 1 min, 36 µl of prewarmed EB buffer (50 °C) was applied to the 
column center and incubated at RT for 5 min. To recover the eluate, the column was centrifuged 
at RT for 1 min at 9500xg. Residual EB buffer on the purple ring as well as the flow-through was 
transferred back onto the column that was centrifuged again. The final volume of the eluate was 
34 µl. 
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The next step introduced an A-overhang to the 3’ end of the phosphorylated blunt ends of the 
DNA fragments and was required for subsequent ligation of adapters (see Table 4-31). 
 
Table 4-31 Reaction composition for A-overhang introduction (NGS library protocol I) 
Component  Volume  Final concentration  
Klenow Buffer (10x) 5 μl 1x 
dATP (1 mM) 10 μl 200 µM 
Klenow fragment (3’ to 5’ exo minus) 1 µl n.a. 
End-repaired IP sample 34 μl n.a. 
Final Volume 50 µl 
 
The reaction mix was incubated at 37 °C for 30 min in a thermal cycler and subsequently purified 
using the QIAquick MinElute PCR Purification Kit (Qiagen) according to the advanced protocol 
described above. Elution was performed with 12 µl prewarmed EB buffer (50 °C) to recover 10 µl 
of the eluate. 
 
The next step ligated adapters to the end of the DNA fragments to allow later hybridization to an 
Illumina Next Generation Sequencing flow cell. 
 
Table 4-32 Reaction composition for adapter ligation (NGS library protocol I) 
Component  Volume  Final concentration  
Quick DNA ligase buffer (2x) 15 µl 1x 
Adapter (1:10 dilution, 1.5 pmol/µl) 1 μl 50 µM 
Quick DNA ligase 1 µl n.a. 
Nuclease-free ddH2O 3 µl n.a. 
IP sample (with A-overhang) 10μl n.a. 
Final Volume 30 µl 
 
The reaction mix was incubated at 20 °C for 15 min in a thermal cycler and subsequently purified 
using the QIAquick MinElute PCR Purification Kit (Qiagen) according to the advanced protocol 
described above. Elution was performed with 12 µl prewarmed EB buffer (50 °C) to recover 10 µl 
of the eluate. 
 
The next step removed excess adaptors and also includes a size selection. For each sample, a 
separate 2% agarose gel (50 ml) with small, thin pockets was prepared with TAE (1x) buffer. To 
each of the samples, 3 µl DNA light loading dye (6x) was added. In parallel, 0.5 µg Generuler 50 
bp ladder was run on both sides of the sample with one empty lane in between (60 V, 90 min. 
With a clean razor, the region of 175-225 bp as indicated by the ladder was excised from the gel. 
The DNA fragments trapped in the excised gel were extracted using the QIAquick Gel Extraction 
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Kit (Qiagen) with an advanced protocol. The gel pieces was weighted and transferred to 6 Vol QG 
buffer and incubated at RT on a rotor until gel is dissolved completely (~ 10 min). The dissolved 
gel sample was mixed with 2 Vol Isopropanol by pipetting. The mix was loaded onto a column by 
centrifugation at RT for 30 sec at 13000xg. The flow-through was loaded again onto the column 
and the column centrifuged until the entire volume has passed through the column. The flow-
through was discarded and the column washed with 500 µl QC buffer. The column was washed 
twice with 750 µl PE buffer and centrifuged at RT for 45 sec at 13000xg. The empty column was 
centrifuged again at RT for 1 min at 13000xg and transferred to a new 1.5 ml tube. After residual 
PE buffer was aspirated from the purple ring, the column was air-dried for 1 min. To elute the 
bound DNA fragments, the column was incubated with 38 µl prewarmed EB buffer (50 °C) for 
3 min at RT and subsequently centrifuged at RT for 1 min at 13000xg. The column was rotated by 
180 ° within the 1.5 ml tube and centrifuged again. 36 µl elute were recovered. 
Following excess adapter removal and size selection, the adapter-modified DNA fragments were 
enriched by PCR according to Table 4-33 & Table 4-34. 
 
Table 4-33 Reaction composition for PCR enrichment (NGS library protocol I) 
Component  Volume  Final concentration  
Phusion HF buffer (5x) 10 1x 
dNTP mix (10 mM each) 1.5 µl 300 µM each 
PCR primer 1.1 (25 µM) 1 µl 0.5 µM 
PCR primer 2.1 (25 µM) 1 µl 0.5 µM 
Phusion polymerase 0.5 n.a. 
Size-selected DNA fragments 36 µl n.a. 
Final Volume 50 µl 
 
Table 4-34 Cycling protocol for PCR enrichment (NGS library protocol I) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  30 sec 1× 
Denaturation  98 °C 10 sec 
18× Annealing 65 °C 30 sec 
Extension 72 °C  30 sec 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
The PCR-enriched DNA fragments were purified with the QIAquick MinElute PCR Purification Kit 
(Qiagen) according to the advanced protocol described above. To increase purity and yield, the 
column was washed twice with PE buffer and elution was performed in two steps with 10 µl 
prewarmed EB buffer (50 °C) each and 3 min incubation at RT. The final volume of the eluate was 
16 µl. To validate the successful enrichment of the size-selected DNA fragments, 1 µl of the library 
sample was analyzed on a Bioanalyzer DNA HS assay. 
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The library samples were further processed for NGS data acquisition by the KFB (Biopark, 
Regensburg). 
NGS library protocol II 
Using Enzymatics enzymes (NEB) and NEXTflex indexed adapters (Bioo Scientific) the IP sample 
was first subject to end repair to convert overhangs of double stranded DNA fragments into 
phosphorylated blunt ends (see Table 4-35).  
 
Table 4-35 Reaction composition for end repair (NGS library protocol II) 
Component  Volume  Final concentration  
Nuclease-free ddH2O 3.34 μl n.a. 
T4 DNA ligase buffer (10x) 5 μl 1x 
dNTP mix (10 mM each) 1 μl 0.2 mM each 
T4 DNA polymerase 0.3 μl n.a. 
Klenow Fragment 0.06 μl n.a. 
T4 Polynucleotide Kinase 0.3 µl n.a. 
IP DNA sample* 40 μl n.a. 
Final Volume 50 µl 
* For input: 10 ng, add 40 µl nuclease-free ddH2O 
 
The reaction mix was incubated at 20 °C for 30 min in a thermal cycler and subsequently purified 
using the QIAquick MinElute PCR Purification Kit (Qiagen) with an advanced protocol: After 
binding the sample to the column by centrifugation at RT for 30 sec at 9500xg, the flow-through 
was transferred back onto the column and centrifuged again. After washing twice with 750 µl PE 
buffer (centrifugation at RT for 45 sec at 13000 g), the column was transferred to a new collection 
tube and the empty column centrifuged at RT for 2 min at 13000xg. The column was transferred 
to a new 1.5 ml tube and the residual PE buffer was aspirated from the purple ring inside the 
column. After air-drying the column for 1 min, 10.25 µl of prewarmed EB buffer (50 °C) was 
applied twice to the column center and incubated at RT for 5 min. To recover the eluate, the 
column was centrifuged at RT for 1 min at 9500xg. Residual EB buffer on the purple ring as well 
as the flow-through was transferred back onto the column that was centrifuged again. The final 
volume of the eluate was 18 µl. 
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The next step introduced an A-overhang to the 3’-end of the phosphorylated blunt ends of the 
DNA fragments and was required for subsequent ligation of adapters (see Table 4-36). 
 
Table 4-36 Reaction composition for A-overhang introduction (NGS library protocol II) 
Component  Volume  Final concentration  
Blue Buffer (10x) 2 μl 1x 
dATP (10 mM) 0.4 μl 195 µM 
Klenow fragment (3’ to 5’ exo minus) 0.2 µl n.a. 
End-repaired IP sample 18 μl n.a. 
Final Volume 20.6 µl 
 
The reaction mix was incubated at 37 °C for 30 min in a thermal cycler. 
The next step ligated adapters to the end of the DNA fragments to allow later hybridization to an 
Illumina Next Generation Sequencing flow cell. Beforehand, 0.5 µl of indexed NEXTflex adapters 
(Bioo Scientific) were diluted 1:20 with 1x T4 DNA ligase buffer (10x T4 DNA ligase buffer diluted 
1:10 with nuclease-free ddH2O). Then, 20.6 µl of the prepared IP sample were mixed on ice with 
22.6 µl Rapid Ligation Buffer (2x). Subsequently, 1 µl of the diluted adapter mix were added on 
ice, as well as 1 µl of T4 DNA Ligase. The reaction mix was mixed on ice and incubated at 30 °C 
for 10 min. Finally, 4.8 µl nuclease-free ddH2O were added to adjust the volume to 50 µl. 
 
Excess adapters were removed by clean up with AMPure XP magnetic beads (equilibrated for 
30 min at RT on a rotor) at a ratio 1:1.1. 55 µl beads were added to the ligation mix (50 µl), 
vortexed (speed 6) two times, inverted and vortexed again and then incubated at RT for 5 min. 
The tube was placed on a magnetic particle concentrator (MPC) for 2 min to remove the 
supernatant. The trapped beads were washed twice with 500 µl Ethanol (70%, prepared freshly). 
To remove residual Ethanol, the beads were air-dried at 37 °C for 2-5 min. The bound DNA 
fragments were eluted by incubation with 50 µl nuclease-free ddH2O at RT for 5 min. After 
centrifugation at RT for 1 sec at 13000xg, the tubes were placed on a MPC for 2 min and the 
supernatant was transferred to a new 1.5 ml tube for a second round of clean up. Elution volume 
of the second clean up depended on the IP procedure; ChIP samples were eluted with 37.5 µl 
nuclease-free ddH2O and MCIp samples with 25 µl, respectively. 
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Following excess adapter removal, the adapter-modified DNA fragments were enriched by PCR 
according to the following tables. 
 
Table 4-37 Reaction composition for PCR enrichment of ChIP samples (NGS library protocol II) 
Component  Volume  Final concentration  
Phusion HF buffer (5x) 10 1x 
dNTP mix (10 mM each) 1.5 µl 300 µM each 
BiooPrimer1 (100 µM) 0.25 µl 0.5 µM 
BiooPrimer2 (100 µM) 0.25µl 0.5 µM 
Phusion polymerase 0.5 n.a. 
Adapter-ligated ChIP sample 37.5 µl n.a. 
Final Volume 50 µl 
 
Table 4-38 Reaction composition for PCR enrichment of MCIp samples (NGS library protocol II) 
Component  Volume  Final concentration  
Phusion HF buffer (5x) 10 1x 
Betaine (5 M)* 13 1.3 M 
dNTP mix (10 mM each) 1.0 µl 200 µM each 
BiooPrimer1 (100 µM) 0.25 µl 0.5 µM 
BiooPrimer2 (100 µM) 0.25µl 0.5 µM 
Phusion polymerase 0.5 n.a. 
Adapter-ligated ChIP sample 25 µl n.a. 
Final Volume 50 µl 
* to dissolve GC-rich sequences 
 
Table 4-39 Cycling protocol for PCR enrichment of ChIP samples (NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  30 sec 1× 
Denaturation  98 °C 10 sec 
18× Annealing 65 °C 30 sec 
Extension 72 °C  30 sec 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
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Table 4-40 Cycling protocol for PCR enrichment of MCIp samples (NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  2 min* 1× 
Denaturation  98 °C 30 sec* 
18× Annealing 65 °C 30 sec 
Extension 72 °C  45 sec* 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
* to dissolve GC-rich sequences 
 
Excess primers were removed by two times clean up with AMPure XP magnetic beads 
(equilibrated for 30 min at RT on a rotor) at a ratio 1:1.1. 55 µl beads were added to the PCR 
reaction mix (50 µl) and processed as before. After the first clean up, the bound DNA fragments 
were eluted with 50 µl nuclease-free ddH2O, after the second clean up with 12 µl. 
 
Size selection of the amplified DNA fragments was performed gel electrophoresis and excision of 
the desired fragment size. The eluate (12 ml) was mixed with 2 µl loading dye (6x) and loaded 
together with 1 µg 50 bp DNA ladder (NEB) (separated by one lane) on a 2% low-melting agarose 
gel (50 ml, 1x TAE). The gel was run for 60 min at 100 V with pre-cooled running buffer. Using a 
clean razor, fragments in the range of 200-350 bp were excised and subject to DNA extraction 
with the QIAquick Gel Extraction Kit. The gel piece was weighted and dissolved in 6 Volumes OC 
buffer by incubation at RT (approx. 5 min). The dissolved gel sample was mixed with 2 Volumes 
Isopropanol and loaded twice onto the column by centrifugation at RT for 30 sec at 9500xg. The 
following clean up procedure was similar to NGS library protocol I. The bound DNA fragments 
were eluted with 13 µl prewarmed EB buffer (50 °C). The final volume of the eluate was 11 µl. To 
validate the successful enrichment of the size-selected DNA fragments, 1 µl of the library sample 
was analyzed on a Bioanalyzer DNA HS assay. 
The library samples were further processed for NGS data acquisition by the KFB (Biopark, 
Regensburg). 
NGS library protocol III 
This protocol is similar to NGS protocol II except for the PCR enrichment and size selection 
procedure. The protocol stated was established for ChIP and MCIp samples. For this work, NGS 
library protocol III was only performed on a BAC pool sample, which was treated similar as ChIP 
samples. Relevant alterations to the established protocol are stated accordingly. 
The pool of BACs was fragmented by Focused Ultrasonication (Covaris, see section 4.3.1.3) 
using the 200 bp setting for genomic DNA in 130 µl TE (0.09x). The volume was reduced by 
lyophylization to ~30 µl and the concentration determined with the Qubit HS DNA assay. In 
parallel, 130 µl TE (0.09x) were also lyophilized to the same degree for later size selection with 
the Caliper LapChip approach. 
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Following excess adapter removal, the adapter-modified DNA fragments were enriched by PCR in 
two rounds; round one was performed according to the following tables. In between the two PCR 
reactions, size selection using the Caliper LabChip approach (PerkinElmer) was performed. 
 
Table 4-41 Reaction composition for PCR enrichment of ChIP samples (NGS library protocol III) 
Component  Volume  Final concentration  
Phusion HF buffer (5x) 10 1x 
dNTP mix (10 mM each) 1.5 µl 300 µM each 
BiooPrimer1 (100 µM) 0.25 µl 0.5 µM 
BiooPrimer2 (100 µM) 0.25µl 0.5 µM 
Phusion polymerase 0.5 n.a. 
Adapter-ligated ChIP sample 37.5 µl n.a. 
Final Volume 50 µl 
 
Table 4-42 Reaction composition for PCR enrichment of MCIp samples (NGS library protocol III) 
Component  Volume  Final concentration  
Phusion HF buffer (5x) 10 1x 
Betaine (5 M)* 13 1.3 M 
dNTP mix (10 mM each) 1.0 µl 200 µM each 
BiooPrimer1 (100 µM) 0.25 µl 0.5 µM 
BiooPrimer2 (100 µM) 0.25µl 0.5 µM 
Phusion polymerase 0.5 n.a. 
Adapter-ligated ChIP sample 25 µl n.a. 
Final Volume 50 µl 
* to dissolve GC-rich sequences 
 
Table 4-43 Cycling protocol for PCR enrichment (part 1) of ChIP samples 
(NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  30 sec 1× 
Denaturation  98 °C 10 sec 
4× Annealing 65 °C 30 sec 
Extension 72 °C  30 sec 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
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Table 4-44 Cycling protocol for PCR enrichment (part 1) of MCIp samples 
(NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  2 min* 1× 
Denaturation  98 °C 30 sec* 
4× Annealing 65 °C 30 sec 
Extension 72 °C  45 sec* 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
* to dissolve GC-rich sequences 
 
Excess primers were removed by clean up with AMPure XP magnetic beads (equilibrated for 
30 min at RT on a rotor) at a ratio 1:1.8. 90 µl beads were added to the PCR reaction mix (50 µl) 
and processed as before. The bound DNA fragments were eluted with 10 µl nuclease-free ddH2O 
and transferred to a new tube for the Caliper approach. Normally, 2 µl dye was added to the 
eluted fragments and fragments of 275 bp  15% (234-316 bp) using the LabChip XT DNA 300 
Chip were recovered. Input DNA was recovered at a size range of 250 bp  15% (213-287 bp). 
The recovery volume was 20 µl. In case of the pooled BACs, the ladder was diluted in the 
lyophilized TE sample 
 
After adjusting the sample volume with nuclease-free ddH2O to 37.5 µl for ChIP samples or 25 µl 
for MCIp samples, respectively, the second round of PCR enrichment of the size selected DNA 
fragments was performed. For round two, reaction composition is the same as for round one (see 
Table 4-41 and Table 4-42), but the cycle number was increased (see Table 4-45 & Table 4-46) 
 
Table 4-45 Cycling protocol for PCR enrichment (part 2) of ChIP samples 
(NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  30 sec 1× 
Denaturation  98 °C 10 sec 
12× Annealing 65 °C 30 sec 
Extension 72 °C  30 sec 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
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Table 4-46 Cycling protocol for PCR enrichment (part 2) of MCIp samples 
(NGS library protocol II) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  98 °C  2 min* 1× 
Denaturation  98 °C 30 sec* 
12× Annealing 65 °C 30 sec 
Extension 72 °C  45 sec* 
Final extension  72 °C  5 min 1× 
Cooling 4 °C hold 
* to dissolve GC-rich sequences 
 
The PCR product was again depleted of excessive primers with AMPure XP beads (twice) as 
described above (1:1.1 ratio). Elution volume of the first round was 50 µl nuclease-free ddH2O, of 
the second 11 µl. 1 µl of the final eluate was run on a Bioanalyzer DNA HS Chip to validate 
successful enrichment of size-selected DNA fragments. 
The library samples were further processed for NGS data acquisition by the KFB (Biopark, 
Regensburg). 
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4.3.1.19 Next generation sequencing on the Illumina platform 
High-throughput DNA Sequencing with the Solexa Sequencing-by-Synthesis Technology 
(Illumina) (next generation sequencing, NGS) is based on iterative sequencing using reversible 
terminator chemistry. Labeling the modified nucleotides with different fluorescent dyes permits 
parallel readout of all immobilized library molecules. The sequencing-by-synthesis workflow is 
illustrated in Figure 4-3. The advantage to Sanger sequencing is the massive parallel sequencing 
of millions of DNA fragments. Due to the high sequencing depth, up to 4 billion reads per lane, 
multiplexing of samples by using barcoded libraries dramatically reduces costs. Samples analyzed 
by NGS in this work included ChIP, MCIp, RNA, and pooled BAC samples. 
 
 
 
 
Figure 4-3 Workflow of Illumina’s NGS technology 
1, 2 – Single strands of the NGS library generated according to the NGS library protocols listed in section 
4.3.1.18 bind to complementary adapters. 3-6 – Clusters with more than 100 copies of the starting library 
molecule are generated by bridge amplification. 7 – Sequencing primer anneal to the adapter sequence of 
the cluster molecule and 3’-terminated, fluorescent-labeled nucleotides are incorporated at the 3’ end of the 
sequencing primer by a modified polymerase (due to the 3’ terminating modification, only one nucleotide per 
cycle is incorporated). 8 – Using different lasers for excitation and filters, an image is generated of the 
attached fluorophores, which reflects the incorporation positions of the individual nucleotides. 9-11 – 
Following each imaging cycle, the 3’ terminators as well as the fluorescent labels are chemically removed 
permitting for a new cycle of incorporation and imaging. The read length for all clusters is determined by the 
numbers of repeated incorporation and imaging cycles. Barcodes of pooled libraries are encoded in the 
adapter sequence and assessed accordingly. Different sequences of left and right adapter allows for paired-
end sequencing. 12 – Following sequencing, the Illumina base caller analyzes the images. The collected 
sequence data are aligned and compared with a reference sequence. (Taken from Illumina, 
www.illumina.com) 
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4.3.1.20 BAC library screening with DIG-labeled probes 
BACPAC Resources harbours BAC libraries from a multitude of organisms; however, most of 
BAC clones have not been mapped yet, inter alia BALB/cByJ (CHORI-28). To identify BACs of 
interests, BACPAC Resources provides filter membranes with spotted BAC clones representing 
the whole library. Each membrane carries over 18000 distinct BAC clones in duplicates and 
statistically represents the genome once. To statistically obtain 3x coverage of the region of 
interest three membranes were screened. 
Probe design 
Hybridization probes were generated by PCR. PCR primers were designed with the PerlPrimer 
software according to the following criteria. 
(i) one amplicon per 50 kb window within region mm9_chr12:16902483-26024113 (to enhance the 
detection signal for each BAC), (ii) The melting temperature Tm was restricted to 63-65 °C 
(max=2 °C) (to yield an annealing temperature of ~60 °C), (iii) The amplicon length was set to 
400-500 bp (to provide for a reasonable number of DIG-labeled bases per amplicon), (iv) the 
length of the oligos was set to 21-28 bp (to facilitate BLATing in UCSC genome browser as well 
as appropriate Tms), (v) sequences with high GC content were excluded (for similar PCR 
conditions), (vi) GC clamp at the 3’ end of oligos was preferred (to ensure primer specificity), (vii) 
at least one oligonucleotide per amplicon needed to map less than three times by BLAT (UCSC 
genome browser) (to generate distinct amplicons), (viii) the amplicons returned by In-Silico PCR 
(UCSC genome browser) must to fall within the 9 Mb candidate region and if criterion (vii) could 
not be fulfilled, were limited to three distinct amplicons per oligonucleotide pair. 
- Primer binding sites must not to contain known SNPs 
- Primer binding sites should not overlap with repetitive sequences 
If criterion (vii) was omitted and up to three different 50 kb windows within the candidate region 
were covered with one probe, additional probe design for these regions was refrained from. 
 
Furthermore, the theoretical hybridization temperature for the amplicons was calculated according 
to the following formula: 
   Thyb=Tm - (20 to 25 °C) 
Tm’=49.82 + 0.41(%GC) - 600/length(bp) 
(for 80-100% sequence homology) 
 
Since probe design for the repetitive regions was difficult in general, only probes of the conserved 
regions were limited to an intermediate hybridization temperature of THyb=42-50°C (formula see 
below). 
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PCR labeling  
PCR was initially performed with normal dNTPs to optimize the amplification conditions as well as 
to control for specificity. PCR was performed as described in Table 4-47 & Table 4-48, but scaled 
up to 50 µl total reaction volume and with dNTP mix (2mM) instead of PCR DIG Probe Synthesis 
Mix (10x). 5 µl of the PCR product were analyzed by gel electrophoresis on a 1.5% agarose gel 
(120 V, 120 min). In case of insufficient PCR product, the setting were adjusted individually 
(setting ranges are listed below Table 4-48). The residual 45 µl of probes with multiple amplicons 
were separated on a second 1.5% agarose gel (120 V, 120 min) and the amplicons with the 
expected size were cut out and amplified DNA purified with the QIAquick GelExtraction Kit. The 
concentration of the purified amplicons was assessed with the NanoDrop apparatus and adjusted 
to ~300 pg/µl with nuclease-free ddH2O. The probes were labeled with Digoxigenin during PCR 
amplification of genomic DNA from BALB/cByJ or amplicon DNA, respectively, with the PCR DIG 
Probe Synthesis Kit (Roche). 
 
PCR was performed in 96-well PCR plates. Mixes for multiple reactions were prepared according 
to Table 4-47 and dispensed to the wells in the following order. 6 µl of nuclease-free ddH2O was 
dispensed to each well as well as 2 µl Primer mix (containing sense and antisense Primers at a 
concentration of 6.25 µM each). Subsequently, 7 µl of Mix1 was added to each well, as well as 
10 µl of Mix2.  
 
Table 4-47 Reaction composition for DIG PCR labeling 
Component  Volume  Final concentration  
Mix1 (for genomic DNA) 
Nuclease-free ddH2O 4 μl n.a. 
PCR DIG Probe Synthesis Mix (10x) 2.5 μl 1x (200 µM of each nucleotide) 
genomic DNA 0.5 μl 10 ng 
Final Volume 7 µl 
Mix1 (for amplicon DNA) 
Nuclease-free ddH2O 3.5 μl n.a. 
PCR DIG Probe Synthesis Mix (10x) 2.5 μl 1x (200 µM of each nucleotide) 
amplicon DNA (1:60 dilution) 1 µl 5 pg 
Final Volume 7 µl 
Mix2 
Nuclease-free ddH2O 7.125 μl n.a. 
PCR Buffer (10x) 2.5 µl 1x 
Enzyme Mix (3.5 U/ml) 0.375 µl 1.3 U 
Final Volume 10 µl  
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The plate content was mixed on a vortexer and incubated on a thermal cycler according to Table 
4-48. 
 
Table 4-48 General cycling protocol for DIG PCR labeling 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  95 °C  4 min 1× 
Denaturation  95 °C  30 sec 
30×*** Annealing 62 °C* 30 sec 
Extension 72 °C  25 sec** 
Final extension  72 °C  7 min 1× 
Cooling 4 °C hold 
* 56-62 °C, ** 25-30 sec, ***30 or 32 cycles 
 
For hybridization, 2-4 µl of the individual probe would be mixed with 1 ml DIG Easy Hyb buffer. 
The individual volume of each probe depended on the labeling efficiency that was assessed by 
Dot plot analysis (see below). Since the probes were pooled for parallel hybridization, less amount 
of the individual probe was required per ml DIG Easy Hyb buffer. Depending on the number of 
combined probes and the labeling efficiency of the individual probes, 0.029 – 0.087 µl of the 
individual probe was contained per ml hybridization solution. 
Dot plot 
Prior to hybridization the labeling efficiency for each probe was tested in a dot plot experiment. A 
dilution series of each probe was spotted on a positively charged nylon membrane, UV-
crosslinked (120 mJ, 3-5min), and subject to DIG-antibody-based chemiluminescent detection 
(see following section). 
Probe hybridisation and detection 
Hybridizing colony filters for the 1
st
 time, cell debris from the spotting procedure have to be 
removed. The membranes were incubated twice for 10 min at RT in 150 ml SSC (2x) on a shaker 
followed by two times incubation for 15 min at RT in 150 ml SSC (2x, 1.5% SDS) on a shaker. The 
membrane was then placed on a soaked 3MM Whatman paper (2x SSC), DNA side facing up, 
and covered firmly with a wet sheet of 3MM Whatman paper (sterile ddH2O). A ruler was used to 
apply constant pressure. Afterwards the membrane was washed twice for 3 min at RT in 150 ml 
sterile ddH2O on a shaker. 
The precleared membrane was then equilibrated for min. 15 min at RT in 150 ml SSC (2x) and 
placed on a hybridization mesh also soaked in SSC (2x). The same applies for stripped 
membranes. Both mesh and membranes were rolled up, placed in a hybridization bottle 
containing 40 ml prewarmed DIG Easy Hyb buffer (Roche) and incubated in a rotating 
hybridization oven for 1.5-3 h at the theoretically determined hybridization temperature (Thyb) 
determined above. 
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Hybridization solution was prepared by adding 2 µl denatured probe mix (98 C, 10 min  on 
slushy ice, min. 5 min) per ml prewarmed (Thyb) DIG Easy Hyb buffer (Roche). Used hybridization 
solutions can be stored at -20 °C and reused 3-4 times. Prior to reusing stored hybridization 
solutions it was incubated at 68 °C for 10 min and cooled immediately on slushy ice for 10 min. 
After pre-hybridization, DIG Easy Hyb Buffer was replaced by prewarmed hybridization solution 
and the membrane was incubated with the hybridization solution for 24 h at Thyb in a rotating 
hybridization oven. 
The membrane was washed 3 times for 3 min in 250 ml Low Stringency Buffer in the hybridization 
bottle, which was shaked by hand. The membrane was then transferred to a new, prewarmed 
(68 °C) hybridization bottle, filled with 250 ml prewarmed (68 °C) High Stringency Buffer and 
placed in the hybridization oven. The High Stringency Buffer was replaced 3 times during 30 min 
incubation at 68 °C. Hybridized membranes can be stored or used directly for chemiluminescent 
detection of hybridized probes. 
For storage, membranes were air-dried and kept between two sheets of 3MM Whatman paper in 
a sealed bag at 4 °C. Stored membranes cannot be stripped and re-probed after detection. 
For chemiluminescent detection of hybridized probes the membrane was washed twice in 250 ml 
Washing Buffer (1x, Roche) for 2 min and blocked for at least 30 min (up to 3 h) in 400 ml 
Blocking Solution (1x, Roche). The blocked membrane was incubated in 75 ml Antibody Solution 
(Roche) for 30 min and washed again twice in 300 ml Washing Buffer (1x, Roche) for 15 min. The 
antibody binds to the DIG epitope of hybridized probes, whereas unspecifically bound antibodies 
are washed away. The membrane was then equilibrated in 60 ml Detection Buffer (1x, Roche) for 
2-5 min. All previous steps were carried out at RT on a shaker. For detection the equilibrated 
membrane was placed onto plastic foil with the DNA side facing up, sprinkled with 3 ml/100 cm
2
 of 
CDP-Star substrate (Roche) and immediately covered with another sheet of plastic foil in a way 
that allows for even spreading of the CDP-Star substrate. The bound antibody is linked to an 
enzyme emitting detectable light upon the addition of substrate. After 5 min incubation at RT, 
excessive substrate was removed and the two sheets of plastic foil were weld together. The 
chemiluminescent signal was detected on GelDoku (Bio-Rad) for 60-90 min with pictures taken 
every 90 sec. The signal is detectable up to 2 days after substrate addition. 
Membranes that were not air-dried after probe hybridization were stripped after chemiluminescent 
detection of the hybridized probes. The membrane was rinsed in 300 ml sterile ddH2O for 1 min 
and incubated twice in 250 ml Stripping Buffer for 15 min at 37 °C on a shaker. The membrane 
was rinsed in SSC (2x) for 5 min at RT and stored wet between two sheets of 3MM Whatman 
paper in SSC (2x) at 4 °C. 
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Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
SSC    2x  50 ml UltraPure SSC Buffer (20x) 
       (Gibco/Life Tech. # 15557-044) 
      450 ml sterile ddH2O 
 
SDS    10%  100 g Sodium dodecyl sulfate 
       (Sigma-Aldrich, #L4390) 
       Ad 1 l nuclease-free ddH2O 
 
 
SSC (2x, 1.5% SDS)    50 ml UltraPure SSC Buffer (20x) 
       (Gibco/Life Tech. # 15557-044) 
      75 ml SDS (10%) 
 
DIG Easy Hyb Buffer     DIG Easy Hyb 
(Roche, #11603558001) 
 
Low Stringency Buffer    75 ml UltraPure SSC Buffer (20x) 
       (Gibco/Life Tech. # 15557-044) 
      7.5 ml SDS (10%) 
      667.5 ml sterile ddH2O 
 
High Stringency Buffer    5 ml UltraPure SSC Buffer (20x) 
       (Gibco/Life Tech. # 15557-044) 
      10 ml SDS (10%) 
      985 ml sterile ddH2O 
 
DIG Wash and Block Buffer Set    Roche (#11585762001) 
 Maleic Acid Buffer (1x)   10 ml Maleic Acid Buffer (1x, RT) 
     90 ml sterile ddH2O 
      Stable at RT; 
 Blocking Solution (1x)   10 ml Blocking Solution (10x, RT) 
     90 ml Maleic Acid Buffer (1x, RT) 
      Prepare fresh and place at 4 °C; 
 Washing Buffer (1x)   10 ml Washing Buffer (10x, RT) (shake well!) 
90 ml sterile ddH2O 
      Stable at RT; 
 Detection Solution (1x)   10 ml Detection Buffer (10x) 
90 ml sterile ddH2O 
      Stable at RT; 
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Antibody Solution     Anti-Digoxigenin-AP Fab fragments 
       (Roche, #11093274910, 4 °C) 
  5min, 10’000 rpm, 4 °C 
1 µl ‘cleared’ Antibody 
10 ml Blocking Solution (1x) 
 Prepare fresh, stable for 12 h at 4 °C; 
 
CDP-Star substrate     CDP-Star ready-to-use 
       (Roche, #12041677001, 4 °C) 
 
Stripping Buffer     60 ml Sodium hydroxide solution (1M) 
       (Merck/Millipore, #109137) 
      3 ml SDS (10%) 
236 ml sterile ddH2O 
 
Hybridization bottle     Large hybridization bottle 
       (Biometra #846052001) 
 
Hybridization oven     Hybridization Oven 6/12 
       (Unitherm) 
 
Hybridization mesh     Mesh (23 cm x 23 cm) 
       (Labnet, #H9088) 
 
Plastic tray      Nunc™ Square BioAssay Dishes 
       (Thermo Scientific, #240835) 
 
Plastic foil      Weichfolien-Prospekthülle (DIN-A4) 
       (Milan #803) 
 
Welding apparatus     HS 250 
(Janke & Kunkel) 
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4.3.2 Preparation and analysis of ribonucleic acids (RNA) 
4.3.2.1 Isolation of total RNA (larger than 200 nt) 
Total RNA (>200 nt) was isolated using the RNeasy Midi, mini or Micro Kit (Qiagen) depending on 
the available number of cells according to the manufacturer’s instructions. In case of fresh or 
RNAlater-stabilized tissues, the tissue was homogenized with the TissueLyser (3 min, 20 Hz) and 
filtering through a QIAshredder column by centrifugation at RT for 3 min at 13000xg. To remove 
potential DNA contaminations, on-column DNA digestion with the RNase-free DNase Set 
(Qiagen) was integrated according to the protocol. RNA concentration was determined with the 
NanoDrop 1000 spectrophotometer. RNA integrity and quality was assessed with the Agilent 
Bioanalyzer RNA 6000 Chip assay (Agilent Technologies) according to the manufacturer’s 
instructions. 
 
4.3.2.2 Reverse transcription quantitative real-time PCR (RT-qPCR) 
To analyze transcription levels, total RNA was transcribed into complementary DNA (cDNA) with 
the M-MLV RT (H- point mutant) enzyme (Promega). Random decamers (Promega) were used to 
prime cDNA synthesis. Individual expression levels were subsequently assessed by quantitative 
PCR (see section 4.3.1.10) on cDNA level. 
The volume of 1 µg of total RNA was adjusted to 13 µl with nuclease-free ddH2O and mixed with 
1 µl Random Decamers (Promega) and 1 µl dNTPs (10 mM) on ice. Secondary structures are 
dissolved by 5 min incubation at 65 °C followed by immediate incubation ice for 1 min. After 
mixing with 4 µl M-MLV Buffer (5x) the sample was incubated at 42 °C for 2 min. Reverse 
transcription started upon addition of 1 µl RT enzyme (50 min, 42 °C) and was stopped by heat 
inactivation of the enzyme (15 min, 70 °C). CDNA samples are stable at -20 °C. 
 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
 
M-MLV RT (H- point mutant)    Promega (#M368B), -20 °C 
 
M-MLV Buffer (5x)     Promega (#M531A), -20 °C 
 
Random Decamers (Retroscript)    Ambion/Life Tech. (#5722G), -20 °C 
 
dNTPs    10 mM  100 µl dATP/dCTP/dGTP/dTTP each (100mM) 
       (Roche, # 11969064001) 
       Ad 1 ml nuclease-free ddH2O, store at -20 °C 
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4.3.2.3 Whole genome expression analysis by RNA-seq 
The Next generation sequencing technology can also be applied to analyze whole genome gene 
expression based on cDNA derive from RNA samples (RNA-seq). RNA-seq libraries from 
differentiating ESCs were prepared from RNA isolated according to section 4.3.2.1. 4.5 µg of RNA 
from BALB/c day0, day1, day2, and day4 as well as JM8 day0 and day4 was subject to ribosomal 
RNA (rRNA) depletion using the RiboZero (Mouse) Kit (Epicentre) according to the manufacturer’s 
instruction. The following variations of the protocol were applied: After washing the bead-bound 
RNA strands, the mixture was centrifuged for 5 min at 12000 g; to recover the eluted RNA 
strands, centrifugation was prolonged to 1:30 min; Ethanol precipitation to recover the cleaned 
rRNA-depleted RNA samples was performed o/n. The precipitated RNA was resuspended in 
5.5 µl nuclease-free ddH2O. Successful rRNA depletion was validated with the Bioanalyzer mRNA 
Nano assay (Agilent Technologies). According to the Bioanalyzer assay, recovered RNA amounts 
varied between 50 and 280 ng. Up to 210 ng rRNA-depleted RNA was further processed 
ScriptSeq (v1) RNA-seq Library Kit according to the manufacturer’s instructions. CDNA 
purification was performed with the QIAquick MinElute PCR Purification Kit according to the NGS 
library protocol I (see 4.3.1.18) and elution with 20 µl EB buffer (37 °C). To amplify the cDNA 
fragments, an alternate PCR cycling program to account for the use of Phusion Taq polymerase 
(which requires 72 °C for Elongation and is twice as fast). 
 
Table 4-49 Cycling protocol for PCR enrichment (RNA-seq library protocol v1) 
Cycle step  Temperature  Time  Number of cycles  
Initial denaturation  95 °C  30 sec 1× 
Denaturation  95 °C 30 sec 
11*× Annealing 55 °C 30 sec 
Extension 72 °C  1:45 min 
Final extension  72 °C  7 min 1× 
Cooling 4 °C hold 
* in case of BALB/c d0 (50 ng input) 12 cycles were used. 
 
The library fragments were purified using AMPure XP beads according to the manufacturer’s 
instructions and eluted in 25 µl nuclease-free ddH2O. Libraries were further processed for NGS at 
the KFB (Biopark, Regensburg). 
 
The RNA-seq libraries for JM8 day1 and day2 performed at a later stage and with newer versions 
of the above used Kits. RRNA removal was performed on 4.5 µg RNA with the rRNA Removal 
Magnetic Kit (Epicentre) according to the manufacturer’s instructions. After Ethanol precipitation 
o/n, the precipitated RNA was resuspended in 10 µl nuclease-free ddH2O. To validate rRNA-
removal, 1 µl of the rRNA-depleted RNA was diluted with 9 µl nuclease-free ddH2O and analyzed 
on a Bioanalyzer mRNA Pico assay (Agilent Technologies). As recommended by the 
manufacturer’s instructions, 15 ng of rRNA-depleted RNA were further processed with the 
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ScriptSeq v2 RNA-Seq Library Kit. PCR enrichment was validated on a Bioanalyzer DNA HS Chip 
assay (Agilent Technologies) and the libraries further processed for NGS at the KFB (Biopark, 
Regensburg). 
4.3.3 Molecular cloning 
4.3.3.1 Cloning of vectors for Sanger sequencing 
Subcloning of PCR products into a sequencing vector was either done with the StrataClone
TM
 
PCR Cloning Kit (Agilent Technologies) or the TOPO
®
 TA Cloning
®
 Kit (Life Technologies), 
respectively. 
Chemically competent E. coli were thawed on ice. Transformation with the ligation mix was 
performed according to the manufacturer’s instructions except that in general only half of the 
recommended Volumes were used. 250 µl SOC medium was added to the bacteria and the 
suspension was incubated at 37°C for one hour on a shaker in order to express the resistance. 
For blue/white screening of insert-containing clones, 40 µl of X-gal was dispersed on a prewarmed 
LBamp plate prior to use and incubated at 37°C for an additional 30 min. Afterwards 50-150 µl of 
the transformation reaction were plated and incubated at 37°C over night on LBamp plates. 
 
Required reagents and material: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
SOC medium   2%  20 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
    10 mM  0.6 g Sodium chloride 
       (AppliChem, #A3597) 
    3 mM  0.2 g Potassium chloride 
       (Merck Millipore, #1049360250) 
 Ad 1 l nuclease-free ddH2O, autoclave 
 Add to cooled solution: 
10 mM  10 ml MgCl2 (1 M), sterile-filtered 
    10 mM  10 ml MgSO4 (1 M), sterile-filtered 
    20 mM  10 ml Glucose (2 M), sterile-filtered 
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LB (Lysogeny broth) medium 170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave 
X-gal    40 mg/ml 40mg X-gal (5-bromo-4-chloro-3-indolyl- 
ß-D-galactoside) 
 Dissolve in 1 ml DMF 
 Store at -20°C protected from light 
4.3.3.2 BAC recombination with the Cre/LoxP system 
Cloning additional sequences like resistency-conferring genes can be achieved by recombination 
of LoxP sequence elements in the presence of active Cre recombinase. In a topoisomerase I like 
mechanism the enzyme performs site specific recombination event between two DNA segments 
containing the 34 bp long LoxP recognition site 
(ATAACTTCGTATANNNTANNNTATACGAAGTTAT)
272
. 
BACs selected from the CHORI-28 Mouse BALB/cByJ (Mus musculus) BAC libraries according to 
section 4.3.1.20 only contain a Chloramphenicol resistency not suitable for selection of 
transfected eukaryotic cells. Using the LoxP/Cre recombination system, the pNel plasmid, which 
carries similar to the BAC clones a LoxP recognition site, was integrated into the BAC backbone. 
PNel promotes prokaryotic resistency to Kanamycin and Spectinomycin, but also eukaryotic 
resistency to Geneticin (G418). PNel also encodes for an Enhanced Green Fluorescent Protein 
(eGFP) gene under the control of the eukaryotic CAG promoter and thus enables visualization of 
transfection efficiency. Without integration into the BAC backbone, pNel cannot be maintained in 
neither DH10B nor SW106 cells since its R6K ori requires the expression of the pir gene for 
replication. 
Retrofitting in the Cre-expressing E. coli strain SW106 
The SW106 cells express Cre recombinase after induction with L-(+)-Arabinose. The 
transformation of the BAC was done with 2 µl BAC preparations according to section 4.3.1.1 with 
the exception that the precipitated BAC DNA was resuspended in 6 µl nuclease-free ddH2O. 
SW106 cells were in general cultured at 30 °C. BAC DNA was electroporated into 
electrocompetent SW106 cells according to section 4.1.2.2. Selection for BAC-containing clones 
(sBACs) was done on LBCM agar plates incubated o/n at 30 °C (see Table 4-2). In general, one 
Glycerol stock per BAC was prepared from a single colony. For electroporation of sBACs with 
pNel 20 ml LBCM was inoculated with 1 ml of 2 ml LBCM o/n culture and shaked vigorously at 
30 °C for 1 h. Cre expression was induced by adding 0.1% L-(+)-Arabinose and further incubation 
at 30 °C for 1h. The cells were cooled on ice on a shaker for 15 min and harvested by 
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centrifugation (15 min, 2900xg, 4 °C). The pellet was washed twice with 2 ml and 1 ml ice-cold 
sterile ddH2O and once with 1 ml ice-cold sterile Glycerol/ddH2O (10%). The pellet was finally 
resuspended in 80 µl ice-cold sterile Glycerol/ddH2O (10%), which rendered ~90 µl of 
electrocompetent, Cre-expressing bacteria. 40 µl of the electrocompetent sBACs were used 
directly for electroporation, the remaining cells were stored at -80 °C as back up. 
The cells were transformed with 500 ng of pNel according to section 4.1.2.2 and plated on 
LBCM+Kan+Sp agar plates (see Table 4-2). After 24-36 h incubation at 30 °C several clones were 
picked and the retrofitted BACs (nBACs, in SW106 strain) were prepared according to section 
4.3.1.1. The HindIII digestion pattern of the individual nBACs was compared to the original BAC 
(oBACs, in DH10B strain) and a glycerol stock was prepared for a positive nBAC. 
Retrofitting with the Cre-encoding pJM2545 plasmid 
The pJM2545 plasmid constantly expresses Cre recombinase, but has a temperature-sensitive 
replication ori. BAC-containing cells co-transformed with both pNel and pJM2545 will experience 
LoxP/Cre recombination until they are incubated at high temperature, which leads to the loss of 
pJM2545 during replication. Individual oBAC clones were prepared for electroporation as 
described above for sBACs with the exception that the cells were incubated at 37 °C and no 
supplement was added to the medium except selecting antibiotic. Furthermore, the washed cell 
pellet was resuspended 30 µl ice-cold sterile Glycerol/ddH2O (10%) and used completely for 
electroporation with 200 ng pJM2545 and 500 ng pNel (settings according to section 4.1.2.2). 
After 1 h recovery in 250 µl SOC medium, the cells were plated on 2xYTCM+Sp agar plates and 
incubated for 1 h at 30 °C followed by o/n incubation at 42 °C. Several clones were picked and the 
retrofitted BACs (njBACs, in DH10B strain) were prepared according to section 4.3.1.1. The 
HindIII digestion pattern of the individual njBACs was compared to the oBACs and a Glycerol 
stock was prepared for a positive njBAC. 
 
Required reagents and materials: 
(Stated volume-/weight-% or molarities refer to final concentrations, storage according to manufacturer’s 
instructions or at RT if not stated otherwise) 
SOC medium   2%  20 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
    10 mM  0.6 g Sodium chloride 
       (AppliChem, #A3597) 
    3 mM  0.2 g Potassium chloride 
       (Merck Millipore, #1049360250) 
 Ad 1 l nuclease-free ddH2O, autoclave 
 Add to cooled solution: 
10 mM  10 ml MgCl2 (1 M), sterile-filtered 
    10 mM  10 ml MgSO4 (1 M), sterile-filtered 
    20 mM  10 ml Glucose (2 M), sterile-filtered 
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LB (Lysogeny broth) medium 170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave 
 
LB agar plates   1.5%  15 g Bacto
TM
 Agar 
       (BD, #214010) 
    170 mM  10 g Sodium chloride 
       (AppliChem, #A3597) 
    1%  10 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    0.5%  5 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with 1 M NaOH to pH 7.5 
 Ad 1 l ddH2O, autoclave, and cool to 50 °C 
 Add required antibiotics (see Table 4-2) 
 Pour into 10 cm Petri dishes, store inverted at 4 °C 
 
2xYT agar plates   1.5%  15 g Bacto
TM
 Agar 
       (BD, #214010) 
    85 mM  5 g Sodium chloride 
       (AppliChem, #A3597) 
    1.6%  16 g Bacto
TM
 Tryptone 
       (BD, #211705) 
    1%  10 g Bacto
TM
 Yeast extract 
       (BD, #212720) 
       Adjust with 1 M NaOH to pH 7.0 
 Ad 1 l ddH2O, autoclave, and cool to 50 °C 
 Add required antibiotics (see Table 4-2) 
 Pour into 10 cm Petri dishes, store inverted at 4 °C 
 
NaOH    1 M   Sodium hydroxide solution 
       (Merck/Millipore, #109137) 
 
Petri dishes   9.4 cm   Greiner Bio-one, #633102 
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4.4 Analysis of NGS data sets 
Bioinformatic analyses of next generation sequencing (NGS) data were performed on a Linux 
Debian workstation with the indicated programs and versions. Raw read files were delivered in 
fastq format from the sequencing facilities. 
4.4.1 ChIP-seq and MCIp-seq data 
ChIP-seq data sets from spleen chromatin were generated by non-indexed single 36 bp 
sequencing on a GAII (Illumina) using sequencing chemistry SBSv1 (Illumina). ChIP-seq data 
from cerebellum chromatin as well as MCIp-seq data from both tissues were generated by 
indexed (6 samples/lane) single 50 bp sequencing on a HiSeq1000 (Illumina) using sequencing 
chemistry SBSv3 (Illumina). The general NGS workflow is stated in section 4.3.1.19. 
 
4.4.1.1 Identification of novel candidate DMRs using ChIP-seq 
ChIP-seq data from spleen chromatin (both C57BL/6 and BALB/c; H3K4me1, H3K4me3, 
H3K27ac, and input each) were initially analyzed according to the following script to identify 
regions marked by active histone in a strain-specific manner. Regions for MALDI-TOF MS-based 
DNA methylation analysis listed in Appendix IV (Table 10-4) were selected from strain-specific 
ChIP-seq peaks. 
The following script for C57BL/6 spleen H3K4me3 is representative for all analyzed samples. 
Strain- and mark-specific alterations are indicated. If not stated otherwise in the command line, 
default settings were applied. 
 
###Software versions 
#Fastqc  0.10.1 
#bowtie  0.12.7 
#homer  3.0 
 
 
###Quality assessment with Fastqc. 
 
 
###Alignment of raw reads to mm9 reference genome with bowtie. 
% bowtie –q -–best –k 1 –m 1 –p <#CPU> mm9 /path-to-input-file/C57_spl_K4me3.fastq > \ 
/path-to-output-file/C57_spl_K4me3.txt; 
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###Creating Tag Directories with the homer tool pipeline. 
% makeTagDirectory /path-to-output-folder/C57_spl_K4me3 \ 
/path-to-alignment-file/C57_spl_K4me3.txt; 
###Creating UCSC custom tracks to visualize aligned sequence tags for each sample (homer 
###v3.0). 
% makeUCSCfile /path-to-tag-directory/C57_spl_K4me3 –o auto; 
##The UCSC browser track is accessible at http://genome.ucsc.edu/cgi-
bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=juwelll&hgS_otherUserSessionName=C57
vsBc_spleen_%20%09ChIP%2Dseq_H3K4me1_H3K4me3_H3K27ac_mm9 
 
 
###Identifying peaks (ChIP-enriched regions) with the homer tool pipeline. 
% findPeaks /path-to-tag-directory/C57_spl_K4me3 –i /path-to-tag-directory/C57_spl_input \ 
-size 1000 –L 0 –min-Dist 2500 –o /path-to-output-file/C57_spl_K4me3_peaks.txt; 
 
###Merging peak files from both strains for individual histone marks with the homer tool 
###pipeline. 
% mergePeaks –d 500 /path-to-peak-file1/C57_spl_K4me3_peaks.txt \ 
/path-to-peak-file2/Bc_spl_K4me3_peaks.txt > \ 
/path-to-output-file/merged_C57+Bc_spl_K4me3_peaks.txt; 
 
###Annotate peaks (tag information and mm9 genomic information) in merged peak file with 
###the homer tool pipeline. 
% annotatePeaks.pl /path-to-merged-peak file/merged_C57+Bc_K4me3_peaks.txt mm9 > \ 
/path-to-output-file/merged_C57+Bc_K4me3_peaks.ann.txt; 
#The annotated merged peak files for H3K4me1, H3K4me3, and H3K27ac 
#(merged_C57+Bc_*_peaks.ann.txt) were loaded and combined in an Excel (2007) file and 
#further analyzed to identify regions (peaks) strain-specifically enriched for active 
#histone marks as stated in section 5.2.1. 
4.4.1.2 Comparison of ChIP-seq and MCIp-seq data sets 
ChIP-seq data from spleen were complemented with data from cerebella of the same individuals 
for all three histone marks (both C57BL/6 and BALB/c; H3K4me1, H3K4me3, H3K27ac, and input 
each). Furthermore, genome-wide DNA methylation data from both tissues in both strains were 
accessible by MCIp-seq data. The following scripts were used to compare ChIP-seq data from 
different tissues as well as ChIP-seq and MCIp-seq data within the same strain/tissue and 
between different strains/tissues. 
 
The following script for C57BL/6 spleen H3K4me3 and/or MCIp samples is representative for all 
analyzed samples. Strain- and mark-specific alterations are indicated. If not stated otherwise in 
the command line, default settings were applied. 
 
###Software versions 
#Fastqc  0.10.1 
#bowtie2 2.1.1 
#homer  4.6 
#R  3.1.0 
###Quality assessment with Fastqc. 
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###Alignment of raw reads to mm9 reference genome with bowtie2. 
% bowtie2 -x /path-to-bowtie2-programs/indexes/bt2-mm9 /path-to-file/C57_spl_K4me3.fastq \ 
-S /path-to-file/C57_spl_K4me3.sam; 
 
 
###Creating Tag Directories with the homer tool pipeline. 
##For MCIp: add ‘-keepone’ option 
% makeTagDirectory /path-to-output-folder/C57_spl_K4me3 /path-to-file/C57_spl_K4me3.sam \ 
-genome mm9 –checkGC (-keepone); 
 
 
###Creating MultiWigHub for layered visualization in UCSC genome browser with the homer 
###tool pipeline. 
##For ChIP-seq, one MultiWigHub was created for each strain and each tissue containing 
##input, H3K4me1, H3K4me3, and H3K27ac. 
% makeMultiWigHub.pl C57_spl_ChIP mm9 –fsize 1e8 –d \  
/path-to-tag-directory/C57_spl_input /path-to-tag-directory/C57_spl_K4me1 \  
/path-to-tag-directory/C57_spl_K4me3 /path-to-tag-directory/C57_spl_K27ac –webdir \  
/path-to-web-directory/ -url http:/www.ag-rehli.de/ChIP+MCIp; 
 
## For MCIp-seq, one MultiWigHub was created for each strain containing aligned MCIp-seq 
##reads for both tissues. 
% makeMultiWigHub.pl C57_MCIp mm9 –fsize 1e8 –d /path-to-tag-directory/C57_spl_MCIp \ 
/path-to-tag-directory/C57_cer_MCIp –webdir /path-to-web-directory/ \ 
-url http:/www.ag-rehli.de/ChIP+MCIp; 
#The contents of the track information file (trackdb.txt) of all tracks within one hub 
#were combined in one trackdb.txt file to facilitate layered visualization. 
#The multi-layered track hubs are accessible at http://genome-euro.ucsc.edu/cgi-
bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=juwelll&hgS_otherUserSessionName=mm9
_DRRs%26DMRs. 
 
 
###Identifying peaks (enriched regions) for each sample with the homer tool pipeline. 
##H3K4me3, H3K27ac (to account for mapping bias, adjust enrichment over input: C57 default 
##(-F 4), BALB/c –F 3). 
% findPeaks /path-to-tag-directory/C57_spl_K4me3 -region –size 250 –L 0 –minDist 350 \  
–ntagThreshold 10 (-F 3) –i /path-to-input-tag-directory/ \  
–o /path-to-output-file/C57_spl_K4me3_regions.txt; 
 
##H3K4me1 data are processed differently to account for broader and lower H3K4me1 peaks 
##(to account for mapping bias, adjust enrichment over input: C57 -F 3, BALB/c –F 2). 
% findPeaks /path-to-tag-directory/C57_spl_K4me1 -region –size 400 –L 0 –minDist 600 \  
–ntagThreshold 10 -F <2 or 3> –o /path-to-output-file/C57_spl_K4me1_regions.txt; 
 
##MCIp data are processed differently, since no Input data was available. 
%findPeaks /path-to-tag-directory/C57_spl_MCIp -region –size 250 –L 0 –minDist 350 \ 
ntagThreshold 10 –o /path-to-output-file/C57_spl_MCIp_regions.txt; 
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###Identifying strain-specifically enriched regions for each mark with the homer tool 
###pipeline. 
##Merging corresponding region files for subsequent identification of differential regions 
##(=differential peaks) with homer v4.6. 
% mergePeaks /path-to-region-file1/C57_spl_K4me3_regions.txt \ 
/path-to-region-file2/Bc_spl_K4me3_regions.txt > \ 
/path-to-output-folder/merged_C57+Bc_spl_K4me3_regions.txt; 
 
##Identifying differentially enriched regions within merged region files for each 
##strain/tissue combination and mark with the homer tool pipeline. 
% getDifferentialPeaks /path-to-merged-region-file/ merged_C57+Bc_spl_K4me3_regions.txt \ 
/path-to-target-tag-directory/C57_spl_K4me3 \ 
/path-to-background-tag-directory/Bc_spl_K4me3 –F 2 (-rev) > \ 
/path-to-output-file/C57_over_Bc_F2_spl_K4me3.txt; 
#’-rev’ option looks for specified fold-enrichment of background tag directory over 
#target directory and is applied separately for all strain/tissue combination and marks. 
 
##Identifying tissue-independently enriched regions for H3K4me3 and H3K27ac in each 
#strain. 
#Merging regions with peak center distance <300bp (use –prefix option to separate common 
#and unique regions). The command was used in both directions for both histone marks. 
% cd /path-to-output-folder/; 
% mergePeaks -d 300 -prefix tissue300 \ 
/path-to-input-file1/Bc_over_C57_F2_cer_ac.txt \ 
/path-to-input-file2/Bc_over_C57_F2_spl_ac.txt\; 
#The two output files containing tissue-independent H3K4me3 (or H3K27ac) regions for each 
#direction (enriched in C57BL/6 or BALB/c, respectively) were combined (>F2_H3K4me3.txt, 
#F2_H3K27ac.txt). 
 
#Merging the combined files for tissue-independent H3K4me3 and H3K27ac regions. 
% mergePeaks -d 300 /path-to-input-file1/F2_H3K27ac.txt \ 
/path-to-input-file2/F2_H3K4me3.txt \ 
> /path-to-output-folder/F2_H3K4me3andorH3K27ac.txt; 
#Annotating the resulting list of tissue-independently strain-specific H3K4me3 and/or 
#H3K27ac regions with genomic context (mm9) and tag information. 
% annotatePeaks.pl /path-to-region-file/ F2_H3K4me3andorH3K27ac.txt mm9 -size given \ 
-noann –d <space-separated list of tag directories> \ 
> /path-to-output-folder/F2_H3K4me3andorH3K27ac_ann.txt 
#Regions associated with the same gene were grouped. 
 
###Comparing general enrichment of active histone marks and MCIp-enriched regions within 
###same strain and tissue by generating scatterplots. 
##Merging corresponding ChIP-seq region file and MCIp-seq region file. 
% mergePeaks /path-to-region-file1/C57_spl_K4me3_regions.txt \ 
/path-to-region-file2/C57_spl_MCIp_regions.txt > \ 
/path-to-output-file/C57_spl_K4me3+MCIp_regions.txt; 
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##Figure 5-17A: Annotating merged region files with corresponding tag information (log-
##transformed). 
% annotatePeaks.pl /path-to-merged-region-file/C57_spl_K4me3+MCIp_regions.txt mm9 \ 
-size given –noann –log –d /path-to-tag-directory/C57_spl_input \ 
/path-to-tag-directory/C57_spl_K4me3 /path-to-tag-directory/C57_spl_MCIp > \ 
/path-to-output-file/C57_spl_K4me3+MCIp_regions.ann.txt; 
#Log-transformed tag information for all (common and unique) H3K4me3 and MCIp peaks 
#within one strain and tissue were plotted against each other in R on a Windows7 PC to 
#generate scatterplots. 
 
 
###Figure 5-17B: Creating histograms of strain-specifically enriched histone marks and 
###MCIp-enriched regions by annotating strain-specific region files with tag information 
###of all other marks with the homer tool pipeline. 
% annotatePeaks.pl /path-to-region-file/C57_spl_K4me3 _regions.txt mm9 -size 6000 \ 
–hist 25 –d <all desired tag directories in a space-separted list> \ 
/path-to-output-file/C57_spl_K4me3.hist.txt; 
#Respective tag counts were plotted in Excel 2010 on a Windows7 PC against genomic 
#position around the underlying regions file to create histograms with genomic 
#distributions. 
 
 
###Figure 5-17C: Calculating statistics of pairwise comparisons for Venn diagrams 
###homer v4.6. 
% mergePeaks -d 300 /path-to-region-file1/C57_spl_K4me3_regions.txt \ 
/path-to-region-file2/C57_cer_K4me3_regions.txt –venn venn_C57_K4me3.txt; 
#Output files contain numbers of unique and common peaks and were visualized by Venn 
#diagrams. 
4.4.1.3 Repeat analysis with MCIp-seq data 
When NGS reads are aligned to a reference genome, in general only uniquely mapable reads are 
kept for subsequent analysis. However, to analyze enrichment of repetitive regions, the alignment 
can be adjusted to retain the best alignment of repetitive sequences. 
 
The HOMER pipeline allowed for analysis of repetitive regions with the analyzeRepeats.pl tool, 
which used a repeat-annotated genome to determine read abundancy at repetitive regions. 
Subsequent statistical analysis with EdgeR (implemented in tool pipeline) was performed to 
identify differentially enriched repeat classes between C57BL/6 and BALB/c samples. 
 
 
The following script for C57BL/6 spleen MCIp sample is representative for all analyzed samples. If 
not stated otherwise in the command line, default settings were applied. 
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###Software versions 
#bowtie2 2.1.1 
#homer  4.6 
#R  3.1.0 
#EdgeR  3.4.2 
 
 
###Alignment of MCIp reads to the mm9 reference genome. 
##Mapping MCIp reads to the mm9 reference genome with bowtie 2 (same as in ‘Comparison of 
##ChIP-seq and MCIp-seq data’). 
% bowtie2 -x /path-to-bowtie2-programs/indexes/bt2-mm9 /path-to-file/C57_spl_MCIp.fastq \ 
-S /path-to-file/C57_spl_MCIp.sam; 
 
##Creating Tag Directories for the aligned reads with the ‘-keepone’ option to include 
##reads mapped to repetitive regions. 
% makeTagDirectory /path-to-output-folder/C57_spl_K4me3 /path-to-file/C57_spl_K4me3.sam \ 
-genome mm9 –checkGC (-keepone); 
 
 
###Table 5-5: Determing read abundancy at (a subset of) annotated repeats. 
##Options: 
#repeats triggers loading of repeat definition from UCSC for the indicated reference 
#genome 
#-strand both for non-strand-specific reads 
#-noadj  reports the exact number of counted reads 
#-L2 SINE restrict analysis to Alu repeats) 
% analyzeRepeats.pl repeats mm9 -strand both -noadj (-L3 Alu) \ 
 -d <space separated listing of /paths-to-tag-directories/> \ 
> /path-to-output-folder/MCIp_allRepeats.txt; 
 
 
##Estimating differential enrichment. 
#Statistical analysis using the implemented EdgeR script (with pairing of cerebellum and 
#spleen samples from the same strand as de facto replicates). 
% getDiffExpression.pl /path-to-input-file/MCIp_allRepeats.txt Bc Bc C57 C57 \ 
-repeats >/path-to-output-folder/DiffExpr_MCIp_allRepeats_replicates.txt; 
#Results were further analyzed in Excel 2010. 
4.4.2 RNA-seq data from differentiating ESCs 
RNA-seq data from differentiating ESCs were generated by non-indexed paired-end 200 bp 
sequencing on a HiSeq1000 (Illumina) using sequencing chemistry SBSv3 (Illumina). The general 
NGS workflow is stated in section 4.3.1.19. Raw data was delivered as compressed fastq files 
Since important RNA-seq generated from BALB/c ESCs might be omitted by mapping reads to 
the C57BL/6-derived mm9 reference genome, an unbiased de novo assembly of the reads into 
transcripts was favored. The Trinity software package includes this assembly step and functions 
independent of any reference genome. 
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The following script was applied to identify differentially expressed transcripts between 
differentiating C57BL/c and BALB/c ESCs (see section 5.1.7). 
The following script for JM8 (C57BL/6) RNA-seq data is representative for all analyzed samples. 
De novo transcript assemblies were performed on the athene1.uni-regensburg.de cluster due to 
memory limitation on the available Linux workstation. All subsequent analyses were performed on 
the in house Linux workstation. 
 
###Software versions 
#Trinity trinityrnaseq_r20140413p1 
#bowtie  0.12.7 
#RSEM  1.2.11 
#EdgeR  3.4.2 
#R  3.0.2 
 
 
###To reduce verbosity of the command line for the de novo assemblies, all read 1 and 
###read2 fastq files, respectively, from each sample were concatenated. 
% cat /path-to-read1-folder_C57_d0/*_1.fastq > /path-to-output-file/C57_d0_read1.fq; 
% cat /path-to-read1-folder_C57_d0/*_2.fastq > /path-to-output-file/C57_d0_read2.fq; 
 
 
###De novo assembly of transcripts with the Trinity tool pipeline. 
##*_read1.fastq and *_read2.fastq files were transferred to the athene cluster and 
##analyzed with trinity using job scripts (example see below). Several options were used 
to ##reduce the memory requirements to enable de novo assembly at the local cluster. 
#Options: 
#--normalize_reads 
#--normalize_max_read_cov 30 
#--normalize_by_read_set 
#--min_kmer_cov 2 keeps only those kmers in RAM that appeared at least 2x (also 
#reduces RAM requirement, but only minor impact on sensitivity) 
 
#Exemplary job script for the de novo transcript assembly from all available JM8 samples. 
> 
 
#PBS -q serial 
#PBS -l nodes=1:ppn=16 
#PBS -l mem=128000m 
#PBS -l walltime=48:00:00 (was manually extended by tech support if required) 
#PBS -m be 
#PBS -M julia2.wimmer@ukr.de 
 
$ path-to-Trinity/Trinity --normalize_reads --normalize_max_read_cov 30 -- \ 
normalize_by_read_set --seqType fq --JM 120G --min_kmer_cov 2 \ 
--left /path-to-C57_d0_read1.fq/C57_d0_read1.fq, \ 
/path-to-C57_d1_read1.fq/C57_d1_read1.fq, \ 
/path-to-C57_d2_read1.fq/C57_d2_read1.fq, \ 
/path-to-C57_d4_read1.fq/C57_d4_read1.fq, \ 
--right /path-to-C57_d0_read2.fq/C57_d0_read2.fq, \ 
/path-to-C57_d1_read2.fq/C57_d1_read2.fq, \ 
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/path-to-C57_d2_read2.fq/C57_d2_read2.fq, \ 
/path-to-C57_d4_read2.fq/C57_d4_read2.fq, \ 
--SS_lib_type FR --CPU 16 --output /path-to-output-folder/; 
 
< 
#The generated files were transferred back to the Linux work station for further 
#analysis. The generated Trinity.fasta files contain all de novo assembled transcripts 
#generated from the respective samples and are used in subsequent analyses (e.g. by RSEM 
#for abundancy estimations or for similarity analyses). 
 
 
###Quality assessment of the de novo assembled transcriptomes. 
##Obtain the total number of transcripts for each assembly. 
% grep -c '>' /media/disk4/JW_TRINITY/trinity_C57_norm30_kmercov2_128G/Trinity_C57.fasta 
 
##Examine the average length coverage of annotated transcripts. 
#Create a reference transcriptome database based on the mRNA sequence of annotated 
#RefGenes (mm10). The required information in fasta format (refGene_mm10_mRNA.fasta) was 
#obtained on the XXX from the UCSC table browser. 
% makeblastdb -in /path-to-fasta-file/refGene_mm10_mRNA.fasta -dbtype nucl; 
 
#Query the de novo assembly fasta file against the reference transcriptome database with 
#megablast and high stringency (evalue <1e-20) and analyze the top database hits for the 
#length coverage. 
% blastn -query /path-to-C57-assemmbly-file/Trinity.fasta \ 
-db /path-to-reference-database/refGene_mm10_mRNA.fasta \ 
-out /path-to-output-folder/TrinityC57_vs_refGene_mm10_mRNA.blastn \ 
-evalue 1e-20 -dust no -task megablast -num_threads 6 -max_target_seqs 1 -outfmt 6; 
%analyze_blastPlus_topHit_coverage.pl \ 
/path-to-blastn-result/TrinityC57_vs_refGene_mm10_mRNA.blastn \ 
/path-to-C57-assemmbly-file/Trinity.fasta \ 
/path-to-reference-database/refGene_mm10_mRNA.fasta \ 
> /path-to-output-folder/; 
#The generated *.blastn.hist file contains the number of top database hits (= reference 
#transcripts with at least 20% sequence coverage by de novo assembled transcripts) as well 
#as the number of reference transcripts with higher coverage (in 10% bins). Here 
#exemplarily shown for de novo assembled transcripts from all JM8 samples. 
“#hit_pct_cov_bin count_in_bin >bin_below 
100 4142 4142 
90 1304 5446 
80 1476 6922 
70 1811 8733 
60 2173 10906 
50 2329 13235 
40 2282 15517 
30 2479 17996 
20 2992 20988 
10 0 20988 
0 0 20988” 
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##Estimating transcript abundancy with RSEM to assess expression levels of control genes 
##as well as for a general comparison of the individual RNA-seq data sets. 
#Prepare the assembly files for alignment and abundancy estimation. 
% align_and_estimate_abundance.pl \ 
--transcripts /path-to- C57-assemmbly-file/Trinity.fasta --est_method RSEM \ 
--aln_method bowtie --trinity_mode --prep_reference; 
 
#Individual read abundancy estimation for each sample with RSEM. 
% align_and_estimate_abundance.pl \ 
--transcripts /path-to- C57-assemmbly-file/Trinity.fasta \ 
--seqType fq --left /path-to-C57_d0_read1.fq/C57_d0_read1.fq \ 
--right /path-to-C57_d0_read2.fq/C57_d0_read2.fq --est_method RSEM --aln_method bowtie \ 
--SS_lib_type FR --trinity_mode --output_dir /path-to-output-folder/ \ 
--output_prefix Bc_d0 --thread_count 6; 
#The generated *.genes.results and *.isoforms.results files contain inter alia the raw 
#read counts for each analyzed sample (on gene and isoform level, respectively). 
 
#Comparing estimated transcript abundancies of individual samples of each strain with 
#EdgeR. 
% abundance_estimates_to_matrix.pl --est_method RSEM --out_prefix <gene or isoform> \ 
<space-separated list of required *.genes.results/*.isoforms.results files> \ 
> /path-to-output-folder/; 
% run_DE_analysis.pl --matrix /path-to-afore-generated-read-count-matrix/*.counts.matrix -
-method edgeR; 
#For each pairwise comparison of samples represented in the expression matrix a MA plot is 
#generated. The MA plots for pairwise comparison of BALB/c samples or JM8 samples based on 
#the strain-specific de novo transcript assembly are depicted in Figure 5-13. 
 
##Estimating transcript abundancy of selected control genes. 
#Screening the de novo assembled transcriptomes for transcripts similar to selected 
#control genes: Query the assembly fasta files against a database of annotated 
#Mus musculus proteins (here: annotated RefSeq proteins
273
). 
#Create a database for blastx. 
% segmasker -in /path-to-protein-fasta-file/mouse.protein.faa -infmt fasta \ 
-parse_seqids -outfmt maskinfo_asn1_bin \ 
-out /pat-to-output-folder/refseq_mouse.protein_seg.asnb; 
% makeblastdb -in / path-to-protein-fasta-file/mouse.protein.faa -dbtype prot \ 
-parse_seqids -mask_data /path-to-masking-file/refseq_mouse.protein_seg.asnb \ 
-out /path-to-output-folder/refseq_mouse.protein -title "RefSeq Mouse Protein Database"; 
 
#Check the created database to retrieve masking algorithm ID. 
% blastdbcmd -db /path-to-database/refseq_mouse.protein -info; 
“Database: RefSeq Mouse Protein Database 
 77,941 sequences; 51,201,547 total residues 
 
Date: Jul 28, 2014  1:32 PM Longest sequence: 35,463 residues 
Available filtering algorithms applied to database sequences: 
Algorithm ID  Algorithm name      Algorithm options                        
21            seg                 window=12; locut=2.2; hicut=2.5          
 
Volumes: 
 /path-to-database/refseq_mouse.protein” 
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#Create a list (one entry per line) of GI number of the proteins of interest (retrieved 
#from original mouse.protein.faa fasta file of annotated Mus musculus RefSeq proteins). 
 
#Query the assembly fasta files against the created database for the selected genes 
#represented by the GI list with high stringency (evalue <1e-20). 
% blastx -query /path-to-de-novo-assembly-fasta-file/Trinity_C57.fasta \ 
-gilist /path-to-gilist/ControlGenes_GIlist -db /path-to-database/refseq_mouse.protein \ 
-outfmt 7 -out /path-to-output-folder/C57_blastx_controlgenes.out -db_soft_mask 21 \ 
-evalue 1e-20 -num_threads 6; 
% grep -e "^c" /path-to-similar-transcripts-file/C57_blastx_controlgenes.out \ 
> /path-to-output-folder/all_blastx_controlgenes_hits.out; 
% sed -e 's/^\([^\t]*\).*/\1/' /path-to-hits-file/C57_blastx_controlgenes_hits.out \ 
> /path-to-output-folder/C57_blastx_controlgenes_hits.short.out; 
#The generated *_hits.short.out file contains the list of de novo assembled transcripts 
#with high similarity to proteins listed in the GI list. These identifiers were then used 
#to retrieve the expression values from the respective read count matrix generated before. 
 
##Assess representation (coverage) of control genes by de novo assembled transcripts by 
##retrieving sequences of similar transcripts from de novo assembly fasta file. 
% sed -e 's/^\([^\t]*\).*/\1/' /path-to-de-novo-assembly-fasta-file/Trinity.fasta \ 
> /path-to-output-folder/Trinity.short.fasta; 
% xargs samtools faidx /path-to-shortened-fasta-file/Trinity.short.fasta \ 
< /path-to-list-of-selected-transcripts/C57_blastx_controlgenes_hits.short.out \ 
> /path-to-output-folder/Trinity_C57_controlgenes.short.fasta; 
#The obtained transcript sequences were then subject to UCSC’s blat algorithm 
#(www.ucsc.com). 
 
###Analyzing transcripts similar to the candidate epigenetic modifier Nol10. 
##The same protein database was queried with the same settings as for control genes. The 
##GI list was adjusted to query only for transcript similar to Nol10 (GI identifier 
##retrieved from original mouse.protein.faa fasta file of annotated Mus musculus RefSeq 
##proteins). 
% blastx -query /path-to-de-novo-assembly-fasta-file/Trinity_C57.fasta \ 
-gilist /path-to-gilist/Nol10_GIlist -db /path-to-database/refseq_mouse.protein \ 
-outfmt 7 -out /path-to-output-folder/C57_blastx_Nol10.out -db_soft_mask 21 \ 
-evalue 1e-20 -num_threads 6; 
% grep -e "^c" /path-to-similar-transcripts-file/C57_blastx_Nol10.out \ 
> /path-to-output-folder/all_blastx_Nol10_hits.out; 
% sed -e 's/^\([^\t]*\).*/\1/' /path-to-hits-file/C57_blastx_Nool10_hits.out \ 
> /path-to-output-folder/C57_blastx_Nol10_hits.short.out; 
#The generated *_hits.short.out file contains the list of de novo assembled transcripts 
#with high similarity to the Nol10 protein. These identifiers were then used to retrieve 
#the expression values from the respective read count matrix generated before. Retrieving 
#the corresponding transcript sequences from the original Trinity.fasta file was performed 
#as for the control genes. 
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4.4.3 General representation of the MIso-encoding candidate 
region by BAC clones 
Sequencing data of a pool of BACs were generated by indexed (6 samples/lane) single 50 bp 
sequencing on a HiSeq1000 (Illumina) using sequencing chemistry SBSv3 (Illumina). The general 
NGS workflow is stated in section 4.3.1.19. 
The following script was applied to evaluate the coverage of region 
mm9_chr12:16902483-26024113 selected by BAC library screening (see section 4.3.1.20 & 
5.1.6.2). 
 
###Software versions 
#bowtie2 2.1.0 
#samtools 0.1.18 
#bedtools v2.16.2 
#R  3.0.2 
 
 
###Indexing reference genomes for bowtie2. 
##For chromosome 12 (mm9) 
##(http://hgdownload.cse.ucsc.edu/goldenPath/mm9/chromosomes/chr12.fa.gz) 
% bowtie2-build /path-to-fasta-file/mm9_chr12.fa \ 
/path-to-bowtie2-programs/indexes/mm9_chr12only; 
 
##For E. coli genome (E. coli K12, NC_000913.3) 
##(http://www.ncbi.nlm.nih.gov/nuccore/556503834?report=fasta) 
% bowtie2-build /path-to-fasta-file/EcoliK12.fa \ 
/path-to-bowtie2-programs/indexes/EcoliK12; 
 
###Removing reads generated by E. coli gDNA contamination with bowtie2. 
% bowtie2 -p7 -x EcoliK12 -U /path-to-fastq-file/BAC_Mix_159.fastq \ 
S /path-to-alignment-output-file/alignmentEcoliK12.sam \ 
--un /path-to-file-for-unaligned-reads/BACmix159_woEcolireads.fastq; 
#The BACmix159_woEcolireads.fastq contained raw reads removed from E. coli contaminations 
#and was further processed. 
 
###Mapping E. coli-depleted raw reads to chromosome 12 with bowtie2. 
% bowtie2 -p7 -x mm8_chr12only -U /path-to-fastq-file/BACmix159_woEcolireads.fastq \ 
-S /path-to-alignment-output-file/BACmix159_woEcoli_chr12only.sam; 
 
###Extracting reads, which mapped to candidate region (mm9_chr12:16902483 26024113). 
##Converting SAM file to BAM file with samtools. 
% samtools view -bSh /path-to-SAM-file/BACmix159_woEcoli_chr12only.sam > \ 
path-to-output-file/BACmix159_woEcoli_chr12only.bam; 
##Converting BAM file to BED file. 
% bamToBed -i /path-to-BAM-file/BAC159aligned_woEcoli_chr12only.bam > \ 
/path-to-output-file/BAC159aligned_woEcoli_chr12only.bed; 
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##Removing all reads not mapped to candidate region. 
#BAC159aligned_woEcoli_chr12only.bed was opened in text editor and positions 
#< chr12:16902483 were manually removed and saved as 
#BAC159aligned_woEcoli_chr12only_16902483-end.bed. Positions greater chr12:26024113 were 
#removed using the sed command. 
% sed -n '1,/HWI-1KL143:88:D2DVPACXX:7:1101:9955:67001/ p' \ 
/path-to-BED-file/BAC159aligned_woEcoli_chr12only_16902483-end.bed > \ 
/path-to-output-file/BAC159aligned_woEcoli_chr12only_16902483-26024113.bed; 
#’HWI-1KL143:88:D2DVPACXX:7:1101:9955:67001’ was read name of first read, which mapped to 
#position > chr12: 26024113 (looked up manually). 
 
 
###Removing reads mapped to known repeats (mm9) using bedtools ((rmsk_mm9.bed created with 
UCSC table browser). 
% intersectBED -v \ 
-a /path-to-BED file1/BAC159aligned_woEcoli_chr12only_16902483-26024113.bed \ 
-b /path-to-BED-file2/rmsk_mm9.bed > \ 
/path-to-output-file/BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats.bed; 
 
 
###Adjusting read length (50 bp) to average fragment length (170 bp, identified by size 
###distribution on a Bioanalyzer DNA HighSensitivity Chip) with bedtools. 
% bedtools slop \ 
-i /path-to-bed-file/BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats.bed \ 
-g /path-to-bedtools-programs/genomes/mouse.mm9.genome -s -r 120 -l 0 > \ 
path-to-output-file/BAC159aligned_woEcoli_chr12only_16902483-
26024113_worepeats_120bp_added.bed; 
 
 
###The following steps were done for both BED files 
###(BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats.bed, 
###BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats_120bp_added.bed). 
 
##Creating a read count table (one entry per base) for candidate region 
##(mm9_chr12:16902483 26024113) excluding known repeats and assembly gaps of mm9 
##(rmsk_mm9.bed & gaps_mm9.bed created with UCSC table browser). 
% bash -c 'for i in {16902483..26024113}; do echo \  
-e "chr12\tjust\tgenomicposition\t$i\t$i\t1000\t.\t.\t$i"; done' > \ 
/path-to-output-file/9MB.gff; 
#(subsequently add first line [seqname generated by feature start stop score 
#strand frame group] manually to 9MB.gff). 
% intersectBed -v -a /path-to-file1/9MB.gff -b /path-to-file2/gaps_mm9.bed > \ 
/path-to-output-file/9MB_wo_gaps.gff; 
% intersectBed -v -a /path-to-file1/9MB_wo_gaps.gff -b /path-to-file2/rmsk_mm9.bed > \ 
/path-to-output-file/9MB_wo_gaps_wo_repeats.gff; 
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##Counting reads from BED files into read count table with bedtools. 
% bedtools coverage \ 
-a /path-to-BED-file/BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats.bed \ 
-b /path-to-gff-file/9MB_wo_gaps_wo_repeats.gff > \ 
/path-to-output-file/countsperbase_wor_nonadj.gff 
% bedtools coverage \ 
-a /path-to-BED-
file/BAC159aligned_woEcoli_chr12only_16902483-26024113_worepeats_120bp_added.bed \ 
-b /path-to-gff-file/9MB_wo_gaps_wo_repeats.gff > \ 
/path-to-output-file/countsperbase_wor_120.gff 
 
##Counting bases with zero reads and non-zero reads with R to estimate BAC coverage of 
##candidate region. The following script is representative for nonadjusted and fragment 
##size-adjusted reads. 
#Loading read count table with read counts into R. 
% countsperbase_wor_nonadj<-
read.table(file="/media/disk3/JuliaW_Analysis/BAC159mix_50bp_se/coverage/countsperbase_wor
_nonadj.gff", nrows=4487730, 
col.names=c("seqname","source","feature","start","end","score","strand","frame","group","r
eads","non-zero bases","featurelength","%non-zero bases")); 
#Retrieving numerical vector of read counts. 
% reads <-countsperbase_wor_nonadj$reads; 
#Creating a logical vector (TRUE/FALSE) for reads_wor_nonadj regarding entries with value 
#‘0’. 
% zero.reads<- reads ==0; 
#Returning total numbers of TRUE (= zero BAC reads) and FALSE (= non-zero BAC reads) 
#entries in vector ‘zero.reads’. 
% table(zero.reads); 
 
##Creating coverage plot with R. 
#Loading read count table with read counts into R. 
% countsperbase_wor_120<-
read.table(file="/media/disk3/JuliaW_Analysis/BAC159mix_50bp_se/coverage/countsperbase_wor
_130.gff", nrows=4487730, 
col.names=c("seqname","source","feature","start","end","score","strand","frame","group","r
eads","non-zero bases","featurelength","%non-zero bases")); 
#Retrieving numerical vectors of read counts and base position. 
% base<-countsperbase_wor_120.gff$start 
% reads<-countsperbase_wor_120.gff$reads 
% plot(base,reads, xlab="chr12:16902483-26024113 (mm9)", ylab="read per base", type="l") 
 
#Calculating average read coverage of covered (non-zero) bases. 
% nonzero_countsperbase_wor_120<-countsperbase_wor_120[!countsperbase_wor_120$reads==0, ] 
% mean(nonzero_countsperbase_wor_120) 
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5 Results 
5.1 Identification of MIso: a strain-specific epigenetic 
modifier, which regulates DNA methylation at the 
Isoc2b promoter 
The effects of DNA methylation have been subject of extensive studies, but still very little is known 
about the extent, establishment, and inheritance of individual patterns of this mark. Inbred mice 
represent a well-suited model organism to address these questions. They have a distinct genetic 
background and reproducible breeding conditions minimize environmental effects on epigenetic 
modifications. 
Preliminary work in our laboratory identified the nuclear Isoc2b locus as one of numerous mouse 
strain-specifically methylated regions. Depending on the methylation status of its promoter, the 
Isoc2b gene, which encodes for the isochorismatase domain containing 2b protein, is differentially 
expressed in inbred mouse strains
261
. Analyses regarding the inheritance of the methylation status 
suggested a regulation in trans by a yet unknown epigenetic modifier. 
Since only few site-specific epigenetic regulators are known so far, the identification of further 
factors, their targets as well as their mode of action are of great interest. The present work aimed 
at the identification of the strain-specific epigenetic modifier responsible for the differential DNA 
methylation pattern at the Isoc2b promoter. 
5.1.1 Preliminary work 
The experimental work, which identified the differentially methylated region at the Isoc2b 
promoter, was published in the journal Genome Research
261
. In summary, microarray-based 
expression analysis of bone marrow-derived macrophages (BMM) from inbred C57BL/6J and 
BALB/cAnNCrl mouse identified Isoc2b to be C57BL/6-specifically expressed, which was 
confirmed by RT-qPCR. The Isoc2b locus was analyzed regarding strain-specific DNA 
methylation (together with other differentially expressed genes) using a comparative Methyl-CpG 
immunoprecipitation(MCIp)-on-ChIP approach established in our laboratory. A representative set 
of 18 differentially methylated regions (DMRs) was chosen for validation and further quantitative 
methylation analysis at single CpG dinucleotides (CpG) resolution by Matrix-Assisted Laser 
Desorption/Ionisation combined with mass spectrometry analysis by Time-of-flight (MALDI-TOF 
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MS) (EpiTYPER technology, Sequenom). This approach facilitates simultaneous quantification of 
the methylation level at multiple CpGs across various samples (see method section 4.3.1.14 for 
more details). 
The selected DMRs comprised promoter-associated, intergenic as well as intragenic regions. 
Average DNA methylation levels at the selected DMRs correlated well in BMM and spleen of male 
and female mice of both strains excluding cell culture artefacts as well as gender-dependent 
methylation patterns
261
.  
Since the inter-generational inheritance of epigenetic patterns is poorly understood, DNA 
methylation levels of somatic tissues and germ line cells (testis) were compared between wild 
type mice and F1 hybrids (reciprocal crosses). The majority of the validated DMRs seemed to be 
re-established within each generation. The differential DNA methylation patterns detected in 
somatic cells were scarcely found in germ line cells. In addition, DNA methylation levels in 
somatic tissues from F1 hybrids showed an intermediate degree of methylation compared to 
parental wild type strains. In most cases, MALDI-TOF MS-derived average DNA methylation level 
of individual CpGs in F1 hybrids were similar to the mean parental methylation levels indicating 
allele-specific inheritance of DNA methylation patterns. Only three of the analyzed DMRs 
displayed a loss or gain of methylation in F1 hybrids (Figure 5-1A). 
To address the notion of allele-specific inheritance, bisulfite sequencing (see section 4.3.1.13), 
which is able to determine the methylation status of individual CpGs within their genomic context, 
is required. The EpiTYPER technology only allows for average quantification of the methylation 
level of individual CpGs. However, allele-specific bisulfite sequencing depends on allelic 
sequence variations still detectable after bisulfite treatment. Not all DMRs were suitable for allele-
specific bisulfite sequencing, due to the lack of informative sequence variations. In total, six 
regions were analyzed including the Isoc2b promoter. Except for Isoc2b, all analyzed regions 
showed allele-specific DNA methylation patterns, i.e. their methylation status seemed to be 
determined by local sequence variation (cis regulation). The Isoc2b promoter exhibited reduced, 
but unbiased methylation of both alleles in F1 hybrids. These findings argued for an epigenetic 
modifier regulating the methylation status in trans (Figure 5-1B). 
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Figure 5-1 Preliminary work – With only few exceptions, strain-specifically methylated regions 
are regulated in cis 
(A) Methylation levels of individual CpGs were assessed by MALDI-TOF MS in BMM of wild type mice (n=3 
for each strain) and F1 hybrids (n=5). Mean average CpG methylation levels of parental BMM are plotted 
against average CpG methylation levels of F1 hybrids (exemplarily shown for CB6F1 hybrids) for individual 
CpGs. Regions that either gained or lost methylation in F1 hybrids compared to the mean parental 
methylation level are highlighted. (B) Allele-specific bisulfite sequencing of Isoc2b promoter in BMM from 
C57BL/6, BALB/c, and F1 hybrids (reciprocal crosses). The genomic position of CpGs within the amplicons is 
shown at the top. The sequence variations used to distinguish the different parental alleles are marked in red 
(C57BL/6) and blue (BALB/c). Individual CpGs are represented by either white (unmethylated) or black 
(methylated) squares. Lines of squares represent independently sequenced clones derived from two 
independent sample preparations. (Adopted from Schilling et al. 
261
) 
 
 
The general notion drawn from these findings was that DMRs were mainly regulated in cis and re-
established after fertilization. Interestingly, bisulfite sequencing of the DMR at the Isoc2b promoter 
indicated regulation in trans by an epigenetic modifier rather than in cis by the local sequence. 
This was of particular interest, since epigenetic modifiers have been scarcely characterized as 
yet. With the present work, I aimed at the identification and characterization of the responsible 
epigenetic modifier. 
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5.1.2 Epigenetic profile of the Isoc2b promoter region in somatic 
tissues 
To recapitulate the preliminary MCIp-on-Chip data for the Isoc2b promoter region, I performed 
methylated CpG immunoprecipitation (MCIp) experiments with spleen- and cerebellum-derived 
genomic DNA and assessed the enriched DNA fragments by next generation sequencing (MCIp-
seq). To address additional epigenetic modifications, next generation sequencing data of 
chromatin immunoprecipitation (ChIP-seq) of active histone marks (H3K4me1/3, H3K27ac) for 
both tissues from C57BL/6 and BALB/c mice were generated (both data sets are further 
discussed in section 5.2.4). In line with the published data of Schilling et al. 
261
, only C57BL/6-
derived tissues were marked with active histone marks, whereas enrichment of highly methylated 
fragments by MCIp was only detected in BALB/c-derived tissues (Figure 5-2A). 
Interestingly, the Isoc2b homolog, Isoc2a
274
, which is located downstream of Isoc2b in a head-to-
head orientation, did not display strain-specific epiphenotypes (Figure 5-2A) and was expressed in 
both mouse strains (Figure 5-2B). Moreover, BALB/c seemed to express Isoc2a at a level twice as 
high as C57BL/6, thereby potentially compensating the lack of Isoc2b expression. The 
comparison of the nucleotide sequences (1000 bp) upstream of the coding sequences of both 
homologs by Blastn (NCBI) revealed no significant sequence similarities. 
 
 
 
 
Figure 5-2 Epigenetic profiles of the Isoc2b and Isoc2a promoter regions, respectively, are in 
line with the detected expression statuses 
(A) The represented 15 kb window displays the promoter regions of the duplicated genes Isoc2a (right) and 
Isoc2b (left). Enrichment of regions by MCIp and ChIP (H3K4me1/3, H3K27ac) experiments with spleen and 
cerebellum are indicated by color-coded peaks. (B) Expression levels of each of the two duplicated genes of 
interest (GOI) were assessed by RT-qPCR with total RNA from spleen tissue (n=2) and normalized to 18S 
ribosomal RNA (error bars represent standard deviation). 
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5.1.3 The Isoc2b promoter region displays two distinct DNA 
methylation phenotypes in homozygous inbred strains 
To further test the notion of regulation in trans by an epigenetic modifier, I analyzed the Isoc2b 
promoter methylation phenotype in spleen DNA from six additional inbred mouse strains 
(129S1/SvImJ, A/J, C3H/HeJ, CBA/J, DBA/2J, NOD/ShiLtJ) by MALDI-TOF MS. Five of the six 
strains displayed a hypomethylated phenotype at the Isoc2b promoter region similar to C57BL/6. 
Only A/J exhibited a hypermethylated phenotype similar to BALB/c (Figure 5-3A). According to the 
Mouse Genomes Project
275
 (REL-1003), all six strains display BALB/c SNP and indel variants at 
those positions that distinguish BALB/c and C57BL/6 mice in the analyzed region 
(mm9_chr7:4817304-4818396). These findings further argue against a regulation in cis by the 
local sequence. 
DNA methylation analysis in substrains of BALB/c and C57BL/6 revealed consistent strain-specific 
methylation phenotypes for the Isoc2b promoter region (Figure 5-3B). 
 
 
 
 
Figure 5-3 DNA methylation analysis for the Isoc2b promoter region in common inbred mouse 
strains reveals two distinct phenotypes 
Methylation levels of individual CpGs were obtained by MALDI-TOF MS analysis of bisulfite-treated DNA in 
spleen of indicated mouse strains and from pale purple (0% methylation) to dark purple (100% methylation). 
The relative position of sequence variations, CpGs, and EpiTYPER amplicons within the Isoc2b promoter 
region as well as the detected methylation levels for the generally used BALB/c and C57BL/6 strain are 
indicated at the top. (A) Isoc2b promoter methylation in spleen from six common inbred strains (n=2 per 
gender). (B) Isoc2b promoter methylation in spleen of the BALB/cJ and BALB/cByJ substrains (2 technical 
replicates each) as well as the C57BL/6N substrain (n=2). 
Strain-specific variants of indicated SNPs and Indels are positioned relative to analyzed CpGs.  
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5.1.4 Linkage analysis maps MIso to chromosome 12 
Preliminary data revealed distinct differential DNA methylation levels at the Isoc2b promoter 
region in BMM from C57BL/6, BALB/c, and F1 hybrids (Figure 5-1B). In F1 hybrids, both parental 
alleles display similar DNA methylation patterns excluding cis regulation by local sequence 
differences. Furthermore, the low methylation level observed in F1 hybrids could be explained by 
a gene dose effect. These findings support the notion of trans regulation by an epigenetic 
modifier. To identify the modifier of Isoc2b (MIso), I mapped its approximate localization within the 
mouse genome by linkage analysis (LA). 
5.1.4.1 Principles of linkage analysis 
Genetic markers, for example SNPs, are polymorphic features of the genomic sequence that can 
be followed over generations and enable to distinguish individuals by their alleles. The 
characteristics of these markers are accessible by various genotyping approaches, such as 
pyrosequencing
276
 and mass spectrometric assays (i.e. iPLEX technology, see section 4.3.1.14). 
Two genetic markers located on different chromosomes will be inherited independently and 
separated with 50% probability in the next generation according to the 2
nd
 Mendelian Law (Law of 
Independent Assortment)
277
. Genetic markers on the same chromosome are not inherited 
independently
278,279
, but can be separated in the next generation due to meiotic recombination 
events during gametogenesis
191
. The probability of linked inheritance increases with declining 
distance between two genetic markers on the same chromosome due to a decreased frequency 
of recombination events between the two markers
279
. 
The same accounts for any genetic trait. Located in close vicinity, a phenotype-causing genetic 
trait and a genetic marker will be inherited together more frequently than expected by random 
chance (linkage disequilibrium)
280
. This phenomenon provides the basis for LA, an approach to 
investigate the shared inheritance of selected genetic markers among 1
st
 degree relatives, which 
are similar regarding the phenotypic characteristic of interest
281
. If a marker is not located close to 
the phenotype-causing genetic trait, its alleles will be randomly distributed among the individuals. 
With decreasing distance to the genetic trait, the allele frequency observed in 1
st
 degree relatives 
grouped according to the relevant phenotype will diverge from the expected frequency. 
Murine backcrosses, i.e. offspring of a heterozygous individual mated with a homozygous 
individual, are particularly suitable for LA. The haploid gametes arising from heterozygous 
individuals display a mosaique array of the heterozygous parental diploid genome due to meiotic 
recombination between homologous chromosomes. Recombination also takes place in the 
homozygous individuals, but is without consequence resulting in a haploid genome similar to the 
homozygous parental genome. If the heterozygous parent represents a F1 hybrid (generated by 
mating of two homozygous inbred strains), the expected allele frequency is 50%. This assumption 
also accounts for the generally expected genotype frequency of individual genetic markers 
(heterozygous versus homozygous) in backcrosses (1
st
 Mendelian Law – Law of Segregation) 
grouped according to the phenotype of interest. However, regions linked to the phenotype-causing 
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genetic trait will display an increased number matching (concordant) phenotypes-genotype 
combination (linkage disequilibrium). Based on the observed concordant phenotypes-genotype 
combinations, the logarithm of the odds (LOD) score is used to estimate the likelihood that two 
loci (e.g. genetic marker and genetic trait) are subject to linked inheritance during meiosis and 
thus located in close vicinity
282
. 
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  n  total number of analyzed individuals 
  k  number of individuals with concordant phenotype/genotype combinations 
  p  expected allele frequency for independent inheritance 
 
Genetic markers not linked to the phenotype-causing genetic trait will return similar numbers of 
concordant and discordant phenotype-genotype combination resulting in low LOD scores. In 
contrast, linked genetic markers will display a high level of concordance resulting in a high LOD 
score. LOD scores higher than three indicate linkage. It implies that the observed ratio of 
concordant and discordant combinations is with a 10
3
-fold higher probability caused by linked 
rather than by independent inheritance. 
Evidences support the existence of recombination hotspots as well as linkage blocks of different 
size that are always inherited together
280
. However, when calculating the requirements for LA, a 
genome-wide random and unbiased appearance of recombination events is assumed. In mouse, 
the total length of the genetic map was determined as 1361 cM
283
. Taking the size of the mouse 
genome (2.58 Gb
284
) into account, one cM represents on average 2 Mb. The theoretical number of 
backcrosses required for a specific linkage map resolution can be calculated according to the 
following formula: 
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  N  number of required backcrosses 
  x  requested resolution 
 
5.1.4.2 Genome-wide linkage analysis in C;B6 hybrids  
To map the assumed trans-acting epigenetic modifier responsible for the strains-specific Isoc2b 
promoter methylation, I performed linkage analysis in backcrossed C;B6 hybrids 
((BALB/cxC57BL/6)F1 x BALB/c). F1 hybrids were generated from the C57BL/6NCrl substrain 
due to availability at the breeding center (Charles River Laboratories). Although the DMR was 
initially identified in C57BL/6J mice, DNA methylation analysis in C57BL/6NJ (Figure 5-3B) as well 
as derived F1 hybrids (Figure 5-4) revealed similar DNA methylation levels in the two substrains 
and their offspring. Recently, C57BL/6NJ, BALB/cJ as well as 15 other commonly used mouse 
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inbred strains were subject to resequencing by the Mouse Genomes Project of the Wellcome 
Sanger Institute
275
. The provided database was used to select informative genetic markers for LA. 
As described above, backcrossed C;B6 hybrids (CB6F1 x BALB/c) displays a unique alteration of 
homozygous and heterozygous regions due to meiotic recombination in the F1 parent and 
represent 1
st
-degree relatives suitable for LA. Since the DMR at the Isoc2b promoter was also 
detected in spleen, which is enriched for macrophages (Figure 5-3), LA was performed with 
spleen-derived genomic DNA. The breeding strategy to generate C;B6 hybrids was restricted to 
BALB/c sires, since allelic methylation levels in F1 hybrids were not influenced by the parental 
origin of the alleles (non-imprinted locus) (Figure 5-1B). 
Backcrosses display two distinct Isoc2b promoter methylation phenotypes 
Taking advantage of high-throughput DNA methylation analysis with the EpiTYPER technology, 
the methylation frequency at the Isoc2b promoter was easily accessible. Assays applied in other 
studies to examine differential DNA methylation patterns included bisulfite sequencing and a 
combination of mCpG-sensitive digestion, southern blotting, and (radioactive) site-specific 
probing. These approaches mainly relied on the methylation status of only few CpGs
285-287
. In 
contrast, this non-radioactive method yields reproducible quantitative average levels of DNA 
methylation of multiple CpGs of numerous samples within a short time and requires only small 
amounts of input DNA (see section 4.3.1.14). 
Assuming regulation in trans by a monogenetic trait, C;B6 hybrids displaying high DNA 
methylation levels at the Isoc2b promoter were expected to be homozygous for the genetic trait 
(similar to BALB/c mice). Vice versa, individuals with intermediate methylation levels were 
expected to be heterozygous for the genetic trait (similar to the F1 hybrids) (compare with Figure 
5-1B). These two genotype-phenotype combinations represent concordant combinations. 
Average DNA methylation levels at the Isoc2b promoter region (mm9_chr7:4818016-4818396)  of 
spleen genomic DNA from BALB/c mice (n=6), F1 hybrids (both reciprocal crosses; CB6F1: n=5 / 
B6CF1: n=3), and an initial set of 45 C;B6 hybrids (10-12 weeks old) were acquired by MALDI-
TOF MS. Based on the average DNA methylation frequency, I calculated an initial phenotype 
discriminator of 58.5% average DNA methylation by clustering the individuals with the Partitioning 
Around Medoids (PAM) Algorithm (number of groups k=2) (“intermediate”/“high”, Figure 5-4). The 
discriminator was used to group the C;B6 hybrids for genome-wide linkage analysis (see section 
5.1.4.2). 
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Figure 5-4 C;B6 backcrosses display two distinct Isoc2b promoter methylation phenotypes 
Mean DNA methylation of the Isoc2b promoter region was determined by MALDI-TOF MS in spleen DNA 
from an initial set of 45 C;B6 backcrosses (CB6F1 x BALB/c) and compared to BALB/c wild type (WT) mice 
(“high” methylation phenotype, n=6) and F1 hybrids (“intermediate” methylation phenotype, CB6F1: n=5 / 
B6CF1: n=3). Values represent averages of all measured CpGs within chr7:4818016-4818396 (mm9). A 
methylation level of 58.5% was calculated by PAM clustering (k=2) to separate the analyzed C;B6 hybrids in 
two distinct groups with either an “intermediate” or a “high” methylation phenotype. 
 
 
SNP genotyping deciphers genetic mosaicism in C;B6 hybrids 
Using the resequencing data available from the Mouse Genomes Project
275
 (REL-1003), I chose 
C57BL/6- and BALB/c-discriminating SNPs for an initial genome-wide linkage analysis. The 
selected SNPs needed to fulfill the criteria listed in section 4.3.1.14 to reduce the probability of 
being uninformative. In total, 265 SNPs located across the entire mouse genome were selected 
and genotyped with the iPLEX approach (Sequenom, see section 4.3.1.14). The major advantage 
of this genotyping approach is its multiplexing capacity; up to 36 distinct genetic positions in one 
reaction can be genotyped, while only requiring minimal amounts of input material (10 ng DNA per 
reaction). The use of mass-modified terminator-tagged nucleotides in a single base extension 
(SBE) MassEXTEND assay enables precise detection of SNP variants and facilitates reliable 
discrimination of homozygous and heterozygous genotypes (AA versus aa versus Aa). The 
genomic context of each SNP was obtained from the mm9 reference genome. Assays for the 
selected SNPs were designed and multiplexed with Typer4.0 software (Sequenom). 
The initial panel of 265 SNPs was evaluated by genotyping five individuals of each wild type strain 
(C57BL/6 and BALB/c) as well as four F1 hybrids. All assays were further tested for perturbing 
primer dimerization in a template-free reaction. Of the initial SNP panel, 238 SPNs proved suitable 
for linkage analysis. All 45 C;B6 hybrids were genotyped for the evaluated reduced SNP panel. 
The individuals were grouped according to the determined phenotype discriminator of 58.5% 
(Figure 5-4). The LOD score for each genetic marker was calculated based on the observed 
numbers of concordant and discordant phenotype-genotype combinations for the 45 C;B6 hybrids. 
As depicted in Figure 5-5A, a subset of adjacent SNPs showed increased LOD scores. The 
highest LOD score (13.5) was determined for SNP rs29160274. For this marker, the PAM-
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calculated phenotype discriminator of 58.5% average DNA methylation yielded exclusively 
concordant phenotype-genotype combination indicating a more than 10
13
-fold higher probability of 
linked compared to independent assortment. Although another region rendered increased LOD 
scores of up to 3.8, the strong indication for linkage to SNP rs29160274 supported the idea of a 
monogenetic trait responsible for the observed strain-specific DNA methylation phenotypes. 
These findings suggested that the genetic trait encoding for MIso is most probably located in a 
19 Mb region on chromosome 12, which is confined by the SNPs rs29180275 and rs4229294 
(mm9_chr12:7990826-26992720). The genotyping and phenotyping results as well as the 
corresponding LOD scores are listed in Table 10-1 (see Appendix I). 
 
 
 
 
Figure 5-5 Linkage analyses in C;B6 hybrids reliably maps MIso to a 9 Mb region on 
chromosome 12 
(A) LOD scores indicate linkage probabilities between genetic markers and Isoc2b promoter methylation 
(mm9_chr7:4818016-4818396). For genome-wide mapping (left), 238 genome-wide SNPs were genotyped 
in spleen-derived genomic DNA from 45 C;B6 hybrids. Absolute concordance (45 of 45 individuals) of 
zygosity and Isoc2b methylation phenotype was detected for SNP rs29160274. Fine mapping the initial 19 
Mb candidate region surrounding SNP rs29160274 (right) was performed with 184 additional C;B6 hybrids at 
29 additional SNPs. (B) Linkage analysis in the initial set of 45 C;B6 hybrids positively maps the genetic trait 
for the differential coat color of C57BL/6 (black) and BALB/c (white) (Tyr, mm9_chr7:94575915-94641921) to 
a 17 Mb region on chromosome 7 (mm9_chr7:82114282-98849561).  
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To evaluate the linkage analysis approach, I used the coat color of the same C;B6 hybrids to map 
the genetic trait responsible for the albinism found in BALB/c mice. A loss-of-function point 
mutation in the tyrosinase gene (Tyr, mm9_chr7:94575915-94641921) in BALB/c mice results in 
the complete lack of melanin pigments in the skin and the retina
288
 (Figure 5-5B). The C;B6 
hybrids exhibited either a white (homozygous background of the genetic trait) or a brownish grey 
coat color (heterozygous background of the genetic trait). Using the genotyping data from the 
genome-wide SNP panel, the genetic trait for the coat color could be positively mapped to the Tyr-
encoding region on chromosome 7 (mm9_chr7:82114282-98849561). 
5.1.4.3 Fine-mapping the genetic trait for MIso on chromosome 12 
I repeated LA within the candidate region on chromosome 12 with additional C;B6 hybrids and a 
higher marker density to further narrow down the MIso-encoding region. SNPs were selected 
according to the criteria listed in 0 with an average distance of 0.5 Mb between genetic markers 
(39 SNPs within mm9_chr12: 7990826-26992720). The fine-mapping SNP panel was designed 
and evaluated as described above resulting in panel of 32 SNPs (with, on average, one genetic 
marker per 0.6 Mb). According to the formula in section 5.1.4.1, a minimum of 334 individuals 
would be required to achieve this resolution. In addition to eight individuals from the genome-wide 
LA, which exhibited recombination in the 19 Mb candidate region, 184 new C;B6 backcrosses 
were analyzed regarding the DNA methylation phenotype at the Isoc2b promoter region and 
genotyped with the fine-mapping SNP panel. Twenty-nine of the additional 184 C;B6 hybrids were 
informative and displayed recombination within the 19 Mb region. Due to an overlap of the 
“intermediate” and “high” methylation phenotype for 154 non-informative heterozygous and 
homozygous C;B6 hybrids, the phenotype discriminator was re-defined to a level of 61.5±3.5% 
average DNA methylation (Figure 5-6A). In total, 20 C;B6 hybrids, including 4 informative 
individuals, exhibited DNA methylation levels within this range and were excluded from further 
analysis. Together with the eight informative individuals from the genome-wide LA, the remaining 
164 individuals were used for fine mapping LA. Applying the re-defined methylation discriminator, 
99.4% concordance with only one non-concordant individual was observed for a subset of fine-
mapping SNPs. The resulting 9 Mb candidate region (mm9_chr12:16902483-26024113) was 
confined by the SNPs rs29160274 and rs29188895 (Figure 5-5A). The genotyping results for the 
fine-mapping SNP panel for all informative C;B6 hybrids are listed in Table 10-2 (see Appendix II). 
Since the recombination frequency within the 19 Mb candidate region was unexpectedly low, the 
phenotyping and genotyping of additional C;B6 hybrids was not continued. High sequence 
variability among C57BL/6 and BALB/c mice in the candidate region could interfere with 
homologous recombination. 
To improve the recombination frequency, further backcrosses were bred from BALB/c and 
NOD/ShiLtJ mice. Together with five other inbred mouse strains included in the Mouse Genomes 
Project
275
, the NOD/ShiLtJ strain exhibited an Isoc2b methylation phenotype similar to C57BL/6 
(see Figure 5-3), but seemed genetically more similar to BALB/c with regards to the total number 
of distinguishing SNPs and indels in the candidate region (REL-1003). In total, 293 C;NOD 
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hybrids (2 weeks old, bred and raised in the in-house animal facilities) were phenotyped and 
genotyped. This time backcrosses derived from reciprocal crosses with CNODF1 as well as 
BALB/c sires. The fine-mapping SNP panel was adjusted to contain 17 genetic markers to 
distinguish BALB/c from NOD alleles in the 9 Mb candidate region 
(mm9_chr12:16902483-26024113) in agreement with the criteria listed in 5.1.4.2 at an average 
distance of 0.5 Mb and evaluated with wild type DNA samples. 
However, LA with C;NOD hybrids failed to further reduce the size of the candidate region. One 
individual showed recombination in the candidate region, but only at the outer border of the 
previously defined 9 Mb candidate region between SPNs rs29181570 and rs29201729. 
Furthermore, C;NOD hybrids could not be separated well according to the two expected 
methylation phenotypes (“intermediate”/”high”) (Figure 5-6B, top panel). The blurred phenotype 
pattern could not be explained by mixing of both reciprocal crosses since separate analysis did 
not alleviate the phenotype grouping (Figure 5-6B, bottom panel). Also an effect of characterizing 
younger individuals could be excluded, since the methylation pattern is established during 
embryogenesis (see section 5.1.5). The simplest explanation might be differential environmental 
effects on the backcrosses and their parents, since factors such as nutrition seem to have a 
general effect on epigenetic patterns
251,289
 CNODF1 as well as C;NOD hybrids were produced in 
the in-house animal facilities, whereas the breeding involving C57BL/6 was carried out at Charles 
River Laboratories. 
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Figure 5-6 Discrimination of Isoc2b promoter methylation phenotypes in C;B6 and C;NOD 
backcrosses 
Non-informative individuals without any recombination in the initial 19 Mb candidate region were identified by 
MALDI-TOF MS-based genotyping and grouped according to their zygosity (transparent bars: heterozygous 
(F1) genotype, solid bars: homozygous (BALB/c) genotype). For each zygosity group, non-informative (A) 
C;B6 hybrids and (B) C;NOD hybrids, respectively, were clustered in 1% bins based on the average 
methylation DNA levels of the Isoc2b promoter region (mm9_chr7:4818016-4818396) determined by 
MALDI_TOF MS. The height of each bin represents the number of comprised individuals. Overlapping DNA 
methylation levels of the two genotype groups are highlighted by (A) orange and (B) grey background. The 
dashed line in (A) represents the redefined phenotype discriminator of 61.5 +/- 3.5%. 
 
 
In summary, the initial genome-wide LA identified a monogenetic trait for MIso encoded within a 
19 Mb candidate region on chromosome 12. This region was further reduced by fine-mapping with 
additional animals and SNPs to 9 Mb (mm9_chr12:16902483-26024113). The 9 Mb region 
contains about 50 annotated genes as well as excessive repetitive regions. Initially, none of the 
included genes was regarded as a suitable candidate gene to encode MIso. Therefore, region-
wide approaches were applied to further characterize MIso. 
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5.1.5 In vitro ESC differentiation models display DNA methylation 
phenotypes observed in vivo 
Preliminary DNA methylation data from somatic tissues (BMM, spleen) as well as germ line cells 
indicated de novo methylation at the Isoc2b promoter region in each generation of BALB/c strain 
and its offspring. 
Analyzing DNA methylation levels at the Isoc2b promoter in additional somatic tissues (brain, 
liver) of both wild type strains, I could demonstrate that the differential methylation pattern is 
established not only in mesodermal tissues, but also in somatic tissues arising from the embryonic 
ectoderm and endoderm, respectively (Figure 5-7). The lack of tissue-specificity indicated that de 
novo methylation at the Isoc2b promoter takes place during early embryonic development before 
the embryo gives rise to the three germ layers. This process, called gastrulation, starts 6.5 days 
post coitum (dpc) (embryonic day (E) 6.5)
290
. At this point, the mouse embryo forms the primitive 
streak and the precursors of the different germ layers are allocated. The primordial germ cells 
(PGCs), which later give rise to the mature germ line cell lineage, start to specify around E7.5. 
The Isoc2b promoter is most probably affected by the genome-wide reprogramming in PGCs that 
erases DNA methylation patterns acquired in the epiblast and leads to the generally unmethylated 
state found in germ line cells (testis) of both strains. 
Since early embryonic stages render very little material to address DNA methylation and gene 
transcription, I applied an in vitro embryonic stem cells (ESC) differentiation model to overcome 
these limitations. Similar to germ line cells, pluripotent ESCs of both strains (generated from male 
E3.5 blastocysts) displayed a hypomethylated phenotype at the Isoc2b promoter (Figure 5-7) as 
assessed by MALDI-TOF MS. Furthermore, ESCs can be driven into unspecific as well as 
cell type-specific differentiation
291-293
. These findings emphasize the potential of the ESC 
differentiation model in further investigations regarding MIso. 
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Figure 5-7 The strain-specific Isoc2b methylation phenotype is present in somatic tissues, but 
not in germ line cells and ES cells  
The relative position of repeats, sequence variations, CpGs, and EpiTYPER amplicons within the Isoc2b 
promoter region are indicated at the top. Methylation levels of individual CpGs obtained by MALDI-TOF MS 
analysis of bisulfite-treated DNA in indicated cells and tissues of C57BL/6 and BALB/c are shown color-
coded. The scale ranges from pale purple (0% methylation) to dark purple (100% methylation). For ESCs, 
three independent batches of the same cell lines were analyze. For germ line cells and somatic tissues, three 
biological replicates are analyzed. Strain-specific variants of indicated SNPs and Indels are positioned 
relative to analyzed CpGs. 
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5.1.5.1 De novo methylation of the Isoc2b promoter in differentiating 
ESCs 
Weng et al. have already shown in 1995 that strain-specific developmental gene silencing can be 
recapitulated in differentiating ESCs
294
. I adapted a procedure described by Bibel et al.
266
 to drive 
pluripotent ESCs of both strains into unspecific differentiation by embryoid body (EB) formation 
(see section 4.1.1.1).  
Although the DMR at the Isoc2b promoter was initially identified in C57BL/6J and BALB/cAnNCrl 
mice, I could show that the substrains of C57BL/6 and BALB/c, respectively, revealed similar 
methylation phenotypes at the Isoc2b promoter region (Figure 5-3B). Thus, working with the 
available ESCs from C57BL/6NJ (JM8) as well as BALB/cJ was expected to have no effect on the 
experimental outcome. 
 
In agreement with the assumed early onset of de novo methylation in BALB/c wild type mice, I 
detected gradually increasing levels of DNA methylation at the Isoc2b promoter shortly after EB 
formation in the BALB/c ES cell line, but not in the JM8 cells (Figure 5-8A). The dynamics of de 
novo methylation observed in repeated differentiation kinetics of BALB/c ESCs varied, but 
generally reached a methylation level similar to that in spleen of the corresponding the BALB/cJ 
substrain (Figure 5-8A). The variable dynamics between different kinetics and even between EBs 
within the same culture was previously described
295,296
. 
Differences in the cellular potential of the BALB/c ESCs used for EB formation might also 
constitute a possible explanation as it is visible in the altered methylation of undifferentiated ESCs 
(d0) depicted in Figure 5-8A. BALB/c ESC cells could only be maintained in a pluripotent state 
when cultured on mouse embryonic fibroblasts (MEF). However, removal of MEFs is required for 
EB formation, since MEFs represent a differentiated cell type contaminating the differentiating 
ESCs. Counterproductively, BALB/c ESCs seemed to lose their pluripotency rapidly when cultured 
without MEFs. In contrast, JM8 ESCs were maintained without MEFs on gelatine-coated culture 
dishes without any effects on their pluripotency. The pluripotent state of ESCs and EBs was 
assessed by expression analyses of pluripotency genes, which are repressed upon 
differentiation
296
. RT-qPCR data of total RNA from differentiating ESCs revealed an inverse 
correlation of de novo methylation at the Isoc2b promoter with expression levels of the 
pluripotency markers Oct4
225
 (Figure 5-8D). An additional marker of the pluripotency potential of 
ESCs seemed to be the methylation level at an intragenic region of the pluripotency marker 
Nanog (mm9_chr6:122658540-122658757). Assessed by MALDI-TOF MS, the detected average 
DNA methylation levels at this locus correlated well with the Isoc2b promoter methylation in 
differentiating BALB/c ESCs (Figure 5-8B). Increasing levels of DNA methylation at this control 
locus was be used as an indicator for the progression of ESC differentiation. 
Comparing DNA methylation levels of the Nanog-associated region between parallel time courses 
of differentiating JM8 and BALB/c ESCs did not correlate as well and indicated a deferred 
differentiation of JM8 ESCs in comparison to BALB/c ESCs (Figure 5-8C). This was also 
detectable at the expression level of the pluripotency marker Oct4 (Figure 5-8D). However, after 
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ten days of differentiation not only BALB/c ESCs seemed to generally reach the maximum of 
Isoc2b promoter methylation, but also JM8 cells achieved a differentiation level similar to BALB/c 
ESCs (according to Nanog methylation). 
 
 
 
 
Figure 5-8 DNA methylation and gene expression analysis in differentiating ESCs 
(A) – (C) Average DNA methylation levels of the stated genomic regions were assessed by MALDI-TOF MS. 
(A) Isoc2b promoter methylation (mm9_chr7: 4817621-4817948) in germ line cells (left, n=2-3), 
differentiating ESCs (middle) and spleen (right, n=2-6) of both wild type strains (C57BL/6: red, BALB/c: blue). 
For differentiating ESCs, three independent time courses are depicted (matching color intensities indicate 
parallel generation of differentiation kinetics for JM8 and BALB/c ESCs). The light red and light blue kinetics 
were generated over the course of a master thesis
297
. (B) Correlation of DNA methylation levels in three 
independent differentiation kinetics of BALB/c ESCs at the Isoc2b promoter (mm9_chr7: 4817621-4817948) 
and an intragenic region of Nanog (mm9_chr6:122658540-122658757) (Pearson correlation, r
2
=0.8104). (C) 
Correlation of DNA methylation levels in three parallel differentiation kinetics of JM8 and BALB/c ESCs at an 
intragenic region of Nanog (mm9_chr6:122658540-122658757) (Pearson correlation, r
2
=0.5045). (D) 
Expression analysis of the pluripotency marker Oct4 in three independent kinetics of differentiating ESCs of 
both wild type strains. Expression levels were determined by RT-qPCR and normalized to 18S.  
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Figure 5 -8 
Continued from previous page. 
 
 
These findings further supported the notion of a strain-specific epigenetic modifier and 
demonstrated the applicability of the in vitro ESC differentiation model for further experiments 
such as expression analysis in the candidate region during de novo methylation. 
The results are presented in the following section. 
5.1.5.2 Hydroxymethylcytosine accounts for higher methylation level in 
BALB/c ESCs 
Although germ line cells as well as embryonic stem cells exhibited a hypomethylated phenotype at 
the Isoc2b promoter in both strains when compared to somatic tissues, BALB/c ESCs always 
displayed a slightly increased methylation level. Another modification of the DNA, 
hydroxymethylation of cytosines (5hmC, an intermediate of the active DNA demethylation 
pathway), was previously detected at its highest level in mammals in neuronal cells, but also in 
ESCs
82,298,299
. However, bisulfite treatment-based methylation analysis do not allow for the 
discrimination of contributions of methylated cytosines (5mC) and 5hmC, respectively
300
. To 
investigate the presence and dynamics of 5hmC during ESC differentiation, I performed 
hydroxymethylcytosine methylated DNA immunoprecipitation (hMeDIP), which involves a 5hmC-
specific antibody. Using qPCR, local enrichment of 5hmC was assessed. 
Results 
  147 
I performed the hMeDIP assay with one set of parallel differentiation kinetics depicted in Figure 
5-8A (JM8: dark red, BALB/c: dark blue) and subsequently analyzed 5hmC enrichment in a 3 kb 
region surrounding the Isoc2b promoter by qPCR. The relative locations of the qPCR amplicons 
and the EpiTYPER amplicons used for MADI-TOF MS-based DNA methylation analysis are 
depicted in Figure 5-9A. Specific enrichment of hydroxymethylated DNA fragments was confirmed 
by parallel analysis of a control region devoid of CpGs (“empty”, see section 3.10.3),. 
Interestingly, undifferentiated BALB/c ESCs exhibited a higher level of 5hmC in the core region 
(grey background) compared to JM8 ESCs (Figure 5-9B), which might account for the slightly 
increased DNA methylation s observed in BALB/c ESCs (Figure 5-8A). Furthermore, 5hmC levels 
at the Isoc2b promoter as well as adjacent regions declined rapidly upon differentiation of BALB/c 
ESC, whereas JM8 ESCs seemed to steadily gain 5hmC during differentiation at the border of the 
DMR. 
 
 
 
 
Figure 5-9 JM8 and BALB/c ESCs exhibit dynamic, but individual patterns of 5hmC during 
differentiation 
(A) The represented 3 kb window displays the relative position of qPCR (red) and EpiTYPER amplicons 
(green) within the promoter regions of the Isoc2b gene. (B) 5hmC levels were determined in differentiating 
JM8 (left) and BALB/c ESCs (right) by hMeDIP and qPCR for the core region (grey background) as well as 
adjacent regions (as indicated in (A)). 
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5.1.6 Complementation assay in ESCs 
In addition to limited availability of mouse embryos, manipulation of the latter is a difficult task, 
especially during early embryonic stages. However, stain-specific de novo methylation of the 
Isoc2b promoter takes place during these early stages of embryogenesis. In contrast, ESCs are 
comparably easy to manipulate and represent a convenient model to examine the effects of 
exogenous factors on DNA methylation. Since de novo methylation occurs to the same extent at 
both alleles in F1 hybrids, a transgene encoding for MIso was assumed to be able to complement 
the genetic trait and enforce the associated phenotype to ESCs. 
The existing data did not reveal whether MIso prevents or promotes de novo methylation at the 
Isoc2b promoter. Known epigenetic modifiers, which target DNA methylation during early 
embryogenesis, often involve a DNA methylation-promoting mechanism (Table 6-1). Based on 
these findings, I performed complementation assays in normally non-methylating JM8 ESCs with 
sequences derived from the methylating strain (BALB/c) to subsequently analyze the Isoc2b 
promoter methylation after differentiation in EBs. For that purpose, the CHORI-28 BAC library 
(BALB/cByJ, obtained from BACPAC Resources) was screened for Bacterial Artificial 
Chromosomes (BACs) representing the 9 Mb candidate region (see section 4.3.1.20). Since 
BALB/cByJ exhibited DNA methylation levels at the Isoc2b promoter (Figure 5-3B) similar to 
BALB/cAnNCrl, sequences from both substrains were assumed to have the same effect in 
complementation assays. 
5.1.6.1 Identification of candidate BACs 
For library screening purposes, filter membranes are available from BACPAC resources. Each 
membrane contains over 18000 individual BAC clones of specific BAC libraries in duplicates. The 
CHORI-28 BAC library is represented by eleven membranes (2 sets of five and six membranes 
are available), each spotted with BAC clones carrying genomic inserts at an average of 170 kb. 
Each membrane theoretically provides a one-fold coverage of the BALB/cByJ genome. 
Probe design was impeded by the repetitiveness of the candidate region. To provide for specific 
detection of candidate BACs, I designed oligos to generate labeled probes with PerlPrimer 
software
301
 according to the criteria listed in section 4.3.1.20. 
Probes were generated and labeled by PCR with the designed primers on spleen DNA from 
BALB/cByJ (purchased from Jackson Laboratories) (see section 3.10.5). In total, 146 probes were 
hybridized to each of three different membranes from the second segment of the CHORI-28 BAC 
library (7H, 8H, 9H) yielding a theoretical three-fold coverage of the candidate region. The readout 
of hybridized membranes based on the relative arrangement of the duplicate clones and their 
position on the membrane was performed according to BACPAC’s instruction. 
In total, 160 candidate BACs were identified. Based on the size of the candidate region (9 Mb) 
and the average genomic insert per BAC (170 kb), the total number of identified BAC clones was 
in line with an estimated three-fold coverage and suggesting a low false-positive rate despite the 
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repetitiveness of the candidate region. Candidate BACs selected from the CHORI-28 BAC library 
are listed in Table 3-1. 
5.1.6.2 Representation of the candidate region by selected BACs 
As an initial attempt to estimate the coverage of the candidate region, I sequenced a pool of 159 
BACs prepared by pulsed-field gel electrophoresis (see section 4.3.1.5 and 4.3.1.18 - protocol III) 
on an Illumina HiSeq platform (indexed 50 bp single-end reads). BAC32 was omitted due to 
preparation difficulties. The relative concentration as well as residual contamination by E. coli 
gDNA was determined by qPCR with primers specific for the pTARBAC2.1 backbone of the BACs 
and the E. coli TRPE gene locus, respectively. With few exceptions, E. coli contaminations were 
below 10%. To account for the different content of BAC DNA in the individual preparations, the 
contributing volume to the BAC pool was adjusted according to the individual BAC concentration 
determined by qPCR. The NGS library of pooled BACs was generated according to NGS library 
protocol III (see section 4.3.1.18). The complete command line for processing the NGS data of the 
pooled BACs is stated in section 4.4.3. 
Eighty-nine percent of the candidate region was found to be covered by at least one 50 bp read. 
After adjusting the read length to the actual average fragment length of 170 bp (see section 
4.3.1.18) 94% of the bases in the candidate region were covered. In addition to the six annotated 
50 kb gaps of the mm9 reference genome, only 10 regions of the mm9 reference genome showed 
major alignment gaps larger than 10 kb in size (Figure 5-10), but were mainly comprised of 
repetitive sequences (Table 5-1). The largest gap with ~ 235 kb was located in a conserved and 
well annotated part of the candidate region. The only annotated gene residing in this region is the 
5’ end of Mboat2, a lysophospholipid acyltransferase-encoding gene. Since this gene does not 
appear to be a suitable factor to confer the observed methylation phenotype, this gap was not 
assumed to have a negative effect on the complementation assay. Nevertheless, the Mouse 
Genomes Project
275
 (REL-1211) lists many strain-specific SNPs and Indels for C57BL/6 and 
BALB/c for this region as well as eleven larger structural variances. Hence, closing the gap with 
additional BAC clones would be advisable. 
In summary, the candidate BACs provided for an acceptable region-wide coverage. However, 
complete sequencing of the individual BAC will be necessary to obtain a more reliable picture of 
the actual representation of the candidate region.  
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Figure 5-10 Coverage of the candidate region by BAC clones 
A pool of 159 candidate BACs was sequenced and mapped to chromosome 12 of the mm9 reference 
genome. At the top, the number of reads per non-repetitive base within the candidate region 
(mm9_chr12:16902483-26024113) as well as the average read depth (170 reads per base) at covered bases 
(green dashed line) is depicted. At the bottom, the relative position of the six known mm9 assembly gaps 
(black) within the candidate region as well as coverage gaps > 10 kb (orange). The color intensity of the 
coverage gaps indicates proportion of non-repetitive bases within the gap (light: ≤ 5%, dark: >5%, see also 
Table 5-1). 
 
 
 
Table 5-1 Major gaps (>10 kb) in BAC coverage 
 
  
Genomic location
(mm9)
Length
Fraction of
repetitive sequences
chr12:17865353-17885915 20562 bp > 99%
chr12:17963033-17976874 13841 bp > 99%
chr12:18441887-18455390 13503 bp > 99%
chr12:19713003-19724841 11838 bp 96%
chr12:19817985-19828645 10660 bp > 99%
chr12:20713551-20723740 10189 bp 99%
chr12:21560633-21582762 22129 bp 59%
chr12:23176181-23186853 10672 bp > 99%
chr12:24844859-24855529 10670 bp > 99%
chr12:25432995-25667219 234224 bp 44%
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5.1.6.3 Retrofitting BACs with an eukaryotic selection marker 
In order to perform complementation experiments, a eukaryotic selection marker to select for 
stable transfected ESC clones was a prerequisite. However, the original CHORI-28 BACs only 
carried a Chloramphenicol resistency gene in the pTARBAC2.1 vector backbone to allow for 
maintenance in bacteria. Since a LoxP (ATAACTTCGTATANNNTANNNTATACGAAGTTAT) site was 
encoded in the BAC backbone, I modified (retrofitted) the latter using a LoxP/Cre recombinase 
system (Figure 5-11A) with a Neomycin/Geneticin resistency gene. This gene encodes for an 
aminoglycoside phosphotransferase that inactivates the otherwise cytotoxic compound Geneticin 
(G418) by phosphorylation
302
. The eukaryotic selection marker was introduced to the BAC 
backbone by recombination with the pNel plasmid (see section 4.3.3.2). In addition to the LoxP 
recombination site and the resistency gene, this 9 kb plasmid harbours an eGFP gene. Since the 
resistency gene as well as the eGFP gene is under the control of the eukaryotic CAG promoter, 
ESCs transfected stably with pNel-retrofitted BACs could be selected by G418-supplemented 
medium and visualized by their intrinsic green fluorescence (Figure 5-11B). Of the initial 160 
candidate BACs, 148 BACs could be retrofitted with the eukaryotic selection marker and were 
subject to stable transfection in JM8 ESCs. 
 
 
 
 
 
Figure 5-11 ESCs can be stably transfected with retrofitted BACs 
(A) Retrofitting system: A eukaryotic selection marker (Gen
R
) was introduced to the BAC backbone 
(TARBAC2.1) together with an eGFP expression cassette provided by pNel via the LoxP/Cre recombination 
system. Two different retrofitting strategies were applied (“n”/”nj”, see section 4.3.3.2). (B) Fluorescent 
microscopy of embryonic stem cells (ESCs) and embryoid bodies (EBs) after transfection with H2O (without 
G418 selection) or a representative BAC (after selection with G418 and expansion). EGFP was excited at 
488 nm for 500 ms. 
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5.1.6.4 DNA methylation analysis of transfected embryoid bodies 
MIso was also assumed to favor DNA methylation and thus to be encoded and functional in 
BALB/c strains. Consequently, complementation assays in JM8 ESCs with BALB/c-derived MIso-
encoding sequences might facilitate de novo methylation at the Isoc2b promoter during 
differentiation. Therefore, I transfected pluripotent JM8 ESCs individually with the 148 retrofitted 
candidate BACs selected from the CHORI-28 BAC library (BALB/cByJ). After 10 days of selection 
with G418 and subsequent three passages without selection pressure, stably transfected 
pluripotent cells were subject to unspecific differentiation according to section 4.1.1.1. After a 
differentiation period of 10 days, formed EBs were collected and DNA methylation levels at the 
Isoc2b promoter were determined by the MALDI-TOF MS (see section 4.3.1.14) after bisulfite 
treatment (see section 4.3.1.12). Stable transfection and hence the presence of BAC-derived 
exogenous DNA sequences was confirmed for all differentiated ESC clones by PCR with primers 
specific for the BAC backbone (data not shown). 
Confirmed for both cell lines, the transfection and selection procedure itself did not alter the 
outcome of Isoc2b promoter methylation phenotype after differentiation (Figure 5-12A). As 
described before (see section 5.1.5.1), variation in the differentiation kinetics seems to be a 
common phenomenon. Since the EBs for each depicted time point were collected from separate 
culture dishes, it was not expected to see an exclusive incline in methylation levels at the 
assessed loci. Nevertheless, the combined analyses of methylation levels at the Isoc2b promoter 
as well as control regions (Pdgfrb, Nanog), which also gained methylation during differentiation, 
allowed for reliably estimating the general differentiation state of the respective EB sample. 
Transfected BALB/c ESC clones exhibited substantial levels of DNA methylation at the Isoc2b 
promoter after 10 days of differentiation. Hence, this differentiation period was assumed to be 
sufficient to allow for de novo methylation at the Isoc2b promoter by an exogenous copy of MIso 
in complementation assays with JM8 ESCs. However, de novo methylation at the Isoc2b promoter 
region could not be detected in any of the transfected JM8 ESC clones despite their advanced 
differentiation state (as assessed by methylation levels at the control regions, Figure 5-12B). 
Possible explanations for the failure of the complementation assay will be discussed in chapter 6. 
 
 
Results 
  153 
 
 
Figure 5-12 DNA methylation analysis of stable transfected differentiating ESCs 
The degree of average DNA methylation detected by MALDI-TOF MS at the stated genomic regions is 
shown color-coded. (A) Comparison of methylation dynamics in untransfected (top) as well as BAC-
transfected (bottom) BALB/c (left) and JM8 ESCs (right) during differentiation. Depicted are two regions 
within the DMR at the Isoc2b promoter region (left: mm9_chr7:4817623-4817948; right: mm9_chr7:4828016- 
4818396, only the first 7 CpGs) as well as two control regions (Pdgfrb: mm9_chr18:61225274-61225631; 
Nanog: mm9_chr6:122658540-122658757). (B) Methylation analysis in JM8 EBs (stably transfected with 
BALB/c-derived BAC clones) after ten days of differentiation at the Isoc2b DMR as well as the control regions 
(genomic locations of the analyzed regions are stated in (A)). 
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5.1.7 Comparative expression analysis in differentiating ESCs 
reveals a candidate gene for MIso 
Since the complementation assays with BALB/c BAC clones in JM8 ESCs failed to further reduce 
the candidate region, I used comparative expression analysis of differentiating ESCs as an 
alternative approach for the identification of MIso. Upon differentiation, ESCs established the 
strain-specific Isoc2b methylation phenotype observed in somatic tissues. The Isoc2b promoter 
region was de novo methylated in differentiating BALB/c ESCs, whereas it remained 
unmethylated in differentiating JM8 ESCs. Assuming that the phenotype is regulated by a trans-
acting epigenetic modifier, its presence and activity must coincide with the process of active 
de novo methylation. Based on these findings, region-wide expression levels in both cell lines 
were investigated. 
After identifying the window of active de novo DNA methylation in differentiating BALB/c ESCs 
(see Figure 5-8A), strain-specific transcripts arising from the 9 Mb candidate region were 
assessed by RNA-seq experiments. Several time points during differentiation of both JM8 and 
BALB/c ES cell lines were selected for comparative expression analysis. I purified total RNA from 
pluripotent ESCs as well as from EBs of both cell lines after one, two, and four days of unspecific 
differentiation and processed the samples to generate strand-specific RNA-seq libraries. The 
libraries contained cDNA fragments generated from rRNA-depleted RNA samples with molecules 
longer than 200 nt, thus allowing for sequencing of both protein-coding and long non-coding 
RNAs. Corresponding DNA methylation levels of the Isoc2b promoter at the selected time points 
are depicted in Figure 5-8A (BALB/c: dark red time course; JM8: dark blue time course). 
Ribosomal RNA-depleted RNA-seq libraries were prepared according to section 4.4.2 and 
sequenced on the Illumina HiSeq1000 platform (100 bp paired-end reads, see section 4.4.4) with 
one sample per lane. RNA-seq data were analyzed with the Trinity software package as described 
in section 4.4.2. As a de novo assembling software, the Trinity tool pipeline circumvents the 
difficulties of a not yet available BALB/c reference genome. The complete command line for RNA-
seq data analysis is listed in section 4.4.2. 
 
Three different de novo assemblies were generated; one for each strain from all reads from all 
available time points and one for all reads from both strains from all available time points. The 
de novo assemblies counted in total 615402 (BALB/c), 1287454 (JM8), and 1490539 (combined) 
‘trinity transcripts’ (reconstructed sequence contigs from RNA-seq data) (transcript length > 
200 bp). The large number of transcripts assembled from JM8-derived reads and hence combined 
reads were caused by the increased number of sequencing reads derived from JM8 day 1 and 2 
samples (Table 5-2). This inconsistency is most probably due to the applied advanced library 
preparation and sequencing protocol used for these two samples (see section 4.4.2); the libraries 
were generated and processed at a later time point when only follow-up versions of the originally 
applied kits were available. These technical effects on the reproducibility of RNA-seq data can be 
visualized by pairwise comparison of samples from the same differentiation kinetic. Although no 
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biological replicates were available, samples from consecutive time points of individual kinetics 
can be interpreted as such. To test for the similarity of samples derived from the same 
differentiation kinetic, abundancy levels of the de novo assembled transcriptome generated from 
all samples were estimated and compared. As expected for quasi biological replicates, 
differentially expressed genes were rare between consecutive BALB/c samples, but increase with 
proceeding distance of the samples in the differentiation kinetic (Figure 5-13A). In contrast to the 
BALB/c RNA-seq libraries that were generated with the same kits in one experiment, the 
comparison of JM8 samples revealed less reproducibility most probably due to the different 
processing of day 0 and 4 and day 1 and 2 samples (Figure 5-13B). 
 
 
 
Figure 5-13 Reproducibility of RNA-seq data 
MA plots of pairwise comparisons (vertical over horizontal) of BALB/c (A) and C57BL/6 (B) samples, 
respectively, are depicted. Transcript abundancies were calculated for transcripts de novo assembled from 
the combined analysis of RNA-seq reads of all samples. Differential expression (DE) and false discovery rate 
(FDR) were estimated using the EdgeR script stated in 4.4.2. Red dots represent differentially expressed 
transcripts (p<0.05, FDR <0.05) in each individual comparison. 
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Nevertheless, quality assessment of the generated de novo assemblies implicated successful and 
reliable assemblies. The transcripts from each de novo assembly were compared to the mRNA 
nucleotide sequences of the RefSeq Genes transcriptome (mm10, obtained from UCSC table 
browser) by performing megablast (NCBI). Transcripts of the BALB/c, JM8, and combined de 
novo assemblies that covered reference transcripts by more than 10% (alignment expectation 
value <1e
-20
) represented 56% (18566), 64% (20988), and 67% (22248), respectively, of the 
33004 reference transcripts. Of these represented reference transcripts, 58% (10798/18566), 52% 
(10906/20988), and 53% (11745/22248), respectively, were covered by more than 50%. The 
partial coverage of the reference transcriptome can be explained by the complexity of the gene 
expression programs found in a highly developed multicellular organism such as Mus musculus. 
On the one hand, only parts of the available genes are expressed in each cell type. On the other 
hand, the deep sequencing approach will also detect minimal amounts of RNA fragments derived 
from transcriptional background noise resulting in incomplete transcripts with very low abundancy. 
This background noise is accumulating with increasing read depth, which accounts for the 
samples JM8 day 1 and 2. To test this hypothesis, a JM8 de novo assembly was also generated 
only from JM8 day 0 and 4 samples. This assembly rendered similar results when compared to 
the reference transcriptome: The 565736 de novo assembled transcripts covered 54% (17946) of 
the reference transcripts (33004) by more than 10% (expectation value <1e
-20
) and of these 
reference transcripts 51% (9215/17946) were covered by more than 50%. Nevertheless, the 
informational content of the de novo assembled transcriptomes from all four JM8 samples and all 
eight combined samples, respectively, is expected to be higher, despite increased background 
noise. Therefore, further analyses were performed with the transcriptomes assembled from all 
available samples. 
The high number of de novo assembled transcripts, especially those generated from JM8 and the 
combination of all samples, is also associated with an increased number of incomplete isoforms, 
especially for highly expressed genes as shown for several control genes (Table 5-2). These 
control genes represent housekeeping genes (Actb, Gapdh), pluripotency-associated genes 
(Nanog, Oct4, Sox2) as well as genes known to be expressed in differentiated cells (Isoc2b, 
Myod1) and were all (except for Myod1) represented in full length by at least one of the 
assembled transcripts. Normalized expression values for corresponding ‘trinity genes’ (sum of 
related isoforms) are listed in Table 5-3. Housekeeping genes were detected at high abundancy at 
all time points, whereas pluripotency-associated genes were gradually repressed with progressing 
differentiation. In contrast, genes that are known to be transcribed only differentiated cells were 
detected only at background levels. Again, although accompanied by an increased background 
noise (no-full-length isoforms), using sequencing data from all available JM8 samples rendered a 
more complete picture of the transcriptome as assessed by detection of full-length isoforms. 
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Table 5-2 Overview of detected isoforms of selected control genes 
 
 
 
Table 5-3 Normalized expression values of selected control genes 
 
*fpkm: fragments per kilo base per mapped million reads 
 
General and local quality assessment supported the reliability of the available RNA-seq data sets 
as well as successful de novo assembly of the transcriptome present in differentiating ESCs. 
Further analyses of the de novo assemblies generated from all BALB/c- and JM8-derived samples 
(‘BALB/c-specific’, ‘JM8-specific’, ‘combined’) were aimed at the identification of strain-specific 
transcripts potentially encoding MIso. 
In addition to the search for novel, unannotated strain-specific transcript within the candidate 
region, the list of annotated genes located within mm9_chr12:16902843-26024113 
(mm10_chr12:16895677-25339248) was revised. Initially, none of the annotated genes was 
associated with the observed strain-specific Isoc2b methylation phenotypes. However, recently 
published IP experiments by Cao et al. implicated an interaction of nucleolar protein 10 (Nol10) 
with Eed
185
, a subunit of the Polycomb repressor complex 2 that is involved in gene silencing 
during embryonic development
93
. Nol10, encoded at mm10_chr12:17348493-17430095 and 
composed of 687 amino acids (aa), belongs to a yet uncharacterized family of nucleolar proteins 
that share the NUC153 domain
303
. Adjacent to this domain of unknown function, Nol10 exhibits a 
WD40-repeat-containing domain with five adjoining WD40 repeats. WD40 repeats are found in all 
eukaryotes and seem to act as sites for protein-protein interaction, but can also serve as platforms 
Assembly Samples
Read counts
(2x 100bp)
De novo
assembled
transcripts
Actb Gapdh Nanog Pou5f1 Sox2 Isoc2b Myod1
combined assembly JM8 day 0-4
BALB/c day 0-4 -
1490539 105 / 2
(100%, 0, 0)
(93%, 0, 1)
58 / 1
(100%, 0, 0)
3 / 1
(93%, 0, 1)
16 / 1
(100%, 0, 0)
12 / 2
(100%, 0, 0)
(100%, 0, 0)
8 / 0 1 / 0
JM8 day 0 371417662
JM8 day 1 653891042
JM8 day 2 424313042
JM8 day 4 341866426
BALB/c day 0 282936352
BALB/c day 1 367029208
BALB/c day 2 335016080
BALB/c day 4 374718578
JM8-specific assembly JM8 day 0, day 4
-
565736
54 / 0
19 / 2
(100%, 0, 0)
(100%, 0, 0)
6 / 3
(93%, 0, 1)
(93%, 0, 1)
(93%, 0, 1)
18 / 2
(100%, 0, 0)
(100%, 0, 0)
10 / 0 4 / 0 -
615402
-4 / 0
15 / 1
(100%, 0, 0)
16 / 1
(100%, 0, 0)
2 / 0
39 / 1
(100%, 0, 0)
60 / 1
(100%, 0, 0)
BALB/c-specific assembly
Detected isoforms / full-length isoforms
(identity, mismatches, gaps)
Housekeeping
genes
Pluripotency-associated
genes
Differentiation-specific
genes
1 / 08 / 0
11 / 1
(100%, 0, 0)
28 / 1
(100%, 0, 0)
7 / 4
(93%, 0, 1)
(93%, 0, 1)
(93%, 0, 1)
(93%, 0, 1)
46 / 2
(100%, 0, 0)
(100%, 0, 0)
104 / 4
(99%, 4, 0)
(99%, 4, 0)
(99%, 4, 0)
(98%, 6, 0)
1287454JM8-specific assembly
Gene name Trinity gene ID day 0 day 1 day 2 day 4 day 0 day 1 day 2 day 4
Actb c1247068_g1 2535.370 1918.918 1115.922 1690.708 1027.806 1329.987 1069.797 1382.951
Gapdh c1257627_g3 280.405 197.886 145.817 135.255 218.785 717.390 488.449 237.839
Nanog c1240255_g4 25.061 8.900 9.017 11.042 44.783 26.929 48.881 19.824
Oct4 c1256103_g1 355.599 210.487 168.430 54.556 516.166 351.421 161.258 102.258
Sox2 c1254521_g4 65.289 27.480 22.497 4.090 119.149 103.397 67.193 29.369
Isoc2b c1234267_g4 0.000 0.000 0.484 0.000 0.000 0.000 1.142 0.443
Myod1 c1289921_g1 0.000 0.000 0.000 0.266 0.000 0.000 2.049 0.000
BALB/c
Normalized expression values (fpkm*)
House keeping genes
Pluripotency-associated genes
Differentiation-associated genes
JM8 (C57BL/6)
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for the assembly of protein complexes. The specificity of proteins harbouring WD40-repeat-
containing domains seems to be determined by the sequence outside the repeat-containing 
domain
304,305
. Examining the available genotyping data generated by the Mouse Genomes 
Project
275
 (Rel-1303) for C57BL/6 and BALB/c as well as for the other six inbred mouse strains 
(129S1/SvImJ, A/J, C3H/HeJ, CBA/J, DBA/2J, NOD/ShiLtJ) that were also analyzed for their 
methylation phenotype at the Isoc2b promoter (see Figure 5-3A) further supported a possible 
involvement of Nol10 in the establishment of the observed methylation phenotype. Only the 
hypermethylated strains (BALB/c, A/J) have a consequential SNP variant of rs29160165 
(mm10_chr12:17416714). The G to A mutation in BALB/c and A/J has two consequences 
according to the Mouse Genome Project annotation. On the one hand, the SNP variant induces a 
non-synonymous variant resulting in an alternate protein sequence. On the other hand, the SNP 
position overlaps with a splice junction and might result in an alternate splice variant. 
Visual inspection of de novo assembled transcripts highly similar to the Nol10 protein (expectation 
value <1e
-20
) revealed that, although none of the transcripts represented a full-length isoform of 
Nol10, the combination of related transcripts rendered nearly 100% Nol10 transcript coverage. 
Only transcripts assembled from all JM8 (day 0 to day 4) displayed larger gaps, as the first exon 
as well as a connection of exon 14 and 15 was missing. These gaps, however, were covered by 
transcripts assembled from JM8 day 0 and day 4 (Figure 5-14A). The estimated transcript 
abundancy on gene level further revealed, that Nol10 is expressed to a similar extend in both ES 
cell lines at all analyzed time points (Table 5-4). These findings were validated by RT-qPCR 
(Figure 5-14B). 
Since the non-synonymous SNP had an implication in the post-transcriptional processing of the 
Nol10 transcript, the corresponding de novo assembled transcripts were analyzed in more detail. 
Although rs29160165 resides in a splice region of intron 18, no effect on the splicing of the Nol10 
transcript was detected in RNA-seq-derived transcripts nor on cDNA level. Nevertheless, the SNP 
variant (Guanine to Adenine) seems to have an effect on the amino acid sequence of the Nol10 
protein in BALB/c ESCs (see Appendix III, Table 10-3). The annotated SNP variant was verified 
on transcript and genomic sequence level and causes an amino acid exchange (glutamic acid to 
lysine) at position 532. The WD40 repeats and the NUC153 domain are not affected by the non-
synonymous SNP variant (Figure 5-14C). 
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Figure 5-14 Differentiating ESCs express strain-specific variants of Nol10 
(A) Depicted at the top is the UCSC genome browser track of the Nol10-encoding genomic region 
(mm10_chr12:17348493-17430095). Below BLAT results for de novo assembled transcripts similar to Nol10 
are shown for the individual Trinity assemblies. The non-synonymous SNP variant (G > A) of rs29160165 
resides in a splice region, but does not affect splicing. Other SNP variants between C57BL/6 and BALB/c 
mainly affect intronic sequences or are synonymous. (B) Nol10 expression in ESCs, EBs (mean of 
differentiated EBs day 1-5, day 8) and spleen (n=3-4) assessed by RT-qPCR (normalized to 18s, error bars 
represent standard deviation). (C) The non-synonymous SNP variant (G > A) of rs29160165 (see (A)) at the 
5’-end of exon 19 results in an amino acid exchange (glutamic acid > lysine) at position 532. The beta-
transducin (WD40) repeats as well as the nucleolar protein domain 153 (NUC153) of Nol10 are not affected. 
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Table 5-4 Normalized expression values of de novo assembled transcripts similar to Nol10 
 
 *fpkm: fragments per kilo base per mapped million reads 
 
 
Although further investigations on the functional effect of the strain-specific isoforms of Nol10 are 
required, these findings implicate a potential role of Nol10 in the establishment of the strain-
specific methylation phenotype at the Isoc2b promoter and thus a potential candidate locus 
encoding for MIso. 
Nol10 is a promising candidate gene, but its actual involvement still has to be confirmed. 
Therefore, the RNA-seq data and the generated de novo assemblies will be subject to further 
analysis regarding strain-specific novel transcripts within the candidate region. 
  
Transcript assembly Trinity gene ID day 0 day 1 day 2 day 4
c935471_g1 0.259 0.050 0.552 0.000
c1148681_g11 18.197 42.345 22.404 11.559
c1148681_g12 58.296 62.887 32.784 36.583
c1151945_g7 6.263 16.918 14.160 5.448
c1160331_g4 40.713 57.860 33.324 42.928
c591363_g3 31.631 - - 18.447
c591363_g14 24.380 - - 17.541
c422587_g2 18.689 19.490 21.047 16.912
c423461_g20 16.160 13.558 14.739 10.166
Normalized expression values (fpkm*)
JM8
(day 0 to day 4)
BALB/c
(day 0 to day 4)
JM8
(day 0, day 4)
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5.1.8 DNA methylation frequency at repetitive sequences 
The known epigenetic modifiers were often associated with the silencing of repetitive 
sequences
96,98,306,307
. The strain-specific methylation phenotype observed at the Isoc2b promoter 
might also be caused due to differential methylation of repetitive sequences among the two 
mouse strains, since two repeats of the Alu family (PB1D7, B1_Mus2) reside within the DMR (see 
Figure 5-7). Using MCIp-seq data from spleen and cerebellum of both strains (further described in 
section 5.2.4), differential DNA methylation at known repeats was assessed with the Homer tool 
pipeline. The complete command line for processing the MCIp-seq data is stated in section 
4.4.1.2. Although the methylation profile of several annotated repeats seemed to generally differ 
significantly between both strains (p<0.05, FDR<0.05), no difference was found for the repeats 
located within the Isoc2b DMR (Table 5-5, PB1D7 and B1_Mus2 are highlighted). 
 
Table 5-5 Strain-specific MCIp enrichment of selected repeats 
  
C57BL/6 BALB/c C57BL/6 BALB/c logFC p value FDR
(TCCTG)n|Simple_repeat|Simple_repeat 80.4 149 866 147.6 1081.8 95.5 3.05 1.66E-27 2.02E-24
(CGGAG)n|Simple_repeat|Simple_repeat 83.1 17 1937.21 442.8 1667.12 419.66 2.05 2.23E-23 1.36E-20
(TATTG)n|Simple_repeat|Simple_repeat 65.4 147 221.33 29.35 192.27 19.28 3.09 6.79E-21 2.76E-18
(CATAT)n|Simple_repeat|Simple_repeat 72.5 263 19.34 132.06 13.39 170.8 -3.25 5.86E-15 1.79E-12
SUBTEL_sa|Satellite|Satellite 162.4 31 2159.62 701.75 1837.48 618.01 1.59 1.87E-14 4.57E-12
5S|rRNA|rRNA 80.5 1035 970.22 365.12 963.77 305.79 1.54 2.88E-12 5.85E-10
(CATAG)n|Simple_repeat|Simple_repeat 89.1 52 134.3 504.09 131.42 333.34 -1.63 1.63E-10 2.85E-08
MER70A|LTR|ERVL 280.5 181 377.13 164 324.91 101.01 1.43 7.48E-09 1.14E-06
(TTCCG)n|Simple_repeat|Simple_repeat 76.6 5 399.69 182.99 382.1 137.74 1.30 9.87E-08 1.34E-05
(CTAGT)n|Simple_repeat|Simple_repeat 58.6 24 22.56 3.45 24.34 2.75 2.88 1.79E-05 2.19E-03
MER96|DNA|hAT 116.9 105 44.05 115.66 41.37 126.72 -1.52 1.98E-05 2.20E-03
(CTTCG)n|Simple_repeat|Simple_repeat 40.3 3 106.37 33.66 98.57 35.81 1.55 2.19E-05 2.23E-03
(TTTCC)n|Simple_repeat|Simple_repeat 107.7 1279 645.74 358.21 446.59 203.86 0.97 2.46E-05 2.31E-03
(GCCTG)n|Simple_repeat|Simple_repeat 65.2 78 79.51 23.31 102.22 28.47 1.82 2.99E-05 2.61E-03
(CAGAC)n|Simple_repeat|Simple_repeat 94.1 55 69.84 33.66 90.05 14.69 1.78 5.70E-05 4.61E-03
(CATAA)n|Simple_repeat|Simple_repeat 68.1 94 60.17 15.54 34.07 10.1 1.86 6.04E-05 4.61E-03
tRNA-Ile-ATA|tRNA|tRNA 47.2 26 20.41 1.73 6.08 0 3.72 1.17E-04 8.40E-03
(TGGG)n|Simple_repeat|Simple_repeat 65.1 1064 507.14 308.15 444.16 251.61 0.77 3.66E-04 2.49E-02
G-rich|Low_complexity|Low_complexity 86.7 6134 11920.9 5147.04 12831.96 5821.06 1.17 5.17E-04 3.32E-02
LTR87|LTR|ERVL? 190.4 211 154.72 236.51 114.39 256.2 -0.90 7.95E-04 4.85E-02
FAM|SINE|Alu 82.6 215 56.01 54.61 40.03 45.76 -0.05 8.92E-01 1.00E+00
B1_Mur1|SINE|Alu 122.8 37980 12867.93 13030.13 11517.92 10523.13 0.06 4.18E-01 1.00E+00
FLAM_A|SINE|Alu 69.5 73 12.22 7.91 8.01 12.93 0.00 1.00E+00 1.00E+00
B1_Mur4|SINE|Alu 122.2 40539 13592.04 14013.08 12474.74 11557.74 0.04 8.01E-01 1.00E+00
PB1D9|SINE|Alu 96.7 29287 8373.58 8304.49 7973.53 7923.68 0.02 8.15E-01 1.00E+00
Alu|SINE|Alu 48.9 31 0 7.12 0 3.98 -5.53 2.49E-03 4.97E-02
B1F2|SINE|Alu 110.2 16782 5548.44 5392.81 4842.84 4503.52 0.08 1.74E-01 1.00E+00
B1_Mm|SINE|Alu 131.2 42397 22718.24 22108.64 27817.29 28952.04 -0.01 9.64E-01 1.00E+00
B1_Mur2|SINE|Alu 122 31802 10506.18 10882.18 9424.12 8818.02 0.02 7.34E-01 1.00E+00
B1_Mur3|SINE|Alu 124 24658 8138.32 7893.74 7417.05 6747.82 0.09 1.17E-01 1.00E+00
PB1D10|SINE|Alu 94.4 72983 22350.58 22539.97 20097.31 20304.13 -0.01 9.60E-01 1.00E+00
AluF_3|SINE|Alu 67.9 166 73.33 87.06 29.36 44.77 -0.35 3.94E-01 1.00E+00
B1F|SINE|Alu 109.3 45775 13893.49 14426.21 12322.61 12478.93 -0.03 8.25E-01 1.00E+00
Alu_5|SINE|Alu 44.7 19 0 0.79 2.67 0 1.18 1.00E+00 1.00E+00
B1_Mus2|SINE|Alu 128.1 70597 36720.7 35968.18 42476.59 43056.5 0.01 9.74E-01 1.00E+00
B1_Mus1|SINE|Alu 133.4 93733 36266.48 36305.33 36650.23 37949.13 -0.02 9.17E-01 1.00E+00
PB1|SINE|Alu 95.7 13667 4247.89 4043.42 3775.25 3690.76 0.06 2.98E-01 1.00E+00
PB1D7|SINE|Alu 96.1 24985 7933.61 7768.69 7132.81 7421.3 -0.01 8.91E-01 1.00E+00
B1F1|SINE|Alu 107.8 20755 6876.48 7332.61 6174.65 6161.87 -0.04 4.28E-01 1.00E+00
AluG_3|SINE|Alu 80 282 68.24 76.77 66.72 47.75 0.11 6.44E-01 1.00E+00
Alu repeats
Length
(bp) Spleen Cerebellum
MCIp tags
(normalized to 10 Mio. reads)
significantly differentially methylated repeats
RepeatID
(Name|Class|Family)
Copies
(mm9 )
C57BL/6 versus BALB/c
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5.2 Trans-regulated inter-individual variations in DNA 
methylation are the exception of the rule 
5.2.1 Identification of novel differentially methylated regions in 
inbred mouse strains 
As discussed in section 5.1, inbred mouse strains represent an ideal model organism to study 
epigenetic variations. The MCIp-on-ChIP approach established in our lab
261
 proved suitable to 
detect genome-wide differentially methylated regions (DMRs). However, the method was limited 
to selected differentially expressed regions (DERs) identified by microarray-based expression 
analysis. With the microarray technology available at that time (Whole Mouse Genome 
Expression Array (4x44K), Agilent) only parts of the annotated mouse genome could be screened 
for DERs. Thus, a new approach to discover DMRs on a more global scale was tested. To provide 
for a functional relationship between DNA methylation and gene expression, chromatin 
immunoprecipitation combined with next generation sequencing (ChIP-seq) analysis for active 
histone marks (methylated H3K4, methylated H3K27) were combined with DNA methylation 
analysis. H3 histones methylated at lysine 4 and acetylated at lysine 27 are associated with active 
enhancers and promoters. Since DNA methylation is in general associated with repression, an 
inverse correlation of active histone marks and DNA methylation at regulatory genomic elements 
was expected between the two mouse strains. To test this hypothesis as well as to identify 
additional DMRs, ChIP-Seq and MCIp-seq experiments for cerebellum and spleen tissue of 
BALB/c and C57BL/6 mice were performed and analyzed. 
 
Initially, only ChIP-seq data for spleen tissue of both wild type strains (n=1 each, male) were 
available (library preparation according to protocol I in section 4.3.1.18). In two turns, I selected 
candidate regions for further DNA methylation analysis by MALDI-TOF MS. The premises for Set 
1 were four-fold enrichment of C57BL/6-specific tags for either H3K4me3 or H3K27ac within 
defined peaks and a minimal coverage of 80 tags per peak (normalized to 10
7
 total reads). To 
compensate mapping disadvantages of BALB/c sequences to the C57BL/6-derived mm9 
reference genome, the requirements to detect BALB/c-specifically enriched regions were less 
strict (three-fold enrichment, 60 tags). For Set 2, stringency was further reduced to a general fold 
change of two and tag coverage of 60. The complete command line for processing the ChIP-seq 
data is stated in section 4.4.1.1. The complete list of the 70 novel candidate regions is stated in 
Appendix IV (Table 10-4). Set 1 contained many CpG-rich (15 of 41 regions overlapped CGIs) 
and promoter-associated (13 of 41, seven were CGI-associated) sites similar to the differentially 
methylated region at the Isoc2b promoter. However, most of the analyzed CpG-rich regions were 
detected as demethylated, which is consistent with the generally hypomethylated state of CpG 
islands
34
. Hence, regions selected for Set 2 contained less CpG-rich (three of 29 regions 
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overlapped CGIs) and promoter-associated (five of 29, two were CGI-associated) regions. MALDI-
TOF MS-based DNA methylation analysis in spleen from both wild type strains (n=2-3 for each 
strain) identified 18 differentially methylated regions (DMRs) (Table 5-6) among the 70 selected 
candidate regions. 
 
Table 5-6 Annotated list of novel strain-specific DMRs 
 
*mean of 2-3 individuals (8-12 weeks old) for each strain 
 
 
 
C57BL/6 BALB/c
H3K4me3 chr17:21844143-21845143
Zfp760
(promoter)
BALB/c
(2.1x)
chr17:21844358-21844570 8 17% 1%
H3K27ac chr4:140766411-140767411
6330545A04Rik
(distal)
C57BL/6
(4.7x)
chr4:140766797-140767168 8 72% 92%
H3K27ac chr4:133613961-133614961
Aim1l
(distal)
C57BL/6
(2.4x)
chr4:133614214-133614597 13 30% 54%
chr15:79724111-79724508 7 16% 68%
chr15:79722557-79722852 12 7% 4%
H3K27ac chr9:105973860-105974860
Col6a4
(intragenic)
BALB/c
(7.7x)
chr9:105974425-105974596 6 66% 44%
H3K27ac chr14:51443888-51444888
Parp2
(intragenic)
C57BL/6
(2.7x)
chr14:51444053-51444423 8 25% 59%
H3K27ac chr19:47515636-47516636
Sh3pxd2a
(intragenic)
C57BL/6
(3.3x)
chr19:47515951-47516448 10 25% 51%
chr13:96731300-96731697 19 21% 62%
chr13:96731126-96731439 16 17% 64%
chr3:96077670-96077953 7 25% 1%
chr3:96077988-96078283 7 76% 9%
H3K4me3 chr7:150191605-150192605
Tspan32
(intragenic)
C57BL/6
(2.1x)
chr7:150192677-150192988 6 50% 86%
chr17:48566705-48566973 4 21% 52%
chr17:48566071-48566366 6 31% 79%
H3K27ac chr11:105894819-105895819
Dcaf7
(promoter)
C57BL/6
(5.6x)
chr11:105895046-105895376 7 56% 80%
H3K27ac chr16:30155069-30156069
Hes1
(distal)
C57BL/6
(5.5x)
chr16:30155216-30155568 6 15% 35%
chr5:147874763-147875096 7 46% 10%
chr5:147875405-147875618 4 80% 25%
chr5:123489136-123489456 17 3% 26%
chr5:123489428-123489728 7 6% 68%
H3K27ac chr13:101179103-101180103
Naip1
(intragenic)
BALB/c
(7.8x)
chr13:101179250-101179593 5 84% 7%
H3K27ac chr7:52996858-52997858
Spaca4
(intragenic)
C57BL/6
(3.5x)
chr7:52997182-52997586 9 10% 57%
chr4:132651381-132651641 5 19% 53%
chr4:132651025-132651364 6 10% 47%
Average
CpG methylation
in Spleen*
H3K27ac chr15:79722157-79723157
Apobec3
(promoter)
C57BL/6
(2.2x)
Differential
histone mark
Peak
localization
(mm9 )
Nearest gene
(Rel. position)
Enriched
in
(log2 FC)
Epityper
amplicon
localization (mm9 )
CpGs
Set 1
H3K27ac chr13:96730805-96731805
Sv2c
(intragenic)
C57BL/6
(2.1x)
H3K4me3 chr3:96077378-96078378
Hist2h2bb
(distal)
BALB/c
(4.1x)
Set 2
H3K27ac chr5:123488913-123489913
Morn3
(intragenic)
C57BL/6
(2.1x)
H3K27ac chr4:132650946-132651946
Wasf2
(distal)
C57BL/6
(2.5x)
H3K27ac chr17:48565966-48566966
Apobec2
(intragenic)
C57BL/6
(1.8x)
H3K27ac chr5:147874677-147875677
Lnx2
(intragenic)
BALB/c
(1.8x)
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5.2.2 Tissue specificity of novel DMRs 
In terms of identifying additional targets of MIso, novel DMRs exhibiting a tissue-independent 
strain-specific methylation pattern were of particular interest. Tissue specificity of the newly 
identified DMRs was assessed by MALDI-TOF MS-based DNA methylation analysis in various 
somatic tissues from both wild type strains (Table 5-7). According to the detected different tissue 
specificities, the DMRs were grouped in three categories: Category 1 comprises all regions 
showing strain-specific methylation patterns in all tested somatic tissues as well as germ line cells 
(testis), which applied to two of 18 regions; Category 2 comprises all DMRs with differential DNA 
methylation in all tested somatic tissues, but similar methylation levels in germ line cells, which 
applied four of 18 regions; Category 3 comprises the remaining DMRs with tissue-specific 
differential methylation patterns, which applied to the majority (12) of all analyzed regions. 
The only target known so far for MIso is strain-specifically de novo methylated during early 
embryonic development and its resulting differential methylation pattern is present in tissues from 
all three germ layers. Hence, DMRs from Category 2 – especially those close to Aim1l and Morn3, 
as they were detected as BALB/c-specifically methylated – seemed promising. 
To further assess the mode of inheritance and regulation of the newly identified DMRs and their 
potential role as novel targets of MIso, DNA methylation analysis was extended to F1 hybrids. 
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Table 5-7 Average CpG Methylation of novel DMRs in various somatic tissues and germ line 
cells 
 
*mean of 2-4 individuals (8-12 weeks old) for each strain. **only 1 individual (8-12 weeks old) tested. 
  
C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6 BALB/c
chr3:96077670-96077953 25% 1% 25% 2% 85% 1% 72% 3% 92% 4%
chr3:96077988-96078283 76% 9% 88% 8% 95% 16% 96% 33% 96% 60%
chr7:52997182-52997586
Spaca4
(intragenic)
10% 57% 13% 53% 38% 62% 39% 67% 63% 46%
chr4:133614214-133614597 
Aim1l
(distal)
30% 54% 43% 59% 33% 51% 28% 45% 9% 15%
chr11:105895046-105895376
Dcaf7
(promoter)
56% 80% 73% 90% 45% 86% 61% 87% 84% 87%
chr5:123489136-123489456 3% 26% 5% 29% 6% 19% 3% 7% 2% 7%
chr5:123489428-123489728 6% 68% 11% 75% 22% 65% 5% 25% 4% 8%
chr4:132651381-132651641
Wasf2
(distal)
19% 53% 23% 61% 4% 46% 5% 15% 60% 62%
chr4:140766797-140767168
6330545A04Rik
(distal)
72% 92% 77% 94% 72% 89% 88% 92% 94% 96%
chr17:48566705-48566973 21% 52% 67% 82% 62% 77% 75% 81% 79% 80%
chr17:48566071-48566366 31% 79% 72% 64% 68% 55% 83% 67% 78% 54%
chr15:79724111-79724508
Apobec3
(promoter)
16% 68% 90% 67% 88% 92% 77% 76% 87% 89%
chr9:105974425-105974596
Col6a4
(intragenic)
66% 44% 89% 66% 94% 91% 84% 85% 96% 98%
chr16:30155216-30155568
Hes1
(distal)
15% 35% 6% 20% 22% 30% 61% 68% 14% 9%
chr5:147874763-147875096 46% 10% 70% 18% 75% 74% 55% 55% 76% 83%
chr5:147875405-147875618 80% 25% 87% 52% 71% 54% 39% 50% 82% 62%
chr13:101179250-101179593
Naip1
(intragenic)
84% 7% 78% 7% 67% 50% 69% 48% 30% 50%
chr14:51444053-51444423 
Parp2
(intragenic)
25% 59% 10% 66% 80% 61% 77% 59% 85% 66%
chr19:47515951-47516448 
Sh3pxd2a
(intragenic)
25% 51% 18% 53% 92% 93% 84% 87% 89% 92%
chr13:96731300-96731697 21% 62% 29% 79% 10% 11% 22% 58% 81% 77%
chr13:96731126-96731439 17% 64% 23% 74% 12% 14% 17% 60% 52% 79%
chr7:150192677-150192988
Tspan32
(intragenic)
50% 86% 50% 92% 94% 94% 85% 93% 100% n.a.
chr17:21844358-21844570
Zfp760
(promoter)
17% 1% 26% 2% 4% 2% 8% 2% 3% 3%
Category 1 : Tissue-independent strain-specific DMRs (somatic & germ line)
Category 2 : Tissue-independent strain-specific DMRs (only somatic)
Category 3 : Tissue-specific DMRs
Sv2c
(intragenic)
Hist2h2bb
(distal)
Apobec2
(intragenic)
Lnx2
(intragenic)
Morn3
(intragenic)
Liver Testis**
Average CpG methylation* inEpityper
amplicon
localization (mm9 )
Nearest gene
(Rel. position) Spleen BMM Cerebellum
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5.2.3 Inheritance of strain- and tissue-specific DNA methylation 
patterns in F1 hybrids 
In concordance to previously published data
261
, the newly identified DMRs also often lacked 
differential methylation patterns in germ line cells (Table 5-7). At most regions described by 
Schilling et al. sequence-dependent (allele-specific) de novo methylation or demethylation 
seemed to render the distinct methylation patterns found in somatic tissues. Except for the Isoc2b 
promoter region that was the only confirmed region where the local sequence did not affect 
de novo methylation; in contrast, an epigenetic modifier seemed to regulate the somatic 
phenotype in trans. To identify novel trans-regulated DMRs and thus potential targets of MIso, 
DNA methylation analysis of regions identified in section 5.2.1 was extended to F1 hybrids. 
Although allele-specific DNA methylation analysis is not possible by MALDI-TOF MS, I compared 
averaged CpG methylation ratios of both wild type strains with the average CpG methylation 
levels in F1 hybrids to obtain an initial indication regarding the mode of regulation. As 
demonstrated by Schilling et al., DMRs that were mainly regulated in a sequence-dependent, 
allele-specific manner rendered almost identical average methylation level in F1 hybrids when 
compared to the mean methylation level in parental strains
261
. 
In line with these previous findings, the majority (14) of the 18 analyzed regions exhibited similar 
averaged CpG methylation levels in spleen of F1 hybrids and parental mice indicating allele-
specific differential DNA methylation patterns. Only four regions either gained (6330545A04Rik, 
Svc2) or lost (Naip1, Tspan32) methylation in F1 hybrids compared to the parental strains 
suggesting the involvement of a potential trans-regulating factor in the establishment of the strain-
specific methylation pattern (Figure 5-15). 
 
 
 
 
Figure 5-15 Comparison of mean parental methylation ratios with average methylation levels of 
F1 hybrids at distinct CpGs provides initial indication for mode of inheritance 
Methylation levels of individual CpGs were assessed by MALDI-TOF MS in spleen of wild type mice (n=3 for 
each strain) and F1 hybrids (n=5). Mean average CpG methylation levels of parental spleen are plotted 
against average CpG methylation levels of F1 hybrids derived from BALB/s (left, n=3) or C57BL/6 (right, n=1-
3) dams, respectively. Regions that either gained or lost methylation in F1 hybrids compared to the mean 
parental methylation level are highlighted. 
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Nevertheless, reliable conclusions regarding the mode of regulation can only be assessed by 
bisulfite sequencing (see section 4.3.1.13) that does not only assess the methylation status of 
individual CpGs, but also their sequence context. In the presence of strain-specific sequence 
variations this method allows for allele-specific methylation analysis. 
Unfortunately, only the DMR within the Svc2 gene was suitable for allele-specific bisulfite 
sequencing. The DMRs associated with Tspan32 and 6330545A04Rik did not comprise any 
sequence variation or indels to distinguish the parental alleles in F1 hybrids and were not further 
analyzed. In case of Naip1, PCR of bisulfite-treated DNA did not render a specific amplicon 
resulting in mixed and thus inconclusive sequencing results (data not shown) and might also 
distort the relationship of F1 and parental methylation depicted in Figure 5-15. Despite the implied 
trans regulation, I found the DMR associated with Sv2c to be also differentially methylated in 
dependence of the local sequence (Figure 5-16A). 
As a control, one of the potential cis-regulated regions (Sh3pxd2a) was also analyzed by bisulfite 
sequencing confirming its allele-specific methylation pattern (Figure 5-16B). 
 
 
 
 
Figure 5-16 Allele-specific bisulfite sequencing of selected DMRs determines mode of 
inheritance for strain-specific methylation phenotypes 
The genomic position of CpGs within the amplicons of Sv2c (A) and Sh3pxd2a (B) are indicated at the top. 
Sequence variations that distinguish the parental alleles are marked in red (C57BL/6) and blue (BALB/c). 
The methylation status of the individual CpGs is depicted by white (unmethylated) and black (methylated) 
squares. Each line of squares represents an independently sequenced clone derived from two independent 
sample preparation (one sample preparation for each reciprocal cross for F1 hybrids). 
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5.2.4 Comparison of ChIP-seq and MCIp-seq data sets 
Since the search for novel trans-regulated DMRs and potential targets of MIso was not successful 
as yet, I complemented the ChIP-seq data set from spleen with ChIP-seq data from cerebellum of 
the same individuals (library preparation according to protocol II in section 4.3.1.18). The 
combination of ChIP-seq data from two tissues should alleviate the identification of tissue-
independent differentially regulated regions. Furthermore, the newly established approach of 
high-throughput sequencing of MCIp-enriched DNA fragments (MCIp-seq) was also applied to 
genomic DNA from spleen and cerebellum of both wild type strains (C57BL/6J and 
BALB/cAnNCrl, n=1 each, female) in order to supplement the ChIP-seq data sets with genome-
wide information on highly methylated CpG-rich regions (library preparation according to protocol 
II in section 4.3.1.18). The complete command line for processing the ChIP-seq and MCIp-seq 
data is stated in section 4.4.1.2. 
As it is widely accepted, the vast majority of regions marked by active histone marks (H3K4me3, 
H3K27ac) and highly methylated regions (enriched by MCIp) exclude each other within the same 
specimen (visualized for spleen in Figure 5-17A). However, the assumption to identify novel 
DMRs based on an inverse correlation of active histone marks and highly methylated DNA 
between both wild type strains was not supported by the data. For C57BL/6- and BALB/c-enriched 
peaks, a general enrichment of highly methylated DNA fragments by MCIp in the opposite strain 
could not be detected (Figure 5-17B). Since DMRs at additional target sites of MIso are most 
probably established during early embryonic development, regions with similar epiphenotypes in 
both cerebellum and spleen were of particular interest. However, the level of joint presence of 
strain-specifc active histone marks in both tissues is very low (Figure 5-17C). Visual inspection of 
the 82 regions that showed enrichment (fold change >2) of at least one of the strong active 
histone mark (H3K4me3 or H3K27ac) in both analyzed tissues identified only nine regions with 
inverse correlation of active histone marks and accumulated mCpGs (including the Isoc2b 
promoter). Instead, MCIp-seq data generally displayed strain- and tissue-independent high or low 
enrichment of mCpGs at these sites. Due to the specificity of the MCIp approach for CpG-rich 
hypermethylated regions, it cannot be excluded that DMRs at CpG-poor regions were missed. 
Taken together, active and repressive marks generally exclude each other within a strain, but 
inverse correlation between strains cannot be generally assumed. 
Since the total number of detected tissue-independent strain-specifically regulated regions based 
on active histone modifications is very low, future experiments will focus on the validation of 
tissue-independent strain-specifically methylated region derived from the available MCIp-seq data 
sets (fold change >2 rendered approximately 2200 regions). 
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Figure 5-17 Comparison of ChIP-seq and MCIp-seq data sets 
(A) Correlation of fragment enrichment by MCIp and ChIP experiments for the indicated histone marks in 
spleen tissue from C57BL/6 (left) and BALB/c (right) mice. (B) The genomic location of averaged 
C57BL/6(top)- and BALB/c(bottom)-specific H3K4me3 (left), H3K27ac (middle), and MCIp peaks (right) is 
centered in the middle of each plot (fold change >2). Average genomic distribution of the corresponding 
signal in the opposite strain as well as other histone marks and MCIp signals are plotted relative to the center 
of the strain-specifically enriched peaks. (C) Overlap (peak center distance <300 bp) of strain-specifically 
enriched histone mark peaks (fold change >2) in cerebellum and spleen. The size of the Venn circles does 
not represent relative proportions. 
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6 Discussion & Perspectives 
Although epigenetic mechanisms are widely accepted to affect gene expression without changing 
the actual genomic sequence, little is known about how epigenetic mechanisms are regulated 
themselves. The fact that alterations in the epigenome have implications in disease 
susceptibility
8,9
 demonstrates the importance of this knowledge. In this regard, the extent of inter-
individual variations and how differential epiphenotypes are established and inherited is of 
particular interest. Several publications demonstrated that genetic determinants acting in cis and 
in trans affect individual epigenomes
96,98,260-262
. 
With this thesis, I aimed at the identification of the trans-acting epigenetic modifier responsible for 
the strain-specific epiphenotype at the Isoc2b promoter in C57BL/6 and BALB/c mice, termed 
modifier of Isoc2b (MIso). Epigenetic variations at this particular locus comprise DNA methylation 
as well as histone modifications. It could be demonstrated that MIso is a monogenetic trait 
encoded in a 9 Mb region on the short arm of chromosome 12 and acts during early embryonic 
development. Nucleolar protein 10 (Nol10) was identified as a potential candidate gene encoding 
MIso. I further tried to define additional targets of MIso. However, none of the newly identified and 
evaluated differentially methylated regions seemed to be regulated in trans. 
 
6.1 A novel pipeline to identify mouse strain-specific 
epigenetic modifiers 
The strategies to identify epigenetic modifiers in mice are still limited. A commonly used strategy 
is to employ mutagenesis screenings. Thereby, the expression and epiphenotype of a reporter 
gene is analyzed in the offspring of mutagen-treated mice. Mutations affecting general epigenetic 
modifiers will lead to an up- or downregulation of the reporter gene and can be subsequently 
mapped by linkage analysis. The approach was initially developed in the Drosophila model, in 
order to identify factors involved in position effect variegation during development
308,309
. For 
example, with the help of a N-ethyl-N-nitrosourea (ENU) mutagenesis screening, the group 
around Emma Whitelaw were able to detect known and novel epigenetic modifiers
97,98
. However, 
this approach is not designed to identify site-specific epigenetic modifier as it relies on the effect 
on a single reporter gene. Epigenetic modifiers not affecting the reporter gene, but with targets 
elsewhere in the genome, are missed. Presented in this work is an alternative strategy, which is in 
theory less restrictive. By comparing the individual epigenomes of inbred mouse strains, 
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differences in the general portfolio of epigenetic modifiers, including those with sequence 
specificity, can be examined. This second strategy further allows for the investigation of non-
artificial epiphenotypes with functional effects in healthy organisms. Subsequent localization of the 
strain-specific epigenetic modifiers is based on linkage analysis similar to the first strategy. 
In the present study, I used two commonly inbred mouse strains (C57BL/6 and BALB/c) as a 
model system to assess genetic determinants of inter-individual variations in DNA methylation, the 
most stable epigenetic modification. Inbred mouse strains have the advantage of consistent 
breeding conditions, hence minimizing environmental effects on the individual epigenome. In 
addition, they provide a stable genetic background and an unlimited cohort. 
A few years back, reliable and efficient detection of methylated cytosines on a global scale was 
challenging. Since DNA methylation is generally associated with repression
14,136
, strain-specific 
gene expression differences were used to pre-define candidate DMRs in an earlier study in our 
laboratory
261
. In the present work, I defined regions displaying active strain-specific histone mark 
patterns as candidate regions for differential DNA methylation. Thereby, candidate differentially 
methylated regions (DMRs) were no longer restricted to promoter regions of differentially 
expressed regions, but also included potential distal regulatory elements, which can interact with 
the transcription start site of target genes by DNA looping
310-312
. Limiting candidate DMRs to the 
vicinity of differentially expressed genes tends to ignore regulatory elements at distal sites. The 
switch to global chromatin immunoprecipitation(ChIP)-derived histone mark patterns in order to 
define candidate DMRs partly overcomes the restriction. Active histone marks at transcription start 
sites not only correlate with transcription (H3K4me3, H3K27ac), but also mark intergenic 
enhancers (H3K4me1, H3K27ac)
164,313,314
. 
There are limitations to the approach chosen. Advancing differential DNA methylation from strain-
specific patterns of active histone marks will miss DMRs without inverse correlation to the 
analyzed histone modification. Moreover, analysis of next generation sequencing ChIP (ChIP-seq) 
data from two different tissues (spleen and cerebellum) demonstrated that only a minor fraction of 
the defined histone mark peaks were strain-specifically enriched in both tissues in the individual 
mouse strains. I also generated next generation sequencing methyl-CpG immunoprecipitation 
(MCIp-seq) data, which captured highly methylated regions on a global scale. In comparison to 
the ChIP-seq results, analysis of the MCIp-seq data identified a much larger number of regions 
with strain-specific enrichment in both tissues. Still, enrichment of methylated CpG dinucleotides 
(mCpGs) by MCIp is restricted to highly methylated CpG-rich region. Hence, high-throughput 
sequencing of bisulfite-treated DNA would be the method of choice. However, the method is still 
very expensive when performed on a global scale. It is further difficult to analyze due to PCR 
biases generated from the unbalanced GC content of methylated and unmethylated 
fragments
315,316
. Since the differential methylation pattern at the Isoc2b promoter is captured well 
by MCIp-seq, new candidate DMRs and thus potential novel targets of MIso will be selected 
based on the MCIp-seq data sets in future studies. 
The method of choice to evaluate DNA methylation levels at selected candidate regions was the 
EpiTYPER technology (MassARRAY, Sequenom), which is based on Matrix-assisted laser 
desorption/ionisation combined with mass spectrometry analysis by time-of-flight 
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(MALDI-TOF MS). The method allows for accurate high-throughput quantitative DNA methylation 
analysis up to single CpG resolution at distinct loci
270,317
 and was used to validate strain-specific 
DNA methylation at selected candidate DMRs. 
Previous data generated in our laboratory and also by other groups suggested that the 
methylation phenotype is mainly regulated in cis
260-262
. Only few DMRs appear to be regulated in 
trans by a strain-specific epigenetic modifier. To address the mode of regulation, MALDI-TOF MS-
based methylation analysis is only applicable for an initial estimation. Mean parental methylation 
levels at individual CpGs are compared with the average methylation of the corresponding CpGs 
in F1 hybrids. DMRs with an allele-specific methylation phenotype (i.e. that are regulated in cis) 
generally exhibit similar methylation levels in this comparison, whereas trans-regulated regions 
display diverging methylation levels. A reliable validation of the mode of regulation (cis or trans) 
can only be achieved by bisulfite sequencing (BS). BS detects the methylation state of individual 
CpGs within their genomic context, but depends on a high number of individually sequenced DNA 
strands to permit for quantitative methylation analysis. Since the major purpose of identifying 
additional DMRs was to find other targets of MIso, I used the initial implication on the mode of 
regulation obtained by MALDI-TOF MS-based methylation analysis to restrict BS to potential 
trans-regulated regions. 
 
After identifying a trans-regulated DMR, such as the Isoc2b promoter, the next step in the 
described pipeline towards characterizing responsible epigenetic modifiers is mapping their 
genomic localization. Genetic linkage analysis (LA) is the method of choice. In contrast to earlier 
studies
285-287,318
, single nucleotide polymorphisms (SNPs) instead of microsatellites were used as 
genetic markers. Several reasons favor SNPs: firstly, SNPs seem to be less error prone
319
 ; 
secondly, strain-specific SNPs were available at a very high density allowing for high resolution 
owing to the Mouse Genomes Project of the Sanger Wellcome Trust Institute
275
; finally, the iPLEX 
technology (MassARRAY, Sequenom) a powerful MALDI-TOF MS-based method to reliably 
genotype a high number of SNPs simultaneously was at hand
271
. 
LA categorically relies on homologous recombination. Although its resolution is theoretically 
determined by the density of genetic markers and the number of genotyped individuals, the lack of 
recombination events at highly divergent regions can foreclose a desired resolution in practice. 
This was the case for fine mapping MIso within the initial candidate region. Although the 
experimental setup allowed for a minimal resolution of 1 Mb, no recombination events were 
observed within the current 9 Mb candidate region. 
 
Since no other trans-regulated region was validated as yet, I have executed the complete pipeline 
only for the DMR at the Isoc2b promoter so far. The newly identified DMRs were exclusively 
regulated in cis. This observation may pose another indication for the developmental importance 
of epigenetic modifiers. It was reported that the crossing of heterozygous mutants leads to 
reduced litter sizes due to embryonic lethality of homozygous mutant offspring
98,287
. The 
successful development of a multicellular organism from the fertilized zygote depends on a well-
orchestrated network of epigenetic mechanisms and seems to have little tolerance for 
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dysfunctional components. Based on these findings, only few strain-specific epigenetic modifiers 
can be expected in the healthy system. 
An alternative explanation is that the applied methods to measure DNA methylation are biased 
towards detecting cis-regulated regions. Allele-specific BS depends on strain-specific sequence 
variations to distinguish parental alleles in F1 hybrids, therefore not all potential trans-regulated 
DMRs could be evaluated. In addition, the necessity for sequence variations might favor the 
selection of cis-regulated DMRs. Paradoxically, the sequence variations tend to impede 
comparative MALDI-TOF MS-based methylation analysis due to variation-caused differences in 
the fragmentation pattern; hence, regions with expected disparate fragmentation pattern were 
excluded a priori. 
 
Nevertheless, the pipeline for genome-wide LA in 45 C;B6 hybrids is available and experiments to 
identify additional trans-regulated regions are on-going. As soon as a novel trans-regulated 
candidate region is determined, the corresponding methylation data of the 45 C;B6 hybrids can be 
processed in the described pipeline to localize the responsible epigenetic modifier. Although being 
limited to BS-resistant strain-specific SNPs to validate potential trans-regulated DMRs by allele-
specific BS of F1 hybrids, the power of the pipeline could be demonstrated in practice. Genome-
wide LA was also performed for the potential trans-regulated DMR at the Sfi1 pseudogene 
identified in the initial study
261
. Due to the lack of BS-resistant SNPs in the DMR, allele-specific 
DNA methylation in F1 hybrids could not be completely excluded at this locus. C;B6 hybrids 
further displayed a more complex methylation pattern at the Sfi1 DMR then at the Isoc2b DMR 
indicating the involvement of more than one factor. Nevertheless, LA with the initial 45 C;B6 
hybrids mapped one potential epigenetic modifier to a region on chromosome 4, which overlapped 
with the encoding region for a recently identified novel epigenetic modifier
96
. 
 
In addition to using the iPLEX technology for LA, the assay is of great interest for other 
applications, for example for studying the genetic background of designed mouse models. Recent 
insights in the phenotypic diversity of related mouse substrains
320
 emphasize the importance of a 
pure genetic background in genetically engineered mouse models. With the help of the 
resequencing data provided by the Mouse Genomes Project
275
, SNP panels for specific strains 
can be designed to verify the genetic background of a given mouse strain. Determing the degree 
of cross contamination in individuals could also be used to speed up backcrossing. 
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6.2 MIso, a strain-specific epigenetic modifier, is 
active during early embryonic development 
MALDI-TOF MS-based methylation analysis and bisulfite sequencing (BS) in parental C57BL/6 
and BALB/c mice as well as F1 hybrids implied that the methylation phenotype at the Isoc2b 
promoter was not inherited in an allele-specific manner. The results suggested regulation with 
semi-dominant penetrance by an epigenetic modifier encoded elsewhere, since none of the 
parental phenotypes was fully reestablished in F1 hybrids. This is in line with earlier studies 
demonstrating that the establishment of epigenetic patterns is dose-dependent
287,309
. I performed 
genome-wide LA in C;B6 hybrids to localize the genetic trait of MIso. The experiment not only 
identified a region on chromosome 12 with a very high LOD score (>13), but also indicated the 
lack of additional regions with comparably increased LOD scores. Based on these finding, MIso 
was assumed to be a monogenetic trait. This is in line with the observed phenotypes and fine 
mapping results in C;B6 hybrids. Since the recombination frequency within the initial candidate 
region was unexpectedly low in C;B6 hybrids, additional backcrosses for further fine-mapping 
were generated with another strain than C57BL/6. Several other inbred strains that were part of 
the Mouse Genomes Project
275
 were tested for their DNA methylation frequency at the Isoc2b 
promoter. With the exception of A/J, which displayed a hypermethylated phenotype at the Isoc2b 
promoter, all other strains tested (129S1/SvImJ, C3H/HeJ, CBA/J, DBA2/J, and NOD/ShiLtJ) 
exhibited a hypomethylated phenotype similar to C57BL/6. However, methylation analysis in 
C;NOD hybrids, derived from BALB/c and NOD/ShiLtJ mice, lacked the clear separation of two 
distinct methylation phenotypes. The hybrids displayed a continuous methylation pattern rather 
than two distinct methylation phenotypes suggesting a polygenic control in C;NOD hybrids. 
Nevertheless, for C57BL/6 and BALB/c mice the difference in DNA methylation at the Isoc2b 
promoter regions seems to depend on a monogenetic trait located in a 9 Mb region on the short 
arm of chromosome 12, according to LA. 
 
So far, the available results do not permit for the classification of MIso as either a methylation-
promoting modifier active in the C57BL/6 strain or a methylation-preventing modifier active in the 
BALB/c strain. Interestingly, BALB/c seemed to compensate the hypermethylated phenotype and 
the resulting lack of Isoc2b protein with an increased expression of the neighboring homolog 
Isoc2a. Although initially identified in bone marrow-derived macrophages from C57BL/6 and 
BALB/c mice, I could verify the strain-specific methylation pattern at the Isoc2b promoter also in 
other somatic tissues. Not only spleen, a tissue enriched for macrophages, but also brain and liver 
exhibited the strain-specific epiphenotype. Germ line cells obtained from testis of both strains 
were not differentially methylated but displayed a hypomethylated phenotype in both mouse 
strains. Consequently, the differential epiphenotype seems to be re-established in each 
generation. Since the analyzed somatic tissues originate from the three different germ layers 
during embryonic development, strain-specific de novo methylation at the Isoc2b promoter was 
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expected to take place at pregastrulational stages during early embryogenesis. This assumption is 
consistent with reports connecting the activity of epigenetic modifiers to early developmental 
stages
294,321
. Employing an in vitro embryonic stem cell (ESC) differentiation model with ES cell 
lines derived from C57BL/6NJ and BALB/cJ mice, I could confirm the activity of MIso during early 
embryonic development. Similar to the findings in germ line cells and somatic tissues, both ES cell 
lines displayed a hypomethylated phenotype in the pluripotent state. Upon differentiation, BALB/c 
ESCs actively gained cytosine methylation, whereas C57BL/6 ESCs retained the hypomethylated 
phenotype. Nevertheless, pluripotent ESCs as well as germ line cells from BALB/c always 
exhibited slight increases in the average DNA methylation level when compared to C57BL/6. A 
possible explanation could be that levels of 5-hydroxymethylcytosine (5hmC) differed between 
C57BL/6 and BALB/c. 5hmC is an intermediate of the active demethylation process and found at 
its highest levels in neuronal cells
322
, but also in substantial amounts in early embryos and 
ESCs
66,82
. Methylation analyses based on bisulfite treatment do not distinguish between 5-
methylcytosine (5mC) and 5hmC
300
. In order to assess the presence and dynamics of 5hmC at 
the Isoc2b promoter, I performed hydroxymethylcytosine methylated DNA immunoprecipitation 
(hMeDIP) on genomic DNA from differentiating C57BL/6 and BALB/c ESCs. In fact, 
undifferentiated BALB/c ESCs exhibited increased 5hmC levels throughout the whole DMR at the 
Isoc2b promoter in comparison to C57BL/6 ESCs. Upon differentiation, BALB/c ESCs rapidly lost 
the 5hmC modification. Active demethylation of 5mC seemed to retain the region in a general 
hypomethylated state in BALB/c ESCs. With the onset of differentiation, 5hmC levels decreased 
rapidly leading to the accumulation of 5mC in differentiating BALB/c ESCs. In contrast, the core of 
the DMR completely lacked 5hmC in C57BL/6 ESCs, but its borders slowly gained 5hmC upon 
differentiation. The presence of marginal 5hmC levels in C57BL/6 ESCs could block spreading of 
5mC from the neighboring regions into the DMR. Still, MIso might actively contribute to both 
described scenarios. HMeDIP experiments were repeated with independent differentiation kinetics 
as well as with genomic DNA derived from testes over the course of a master thesis
297
 to validate 
these findings. In C57BL/6 ESCs, 5hmC showed a similar dynamic pattern during differentiation 
with increasing amounts of 5hmC at the border of the DMR, which is in accordance to other 
studies
323,324
. As expected from the low methylation levels detected in testis, C57BL/6 germ line 
cells exhibit no 5hmC modification at the DMR. The hMeDIP experiment for BALB/c ESCs and 
germ line cells is still pending. 
 
The 9 Mb candidate region on chromosome 12 consists of conserved as well as highly repetitive 
regions. The conserved region, which represents roughly one third of the candidate region, is 
found in three blocks and comprises numerous annotated genes. Initially, based on literature-
based annotation, I considered none of the genes as a suitable candidate to promote the strain-
specific DNA methylation phenotype. The bulk of the candidate region appears to be highly 
repetitive with 6 major assembly gaps in the mm9 reference genome. To date, about 32000 
SNPs, 5000 indels, as well as 264 structural variances are annotated for the candidate regions 
according to the Mouse Genomes Project
275
 (REL-1211). The figures are comparable to other 
genomic regions of the same size. However, the low rate of recombination events within the 
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candidate region implies a more complex genomic architecture. Interestingly, the number of 
pseudogenes that seem to reside within the candidate region as annotated by various approaches 
in the UCSC genome browser (gene and gene prediction tracks ‘Yale Pseudo60’ (mm9), 
‘Retroposed genes V2, incl. pseudogenes’ (mm10)) is more than 5-fold higher than in the 
neighboring regions. Thus it was speculated that the repetitive part of the candidate region, 
especially the annotated pseudogenes have the potential to encode an epigenetic modifier. 
 
Although still a poorly understood area in the field of epigenetics, more and more factors targeting 
epigenetic modifications to specific sites in the genome are identified. Table 6-1 gives an overview 
of selected epigenetic modifiers and their suggested regulatory function. 
    
Table 6-1 Epigenetic modifiers and their regulatory mechanisms 
 
Class of
epigenetic modifier
Mode of
action
Target site(s)
Regulatory
consequence
Ssm1b96,325 trans Transgene transcriptional
repression
Rsl1326 trans Slp transcriptional
repression
Znf382327 trans oncogenes (e.g. MYC , CDK6 ),
NF-kB downstream factors (e.g. STAT3 , ID1 )
transcriptional
repression
KS1328,329 trans oncogenes (e.g. Ha-ras , Galpha12 ) transcriptional
repression
ZFP57330 trans group of maternally imprinted genes transcriptional
repression
Artifical
KRAB-ZFP331
trans designed to target Oct4 transcriptional
activation
ZFP206333,334 trans Meis2 , mir-124-a , mir-124-a2  (repression)
Oct4 , Klf5 , Jardic1c (activation)
transcriptional
repession/activation
KDM2B335 trans subset of unmethylated CpG islands transcriptional
repression
- KDM2B forms a complex with RING2 and other PcG proteins
- the complex is targeted to unmethylated CpG island bound by PRC1 and PRC2 via 
the CXXC domain of KDM2B
- the complex ubiquitinylates H2AK119
KDM2A306 centromeric satellite repeats transcriptional
repression
KDM2A maintains heterochromatin at centromeric satellite repeats by interaction 
with HP1
KDM2A336 rDNA promoter transcriptional
repression
KDM2A affects levels of H3K36me0/1/2 at rDNA promoters, which might have 
functional effect on transcription level of rRNA
KDM2A337,338 unmethylated CpG islands unique CpG island
chromatin structure
KDM2A-mediated removal of H3K36me2 creates a functional unique open 
chromatin structure at CpG islands (independent of transcription)
CFP1176,177 trans unmethylated CpG islands unique CpG island
chromatin structure
CFP1 specifically recognizes unmethylated CpG-dense regions and interacts with 
the Set1 complex  methylation of H3K4
Tet1/3,
IDAX66,76
(associated
with Tet2)
trans Marginal areas of CpG-rich promoters,
CpG-poor regulatory sites,
gene bodies
active DNA
demethylation
- Tet1/3 and IDAX exhibit a distinct subclass of CXXC domains with varying binding 
affinity for cytosines and its modified derivates
- mechanisms how Tet enzymes are recruited are still under discussion; one 
possbility is a general association with the transcription machinery 
- (sex- and tissue-specific) targeted DNA binding by the zinc finger domain
- interaction with KAP1/TRIM28 that recruits
   NuRD complex  deacetylation of histone residues
   SETDB1  long-range spreading of H3K9me3
   HP1 (binds to H3K9me3)  stabilization of repressive chromatin
   Dnmts  CpG methylation
trans
- the zinc finger domain targets the epigenetic modifier
- repressor domains mediate context-dependent protein-protein interactions
- both activation and repression were detected:
     repressive mechanism as above
     activating mechanism remains elusive
transcriptional
repession/activation
distinct set of >5000 binding sites
at promoters and in introns
trans
Examples
Proposed mechanism
and co-factors
Krüppel-associated box (KRAB)
repressor domain-containing
zinc finger proteins (ZFP)
SCAN repressor
domain-containing ZFP
CXXC domain-containing
proteins
ZFP263332
1
7
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Class of
epigenetic modifier
Mode of
action
Target site(s)
Regulatory
consequence
XIST203
(lncRNA)
cis X chromosome initiation of
X chromosome
inactivation
- Xist RNA coates future inactivated X chromosomes (regulation in cis )
- mechanism only effective in females at early developmental stages
- Xist-dependent, yet unknown recruitment of PRC2 and PRC1
 chromosome-wide accumulation of H3K27me3/
H2AK119ub, predominantly at promoters of X-linked genes
- cascade of chromatin changes (also DNA methylation)
Kcnq1ot1207
(lncRNA)
cis imprinted genes in Kcnq1  cluster transcriptional
repression
Kcnq1ot1 recruits PRC2 via interaction with Ezh2 to imprinting Kcnq1 cluster
 deposition of H3K27me3
Air339,340
(lncRNA)
cis imprinted genes in Igf2r cluster transcriptional
repression
- Air is required for silencing of the associated gene cluster
- Air interacts with G9a HMTase at the Slc22a3 promoter 
 deposition of H3K9me3
HOTAIR204,341
(lncRNA)
trans HOXD transcriptional
repression
- HOTAIR recruits PRC2 in trans  to HOXD locus  deposition of H3K27me3
- recruitment of Lysine-specific demethylase 1 (LSD1)
 demethylation of H3K4
PTENpg1
asRNA α263
(lncRNA)
trans PTEN transcriptional
repression
- PTENpg1 asRNA α directs EZH2 (PRC2) to PTEN promoter
 deposition of H3K27me3
- also interacts with DNMT3A  de novo  DNA methylation?
Oct4pg5
asRNA342
(lncRNA)
trans Oct4 transcriptional
repression
Oct4pg5 asRNA potentially interacts with EZH2 to maintain a repressive chromatin 
state (H3K27me3) in differentiated cells
ncRNA343 cis/
trans
DHFR transcriptional
repression
- ncRNA forms stable triplex structure with major promoter
 sequence-specific targeting
- ncRNA interacts with TFIIB
 disruption of the preinitiation complex required for transcription
MILI, MIWI2
(piRNAs)307,344
trans retrotransposons,
imprinted Rasgrf1  locus
transcriptional
repression
- piRNAs guide de novo methyation of LINE and IAP elements in male germ line 
cells in a yet unknown mechanisms
-  a retrotransposon upstream of Rasgrf1  is targeted by a piRNA in male germ lines 
resulting in de novo methylation and imprinting
promoter-
associated
RNA (pRNA)345
cis rDNA loci transcriptional
repression
pRNA forms RNA:DNA triple helix at the promoter, which is specifically recognized 
by DNMT3b  de novo  DNA methylation
non-coding RNAs
Examples
Proposed mechanism
and co-factors
1
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51,54,66,76,96-98,176,177,201,203-207,263,306,307,325-351
Class of
epigenetic modifier
Mode of
action
Target site(s)
Regulatory
consequence
TUG1201
(lncRNA)
trans transcriptional
repression
- TUG1 interacts with methylated Pc2/CBX4 (K191me2) under serum starvation 
conditions
- Pc2 associated with TUG1 preferentially binds to H3K27me2
 localization to PcG bodies (repressive nulear environment)
NEAT2/
MALAT1201
(lncRNA)
trans transcritional
activation
- Upon serum stimulation Pc2/CBX4 is demethylated and interacts with NEAT2
- Pc2 associated with NEAT2 preferentially binds to acetylated H2A peptides
 relocalization to interchromatin granule (active nuclear nvironment)
Jpx206,346
(lncRNA)
cis/
trans
Xist transcriptional
activation
- Jpx interacts with CTCF and competes CTCF binding to Xist  promoter
 CTCF removal is essential for Xist  transcription, which in turn is required for X 
inactivation
ecCEBPA205
(lncRNA)
cis CEBPA transcriptional
activation
- ecCEBPA is bound by DNMT1
 CEBPA promoter is shielded from DNMT1 binding and thus DNA methylation
- loci with DNMT1-interacting RNAs are globally represented
CHD RNA347
(ssRNA)
cis E-cadherin transcriptional
activation
Antisense ncRNA of the E-cadherin promoter binds to catalytic domain of DNMT3A 
 inhibition of DNMT3A
Smchd1
97,348,349
trans transgene,
distinct set of CpG islands of
inactivated X-linked genes,
imprinted genes
transcriptional
repression
- Smchd1 site-specific DNA binding is achieved by a
hinge domain
- targeting of slowly methylated inactivated X-linked loci
- a homologuous protein in Arabidopsis  was found
to be involved in RNA-directed DNA methylation
- mechanism in mammals remains elusive
Rfl98 trans transgene transcriptional
activation
- mutation analyses of Rlf indicate active role in preventing
site-specific DNA methylation
- mechanism remains elusive
imprinted genes,
gene bodies of housekepping genes
transcriptional
repression
-expression correlated with establishment of genomic imprinting
- targeting could be achieved by its PHD domain, but also by mediating interaction 
of Dnmt3a/b with specific transcription factors
- direct interaction with Dnmt3a/b might stimulate de novo methylation activity
promoters of bivalent
developmental genes
maintenance of
DNA
hypomethylation
competitve interaction of PRC2 with Dnmt3a/b
in ESCs seems to prevent de novo methylation
E2F1-regulated growth genes
Proposed mechanism
and co-factors
Dnmt3l
51,54,350,351
trans
Other trans -acting factors
non-coding RNAs
Examples
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Of particular interest were Krüppel-associated box (KRAB) repressor domain-associated zinc 
fingers (KZF), since some of the annotated pseudogenes in the candidate region seem to contain 
KRAB or zinc finger domains. This protein family was associated with site-specific silencing in the 
past and is hypothesized to be involved in processes such as DNA damage response, cell cycle 
control, proliferation and tumorigenesis
352-355
. The established facultative heterochromatin was 
also shown to result in methylation of cytosines in the target region when propagated during early 
embryonic development
356
 or prevented the conversion of 5mC to 5hmC in early embryos
232
. Very 
recently, a novel type of KZF (Ssmb1) was identified that methylated a transgene during mouse 
embryogenesis in a strain-specific manner
96
. Interestingly, the region on chromosome 4 encoding 
for Ssm1b matched the region potentially containing one of the factors regulating the strain-
specific methylation phenotype of the Sfi1 pseudogene (as mentioned above). In addition, other 
publications implicated a role of KZFs in the activation of specific genes
331,332
. Nevertheless, the 
involved mechanisms are not known as yet. 
Although there are sequence variations between C57BL/6 and BALB/c affecting the KRAB-
containing pseudogenes located within the candidate region for MIso, none of the variations 
detected to date seems to have a substantial effect on the putative coding sequences. As 
described above, the repetitiveness of the candidate regions hinders reliable sequence calling. 
Since the resequencing approach of the Mouse Genomes Project is still in progress, interesting 
pseudogenes should be under constant surveillance. 
Non-coding RNAs (ncRNAs) constitute another major class of site-specific targeting factors. 
Chromatin modifiers often lack DNA-binding domains, but exhibit motifs for RNA binding
357
. 
NcRNAs that escape nuclear export are able to interact with the modifiers and guide them to 
specific target sites. The best-studied example is the long non-coding RNA (lncRNA) XIST, which 
is required for Polycomb-mediated inactivation of the X chromosome
358-360
 (Table 6-1). Compared 
to this cis-acting lncRNA, HOTAIR was identified as a trans-acting regulator of human HOX loci
204
. 
HOTAIR seems to interact with the Polycomb repressor complex 2 (PRC2) to mediate gene 
silencing. Aberrant HOTAIR expression was detected in several human cancers underlining its 
regulatory importance in particular and that of lncRNA as epigenetic regulators in general
361
. 
Genome-wide studies on novel lncRNAs associated with PRC2 point towards additional trans-
regulating candidates
100,153
. Moreover, it was shown that lncRNAs act during embryonic 
development
362
. The transcriptional regulation mediated by ncRNAs is not restricted to lncRNAs or 
repression, but also includes short ncRNAs and was shown to contribute to gene activation. Table 
6-1 provides further examples for ncRNAs involved in epigenetic mechanisms. In summary, many 
of the known regulatory lncRNAs act as repressors by recruiting Polycomb repressor complexes. 
Sometimes they act in combination with DNA methyltransferases (DNMTs) and facilitate the 
establishment of repressive chromatin structures. But although sequence similarities might direct 
ncRNAs to their target sites, the involvement of other factors is also possible. LncRNAs often act 
in cis or seem to affect sites on the chromosome of origin, still inter-chromosomal targeting cannot 
be excluded. 
Another class of epigenetic modifiers that seems to affect DNA methylation is the cysteine-rich 
CXXC domain-containing family of zinc finger proteins (Table 6-1). Members of the CXXC1 
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subfamily are known to bind to unmethylated CpGs located in CpG islands and account for their 
open chromatin architecture
175,337,363
. The open chromatin structure must not necessarily be 
associated with transcription. CXXC-containing zinc fingers were also shown to cause 
transcriptional repression, for example KDM2B was linked to Polycomb-mediated repression
335
. 
Aside from the targeting of hypomethylated, CpG-dense regions, other sequence-specific 
properties were not found for this class of epigenetic modifiers. Tet enzymes, which are to date 
the only known enzymatic activities to promote active DNA demethylation by converting 5mC into 
5-hydroxymethylcytosine (5hmC) also exhibit a CXXC domain, but belong to another subfamily. 
The targeting mechanisms for Tet enzymes are not well understood as yet
76
. It was proposed that 
the CXXC domain might guide binding towards CpG-rich transcription start sites
70-74
, but due to 
their broad spectrum of targets, Tet enzymes may simply be associated with the general 
transcription machinery. 
The ENU mutagenesis screening performed by the group around Emma Whitelaw identified 
several known, but also novel modifiers of epigenetic reprogramming
98
. Among them the 
rearranged L-myc fusion (Rlf) gene, which, when mutated, caused increased expression of the 
transgenic GFP reporter plus a hypermethylated phenotype at the reporter locus. Genome-wide 
methylation analysis in Rfl null embryos implied an active role of Rlf in preventing DNA 
methylation at specific sites, but the underlying mechanism is still unclear
364
. In general, two 
mechanisms for maintaining a hypomethylated phenotype during embryonic development are 
conceivable. On the one hand, target sites might be shielded to prevent de novo methylation a 
priori. On the other hand, a process involving constant active demethylation by Tet enzymes might 
foreclose the accumulation of 5-methylcytosine (5mC). 
In summary, the majority of described epigenetic modifiers is associated with repression and 
seems to propagate gene silencing by recruiting repressive chromatin modifiers, which introduce 
histone modifications such as H3K27me3 or H3K9me3. Epigenetic modifiers associated with 
activation are less frequent and their mode of action is largely unknown. Protein epigenetic 
modifiers target the epigenetic machinery by zinc finger domains in a trans-acting manner and 
mediate protein-protein interactions by their repressor domains. NcRNAs appear to mainly act in 
cis or at least on the chromosome of origin and often seem to provide a scaffold for the assembly 
of chromatin-modifying complexes. They are often involved in the establishment of imprinting 
patterns. Activation by ncRNAs seems to be achieved by site-specific competitive interaction with 
repressive factors (Table 6-1). 
 
Since the strain-specific de novo methylation of the Isoc2b promoter can be recapitulated in 
differentiating ESCs, comparative expression analysis seemed promising to identify the 
responsible genetic trait. I performed next generation sequencing of RNA samples (RNA-seq) 
derived from of undifferentiated as well as differentiating ESCs of both strains. The selected time 
points of the differentiation kinetics corresponded with de novo methylation in BALB/c ESCs at the 
Isoc2b promoter. I chose the Trinity pipeline, a de novo assembly approach, to analyze the RNA-
seq data to circumvent alignment biases due to mapping to the available reference genome and 
transcriptome (both derived from the C57BL/6 strain). Quality assessment of the de novo 
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assembled transcripts supported their validity. To date no strain-specific transcript related to the 
above-mentioned classes of described epigenetic modifiers has been identified. Although the 
reference genome is excluded during de novo assembly, subsequent characterization of 
transcripts involves comparison to an annotated genome and transcriptome impairing the 
identification of strain-specific transcripts. Analyses regarding strain-specific transcripts generated 
from the candidate region will be continued. To obtain a comprehensive analysis of the RNA-seq 
data, the knowledge of the actual genomic sequence of the candidate region in BALB/c mice 
might be essential. 
 
In addition to RNA-seq experiments, I used complementation assays with BACs in differentiating 
ESCs to further narrow down the MIso-encoding region. Since the majority of the above-described 
epigenetic modifiers acted in a DNA methylation-promoting manner, ESCs from the non-
methylating C57BL/6 strain were complemented with BALB/c-derived genomic sequences of the 9 
Mb candidate region by stable transfection. 
The BALB/c sequences were delivered as Bacterial Artificial Chromosomes (BACs) obtained from 
the CHORI-28 BAC library, which is based on BALB/cByJ genomic DNA. Since BALB/cByJ 
exhibited similar levels of Isoc2b promoter methylation in comparison to BALB/cAnNCrl and 
BALB/cJ, no negative effect on the outcome of the complementation assays was assumed. Initial 
next generation sequencing experiments with the selected BACs implied convenient coverage of 
the candidate region, but the repetitiveness of the candidate region made proper alignment 
difficult. Therefore, to exactly determine the coverage of the candidate region further sequencing 
of individual BACs is required. 
Unfortunately, none of the transfected BACs induced the BALB/c-specific methylation phenotype 
in differentiated C57BL/6 ESCs. Several reasons could explain this outcome. Firstly, the MIso-
encoding sequence might not be covered by the selected BACs. Screening of the BALB/c BAC 
library was performed with probes designed for the candidate region according the C57BL/6-
derived mm9 reference genome hence BALB/c-specific sequences might be missed. Moreover, 
not all selected BACs were part of the complementation assays due to unsuccessful retrofitting of 
the original BAC with a eukaryotic selection marker. Secondly, although the MIso-encoding region 
might be completely covered by the transfected BACs, MIso might not be fully represented by a 
single BAC. Thirdly, the Isoc2b promoter might be primed in BALB/c ESCs thus foreclosing 
de novo methylation in C57BL/6 ESCs. However, bisulfite sequencing results from F1 hybrids 
argue against this assumption, since both alleles were methylated independent of the parental 
origin. Finally, the design of the complementation assay assumed a methylation-promoting activity 
of MIso. Although the majority of epigenetic modifiers seem to repress their targets by promoting 
DNA methylation, methylation-preventing exceptions were also reported (Table 6-1). 
 
Since none of the two candidate region-wide approaches (comparative expression analysis, 
complementation assays) identified a candidate gene, I decided to re-investigate the annotated 
genes encoded in the candidate region. Interestingly, recently published data indicated an 
interaction of nucleolar protein 10 (Nol10) with Eed, a subunit of the PRC2 repressor complex
365
, 
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in ESCs
185
. Nol10 is a member of a yet uncharacterized family of proteins that share the NUC153 
domain of unknown function
303
. Nol10 also exhibits a WD40-repeat-containing domain, which is 
found in all eukaryotes and could serve as protein-protein interaction site
304,305
. Interestingly, the 
two hypermethylated mouse strains (BALB/c, A/J) share a non-synonymous SNP variant at 
rs29160165. All hypomethylated mouse inbred strains (C57BL/6 strains as well as 129S1/SvImJ, 
C3H/HeJ, CBA/J, DBA2/J, and NOD/ShiLtJ) share the reference variant of the SNP. The strain-
specific SNP variants were confirmed on gDNA and RNA level. According to the Mouse Genomes 
Project
275
 (REL-1303), the SNP variant resides in the splice region between exon 18 and 19 of 
Nol10, but splicing did not seem to be affected in transcripts detected in differentiating C57BL/6 
and BALB/c ESCs. Nevertheless, the non-synonymous SNP variant of rs29160165 present in 
BALB/c and A/J causes an amino acid exchange in the COOH-terminal tail of the Nol10 protein. 
Since the specificity of WD40 repeat-mediate protein-protein interaction seems to be determined 
by sequences outside the repeat domain
304
, the non-synonymous SNP variant found in BALB/c 
and A/J could have an influence on interaction partners. To understand how this notion can be 
brought in line with a potential interaction with the PRC2 complex will require further 
characterization of Nol10. Although Nol10 is not related to any of the site-specific epigenetic 
modifiers identified so far, its cellular localization as well as its domain repertoire makes it a 
promising candidate. In addition to BALB/c and A/J, WSB/EiJ is the third strain of the Mouse 
Genomes Project, which exhibits the respective SNP variant at rs29160165. The DNA methylation 
phenotype at the Isoc2b promoter in this strain might further support the involvement of Nol10. To 
date Nol10 is the only promising candidate gene to encode MIso. Future studies will focus on the 
functionality of Nol10 in the context of the DMR at the Isoc2b promoter but also at other yet 
unknown target sites. Of note, it cannot be excluded that the correlation of the SNP variant at 
rs29160165 with the observed methylation phenotype might have appeared by chance. Therefore, 
the search for other candidate genes will be continued until the involvement of Nol10 is clarified. 
 
The present work focused mainly on the analysis of the MIso-encoding candidate region on 
chromosome 12, but further studies concerning the DMR at the Isoc2b promoter also provided 
important information. Some of the epigenetic modifiers listed in Table 6-1 were found to affect the 
silencing of repetitive sequences
96,98,306,307
. Two retrotransposons of the SINE (short interspersed 
elements) class are located within the DMR at the Isoc2b promoter. I analyzed the generated 
MCIp-seq data regarding potential genome-wide differences in the methylation of repetitive 
sequences. Although the two inbred strains showed significant differences in a number of simple 
repeats, none of the retrotransposons present at the DMR associated with the Isoc2b promoter 
seemed enriched differentially by the MCIp-seq procedure. However, the read length (50 bp, 
single end) of the MCIp-seq data set is too short to estimate the abundancy at repetitive elements 
longer than 50 bp reliably. 
In addition, ChIP-seq and expression analyses in differentiating ESCs are available, which were 
generated over the course of a master thesis
297
 in our laboratory. The findings of this thesis 
indicated an involvement of Polycomb-mediated repression of the Isoc2b gene in BALB/c. 
Polycomb-mediated gene silencing is in general associated with the reversible repression of 
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differentiation genes during early embryonic development
366
. Mohn et al. could also demonstrate 
that additional CpG-rich Polycomb targets arise during ESC differentiation and that some of these 
targets were de novo methylated during lineage commitment
178
. De novo methylation could be 
achieved by recruitment of DNMTs by EZH2, a H3K27-specific histone methyltransferase part of 
PRC2
186
, and might lock genes in a silent state. In line with these findings, pluripotent BALB/c 
ESCs displayed bivalent histone modifications: the active mark H3K4me3 as well as the 
repressive mark H3K27me3 was detected at the Isoc2b promoter region. Upon differentiation, the 
level of H3K4me3 declines, whereas the repressive mark H3K27me3 was retained. In contrast, 
C57BL/6 ESCs completely lacked the repressive H3K27me3 mark at the DMR at all analyzed 
time points, but retained high levels of H3K4me3 throughout differentiation. In accordance with 
these findings, expression of Isoc2b was detected only in differentiating C57BL/6 ESCs and 
started between day 9 and day 13 after removal of Leukemia Inhibiting Factor (LIF). In summary, 
the strain-specific epigenetic characteristics and expression profile found in differentiated ESCs 
are in agreement with phenotypes observed in somatic tissues. Due to limitations of chromatin 
specimens, other repressive histone marks have not been analyzed as yet. H3K9me3 will be of 
particular interest, since gene silencing by the recently identified strain-specific epigenetic modifier 
Ssm1b was associated with increasing levels of H3K9me3 and DNA methylation
96,325
. 
The Isoc2b locus seems to be poised to be activated in both strains as indicated by the 
hypomethylated state in both germ line cells and ESCs and the presence of H3K4me3 at the 
promoter in ESCs. The active state was only maintained in differentiating C57BL/6 ESCs and 
resulted in C57BL/6-specific expression of Isoc2b. In contrast, differentiating BALB/c ESCs 
established a repressive epiphenotype marked by the loss of H3K4me3 and the presence of 
H3K27me3 and DNA methylation impeding the expression of Isoc2b. Unexpectedly, BALB/c 
ESCs seemed to be already marked by H3K27me3. The expression level of the pluripotency 
marker Oct4 was similar to other preparations of pluripotent ESCs. But DNA methylation levels of 
the undifferentiated BALB/c ESCs at the Isoc2b promoter and the Nanog-associated control 
region were slightly increased in comparison to other preparations. These findings imply that the 
BALB/c ESCs analyzed in the ChIP experiment might have reached a more committed state, 
which would explain the presence of H3K27me3 at the Isoc2b promoter. To evaluate these 
findings, ChIP experiments in combination with methylation and expression analyses in 
undifferentiated BALB/c ESCs will be repeated. 
How the machinery that establishes the repressive phenotype in BALB/c is directed to the Isoc2b 
promoter remains unclear as yet. With respect to the hypothesized loss-of-function mutation of 
Nol10 in BALB/c, a potential mechanism might involve the spreading of heterochromatin from an 
upstream located H3K27me3 island (Geo database GSE49431
367
). In this scenario, Nol10 might 
take part in effectively blocking the spreading in C57BL/6, but its mutated version fails to do so in 
BALB/c. Further investigations regarding the functionality of Nol10 as well as the dynamic 
chromatin environment at the Isoc2b promoter during the process of de novo DNA methylation will 
help to untangle the regulatory network. 
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Taken together, the data provide strong experimental evidence that the strain-specific 
epiphenotype at the Isoc2b promoter is regulated in trans by a monogenetic trait during early 
embryonic development. With Nol10 a potent candidate gene for MIso is on hand. The fact that so 
far no additional trans-regulated DMRs were identified emphasizes the importance of these 
regulators for accurate development and functionality of a multicellular organism. If their 
functionality was less import, their regulatory effect would be less essential and a higher number 
of trans-regulated variations among individuals were to be expected. Therefore, identification and 
characterization of MIso will provide insights to the regulatory mechanisms that shape the 
epigenome during early developmental stages. 
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6.3 Perspectives 
Linkage analyses located the monogenetic trait encoding MIso, the trans-acting epigenetic 
modifier responsible for the strain-specific DNA methylation phenotype at the Isoc2b promoter, in 
a 9 Mb region on chromosome 12. With Nol10, which is encoded within the candidate region, a 
potential candidate gene is on hand. A non-synonymous SNP variant correlates with the observed 
methylation phenotypes not only in C57BL/6 and BALB/c, but also 129S1/SvImJ, A/J, C3H/HeJ, 
CBA/J, DBA2/J, and NOD/ShiLtJ. Still, its functional participation in the establishment of the 
differentially methylated region (DMR) needs to be validated. The next step will be to analyze 
DNA methylation levels in the third strain (WSB/EiJ) of the Mouse Genomes Project
275
 that carries 
the same mutation as BALB/c and A/J. Assuming a positive correlation of the SNP variant and the 
methylation phenotype, bidirectional complementation assays will be performed with BACs 
representing the candidate gene. Not only C57BL/6 ESCs will be transfected with BALB/c-derived 
BACs, but also BALB/c ESCs with C57BL/6-derived BACs. The assay can further be performed 
with cDNA clones allowing for the expression of a tagged exogenous version of the protein. With 
the help of the tag, immunoprecipitation experiments can be applied to validate the presence of 
Nol10 at the Isoc2b promoter as well as to identify other Nol10 target sites throughout the 
genome. In addition, cDNA clones can be subject to targeted mutation of the coding sequence for 
functional analyses. In this context, ES cell lines with mutations at the endogenous locus will also 
be of interest. To date, 21 different ES cell clones with various mutations at the Nol10 locus are 
listed in the MGI database. In the long term, generation of a transgenic mouse model would be 
desirable. 
Since the involvement of Nol10 is not validated as yet, the available RNA-seq data sets will be 
subject to further analysis. Determing the actual BALB/c sequence of the MIso-encoding 
candidate region on chromosome 12 will be essential to identify strain-specific transcripts or 
transcript variants. Since to date only draft versions of the BALB/c genome are available, 
individual high-throughput sequencing of the screened BALB/c BAC clones should be performed 
to de novo assemble the BALB/c sequence for the MIso-encoding candidate region. 
Furthermore, epigenetic profiling of the DMR at Isoc2b promoter in ESCs should be extended. Not 
only the presence of other histone modifications (such as H3K9me3), but also partial deletion of 
the DMR might provide information on the regulatory mechanism. In this context, it would be 
interesting to assess the Isoc2b promoter methylation in mouse clones of the first and second 
generation generated from ESCs with truncated endogenous Isoc2b promoter sequences. In 
addition to manipulating the endogenous Isoc2b promoter sequence, exogenous fragments of the 
promoter region could be introduced to ESCs to screen for the sequence part that is sufficient to 
recruit the strain-specific DNA methylation machinery. 
Regarding repetitive elements as a potential target of the silencing machinery, it might be 
reasonable to reproduce the high-throughput sequencing of the MCIp samples with longer read 
length and paired ends. In this way, the representation of longer repetitive elements such as those 
present within the DMR at the Isoc2b promoter could be analyzed in a reliable manner. 
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Finally, the identification of additional trans-regulated DMRs will be of high priority. Not only DMRs 
targeted by MIso, but other factors, are of interest to augment the portfolio of strain-specific trans-
acting epigenetic modifiers. Novel candidate DMRs will be defined based on the available MCIp-
seq data sets of both spleen and cerebellum from C57BL/6 and BALB/c. 
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7 Summary 
DNA methylation and histone modifications are epigenetic mechanisms that affect the chromatin 
structure and thus the readout of the underlying DNA sequence. Hence, variations in the DNA 
methylation profiles of individuals may contribute to phenotypic differences and disease 
susceptibility. However, the extent of such epigenetic variations is unclear. With regard to DNA 
methylation, little is known on how these differences are established or inherited. 
This thesis was concerned with elucidating the role that genetic determinants play in maintaining 
specific DNA methylation patterns. Two common inbred mouse strains (C57BL/6 and BALB/c) 
were used to address inter-individual variations in DNA methylation. Little is known about trans-
acting epigenetic modifiers that control the epiphenotype at distinct target loci. Therefore the 
presented work focussed primarily on the identification of the trans-acting epigenetic modifier 
regulating the strain-specific DNA methylation pattern at the Isoc2b promoter. It could be 
demonstrated that the DMR is established during early embryonic development in BALB/c, but not 
in C57BL/6. The DMR could further be found in other inbred mouse strains. Using embryonic stem 
(ES) cell differentiation models, the strain-specific DNA methylation patterns were also detectable 
in vitro. Linkage analysis in C;B6 backcrosses narrowed down the genomic localization of the 
modifier to a highly repetitive 9 MB region on chromosome 12. To further characterize the 
epigenetic modifier gene, complementation assays with BAC clones covering the candidate 
regions as well as expression analyses (RNA-seq) in the in vitro ES cell differentiation models 
were performed. The latter identified Nol10 as a candidate gene to propagate the observed strain-
specific epiphenotypes. Additionally, novel candidate DMRs based on strain-specific patterns of 
active histone modifications were selected and validated to identify additional trans-regulated 
DMRs. In future, the investigation of DMRs will be extended, since to date only novel cis-regulated 
DMRs have been discovered. 
Further characterization of the potential epigenetic modifier Nol10 might provide fundamental 
insights into mechanisms that establish DNA methylation patterns during embryonic development 
and how inter-individual differences can be introduced. 
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Zusammenfassung 
Epigenetische Mechanismen, wie DNA-Methylierung und die post-translationale Modifikation von 
Histonen, beeinflussen die Chromatinstruktur und damit die Zugänglichkeit und Expression der 
assoziierten DNA-Sequenz. Individuelle Variationen im DNA-Methylierungsprofil haben damit das 
Potenzial zu unterschiedlichen Phänotypen und der Anfälligkeit für bestimmte Krankheiten 
beizutragen. Dennoch ist aktuell noch wenig über das Ausmaß solch individueller epigenetischer 
Unterschiede bekannt, ebenso wie diese grundsätzlich etabliert und vererbt werden. 
Diese Arbeit setzt sich mit dem Einfluss von genetischen Faktoren auf spezifische 
DNA-Methylierungsmuster auseinander. Zwei häufig verwendete Inzuchtmausstämme, C57BL/6 
und BALB/c, wurden als Modellsystem gewählt, um der Frage nach inter-individuellen 
Unterschieden im DNA-Methylierungsmuster nachzugehen. Zum heutigen Zeitpunkt ist noch 
wenig über trans-agierende Faktoren bekannt, die gezielt den Epiphänotyp beeinflussen. Die 
vorliegende Arbeit zielte deshalb primär darauf ab, den verantwortlichen Faktor für das 
stammspezifische Methylierungsmuster einer bereits bekannten differentiell methylierten Region, 
dem Isoc2b-Promoter, zu identifizieren. Es konnte gezeigt werden, dass die Methylierung in 
BALB/c-Mäusen im Zuge der frühen Embryonalentwicklung in jeder Generation neu etabliert wird, 
während C57BL/6-Mäuse generell einen hypomethylierten Zustand beibehalten. Dieses 
differentielle Methylierungsmuster gilt auch in anderen Inzuchtmausstämmen und konnte 
außerdem in einem Differenzierungsmodell mit embryonalen Stammzellen (ES-Zellen) 
nachgewiesen werden. Mit Hilfe von Kopplungsanalysen in C;B6-Hybriden wurde die für den 
Faktor kodierende Region auf einen 9 Mb-Bereich auf Chromosom 12 eingeschränkt. Diese 
Region ist allerdings hoch repetitiv. Um das für den Faktor kodierende Gen weiter zu 
charakterisieren, wurden sowohl Komplementierungsassays mit BAC-Klonen, die die 
Kandidatenregion abdecken, als auch Expressionsanalysen mittels RNA-seq im ES-Zell-
Differenzierungsmodell durchgeführt. Letztere identifizierten Nol10 als mögliches Kandidatengen, 
um den beobachteten stammspezifischen Epiphänotyp hervorzurufen. Desweiteren wurden neue 
potentielle DMRs auf Basis von stammspezifischen Histonmodifikationsmustern ausgewählt und 
validiert. Da bisher aber nur weitere in cis regulierte DMRs gefunden wurden, wird die Suche nach 
trans-regulierten DMRs weiter fortgesetzt. 
Die eingehende Charakterisierung des potentiellen epigenetischen Modifiers Nol10 gestattet 
möglicherweise fundamentale Einsichten darüber, wie spezifische Methylierungsmuster während 
der Embryonalentwicklung gesetzt und damit inter-individuelle Unterschiede eingeführt werden 
können. 
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% Percent 
°C Degree Celcius 
µg Microgram 
µl Microliter 
µM Micromolar 
3‘ 3-prime 
5‘ 5-prime 
53BP1 P53-binding protein 1  
5caC 5-carboxycytosine 
5fC 5-formylcytosine 
5hmC 5-hydroxymethylcytosine 
5mC 5-methylcytosine 
A Adenine 
aa Amino acids 
ac Acetylation 
AcOH Acetic Acid 
Amp Ampicillin 
ATP Adenosine triphosphate 
Avy Agouti viable yellow allele 
B6 C57BL/6 
B6CF1 C57BL/6 (f) x BALB/c (m) 
BAC Bacterial Artificial Chromosome 
BAH Bromo-adjacent homology domain 
BER Base excision repair 
BMM Bone marrow-derived macrophages 
bp Base pair 
BS Bisulfite sequencing 
BSA Bovine Serum Albumin 
C Cytosine 
CB6F1 BALB/c (f) x C57BL/6 (m) 
CBM Cell Buffer Mix  
C. briggsea Caenorhabditis briggsea 
cDNA Complementary DNA 
CFP1 CXXC zinc finger protein 1 
CGI CpG island 
ChIP Chromatin immunoprecipitation 
Chr Chromosome 
cm Centimeter 
cM Centimorgan 
CM Chloramphenicol 
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cm2 Square centimeter 
CNODF1 BALB/c (f) x NOD (m) 
CO2 Carbondioxide 
CpG CpG dinucleotide 
CXXC Cysteine-rich zinc finger domain 
Da Dalton 
dATP Desoxyadenosin triphosphate 
DB Dilution Buffer 
ddH2O Double-destilled H2O 
ddNTP Dideoxyribonucleotide triphosphate 
DER Differentially expressed regions 
DIG Digoxigenin 
DMR Differentially methylated region 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
dNTP Deoxyribonucleotide triphosphate 
dpc day post coitus 
DTT Dithiothreitol 
dUTP Deoxyuridine triphosphate 
E Embryonic day 
E. coli Escherichia coli 
EB Embryoid body 
EDTA/Na2EDTA Ethylenediaminotetraacetic acid disodium salt dehydrate 
Eed Enhancer of embryonic development 
eGFP Enhanced green fluorescent protein 
NEU N-ethyl-N-nitrosourea  
ESC / ES cell Embryonic stem cell 
EtBr Ethidium bromide 
EtOH Ethanol 
exRNA Exosomal RNA 
Ezh2 Enhancer of zeste homolog 2  
FBS Fetal  bovine serum 
G Guanine 
g Gram 
G418 Geneticin 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 
GC Guanin/Cytosine 
gDNA Genomic DNA 
GR Glycine-argenine repeat 
H Histone 
h Hour 
HAT Histone acetyltransferase 
HCl Hydrochloric acid 
HCP High-CpG promoter 
HDAC Histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hg18 Human genome assembly 18 
Abbreviations 
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hMeDIP Hydroxymethylcytosine methylated DNA immunoprecipitation 
HMT Histone methyltransferase 
Hz Hertz 
IAP Intracisternal A-particle  
ICM Inner cell mass 
IgG Immunoglobulin G 
IP Immunoprecipitation 
Isoc2a/b Isochorismatase domain containing 2 a/b 
K Lysine 
Kan Kanamycin 
kb Kilo base 
KCl Potassium chloride 
kDa Kilodalton 
KOH Potassium hydroxide 
KRAB Krüppel-associated box domain 
KZF KRAB-containing zinc finger 
l Liter 
LA Linkage analysis 
LB Lysogeny broth 
LIF Leukemia inhibiting Factor 
lncRNA Long non-coding RNA 
LOD Logarithm 209oniza odds 
LSD1 Lysine-specific demethylase 1 
M Molar 
mA Milliampere 
MALDI-TOF MS 
Matrix-assisted laser desorption/ionization coupled with mass spectrometry 
analysis by Time-of-fligth 
Mb Mega base 
MBD Methyl-binding domain 
MBP Methyl-CpG binding protein family 
MCIp Methyl-CpG immunoprecipitation 
mCpG Methylated CpG 
me1 Monomethylation 
me3 Trimethylation 
MeCP Methyl-CpG binding protein 
MEF Mouse embryonic fibroblast 
mg Milligram 
MgCl2 Magnesium chloride 
MHL MutL homolog 1 
min Minute 
Mio Million 
miRNA Micro RNA 
MIso Modifier of Isoc2b 
ml Milliliter 
mM Millimolar 
mm5/9/10 Mus musculus assembly 5/9/10 
MPC Magnetic particle concentrator 
Abbreviations 
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mRNA Messenger RNA 
msec Millisecond 
Myod1 Myogenic differention 1 
NaCl Sodium chloride 
NaHCO3 Sodium hydrogen carbonate 
NaOAc Sodium acetate 
nBAC Retrofitted BAC in SW106 
ncRNA Non-coding RNA 
ng Nanogram 
NGS Next generation sequencing 
NH2 Amino 
njBAC BAC retrofitted in presence of pJM2545 plasmid in DH10B strain 
NLS Nuclear localization signal 
nm Nanometer 
NOD NOD/ShiLtJ  
Nol10 Nucleolar protein 10 
NP95/Uhrf1 Nuclear protein 95 
nt Nucleotide 
NuRD Nucleosome remodeling eacetylase  
o/n Overnight 
oBAC Original BAC in DH10B strain 
ORF Open reading frame 
PAM Partitioning Around Medoids 
PBS Phosphate-buffered saline 
Pc Polycomb 
PcG Polycomb-Group 
PCR Polymerase chain reaction 
Pdgfrb Platelet-derived growth factor receptor, beta polypeptide 
PEG8000 Polyethylenglycol 8000 
PFGE Pulsed-field gel electrophoresis 
PGC Primordial germ cell 
PHD Pleckstrin-homology domain  
piRNA Piwi-interacting RNA 
PMSF Phenylmethanesulfonyl fluoride 
Oct4 POU domain, class 5, transcription factor 1 
POZ/BTB Broad-Complex, Tramtrack and Bric a brac  
PRC(1/2) Polycomb repressor complex (1/2) 
PWWP Proline-tryptophan-tryptophan-proline motif 
qPCR Quantitative Real-time PCR 
RT-qPCR Reverse-transcription quantitative real-time PCR 
RISC RNA-induced silencing complex 
Rn18s 18S ribosomal RNA 
RNA Ribonucleic acid 
RNAi RNA-mediated interferance 
Rnase Ribonuclase 
rpm Rounds per minute 
rRNA Ribosomal RNA 
Abbreviations 
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RT Room temperature 
SAM S-adenosylmethionin 
SAP Shrimp alkaline phosphatase 
sBAC Original BAC in SW106 strain 
SBE Single base extension 
SDS Sodium dodecyl sulfate 
sec Second 
SET Su(var)3-9 and 'Enhancer of zeste' domain 
SINE Short interspresed elements 
siRNA Small interfering RNA 
snoRNA Small nucleolar RNA 
SNP Single nucleotide polymorphism 
snRNA Small nuclear RNA 
Snrpn small nuclear ribonucleoprotein N 
T Thymine 
Ta Annealing temperature 
TAE Tris/Acetate/EDTA 
TE Tris/EDTA 
TET Ten-eleven translocation 
TF Transcription factor 
Tm Melting temperature 
TRD Transcriptional repressor domain  
Tris Tris(hydroxymethyl)-aminomethan 
tRNA Transfer RNA 
TRPE component I of anthranilate synthase 
TrxG Trithorax-group 
Tyr Tyrosinase 
U Unit 
ub Ubiquitinylation 
UCSC University of California, Santa Cruz  
UV Ultra violet 
V Volt 
Vol Volume 
 Ohm 
W Watt 
WBI-III Wash buffer I-III 
w/o Without 
WDR5 WD repeat domain 5 
WT Wild type 
xg G-force acceleration 
X-gal 5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid 
ZF Zinc finger 
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Appendix I – Genome-wide linkage analysis in C;B6 hybrids (section 10.1; page 214) 
Table 10-1 lists the genotyping results for the genome-wide SNP panel for 45 C;B6 hybrids as 
well as their average methylation at the Isoc2b promoter (mm9_chr7:4818016-4818396). The 
homozygous genotype is indicated by black squares, the heterozygous genotype by white 
squares. The classification of the methylation phenotype as high or intermediate according to the 
separating level of 58.5% is indicated by color (black or white, respectively, to match the color of 
the concordant genotype; grey if genotype could not be called reliably). For each SNP, the 
number of concordant individuals (homozygous – high methylation, heterozygous – low 
methylation) in comparison to the total number of genotyped individuals determined the LOD 
score (see section 5.1.4.1). The candidate region potentially encoding the strain-specific 
epigenetic modifier MIso is highlighted by a green box. 
The identity of the individual SNPs will be available upon publication. 
Appendix II – Fine-mapping the candidate region on chromosome 12 (section 10.2; page 
218) 
Table 10-2 lists the genotyping results for the fine-mapping SNP panel for 33 informative (with 
recombination in candidate region) of 172 C;B6 hybrids as well as their average methylation at the 
Isoc2b promoter (mm9_chr7:4818016-4818396). The homozygous genotype is indicated by black 
squares, the heterozygous genotype by white squares. The classification of the methylation 
phenotype as high or intermediate according to the re-defined separating level of 61.53.5% is 
indicated by color (black or white, respectively, to match the color of the concordant genotype). 
For each SNP, the number of concordant individuals (homozygous – high methylation, 
heterozygous – low methylation) in comparison to the total number of genotyped individuals 
determines the LOD score (see section 5.1.4.1). The number of concordant, but non-informative 
individuals is also stated. The candidate region potentially encoding the strain-specific epigenetic 
modifier MIso is highlighted by a green box. 
The identity of the individual SNPs will be available upon publication. 
Appendix III – Strain-specific Nol10 ORFs derived from Trinity–assemled transcripts 
(section 10.3; page 219) 
Strain-specific open reading frames (ORFs) of the Nol10 transcript were analzyed with the ORF 
Finder tool using the combined sequences of the Trinity-assembled transcripts 
c591363_g14_i1/c591363_g3_i2 (JM8, day 0 and 4) and c423461_g20_i7/c422587_g2_i3 
(BALB/c, day 0 to day 4), which rendered nearly full-length coverage of the Nol10 coding 
sequence. The Trinity-derived transcripts were identified by Blastx (evalue <1e
-20
). The annotated 
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Nol10 ORF is covered by both strains, but exhibits a non-synonymous SNP variant (rs29160165) 
in BALB/c causing an amino acid exchange (glutamic acid > lysine, highlighted) at position 532. 
Appendix IV – DNA methylation anaylsis of novel candidate differentially methylated 
regions (DMRs) (section 10.4; page 221) 
The novel candidate DMRs selected from regions strain-specifically marked by active histone 
marks (as determined by ChIP-seq experiments in spleen) are listed in Table 10-4. 
Corresponding UCSC genome browser tracks are available at http://genome.ucsc.edu/cgi-
bin/hgTracks?hgS_doOtherUser=submit&hgS_otherUserName=juwelll&hgS_otherUserSessionN
ame=C57vsBc_spleen_%20%09ChIP%2Dseq_H3K4me1_H3K4me3_H3K27ac_mm9. 
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10.1 Appendix I – Genome-wide linkage analysis in 
C;B6 hybrids 
Table 10-1 Genotyping results of genome-wide linkage analysis with corresponding LOD scores 
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SNP 1 22 45 0.9
SNP 2 25 45 1.0
SNP 3 25 45 1.0
SNP 4 24 45 0.9
SNP 5 24 44 1.0
SNP 6 24 44 1.0
SNP 7 25 45 1.0
SNP 8 28 44 1.6
SNP 9 28 45 1.5
SNP 10 28 45 1.5
SNP 11 29 45 1.7
SNP 12 29 45 1.7
SNP 13 28 45 1.5
SNP 14 28 45 1.5
SNP 15 30 45 2.0
SNP 16 21 44 0.9
SNP 17 22 45 0.9
SNP 18 20 45 1.0
SNP 19 19 43 1.0
SNP 20 22 45 0.9
SNP 21 22 45 0.9
SNP 22 21 44 0.9
SNP 23 22 45 0.9
SNP 24 21 44 0.9
SNP 25 21 43 0.9
SNP 26 22 43 0.9
SNP 27 21 45 0.9
SNP 28 21 44 0.9
SNP 29 23 44 0.9
SNP 30 18 45 1.3
SNP 31 17 45 1.5
SNP 32 17 45 1.5
SNP 33 16 43 1.5
SNP 34 18 45 1.3
SNP 35 18 45 1.3
SNP 36 19 45 1.1
SNP 37 19 44 1.1
SNP 38 19 43 1.0
SNP 39 24 44 1.0
SNP 40 23 43 0.9
SNP 41 22 45 0.9
SNP 42 24 45 0.9
SNP 43 23 43 0.9
SNP 44 25 45 1.0
SNP 45 25 45 1.0
SNP 46 25 44 1.1
SNP 47 29 45 1.7
SNP 48 30 45 2.0
SNP 49 31 45 2.3
SNP 50 29 45 1.7
SNP 51 26 44 1.2
SNP 52 23 45 0.9
SNP 53 20 45 1.0
SNP 54 21 45 0.9
ch
ro
m
o
so
m
e 
1
ch
ro
m
o
so
m
e 
2
ch
ro
m
o
so
m
e 
3
ch
ro
m
o
so
m
e 
4
Individuals
Average
Methylation
(Epi22) LO
D
 s
co
re
To
ta
l
C
o
n
co
rd
a
n
t
Appendix 
  215 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
4
6
%
4
8
%
5
1
%
7
8
%
4
0
%
6
7
%
3
1
%
7
0
%
6
7
%
6
6
%
7
4
%
7
5
%
3
0
%
2
2
%
6
8
%
3
3
%
2
5
%
6
0
%
5
1
%
3
5
%
7
6
%
4
5
%
6
8
%
7
6
%
5
1
%
7
7
%
4
2
%
7
6
%
4
0
%
7
5
%
4
5
%
8
3
%
5
4
%
4
6
%
7
1
%
7
3
%
4
9
%
7
6
%
7
9
%
4
5
%
5
3
%
5
7
%
6
7
%
8
3
%
4
4
%
SNP 55 24 45 0.9
SNP 56 25 45 1.0
SNP 57 26 45 1.1
SNP 58 25 45 1.0
SNP 59 24 45 0.9
SNP 60 25 45 1.0
SNP 61 24 45 0.9
SNP 62 24 45 0.9
SNP 63 23 43 0.9
SNP 64 24 45 0.9
SNP 65 23 44 0.9
SNP 66 23 45 0.9
SNP 67 23 45 0.9
SNP 68 20 45 1.0
SNP 69 22 45 0.9
SNP 70 17 43 1.3
SNP 71 19 45 1.1
SNP 72 18 45 1.3
SNP 73 20 45 1.0
SNP 74 21 45 0.9
SNP 75 22 45 0.9
SNP 76 21 45 0.9
SNP 77 22 45 0.9
SNP 78 24 45 0.9
SNP 79 22 43 0.9
SNP 80 24 45 0.9
SNP 81 23 45 0.9
SNP 82 22 44 0.9
SNP 83 21 45 0.9
SNP 84 21 45 0.9
SNP 85 24 44 1.0
SNP 86 25 45 1.0
SNP 87 23 44 0.9
SNP 88 20 42 0.9
SNP 89 21 43 0.9
SNP 90 22 45 0.9
SNP 91 22 45 0.9
SNP 92 22 44 0.9
SNP 93 18 43 1.1
SNP 94 17 45 1.5
SNP 95 15 43 1.8
SNP 96 17 45 1.5
SNP 97 15 45 2.0
SNP 98 17 44 1.4
SNP 99 20 45 1.0
SNP 100 22 40 0.9
SNP 101 20 43 0.9
SNP 102 20 45 1.0
SNP 103 21 45 0.9
SNP 104 20 43 0.9
SNP 105 19 45 1.1
SNP 106 21 45 0.9
SNP 107 20 44 1.0
SNP 108 18 45 1.3
SNP 109 16 45 1.7
SNP 110 18 45 1.3
SNP 111 21 45 0.9
SNP 112 21 45 0.9
SNP 113 26 45 1.1
SNP 114 26 45 1.1
SNP 115 23 45 0.9
SNP 116 23 43 0.9
SNP 117 22 45 0.9
SNP 118 20 43 0.9
SNP 119 19 45 1.1
SNP 120 19 45 1.1
SNP 121 16 44 1.6
SNP 122 24 45 0.9
SNP 123 22 45 0.9
SNP 124 21 45 0.9
SNP 125 20 44 1.0
SNP 126 21 45 0.9
SNP 127 19 45 1.1
SNP 128 17 45 1.5
SNP 129 19 44 1.1
SNP 130 15 44 1.9
SNP 131 18 43 1.1
SNP 132 17 45 1.5
SNP 133 16 44 1.6
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SNP 134 31 45 2.3
SNP 135 27 45 1.3
SNP 136 25 45 1.0
SNP 137 25 45 1.0
SNP 138 27 45 1.3
SNP 139 25 45 1.0
SNP 140 22 45 0.9
SNP 141 16 43 1.5
SNP 142 19 45 1.1
SNP 143 21 45 0.9
SNP 144 21 44 0.9
SNP 145 22 45 0.9
rs29180275 38 44 6.4
rs29160274 45 45 13.5
rs4229294 43 45 10.6
SNP 149 36 41 6.5
SNP 150 36 45 4.6
SNP 151 34 45 3.5
SNP 152 32 45 2.7
SNP 153 29 45 1.7
SNP 154 25 43 1.1
SNP 155 26 43 1.3
SNP 156 28 45 1.5
SNP 157 28 43 1.8
SNP 158 28 45 1.5
SNP 159 26 44 1.2
SNP 160 24 45 0.9
SNP 161 24 45 0.9
SNP 162 24 45 0.9
SNP 163 24 45 0.9
SNP 164 24 45 0.9
SNP 165 25 45 1.0
SNP 166 25 43 1.1
SNP 167 23 45 0.9
SNP 168 24 45 0.9
SNP 169 24 44 1.0
SNP 170 24 45 0.9
SNP 171 24 45 0.9
SNP 172 27 45 1.3
SNP 173 23 44 0.9
SNP 174 24 43 1.0
SNP 175 23 43 0.9
SNP 176 25 45 1.0
SNP 177 23 43 0.9
SNP 178 26 44 1.2
SNP 179 27 45 1.3
SNP 180 25 44 1.1
SNP 181 28 45 1.5
SNP 182 28 45 1.5
SNP 183 27 45 1.3
SNP 184 27 45 1.3
SNP 185 24 43 1.0
SNP 186 23 43 0.9
SNP 187 22 45 0.9
SNP 188 24 44 1.0
SNP 189 24 45 0.9
SNP 190 22 44 0.9
SNP 191 19 45 1.1
SNP 192 20 45 1.0
SNP 193 20 45 1.0
SNP 194 22 45 0.9
SNP 195 22 44 0.9
SNP 196 23 44 0.9
SNP 197 24 43 1.0
SNP 198 28 45 1.5
SNP 199 30 44 2.2
SNP 200 16 45 1.7
SNP 201 17 45 1.5
SNP 202 16 43 1.5
SNP 203 20 45 1.0
SNP 204 20 44 1.0
SNP 205 18 45 1.3
SNP 206 11 23 0.7
SNP 207 24 45 0.9
SNP 208 22 40 0.9
SNP 209 25 44 1.1
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SNP 210 29 43 2.0
SNP 211 32 44 2.9
SNP 212 34 44 3.9
SNP 213 27 42 1.6
SNP 214 30 45 2.0
SNP 215 29 44 1.9
SNP 216 29 44 1.9
SNP 217 25 45 1.0
SNP 218 18 45 1.3
SNP 219 9 18 0.6
SNP 220 16 45 1.7
SNP 221 14 45 2.3
SNP 222 16 45 1.7
SNP 223 18 45 1.3
SNP 224 18 44 1.2
SNP 225 18 44 1.2
SNP 226 21 45 0.9
SNP 227 19 44 1.1
SNP 228 21 45 0.9
SNP 229 20 44 1.0
SNP 230 22 45 0.9
SNP 231 21 44 0.9
SNP 232 21 44 0.9
SNP 233 21 45 0.9
SNP 234 18 44 1.2
SNP 235 20 44 1.0
SNP 236 18 44 1.2
SNP 237 17 43 1.3
SNP 238 18 44 1.2
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10.2 Appendix II – Fine-mapping the candidate region 
on chromosome 12 
Table 10-2 Genotyping results of the fine-mapping SNP panel for informative C;B6 hybrids 
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rs29180275 137 144 172 19.7
SNP2 137 144 172 19.7
SNP3 137 144 172 19.7
SNP4 137 144 172 19.7
SNP5 137 149 172 23.4
SNP6 137 155 172 28.7
SNP7 137 156 172 29.6
SNP8 137 156 172 29.6
SNP9 137 157 172 30.6
SNP10 137 158 172 31.7
SNP11 137 158 172 31.7
SNP12 137 160 172 33.8
SNP13 137 161 172 34.9
SNP14 137 161 172 34.9
SNP15 137 161 172 34.9
SNP16 137 167 172 42.7
SNP17 137 168 172 44.2
rs29160274 137 170 172 47.6
SNP19 137 171 172 49.5
SNP20 136 170 172 47.6
SNP21 137 171 172 49.5
SNP22 137 171 172 49.5
SNP23 137 171 172 49.5
SNP24 137 171 172 49.5
SNP25 137 171 172 49.5
SNP26 137 171 172 49.5
SNP27 137 171 172 49.5
SNP28 137 171 172 49.5
SNP29 137 171 172 49.5
rs29188895 137 170 172 47.6
SNP31 137 170 172 47.6
rs4229294 136 166 171 42.4
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10.3 Appendix III – Strain-specific Nol10 ORFs derived 
from Trinity–assemled transcripts 
Table 10-3 Strain-specific Nol10 ORFs 
 
Nol10 ORF of JM8 (C57BL/6J) (687aa), derived from Trinity- Nol10 ORF of BALB/c (687aa), derived from Trinity-assembled
assembled transcripts c591363_g14_i1 and c591363_g3_i2 transcripts c423461_g20_i7 and c422587_g2_i3
    112 atgcaggtctccagcctcaacgaagtgaagatttacagcctcagc     112 atgcaggtctccagcctcaacgaagtgaagatttacagcctcagc
        M  Q  V  S  S  L  N  E  V  K  I  Y  S  L  S         M  Q  V  S  S  L  N  E  V  K  I  Y  S  L  S 
    157 tgcggcaagtctcttcccgagtggctttctgacaggaagaagaga     157 tgcggcaagtctcttcccgagtggctttctgacaggaagaagaga
        C  G  K  S  L  P  E  W  L  S  D  R  K  K  R         C  G  K  S  L  P  E  W  L  S  D  R  K  K  R 
    202 gcactgcagaagaagaatgtcgatgttcgtaggagaattgaactt     202 gcactgcagaagaagaatgtcgatgttcgtaggagaattgaactt
        A  L  Q  K  K  N  V  D  V  R  R  R  I  E  L         A  L  Q  K  K  N  V  D  V  R  R  R  I  E  L 
    247 attcaggacttcgaaatgcctactgtgtgtactactatcaaggtg     247 attcaggacttcgaaatgcctactgtgtgtactactatcaaggtg
        I  Q  D  F  E  M  P  T  V  C  T  T  I  K  V         I  Q  D  F  E  M  P  T  V  C  T  T  I  K  V 
    292 tcaaaagatggacagtatattttagcaactggaacatataagcct     292 tcaaaagatggacagtatattttagcaactggaacatataagcct
        S  K  D  G  Q  Y  I  L  A  T  G  T  Y  K  P         S  K  D  G  Q  Y  I  L  A  T  G  T  Y  K  P 
    337 cgggtccggtgttatgacacatatcagttatccctgaagtttgaa     337 cgggtccggtgttatgacacatatcagttatccctgaagtttgaa
        R  V  R  C  Y  D  T  Y  Q  L  S  L  K  F  E         R  V  R  C  Y  D  T  Y  Q  L  S  L  K  F  E 
    382 aggtgcttggattctgaagttgtcacctttgagattttatcagat     382 aggtgcttggattctgaagttgtcacctttgagattttatcagat
        R  C  L  D  S  E  V  V  T  F  E  I  L  S  D         R  C  L  D  S  E  V  V  T  F  E  I  L  S  D 
    427 gactattcaaagattgtcttcttacataatgacagatatattgaa     427 gactattcaaagattgtcttcttacataatgacagatatattgaa
        D  Y  S  K  I  V  F  L  H  N  D  R  Y  I  E         D  Y  S  K  I  V  F  L  H  N  D  R  Y  I  E 
    472 tttcactcacaatcaggcttttactacaaaaccagaattcccaag     472 tttcactcacaatcaggcttttactacaaaaccagaattcccaag
        F  H  S  Q  S  G  F  Y  Y  K  T  R  I  P  K         F  H  S  Q  S  G  F  Y  Y  K  T  R  I  P  K 
    517 ttcggccgagacttctcttaccactatccatcctgtgacttgtac     517 ttcggccgagacttctcttaccactatccatcctgtgacttgtac
        F  G  R  D  F  S  Y  H  Y  P  S  C  D  L  Y         F  G  R  D  F  S  Y  H  Y  P  S  C  D  L  Y 
    562 tttgtaggtgcaagctctgaagtttatagattaaacttagaacaa     562 tttgtaggtgcaagctctgaagtttatagattaaacttagaacaa
        F  V  G  A  S  S  E  V  Y  R  L  N  L  E  Q         F  V  G  A  S  S  E  V  Y  R  L  N  L  E  Q 
    607 gggcggtacctgaatcctctccagacggacgccgcggagaacaat     607 gggcggtacctgaatcctctccagacggacgccgcggagaacaat
        G  R  Y  L  N  P  L  Q  T  D  A  A  E  N  N         G  R  Y  L  N  P  L  Q  T  D  A  A  E  N  N 
    652 gtttgtgacataaatgcagtgcatggcttgttcgccacaggaaca     652 gtttgtgacataaatgcagtgcatggcttgttcgccacaggaaca
        V  C  D  I  N  A  V  H  G  L  F  A  T  G  T         V  C  D  I  N  A  V  H  G  L  F  A  T  G  T 
    697 atagagggtcgagtggaatgctgggatccaagagtaagaaaaagg     697 atagagggtcgagtggaatgctgggatccaagagtaagaaaaagg
        I  E  G  R  V  E  C  W  D  P  R  V  R  K  R         I  E  G  R  V  E  C  W  D  P  R  V  R  K  R 
    742 gttggcgtgttagactgtgcattaaatagtgtcacagcagattca     742 gttggcgtgttagactgtgcattaaatagtgtcacagcagattca
        V  G  V  L  D  C  A  L  N  S  V  T  A  D  S         V  G  V  L  D  C  A  L  N  S  V  T  A  D  S 
    787 gagataaacagcttacccaccatctctgcattgaagtttaatgga     787 gagataaacagcttacccaccatctctgcattgaagtttaatgga
        E  I  N  S  L  P  T  I  S  A  L  K  F  N  G         E  I  N  S  L  P  T  I  S  A  L  K  F  N  G 
    832 gccttgagcatggcagttggaacatccacagggcaggtgttgtta     832 gccttgagcatggcagttggaacatccacagggcaggtgttgtta
        A  L  S  M  A  V  G  T  S  T  G  Q  V  L  L         A  L  S  M  A  V  G  T  S  T  G  Q  V  L  L 
    877 tatgatcttcgctcggataagccgttgctagttaaggatcaccag     877 tatgatcttcgctcggataagccgttgctagttaaggatcaccag
        Y  D  L  R  S  D  K  P  L  L  V  K  D  H  Q         Y  D  L  R  S  D  K  P  L  L  V  K  D  H  Q 
    922 tatgggctgccgattaagtcagttcatttccaggattccctagat     922 tatgggctgccaattaagtcagttcatttccaggattccctagat
        Y  G  L  P  I  K  S  V  H  F  Q  D  S  L  D         Y  G  L  P  I  K  S  V  H  F  Q  D  S  L  D 
    967 ttggttttgtctgcagactctagaattgtcaaaatgtggaacaag     967 ttggttttgtctgcagactctagaattgtcaaaatgtggaacaag
        L  V  L  S  A  D  S  R  I  V  K  M  W  N  K         L  V  L  S  A  D  S  R  I  V  K  M  W  N  K 
   1012 gactccgggaaaatatttacttcgttggagccagaacatgatctt    1012 gactccgggaaaatatttacttcgttggagccagaacatgatctt
        D  S  G  K  I  F  T  S  L  E  P  E  H  D  L         D  S  G  K  I  F  T  S  L  E  P  E  H  D  L 
   1057 aatgatgtttgcctctatcccagctcaggaatgcttcttactgcc    1057 aatgatgtttgcctctatcccagctcaggaatgcttcttactgcc
        N  D  V  C  L  Y  P  S  S  G  M  L  L  T  A         N  D  V  C  L  Y  P  S  S  G  M  L  L  T  A 
   1102 aatgaatcccccaagatgggcatttactacattccggttttgggt    1102 aatgaatcccccaagatgggcatttactacattccggttttgggt
        N  E  S  P  K  M  G  I  Y  Y  I  P  V  L  G         N  E  S  P  K  M  G  I  Y  Y  I  P  V  L  G 
   1147 cctgctcccaggtggtgttccttcctggacaacttgacagaagag    1147 cctgctcccaggtggtgttccttcctggacaacttgacagaagag
        P  A  P  R  W  C  S  F  L  D  N  L  T  E  E         P  A  P  R  W  C  S  F  L  D  N  L  T  E  E 
   1192 ttagaagagaatccagagagcacagtgtatgatgattacaaattt    1192 ttagaagagaatccagagagcacagtgtatgatgattacaaattt
        L  E  E  N  P  E  S  T  V  Y  D  D  Y  K  F         L  E  E  N  P  E  S  T  V  Y  D  D  Y  K  F 
   1237 gtcaccaagaaagaccttgaaaatttagggctcacacatctcatt    1237 gtcaccaagaaagaccttgaaaatttagggctcacacatctcatt
        V  T  K  K  D  L  E  N  L  G  L  T  H  L  I         V  T  K  K  D  L  E  N  L  G  L  T  H  L  I 
   1282 ggatcacctttcctccgagcatatatgcatgggtttttcatggat    1282 ggatcacctttcctccgagcatatatgcatgggtttttcatggat
        G  S  P  F  L  R  A  Y  M  H  G  F  F  M  D         G  S  P  F  L  R  A  Y  M  H  G  F  F  M  D 
   1327 atcagactctaccacaaggtgaaattgatggtcaatccatttgct    1327 atcagactctaccacaaggtgaaattgatggtcaatccatttgct
        I  R  L  Y  H  K  V  K  L  M  V  N  P  F  A         I  R  L  Y  H  K  V  K  L  M  V  N  P  F  A 
   1372 tatgaagaatataggaaagataaaattcgacagaagatagaagaa    1372 tatgaagaatataggaaagataaaattcgacagaagatagaagaa
        Y  E  E  Y  R  K  D  K  I  R  Q  K  I  E  E         Y  E  E  Y  R  K  D  K  I  R  Q  K  I  E  E 
   1417 acacgtgcacagagagtccaattaaagaaactgccaaaagttaac    1417 acacgtgcacagagagtccaattaaagaaactgccaaaagttaac
        T  R  A  Q  R  V  Q  L  K  K  L  P  K  V  N         T  R  A  Q  R  V  Q  L  K  K  L  P  K  V  N 
   1462 aaagaactggcacttaaattaattgaagaggaagaggagaaacaa    1462 aaagaactggcacttaaattaattgaagaggaagaggagaaacaa
        K  E  L  A  L  K  L  I  E  E  E  E  E  K  Q         K  E  L  A  L  K  L  I  E  E  E  E  E  K  Q 
   1507 aagtctacgctgaaaaagaaagttaagagcctccctaatatcctc    1507 aagtctacgctgaaaaagaaagttaagagcctccctaatatcctc
        K  S  T  L  K  K  K  V  K  S  L  P  N  I  L         K  S  T  L  K  K  K  V  K  S  L  P  N  I  L 
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   1552 acggatgatcgatttaaagttatgtttgagaatcccgacttccag    1552 acggatgatcgatttaaagttatgtttgagaatccggacttccag
        T  D  D  R  F  K  V  M  F  E  N  P  D  F  Q         T  D  D  R  F  K  V  M  F  E  N  P  D  F  Q 
   1597 gtggacgaggagagtgaagagttcaggcttctcaaccccctcgtc    1597 gtggacgaggagagtgaagagttcaggcttctcaaccccctcgtc
        V  D  E  E  S  E  E  F  R  L  L  N  P  L  V         V  D  E  E  S  E  E  F  R  L  L  N  P  L  V 
   1642 tcgaggatcagtgagaagaggaagaagcagctgaggctcttggag    1642 tcgaggatcagtgagaagaggaagaagcagctgaggctcttggag
        S  R  I  S  E  K  R  K  K  Q  L  R  L  L  E         S  R  I  S  E  K  R  K  K  Q  L  R  L  L  E 
   1687 cagcaggagctcaaggatgaagaggaggaagaaccggaaggaaaa    1687 cagcaggagctcaaggataaagaggaggaagaaccggaaggaaaa
        Q  Q  E  L  K  D  E  E  E  E  E  P  E  G  K         Q  Q  E  L  K  D  K  E  E  E  E  P  E  G  K 
   1732 cccagtgatgcagaaagttcagagagctcagatgatgagaaaggt    1732 cccagtgatgcagaaagttcagagagctcagatgatgagaaaggt
        P  S  D  A  E  S  S  E  S  S  D  D  E  K  G         P  S  D  A  E  S  S  E  S  S  D  D  E  K  G 
   1777 tgggttgaagaagtcaggaagcagcgcagactccttcagcaggaa    1777 tgggttgaagaagtcaggaagcagcgcagactcctgcagcaggaa
        W  V  E  E  V  R  K  Q  R  R  L  L  Q  Q  E         W  V  E  E  V  R  K  Q  R  R  L  L  Q  Q  E 
   1822 gaaagagtgaagcggcaggagcaactgaaggaggaccagcagaca    1822 gaaagagtgaagcggcaggagcaactgaaggaggaccagcagaca
        E  R  V  K  R  Q  E  Q  L  K  E  D  Q  Q  T         E  R  V  K  R  Q  E  Q  L  K  E  D  Q  Q  T 
   1867 gtcctgaagccccagttctacgagatcaaagcaggcgaagagttc    1867 gtcctgaagccccagttctacgagatcaaagctggcgaagagttc
        V  L  K  P  Q  F  Y  E  I  K  A  G  E  E  F         V  L  K  P  Q  F  Y  E  I  K  A  G  E  E  F 
   1912 aggagcttcaaagagtctgccaccaagcagagactaatgaacaaa    1912 agaagcttcaaagagtctgccaccaagcagagactgatgaacaaa
        R  S  F  K  E  S  A  T  K  Q  R  L  M  N  K         R  S  F  K  E  S  A  T  K  Q  R  L  M  N  K 
   1957 actctggaagatcgtttgaaacttgaagcaaaacatgggacattg    1957 actctggaagatcgtttgaaacttgaagcaaaacatgggacattg
        T  L  E  D  R  L  K  L  E  A  K  H  G  T  L         T  L  E  D  R  L  K  L  E  A  K  H  G  T  L 
   2002 aatgtatcggacaccactgttggcagcaagcagttgacatttact    2002 aatgtatcggacaccactgttggcagcaagcagttgacatttact
        N  V  S  D  T  T  V  G  S  K  Q  L  T  F  T         N  V  S  D  T  T  V  G  S  K  Q  L  T  F  T 
   2047 ctcaagaggtctgaacagcaaaagaagcaacaggaggctgaaaaa    2047 ctcaagaggtctgaacagcaaaagaagcaacaggaggctgaaaaa
        L  K  R  S  E  Q  Q  K  K  Q  Q  E  A  E  K         L  K  R  S  E  Q  Q  K  K  Q  Q  E  A  E  K 
   2092 ctgcatcgtcaggaaaggaaaaatctgcgcaggtcggccagccac    2092 ctgcatcgtcaggaaaggaaaaagctgcgcaggtcggccagccac
        L  H  R  Q  E  R  K  N  L  R  R  S  A  S  H         L  H  R  Q  E  R  K  K  L  R  R  S  A  S  H 
   2137 ctgaggtccagacccagaagaggccggccctttcactga 2175      2137 ctgaggtccagacccagaagaggccggccctttcactga 2175   
        L  R  S  R  P  R  R  G  R  P  F  H  *         L  R  S  R  P  R  R  G  R  P  F  H  * 
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10.4 Appendix IV – DNA methylation analysis of novel 
candidate differentially methylated regions (DMRs) 
Table 10-4 Annotated list of novel candidate mouse strain-specific DMRs 
 
C57BL/6 BALB/c
H3K4me3 chr17:21844143-21845143
Zfp760
(promoter)
BALB/c
(2.1x)
chr17:21844358-21844570 8 17% 1% no
chr5:114625776-114626064 16 3% 2% no
chr5:114625909-114626286 19 3% 3% no
H3K4me3 chr2:168566763-168567763
Atp9a
(promoter)
BALB/c
(3.0x)
chr2:168566798-168567164 27 4% 5% no
H3K4me3 chr11:69233014-69234014
Dnahc2
(promoter)
BALB/c
(3.0x)
chr11:69233742-69233972 17 2% 3% no
chr19:7066713-7067105 17 1% 2% no
chr19:7066441-7066802 14 15% 13% no
chr1:34067828-34068212 15 4% 4% no
chr1:34068252-34068742 55 3% 3% no
H3K4me3 chr6:52108100-52109100
Hoxa1
(promoter)
BALB/c
(1.6x)
chr6:52108174-52108564 27 4% 3% no
H3K4me3 chr11:99247023-99248023
Krt10
(intragenic)
BALB/c
(2.3x)
chr11:99247785-99248012 10 12% 14% no
H3K4me3 chr17:3083852-3084852
Pisd-ps2
(promoter)
BALB/c
(2.0x)
chr17:3084411-3084659 14 2% 2% yes
H3K4me3 chr18:42110177-42111177
Prelid2
(intragenic)
BALB/c
(1.9x)
chr18:42110499-42110973 29 3% 4% no
H3K4me3 chr1:191551704-191552704
Ptpn14
(promoter)
BALB/c
(2.2x)
chr1:191552381-191552797 37 5% 5% no
H3K4me3 chr2:154428841-154429841
Pxmp4
(promoter)
BALB/c
(1.8x)
chr2:154429048-154429440 22 3% 2% no
chr10:42580614-42580915 6 10% 14% no
chr10:42580408-42580781 11 8% 11% no
H3K4me3 chr18:74366816-74367816
Ska1
(promoter)
BALB/c
(1.7x)
chr18:74367379-74367621 18 1% 1% no
chr6:88025082-88025555 24 2% 2% no
chr6:88024951-88025305 22 2% 2% no
H3K4me3 chrX:149441203-149442203
Usp51
(intragenic)
BALB/c
(1.7x)
chrX:149441822-149442102 16 31% 31%
yes
(both)
chr15:51709053-51709247 12 2% 2% no
chr15:51708860-51709163 20 1% 3% no
chr6:124947234-124947572 17 6% 3% no
chr6:124946966-124947256 15 6% 7% no
chr4:62162950-62163369 29 10% 10% no
chr4:62163090-62163566 29 5% 5% no
H3K27ac chr4:140766411-140767411
6330545A04Rik
(distal)
C57BL/6
(4.7x)
chr4:140766797-140767168 8 72% 92% no
H3K27ac chr4:133613961-133614961
Aim1l
(distal)
C57BL/6
(2.4x)
chr4:133614214-133614597 13 30% 54%
yes
(BALB/c)
chr15:79724111-79724508 7 16% 68% no
chr15:79722557-79722852 12 7% 4% no
H3K27ac chr9:105973860-105974860
Col6a4
(intragenic)
BALB/c
(7.7x)
chr9:105974425-105974596 6 66% 44% no
H3K27ac chr14:51443888-51444888
Parp2
(intragenic)
C57BL/6
(2.7x)
chr14:51444053-51444423 8 25% 59% no
H3K27ac chr19:47515636-47516636
Sh3pxd2a
(intragenic)
C57BL/6 (3.3x) chr19:47515951-47516448 10 25% 51% no
chr13:96731300-96731697 19 21% 62%
yes
(BALB/c)
chr13:96731126-96731439 16 17% 64%
yes
(BALB/c)
Enriched
in 
MCIp-seq
Set 1
H3K4me3 chr5:114625485-114626485
Acacb
(intragenic)
BALB/c
(2.7x)
Differential
histone mark
Peak
localization
(mm9 )
Nearest gene
(Rel. position)
Enriched
in
(log2 FC)
Epityper
amplicon
localization (mm9 )
CpGs
H3K4me3 chr19:7066422-7067422
Dnajc4
(promoter)
BALB/c
(1.8x)
H3K4me3 chr1:34067926-34068926
Dst
(promoter)
BALB/c
(1.8x)
Average
CpG Methylation
in Spleen*
H3K4me3 chr15:51708697-51709697
Utp23
(intragenic)
BALB/c
(1.9x)
H3K4me3/
H3K27ac
chr6:124946693-124947693
C530028O21Rik
(intragenic)
BALB/c
(3.1x/2.1x)
H3K4me3 chr10:42580350-42581350s
Scml4
(intragenic)
BALB/c
(1.8x)
H3K4me3 chr6:88024650-88025650
Rpn1
(distal)
BALB/c
(2.2x)
H3K27ac chr13:96730805-96731805
Sv2c
(intragenic)
C57BL/6
(2.1x)
H3K4me3/
H3K27ac
chr4:62162837-62163837
Hdhd3
(promoter)
BALB/c
(1.6x/1.6x)
H3K27ac chr15:79722157-79723157
Apobec3
(promoter)
C57BL/6
(2.2x)
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C57BL/6 BALB/c
chr11:109721598-109721882 7 2% 2% no
chr11:109721864-109722352 8 1% 2% no
H3K27ac chr11:113033555-113034555
2610035D17Rik
(intragenic)
C57BL/6
(5.6x)
chr11:113033795-113034048 8 5% 6% no
H3K27ac
chr9:40771667-40772667
4931429I11Rik
(intragenic)
BALB/c
(6.7x)
chr9:40771817-40772049 8 19% 17% no
H3K27ac chr5:150491416-150492416
B3galtl
(intragenic)
BALB/c
(4.8x)
chr5:150491557-150491924 8 88% 90% no
chr5:77523733-77524198 38 2% 2% no
chr5:77524277-77524728 24 6% 7% no
H3K27ac chr15:74592965-74593965
Ly6d
(intragenic)
C57BL/6
(2.4x)
chr15:74593160-74593293 4 23% 29% no
H3K27ac chr15:74582537-74583537
Lynx1
(intragenic)
C57BL/6
(2.8x)
chr15:74583148-74583564 25 4% 4% no
chr17:13820648-13820981 8 7% 8% no
chr17:13820861-13821052 7 4% 8% no
H3K27ac chr19:47611036-47612036
Obfc1
(promoter)
C57BL/6
(2.1x)
chr19:47611478-47611945 31 3% 4% no
chr11:20365098-20365450 8 76% 80% no
chr11:20364992-20365316 8 74% 77% no
H3K27ac chr19:43721462-43722462
Slc25a28
(distal)
C57BL/6
(5.5x)
chr19:43721671-43721988 6 20% 24% no
H3K27ac chr15:96413816-96414816
Slc38a1
(intragenic)
C57BL/6
(3.3x)
chr15:96414973-96415323 6 92% 94% no
chr11:8588926-8589291 7 26% 39% no
chr11:8588507-8588756 5 86% 86% no
H3K27ac chr4:93001506-93002506
Tusc1
(intragenic)
BALB/c
(1.8x)
chr4:93001381-93001616 23 2% 1% no
chr11:5902166-5902660 7 77% 83% no
chr11:5901432-5901918 6 79% 83% no
chr3:96077670-96077953 7 25% 1% yes
chr3:96077988-96078283 7 76% 9%
yes
(C57BL/6)
H3K4me3 chr7:150191605-150192605
Tspan32
(intragenic)
C57BL/6
(2.1x)
chr7:150192677-150192988 6 50% 86% no
H3K4me3 chr11:43341835-43342835
Ccnjl
(promoter)
BALB/c
(1.6x)
chr11:43342549-43342812 11 2% 2% no
H3K4me3 chr6:136752255-136753255
Hist4h4
(intragenic)
BALB/c
(1.7x)
chr6:136753203-136753439 6 3% 2% no
H3K4me3
chr13:67521833-67522833
Zfp459
(promoter)
BALB/c (1.2x) chr13:67522131-67522439 15 4% 11% no
chr17:48566705-48566973 4 21% 52% no
chr17:48566071-48566366 6 31% 79% no
H3K27ac chr11:105894819-105895819
Dcaf7
(promoter)
C57BL/6
(5.6x)
chr11:105895046-105895376 7 56% 80% no
H3K27ac chr16:30155069-30156069
Hes1
(distal)
C57BL/6
(5.5x)
chr16:30155216-30155568 6 15% 35% no
chr5:147874763-147875096 7 46% 10% no
chr5:147875405-147875618 4 80% 25% no
chr5:123489136-123489456 17 3% 26%
yes
(BALB/c)
chr5:123489428-123489728 7 6% 68% no
H3K27ac chr13:101179103-101180103
Naip1
(intragenic)
BALB/c
(7.8x)
chr13:101179250-101179593 5 84% 7% no
H3K27ac chr7:52996858-52997858
Spaca4
(intragenic)
C57BL/6
(3.5x)
chr7:52997182-52997586 9 10% 57% no
chr4:132651381-132651641 5 19% 53% no
chr4:132651025-132651364 6 10% 47% no
chr8:74967739-74968002 11 2% 2% no
chr8:74967345-74967757 24 10% 13% no
chr2:154845337-154845688 14 6% 13% no
chr2:154844660-154844973 13 6% 7% no
chr16:31066486-31066836 9 18% 32% no
chr16:31068482-31068909 11 76% 81% no
H3K27ac chr11:109721065-109722065
1700012B07Rik
(distal)
C57BL/6
(2.3x)
Differential
histone mark
Peak
localization
(mm9 )
Nearest gene
(Rel. position)
Enriched
in
(log2 FC)
H3K27ac chr11:20364229-20365229
Sertad2
(distal)
C57BL/6 (2.1x)
H3K27ac chr11:8588764-8589764
Tns3
(distal)
C57BL/6
(2.0x)
H3K27ac chr5:77523455-77524455
Hopx
(intragenic)
C57BL/6
(2.6x)
H3K27ac chr17:13819968-13820968
Mllt4
(distal)
C57BL/6
(2.3x)
H3K27ac chr11:5899700-5900700
Ykt6
(intragenic)
C57BL/6
(2.1x)
Set 2
H3K4me3 chr3:96077378-96078378
Hist2h2bb
(distal)
BALB/c
(4.1x)
Wasf2
(distal)
C57BL/6
(2.5x)
H3K27ac chr17:48565966-48566966
Apobec2
(intragenic)
C57BL/6
(1.8x)
H3K27ac chr5:147874677-147875677
Lnx2
(intragenic)
BALB/c
(1.8x)
H3K27ac chr8:74968538-74969538
1700030K09Rik
(intragenic)
C57BL/6
(1.7x)
H3K27ac chr2:154844650-154845650
a
(intragenic)
C57BL/6
(5.2x)
Epityper
amplicon
localization (mm9 )
CpGs
Average
CpG Methylation
in Spleen*
Enriched
in 
MCIp-seq
H3K27ac chr16:31066530-31067530
AI480653
(intragenic)
C57BL/6
(1.8x)
H3K27ac chr5:123488913-123489913
Morn3
(intragenic)
C57BL/6
(2.1x)
H3K27ac chr4:132650946-132651946
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C57BL/6 BALB/c
chr14:51702905-51703187 12 3% 2% no
chr14:51702653-51702968 17 9% 9% no
chr11:57499808-57500157 5 66% 68% no
chr11:57500262-57500560 5 89% 82% no
H3K27ac chr9:48226482-48227482
Gm8884
(distal)
C57BL/6
(1.8x)
chr9:48226834-48227177 8 72% 83% no
chr11:99099757-99100069 11 7% 9% no
chr11:99100022-99100522 7 52% 58% no
chr11:57765183-57765429 5 11% 11% no
chr11:57765947-57766302 4 29% 39% no
H3K27ac chr3:79056735-79057735
LOC100233207
(distal)
C57BL/6 (2.1x) chr3:79057262-79057600 7 11% 44% no
H3K27ac chr8:72345971-72346971
Lpar2
(promoter)
C57BL/6
(1.8x)
chr8:72346241-72346530 17 3% 2% no
chr8:72356942-72357146 6 1% 5% no
chr8:72356368-72356832 36 2% 5% no
H3K27ac chr2:156016009-156017009
Phf20
(distal)
C57BL/6
(1.8x)
chr2:156016184-156016459 5 9% 22% no
H3K27ac chr4:126692793-126693793
Sfpq
(distal)
C57BL/6
(3.3x)
chr4:126692940-126693230 8 6% 9% no
chr3:152591738-152592016 6 68% 77% no
chr3:152590995-152591313 9 92% 93%
yes
(both)
chr9:115401618-115401996 5 12% 14% no
chr9:115402569-115403035 4 94% 87% no
chr7:133916194-133916470 6 91% 84% no
chr7:133916247-133916556 7 85% 83% no
H3K27ac chr14:51702668-51703668
Ang
(distal)
BALB/c
(4.1x)
H3K27ac chr11:57764784-57765784
Larp1
(distal)
C57BL/6
(1.7x)
H3K27ac chr8:72356124-72357124
Pbx4
(promoter)
C57BL/6
(1.9x)
H3K27ac chr11:57499273-57500273
Galnt10
(intragenic)
C57BL/6
(1.8x)
H3K27ac chr11:99099440-99100440
Krt222
(intragenic)
C57BL/6
(1.9x)
H3K27ac chr7:133916447-133917447
Ypel3
(intragenic)
BALB/c
(4.1x)
H3K27ac chr3:152591862-152592862
St6galnac5
(intragenic)
C57BL/6
(3.8x)
H3K27ac chr9:115402330-115403330
Stt3b
(distal)
C57BL/6
(2.0x)
Differential
histone mark
Peak
localization
(mm9)
Nearest gene
(Rel. position)
Enriched
in
(log2 FC)
Epityper
amplicon
localization (mm9)
CpGs
Average
CpG Methylation
in Spleen*
Enriched
in 
MCIp-seq
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